17alpha-hydroxy steroid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	17alpha-hydroxy steroid	go back to main search page
Accession:	CHEBI:35342	browse the term
Definition:	The α-stereoisomer of 17-hydroxy steroid.
Synonyms:	related_synonym:	17-alpha-Hydroxysteroid; 17alpha-hydroxy steroids
	alt_id:	CHEBI:13585; CHEBI:19174; CHEBI:782
	xref:	kegg.compound:C03336

show annotations for term's descendants Sort by:
Rat (5307 ) Mouse (5351 ) Human (5584 ) Chinchilla (0 ) Bonobo (0 ) Dog (6 ) Squirrel (0 ) Pig (21 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (5307)

(20R)-17,20-dihydroxypregn-4-en-3-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

ISO

17 alpha,20 beta-dihydroxypregn-4-en-3-one inhibits the reaction [Metribolone results in increased activity of AR protein]

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

17alpha-estradiol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

estrogen receptor 2

affects binding

EXP

17alpha-estradiol binds to Esr2 protein

RGD

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

17alpha-hydroxypregnenolone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects chemical synthesis
increases metabolic processing
multiple interactions
decreases acetylation
affects metabolic processing

ISO

CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxypregnenolone
CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]
CYP17A1 protein results in decreased acetylation of 17-alpha-Hydroxypregnenolone
CYP17A1 protein affects the metabolism of 17-alpha-Hydroxypregnenolone

PMID:15562394 PMID:16030167 PMID:17194026 PMID:29100959

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

17alpha-hydroxyprogesterone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

androgen receptor

increases activity
multiple interactions

ISO

17-alpha-Hydroxyprogesterone results in increased activity of AR protein
17-alpha-Hydroxyprogesterone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]

PMID:21543282 PMID:33049310

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

EXP

[Diethylstilbestrol results in decreased expression of CYP11A1 protein] which results in decreased abundance of 17-alpha-Hydroxyprogesterone

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects abundance
increases metabolic processing
multiple interactions
affects metabolic processing
affects chemical synthesis

ISO

CYP17A1 protein affects the abundance of 17-alpha-Hydroxyprogesterone
CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]; TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]
CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxyprogesterone

PMID:16030167 PMID:17194026 PMID:21427057 PMID:29100959

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

estrogen receptor 1

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

fatty acid binding protein 4

multiple interactions

ISO

[17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

insulin 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; [17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO

17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of NR3C1 protein

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

progesterone receptor

multiple interactions

ISO

17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of PGR protein

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

solute carrier family 22 member 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

tumor necrosis factor

multiple interactions

ISO

TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

18-hydroxycortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily b, polypeptide 2

affects chemical synthesis

ISO

CYP11B1 protein affects the chemical synthesis of 18-hydroxycortisol

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects chemical synthesis

ISO

CYP11B2 protein affects the chemical synthesis of 18-hydroxycortisol

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

proopiomelanocortin

increases abundance

ISO

POMC protein results in increased abundance of 18-hydroxycortisol

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects chemical synthesis

ISO

CYP11B2 protein affects the chemical synthesis of 18-oxocortisol

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

21-dehydrocortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B15

multiple interactions

EXP

[AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol

NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349

6alpha-methylprednisolone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
increases secretion

ISO

ABCB1 gene polymorphism affects the susceptibility to [Methotrexate co-treated with Methylprednisolone]; ABCB1 protein results in increased susceptibility to [Methotrexate co-treated with Methylprednisolone]; Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Methylprednisolone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Methylprednisolone]
Methylprednisolone results in increased expression of ABCB1 mRNA; Methylprednisolone results in increased expression of ABCB1 protein

PMID:16932953 PMID:22079615 PMID:22464980

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

Methylprednisolone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

atypical chemokine receptor 3

decreases expression

ISO

Methylprednisolone results in decreased expression of ACKR3 mRNA

NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214

G

adenosine A2a receptor

decreases expression

ISO

Methylprednisolone results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

EXP

Methylprednisolone results in decreased phosphorylation of AKT1 protein
naringin inhibits the reaction [Methylprednisolone results in decreased phosphorylation of AKT1 protein]

PMID:15187100 PMID:30878453

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases secretion

EXP

Alendronate inhibits the reaction [Methylprednisolone results in increased secretion of ALPL protein]; Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in increased secretion of ALPL protein]]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

adhesion molecule with Ig like domain 2

decreases expression

ISO

Methylprednisolone results in decreased expression of AMIGO2 mRNA

NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218

G

ANTXR cell adhesion molecule 1

increases expression

ISO

Methylprednisolone results in increased expression of ANTXR1 mRNA

NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892

G

aldehyde oxidase 1

increases expression

ISO

Methylprednisolone results in increased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

androgen receptor

multiple interactions

ISO

Methylprednisolone binds to and results in decreased activity of AR protein; Methylprednisolone binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

Methylprednisolone results in decreased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of BAX mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BAX mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BAX protein]

PMID:17570061 PMID:26093215

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCL2-related protein A1

decreases expression

ISO

Methylprednisolone results in decreased expression of BCL2A1 mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890

G

bone gamma-carboxyglutamate protein

decreases secretion
decreases expression
multiple interactions

EXP

Methylprednisolone results in decreased secretion of BGLAP protein
Methylprednisolone results in decreased expression of BGLAP mRNA; Methylprednisolone results in decreased expression of BGLAP protein
[Nebivolol co-treated with Alendronate] inhibits the reaction [Methylprednisolone results in decreased secretion of BGLAP protein]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP protein]

PMID:30291735 PMID:37659742

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

bone marrow stromal cell antigen 2

decreases expression

ISO

Methylprednisolone results in decreased expression of BST2 mRNA

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

calpain 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide results in increased expression of CAPN2 protein]

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

caspase 3

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

multiple interactions
decreases activity
increases activity

EXP

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of CAT protein; Alendronate inhibits the reaction [Methylprednisolone results in decreased activity of CAT protein]; Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in decreased activity of CAT protein]]
Methylprednisolone results in increased activity of CAT protein

PMID:1942778 PMID:30291735

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 20

decreases expression

ISO

Methylprednisolone results in decreased expression of CCL20 mRNA; Methylprednisolone results in decreased expression of CCL20 protein

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

cellular communication network factor 1

increases expression

ISO

Methylprednisolone results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression

ISO

Methylprednisolone results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 5

increases expression

ISO

Methylprednisolone results in increased expression of CCN5 mRNA

NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062

G

calmegin

decreases expression

ISO

Methylprednisolone results in decreased expression of CLGN mRNA

NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325

G

collagen type I alpha 1 chain

multiple interactions
increases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]
Methylprednisolone results in increased expression of COL1A1 mRNA

PMID:19192274 PMID:26093215

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type IV alpha 1 chain

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA]

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

cathepsin D

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Isoproterenol results in increased expression of CTSD mRNA]

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

C-X-C motif chemokine ligand 1

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL1 mRNA

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 2

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL2 mRNA

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL1 mRNA

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine receptor 4

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCR4 mRNA

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
increases activity

ISO

Methylprednisolone results in decreased expression of CYP3A4 mRNA
Methylprednisolone results in increased activity of CYP3A4 protein

PMID:15964336 PMID:16837568

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

DNA-damage-inducible transcript 4

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of DDIT4 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of DDIT4 protein]

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

iodothyronine deiodinase 2

increases expression

ISO

Methylprednisolone results in increased expression of DIO2 mRNA

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

dystrophin

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form]; Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA]

NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835

G

endothelin 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type B

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDNRB mRNA]

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

EGF containing fibulin extracellular matrix protein 1

increases expression

ISO

Methylprednisolone results in increased expression of EFEMP1 mRNA

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808

G

estrogen receptor 1

multiple interactions

ISO

Methylprednisolone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

coagulation factor VIII

increases expression

ISO

Methylprednisolone results in increased expression of F8 protein

NCBI chr18:155,237...187,186
Ensembl chr18:155,309...186,683

G

fatty acid binding protein 4

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FABP4 mRNA
bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fibulin 1

increases expression

ISO

Methylprednisolone results in increased expression of FBLN1 mRNA

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

F-box protein 32

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FBXO32 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of FBXO32 protein]

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

Fc epsilon receptor II

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 protein]

NCBI chr12:6,540,697...6,552,364
Ensembl chr12:6,540,703...6,549,374

G

forkhead box O1

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FOXO1 protein
echinacoside inhibits the reaction [Methylprednisolone results in increased expression of FOXO1 protein]; Testosterone inhibits the reaction [Methylprednisolone results in increased expression of FOXO1 protein]

PMID:21931329 PMID:38336255

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

guanylate binding protein 1

decreases expression

ISO

Methylprednisolone results in decreased expression of GBP1 mRNA

NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802
Ensembl chr 2:234,190,708...234,206,802

G

glial fibrillary acidic protein

decreases expression

ISO

Methylprednisolone results in decreased expression of GFAP protein

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

gastric inhibitory polypeptide

increases secretion

EXP

Methylprednisolone results in increased secretion of GIP protein

NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216

G

glycoprotein m6b

increases expression

ISO

Methylprednisolone results in increased expression of GPM6B mRNA

NCBI chr X:31,689,485...31,836,199
Ensembl chr X:31,690,359...31,733,272

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

multiple interactions
increases activity

EXP

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of GPX1 protein
Methylprednisolone results in increased activity of GPX1 protein

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

gasdermin E

decreases expression

ISO

Methylprednisolone results in decreased expression of GSDME mRNA

NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 6

decreases expression

ISO

Methylprednisolone results in decreased expression of HERC6 mRNA

NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993

G

hypoxia inducible lipid droplet-associated

decreases expression

ISO

Methylprednisolone results in decreased expression of HILPDA mRNA

NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423

G

heme oxygenase 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

hydroxysteroid 11-beta dehydrogenase 1

decreases expression

ISO

Methylprednisolone results in decreased expression of HSD11B1 mRNA

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

5-hydroxytryptamine receptor 3A

multiple interactions
decreases activity

ISO

[Methylprednisolone co-treated with Metoclopramide] results in decreased activity of HTR3A protein; [Methylprednisolone co-treated with ramosetron] results in decreased activity of HTR3A protein
Methylprednisolone results in decreased activity of HTR3A protein

NCBI chr 8:58,138,514...58,150,960
Ensembl chr 8:58,138,226...58,150,884

G

inhibitor of DNA binding 3

increases expression

ISO

Methylprednisolone results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

interferon, alpha-inducible protein 27

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI27 mRNA

NCBI chr 6:128,355,312...128,361,783
Ensembl chr 6:128,355,079...128,361,781

G

interferon-induced protein 35

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI35 mRNA

NCBI chr10:86,881,270...86,889,523
Ensembl chr10:86,887,122...86,889,750

G

interferon-induced protein 44

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon-induced protein 44-like

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI44L mRNA

NCBI chr 2:243,328,629...243,366,404
Ensembl chr 2:243,328,723...243,366,404

G

interferon induced with helicase C domain 1

decreases expression

ISO

Methylprednisolone results in decreased expression of IFIH1 mRNA

NCBI chr 3:67,635,924...67,683,968
Ensembl chr 3:67,637,545...67,683,968

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

ISO

Methylprednisolone results in decreased expression of IFIT3 mRNA

NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521

G

interleukin 10

increases expression

ISO

Methylprednisolone results in increased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 beta

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor antagonist

decreases expression

ISO

Methylprednisolone results in decreased expression of IL1RN mRNA

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 23 subunit alpha

decreases expression

ISO

Methylprednisolone results in decreased expression of IL23A mRNA

NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434

G

interleukin 4

multiple interactions
decreases expression

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased activity of and results in increased phosphorylation of STAT6 protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of JAK1 protein]
Methylprednisolone results in decreased expression of IL4 protein

PMID:7988651 PMID:11997017

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 4 receptor

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of IL4R protein]

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 5

decreases expression

ISO

Methylprednisolone results in decreased expression of IL5 protein

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]
Methylprednisolone results in decreased expression of IL6 mRNA; Methylprednisolone results in decreased expression of IL6 protein

PMID:19192274 PMID:26093215

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

ISO

cobaltiprotoporphyrin inhibits the reaction [Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

interferon regulatory factor 7

decreases expression

ISO

Methylprednisolone results in decreased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

ISG15 ubiquitin-like modifier

decreases expression

ISO

Methylprednisolone results in decreased expression of ISG15 mRNA

NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656

G

interferon stimulated exonuclease gene 20

decreases expression

ISO

Methylprednisolone results in decreased expression of ISG20 mRNA

NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:142,236,137...142,246,401

G

Janus kinase 1

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of JAK1 protein]

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

laminin subunit beta 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA]

NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760

G

laminin subunit beta 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA]

NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090

G

laminin subunit beta 3

decreases expression

ISO

Methylprednisolone results in decreased expression of LAMB3 mRNA

NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081

G

lymphocyte antigen 6 family member E

decreases expression

ISO

Methylprednisolone results in decreased expression of LY6E mRNA

NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443

G

mitogen activated protein kinase 1

multiple interactions
decreases expression
decreases phosphorylation

EXP

cobaltous chloride inhibits the reaction [Methylprednisolone results in decreased expression of MAPK1 protein modified form]; cobaltous chloride inhibits the reaction [Methylprednisolone results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

myristoylated alanine rich protein kinase C substrate

decreases expression

ISO

Methylprednisolone results in decreased expression of MARCKS mRNA

NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882

G

myelin basic protein

decreases expression

ISO

Methylprednisolone results in decreased expression of MBP protein

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

MET proto-oncogene, receptor tyrosine kinase

decreases expression

ISO

Methylprednisolone results in decreased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

matrix metallopeptidase 10

decreases expression

ISO

Methylprednisolone results in decreased expression of MMP10 mRNA

NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613

G

matrix metallopeptidase 12

decreases expression

ISO

Methylprednisolone results in decreased expression of MMP12 mRNA

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478

G

myeloperoxidase

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MPO protein]
[Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]
Methylprednisolone results in decreased expression of MPO protein

PMID:26093215 PMID:28557239 PMID:30891624

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MUC5AC mRNA]

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

MX dynamin like GTPase 1

decreases expression

ISO

Methylprednisolone results in decreased expression of MX1 mRNA

NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904

G

NDUFA4, mitochondrial complex associated like 2

decreases expression

ISO

Methylprednisolone results in decreased expression of COXFA4L2 mRNA

NCBI chr 7:65,242,169...65,244,296
Ensembl chr 7:65,242,135...65,244,277

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 mRNA]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nidogen 2

increases expression

ISO

Methylprednisolone results in increased expression of NID2 mRNA

NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,506,756...4,562,949

G

neuromedin B

decreases expression

ISO

Methylprednisolone results in decreased expression of NMB mRNA

NCBI chr 1:144,278,678...144,290,523
Ensembl chr 1:144,278,453...144,281,422

G

nitric oxide synthase 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nuclear receptor subfamily 4, group A, member 3

decreases expression

ISO

Methylprednisolone results in decreased expression of NR4A3 mRNA

NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285

G

2'-5' oligoadenylate synthetase 1A

decreases expression

ISO

Methylprednisolone results in decreased expression of OAS1 mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

2'-5'-oligoadenylate synthetase 3

decreases expression

ISO

Methylprednisolone results in decreased expression of OAS3 mRNA

NCBI chr12:41,439,645...41,463,392
Ensembl chr12:41,439,643...41,464,420

G

2'-5'-oligoadenylate synthetase-like

decreases expression

ISO

Methylprednisolone results in decreased expression of OASL mRNA

NCBI chr12:47,343,551...47,356,509
Ensembl chr12:47,343,551...47,356,483

G

phosphoglycerate dehydrogenase

decreases expression

ISO

Methylprednisolone results in decreased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

phospholipase A1 member A

multiple interactions

ISO

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA1A mRNA]

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

phospholipase A2 group 4A

multiple interactions

ISO

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

phospholipid phosphatase 3

decreases expression

ISO

Methylprednisolone results in decreased expression of PLPP3 mRNA

NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

EXP

bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG protein]
Methylprednisolone results in increased expression of PPARG mRNA; Methylprednisolone results in increased expression of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

proline and arginine rich end leucine rich repeat protein

increases expression

ISO

Methylprednisolone results in increased expression of PRELP mRNA

NCBI chr13:47,920,480...47,943,547
Ensembl chr13:47,922,590...47,932,324

G

prostaglandin-endoperoxide synthase 2

decreases expression

ISO

Methylprednisolone results in decreased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

increases activity
multiple interactions

EXP

Methylprednisolone results in increased activity of REN protein
Sodium Chloride inhibits the reaction [Methylprednisolone results in increased activity of REN protein]

PMID:235222 PMID:6277579

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

regulator of G-protein signaling 4

decreases expression

ISO

Methylprednisolone results in decreased expression of RGS4 mRNA

NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884

G

RNA sensor RIG-1

decreases expression

ISO

Methylprednisolone results in decreased expression of RIGI mRNA

NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:60,117,398...60,165,995

G

receptor-interacting serine-threonine kinase 2

decreases expression

ISO

Methylprednisolone results in decreased expression of RIPK2 mRNA

NCBI chr 5:34,428,573...34,459,808
Ensembl chr 5:34,428,573...34,459,663

G

ring finger protein 19B

decreases expression

ISO

Methylprednisolone results in decreased expression of RNF19B mRNA

NCBI chr 5:146,690,453...146,715,729
Ensembl chr 5:146,690,577...146,714,394

G

radical S-adenosyl methionine domain containing 2

decreases expression

ISO

Methylprednisolone results in decreased expression of RSAD2 mRNA

NCBI chr 6:48,774,985...48,788,245
Ensembl chr 6:48,774,985...48,788,320

G

RUNX family transcription factor 2

multiple interactions
decreases expression

EXP

bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of RUNX2 protein]
Methylprednisolone results in decreased expression of RUNX2 mRNA; Methylprednisolone results in decreased expression of RUNX2 protein

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

sirtuin 1

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

solute carrier family 43, member 3

decreases expression

ISO

Methylprednisolone results in decreased expression of SLC43A3 mRNA

NCBI chr 3:90,414,822...90,450,654
Ensembl chr 3:90,415,977...90,436,976

G

solute carrier family 7 member 11

decreases expression

ISO

Methylprednisolone results in decreased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

spermine synthase

decreases expression

ISO

Methylprednisolone results in decreased expression of SMS mRNA

NCBI chr X:41,331,693...41,387,713
Ensembl chr X:41,331,799...41,387,712

G

superoxide dismutase 2

multiple interactions
decreases expression
increases activity

EXP
ISO

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of SOD2 protein
Methylprednisolone results in decreased expression of SOD2 mRNA
Methylprednisolone results in increased activity of SOD2 protein

PMID:1942778 PMID:19192274

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

signal transducer and activator of transcription 1

decreases expression

ISO

Methylprednisolone results in decreased expression of STAT1 mRNA

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 4

decreases expression

ISO

Methylprednisolone results in decreased expression of STAT4 mRNA

NCBI chr 9:56,964,617...57,080,523
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 6

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased activity of and results in increased phosphorylation of STAT6 protein]

NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:65,365,306...65,383,795

G

steroid sulfatase

increases expression

ISO

Methylprednisolone results in increased expression of STS mRNA

NCBI chr X:46,102,524...46,110,868
Ensembl chr X:46,102,548...46,111,104

G

transforming growth factor, beta 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

thrombospondin 1

increases expression

ISO

Methylprednisolone results in increased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

toll-like receptor 2

decreases expression

ISO

Methylprednisolone results in decreased expression of TLR2 mRNA

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

tumor necrosis factor

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TNF mRNA]
[Cyclophosphamide co-treated with Methylprednisolone] inhibits the reaction [Paraquat results in increased expression of TNF protein]
Methylprednisolone results in decreased expression of TNF protein

PMID:8384958 PMID:26093215 PMID:28557239 PMID:33737140

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 2

decreases expression

ISO

Methylprednisolone results in decreased expression of TNFAIP2 mRNA

NCBI chr 6:136,297,388...136,311,106
Ensembl chr 6:136,298,082...136,311,106

G

tripartite motif containing 63

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of TRIM63 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of TRIM63 protein]

NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:151,817,225...151,831,058

G

thioredoxin interacting protein

increases expression

ISO

Methylprednisolone results in increased expression of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

von Willebrand factor

decreases expression
increases expression

ISO

Methylprednisolone results in decreased expression of VWF protein
Methylprednisolone results in increased expression of VWF protein

PMID:7491699 PMID:20405515

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757

6beta-hydroxycortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects chemical synthesis

ISO

CYP3A4 protein affects the chemical synthesis of 6 beta-hydroxycortisol

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
increases secretion

ISO

Beclomethasone inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; Beclomethasone inhibits the reaction [ABCB1 protein results in increased export of fluorexon]; Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Beclomethasone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Beclomethasone]
Beclomethasone results in increased expression of ABCB1 mRNA; Beclomethasone results in increased expression of ABCB1 protein

PMID:15370884 PMID:16442095 PMID:22464980

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

increases expression

ISO

Beclomethasone results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily C member 1

increases expression

ISO

Beclomethasone results in increased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily G member 2

multiple interactions
increases activity

ISO

Beclomethasone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Beclomethasone inhibits the reaction [ABCG2 protein results in increased export of Mitoxantrone]
Beclomethasone results in increased activity of ABCG2 protein

PMID:15365089 PMID:16442095

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

acid phosphatase 5, tartrate resistant

decreases activity

ISO

Beclomethasone results in decreased activity of ACP5 protein

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

adrenoceptor beta 2

increases expression

ISO

Beclomethasone results in increased expression of ADRB2 mRNA

PMID:9032216 PMID:15679717

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

bradykinin receptor B1

decreases expression

ISO

Beclomethasone results in decreased expression of BDKRB1 mRNA

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

bone gamma-carboxyglutamate protein

decreases expression

ISO

Beclomethasone results in decreased expression of BGLAP protein

PMID:7746775 PMID:9232087 PMID:9544892

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

caspase 9

increases activity

ISO

Beclomethasone results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

catalase

increases expression

ISO

Beclomethasone results in increased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 11

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 2

decreases expression

ISO

Beclomethasone results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Beclomethasone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Beclomethasone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

multiple interactions
decreases expression

ISO

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CCL5 protein; [Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CCL5 protein; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]
Beclomethasone results in decreased expression of CCL5 mRNA; Beclomethasone results in decreased expression of CCL5 protein

PMID:8534483 PMID:10903220 PMID:14643170 PMID:15679717

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

CD44 molecule

multiple interactions

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]; Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

colony stimulating factor 2

multiple interactions
decreases secretion
increases activity

ISO

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CSF2 protein; [Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CSF2 protein; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CSF2 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of CSF2 protein]; Beclomethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
Beclomethasone results in decreased secretion of CSF2 protein
Beclomethasone results in increased activity of CSF2 protein

PMID:7545059 PMID:10460758 PMID:10868704 PMID:11167953 PMID:11730731 More...

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

C-X-C motif chemokine ligand 10

decreases secretion

ISO

Beclomethasone results in decreased secretion of CXCL10 protein

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression

ISO

Beclomethasone results in decreased expression of CYP2S1 mRNA

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
increases expression

ISO

1-aminobenzotriazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Mifepristone inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Paraoxon inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Physostigmine inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]

PMID:12538830 PMID:23512537 PMID:24555085

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

eosinophil peroxidase

multiple interactions

EXP

Beclomethasone inhibits the reaction [sephadex results in increased expression of EPX protein]

NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180

G

Fc epsilon receptor Ig

decreases expression

EXP

Beclomethasone results in decreased expression of FCER1G protein

NCBI chr13:86,181,908...86,186,766
Ensembl chr13:86,181,908...86,186,859

G

fibroblast growth factor 2

multiple interactions
decreases activity

ISO

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; [Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibronectin 1

multiple interactions

ISO

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; [Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

ISO

Beclomethasone results in decreased expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

gamma-glutamyltransferase 5

increases activity
increases expression
multiple interactions

ISO

Beclomethasone results in increased activity of GGT5 protein
Beclomethasone results in increased expression of GGT5 mRNA
[Beclomethasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4

NCBI chr20:13,042,694...13,070,960
Ensembl chr20:13,042,696...13,070,892

G

hydroxysteroid 11-beta dehydrogenase 2

increases metabolic processing

ISO

HSD11B2 protein results in increased metabolism of Beclomethasone

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

intercellular adhesion molecule 1

multiple interactions

ISO

Beclomethasone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interleukin 10

decreases secretion

ISO

Beclomethasone results in decreased secretion of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 13

multiple interactions
increases activity

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 protein]
Beclomethasone results in increased activity of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 1 beta

multiple interactions
decreases secretion
decreases expression

ISO

Beclomethasone inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]; Beclomethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
Beclomethasone results in decreased secretion of IL1B protein
Beclomethasone results in decreased expression of IL1B protein

PMID:7545059 PMID:9176529 PMID:9371735 PMID:10460758 PMID:15337628

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor antagonist

decreases expression

ISO

Beclomethasone results in decreased expression of IL1RN protein

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Beclomethasone results in decreased expression of IL2RA protein

PMID:8111605 PMID:9314351

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 3

multiple interactions

ISO

Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL3 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of IL3 protein]

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810

G

interleukin 4

multiple interactions
decreases expression

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]; Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]
Beclomethasone results in decreased expression of IL4 protein

PMID:7988651 PMID:18076728

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

multiple interactions
decreases expression

ISO

Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL5 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of IL5 protein]
Beclomethasone results in decreased expression of IL5 protein

PMID:7988651 PMID:10813552 PMID:11167953

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

kallikrein 1-related peptidase C10

increases expression

ISO

Beclomethasone results in increased expression of KLK3 mRNA

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

lactotransferrin

multiple interactions
decreases secretion

ISO

Beclomethasone inhibits the reaction [methylcholine results in increased secretion of LTF protein]
Beclomethasone results in decreased secretion of LTF protein

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

MEFV innate immunity regulator, pyrin

increases response to substance

ISO

MEFV mutant form results in increased susceptibility to Beclomethasone

NCBI chr10:12,288,514...12,303,337
Ensembl chr10:12,293,782...12,303,333

G

matrix metallopeptidase 2

multiple interactions

ISO

Beclomethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions
decreases expression

ISO

Beclomethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]
Beclomethasone results in decreased expression of MMP9 protein

PMID:10452757 PMID:10455257

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

nitric oxide synthase 2

decreases expression

ISO

Beclomethasone results in decreased expression of NOS2 protein

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Beclomethasone results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 3, group C, member 1

affects localization
increases expression
affects binding
multiple interactions
increases activity

ISO
EXP

Beclomethasone affects the localization of NR3C1 protein
Beclomethasone results in increased expression of NR3C1 mRNA
Beclomethasone binds to NR3C1 protein
[Beclomethasone co-treated with Albuterol] affects the localization of NR3C1 protein; [Beclomethasone co-treated with Formoterol Fumarate] affects the localization of NR3C1 protein; Beclomethasone affects the localization of and results in increased activity of NR3C1 protein; Beclomethasone binds to and results in increased activity of NR3C1 protein
Beclomethasone results in increased activity of NR3C1 protein

PMID:16814 PMID:2207292 PMID:15362971 PMID:15679717 PMID:15860753 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Beclomethasone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

phospholipase A1 member A

multiple interactions

ISO

Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA1A mRNA]

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

phospholipase A2 group 4A

decreases activity
multiple interactions

ISO

Beclomethasone results in decreased activity of PLA2G4A protein
Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]

PMID:15337628 PMID:20573295

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

multiple interactions

EXP

Beclomethasone inhibits the reaction [Acetylcholine results in increased phosphorylation of PPP1R14A protein]

NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:93,708,218...93,719,147

G

ras homolog family member A

multiple interactions

EXP

Beclomethasone inhibits the reaction [[[Antigens, Bacterial co-treated with Allergens] results in increased expression of and results in increased activity of RHOA protein] which results in increased susceptibility to Acetylcholine]; Beclomethasone inhibits the reaction [[Antigens, Bacterial co-treated with Allergens] results in increased expression of and results in increased activity of RHOA protein]; Beclomethasone inhibits the reaction [[Antigens, Bacterial co-treated with Allergens] results in increased expression of RHOA mRNA]

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302

G

ribonuclease A family member 2

decreases expression

ISO

Beclomethasone results in decreased expression of RNASE2 protein

NCBI chr15:26,923,125...26,923,934
Ensembl chr15:26,923,134...26,923,955

G

ribonuclease A family member 3

multiple interactions
decreases expression

ISO

[Salmeterol Xinafoate co-treated with Beclomethasone] affects the reaction [Allergens results in increased expression of RNASE3 protein]; Beclomethasone affects the reaction [Allergens results in increased expression of RNASE3 protein]
Beclomethasone results in decreased expression of RNASE3 protein

PMID:1443864 PMID:10513351 PMID:10573242 PMID:12166584 PMID:12587966 More...

NCBI chr15:26,985,399...26,986,269
Ensembl chr15:26,985,271...26,986,400

G

selectin E

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903

G

solute carrier family 22 member 2

multiple interactions

ISO

Beclomethasone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

Thy-1 cell surface antigen

multiple interactions

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]

NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540

G

TIMP metallopeptidase inhibitor 1

increases expression

ISO

Beclomethasone results in increased expression of TIMP1 protein

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tumor necrosis factor

multiple interactions
decreases secretion

ISO

Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Beclomethasone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]
Beclomethasone results in decreased secretion of TNF protein

PMID:8937731 PMID:9150321 PMID:9819297 PMID:10100995 PMID:10903220 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

vascular cell adhesion molecule 1

multiple interactions

ISO

Beclomethasone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

decreases expression

ISO

Beclomethasone results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aquaporin 4

increases expression

EXP

Betamethasone results in increased expression of AQP4 mRNA

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

androgen receptor

multiple interactions

ISO

Betamethasone binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

C-C motif chemokine ligand 2

decreases expression

ISO

Betamethasone results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Betamethasone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Betamethasone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

early growth response 1

affects expression

ISO

Betamethasone affects the expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

follicle stimulating hormone subunit beta

decreases expression

EXP

Betamethasone results in decreased expression of FSHB protein

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

frataxin

increases expression

ISO

Betamethasone results in increased expression of FXN mRNA

NCBI chr 1:231,300,457...231,323,989
Ensembl chr 1:231,300,150...231,323,989

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

ISO

Betamethasone results in increased expression of and results in increased activity of HPGD protein

NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions
increases metabolic processing

EXP
ISO

Betamethasone inhibits the reaction [HSD11B2 protein affects the metabolism of Corticosterone]
HSD11B2 protein results in increased metabolism of Betamethasone

PMID:16549198 PMID:19490994

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

hydroxysteroid (17-beta) dehydrogenase 4

increases expression

ISO

Betamethasone results in increased expression of HSD17B4 mRNA

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

luteinizing hormone subunit beta

increases expression

EXP

Betamethasone results in increased expression of LHB protein

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases activity
affects binding

ISO

NR3C1 protein alternative form inhibits the reaction [Betamethasone results in increased activity of NR3C1 protein alternative form]
Betamethasone binds to NR3C1 protein

PMID:15362971 PMID:15755863 PMID:16507850 PMID:21543282

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Betamethasone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

vascular endothelial growth factor A

decreases expression

ISO

Betamethasone results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

ISO

Clobetasol results in increased expression of AACS mRNA

NCBI chr12:36,774,471...36,817,835
Ensembl chr12:36,774,471...36,822,543

G

ATP binding cassette subfamily A member 1

increases expression

ISO

Clobetasol results in increased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 2

decreases expression

ISO

Clobetasol results in decreased expression of ABCA2 mRNA

NCBI chr 3:28,642,660...28,662,689
Ensembl chr 3:28,642,758...28,662,681

G

ATP binding cassette subfamily B member 6

increases expression

ISO

Clobetasol results in increased expression of ABCB6 mRNA

NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 1

decreases expression

ISO

Clobetasol results in decreased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily F member 1

decreases expression

ISO

Clobetasol results in decreased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

acetyl-CoA acyltransferase 1A

increases expression

ISO

Clobetasol results in increased expression of ACAA1A mRNA

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-CoA acyltransferase 2

increases expression

ISO

Clobetasol results in increased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

increases expression

ISO

Clobetasol results in increased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acyl-CoA thioesterase 11

increases expression

ISO

Clobetasol results in increased expression of ACOT11 mRNA

NCBI chr 5:126,756,255...126,804,526
Ensembl chr 5:126,756,255...126,804,507

G

acyl-CoA synthetase bubblegum family member 1

increases expression

ISO

Clobetasol results in increased expression of ACSBG1 mRNA

NCBI chr 8:63,887,433...63,943,486
Ensembl chr 8:63,887,435...63,984,178

G

acyl-CoA synthetase short-chain family member 2

increases expression

ISO

Clobetasol results in increased expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin alpha 2, smooth muscle

increases expression

ISO

Clobetasol results in increased expression of ACTA2 mRNA

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

increases expression

ISO

Clobetasol results in increased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, gamma 1

increases expression

ISO

Clobetasol results in increased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

actin related protein 1B

increases expression

ISO

Clobetasol results in increased expression of ACTR1B mRNA

NCBI chr 9:46,424,677...46,434,341
Ensembl chr 9:46,424,678...46,434,341

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

ISO

Clobetasol results in increased expression of ADAMTS1 mRNA

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

ADP-ribosylarginine hydrolase

increases expression

ISO

Clobetasol results in increased expression of ADPRH mRNA

NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452

G

1-acylglycerol-3-phosphate O-acyltransferase 1

increases expression

ISO

Clobetasol results in increased expression of AGPAT1 mRNA

NCBI chr20:4,140,565...4,149,531
Ensembl chr20:4,140,565...4,150,445

G

adenosylhomocysteinase-like 1

increases expression

ISO

Clobetasol results in increased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930

G

AHNAK nucleoprotein

decreases expression

ISO

Clobetasol results in decreased expression of AHNAK mRNA

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675

G

adenylate kinase 3

increases expression

ISO

Clobetasol results in increased expression of AK3 mRNA

NCBI chr 1:236,151,012...236,178,689
Ensembl chr 1:236,151,012...236,178,183

G

adenylate kinase 5

decreases expression

ISO

Clobetasol results in decreased expression of AK5 mRNA

NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366

G

A-kinase anchoring protein 13

decreases expression

ISO

Clobetasol results in decreased expression of AKAP13 mRNA

NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:138,724,150...139,029,401

G

aldo-keto reductase family 1 member B1

increases expression

ISO

Clobetasol results in increased expression of AKR1B1 mRNA

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

activated leukocyte cell adhesion molecule

decreases expression

ISO

Clobetasol results in decreased expression of ALCAM mRNA

NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876

G

aldehyde dehydrogenase 1 family, member A1

increases expression

ISO

Clobetasol results in increased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member L2

decreases expression

ISO

Clobetasol results in decreased expression of ALDH1L2 mRNA

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398

G

ALMS1, centrosome and basal body associated protein

decreases expression

ISO

Clobetasol results in decreased expression of ALMS1 mRNA

NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471

G

autocrine motility factor receptor

increases expression

ISO

Clobetasol results in increased expression of AMFR mRNA

NCBI chr19:11,002,451...11,038,182
Ensembl chr19:11,002,101...11,038,364

G

ankyrin repeat and KH domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ANKHD1 mRNA

NCBI chr18:28,436,296...28,534,954
Ensembl chr18:28,436,394...28,534,954

G

ankyrin repeat domain containing 11

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD11 mRNA

NCBI chr19:67,848,836...68,007,491
Ensembl chr19:67,848,844...68,007,491

G

ankyrin repeat domain 12

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD12 mRNA

NCBI chr 9:113,030,127...113,134,816
Ensembl chr 9:113,030,919...113,134,762

G

ankyrin repeat domain 46

increases expression

ISO

Clobetasol results in increased expression of ANKRD46 mRNA

NCBI chr 7:69,532,303...69,553,311
Ensembl chr 7:69,532,304...69,545,421

G

ankyrin repeat domain 52

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD52 mRNA

NCBI chr 7:1,390,730...1,410,139
Ensembl chr 7:1,391,325...1,407,410

G

aldehyde oxidase 1

increases expression

ISO

Clobetasol results in increased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

adaptor related protein complex 1 subunit mu 1

increases expression

ISO

Clobetasol results in increased expression of AP1M1 mRNA

NCBI chr16:17,620,910...17,636,431
Ensembl chr16:17,616,187...17,636,462

G

adaptor related protein complex 3 subunit delta 1

decreases expression

ISO

Clobetasol results in decreased expression of AP3D1 mRNA

NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:9,620,968...9,656,342

G

APC regulator of WNT signaling pathway

decreases expression

ISO

Clobetasol results in decreased expression of APC mRNA

NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022

G

APC regulator of WNT signaling pathway 2

decreases expression

ISO

Clobetasol results in decreased expression of APC2 mRNA

NCBI chr 7:10,043,010...10,065,037
Ensembl chr 7:10,043,010...10,065,210

G

APC down-regulated 1

decreases expression

ISO

Clobetasol results in decreased expression of APCDD1 mRNA

NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356

G

apelin

decreases expression

ISO

Clobetasol results in decreased expression of APLN mRNA

NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246

G

ARF GTPase 3

increases expression

ISO

Clobetasol results in increased expression of ARF3 mRNA

NCBI chr 7:131,765,039...131,792,075
Ensembl chr 7:131,750,672...131,770,123

G

ARF GTPase 4

increases expression

ISO

Clobetasol results in increased expression of ARF4 mRNA

NCBI chr16:1,903,238...1,920,012
Ensembl chr16:1,903,371...1,920,011

G

ARF GTPase 5

increases expression

ISO

Clobetasol results in increased expression of ARF5 mRNA

NCBI chr 4:58,003,919...58,006,898
Ensembl chr 4:58,003,932...58,006,835

G

ARF guanine nucleotide exchange factor 1

decreases expression

ISO

Clobetasol results in decreased expression of ARFGEF1 mRNA

NCBI chr 5:13,764,507...13,859,237
Ensembl chr 5:13,764,975...13,859,237

G

ARF guanine nucleotide exchange factor 2

decreases expression

ISO

Clobetasol results in decreased expression of ARFGEF2 mRNA

NCBI chr 3:175,966,575...176,052,715
Ensembl chr 3:175,966,579...176,052,713

G

Rho GTPase activating protein 23

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP23 mRNA

NCBI chr10:82,891,021...82,993,230
Ensembl chr10:82,890,853...82,993,228

G

Rho GTPase activating protein 31

affects expression

ISO

Clobetasol affects the expression of ARHGAP31 mRNA

NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076

G

Rho GTPase activating protein 35

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP35 mRNA

NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414

G

Rho GTPase activating protein 5

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP5 mRNA

NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636

G

Rho guanine nucleotide exchange factor 26

decreases expression

ISO

Clobetasol results in decreased expression of ARHGEF26 mRNA

NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538

G

Rho guanine nucleotide exchange factor 4

decreases expression

ISO

Clobetasol results in decreased expression of ARHGEF4 mRNA

NCBI chr 9:44,357,716...44,500,959
Ensembl chr 9:44,357,736...44,501,550

G

AT-rich interaction domain 1B

decreases expression

ISO

Clobetasol results in decreased expression of ARID1B mRNA

NCBI chr 1:47,973,199...48,328,793
Ensembl chr 1:47,973,997...48,328,793

G

AT-rich interaction domain 2

decreases expression

ISO

Clobetasol results in decreased expression of ARID2 mRNA

NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187

G

ARF like GTPase 1

increases expression

ISO

Clobetasol results in increased expression of ARL1 mRNA

NCBI chr 7:25,007,401...25,018,572
Ensembl chr 7:25,006,981...25,019,319

G

ARF like GTPase 2

increases expression

ISO

Clobetasol results in increased expression of ARL2 mRNA

NCBI chr 1:212,863,422...212,875,425
Ensembl chr 1:212,863,423...212,875,373

G

ARF like GTPase 2 binding protein

decreases expression

ISO

Clobetasol results in decreased expression of ARL2BP mRNA

NCBI chr19:10,342,895...10,352,529
Ensembl chr19:10,342,895...10,352,514

G

ARF like GTPase 4A

decreases expression

ISO

Clobetasol results in decreased expression of ARL4A mRNA

NCBI chr 6:62,809,287...62,811,297
Ensembl chr 6:62,804,548...62,820,760

G

ARL6 interacting reticulophagy regulator 1

increases expression

ISO

Clobetasol results in increased expression of ARL6IP1 mRNA

NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232

G

armadillo repeat containing, X-linked 4

decreases expression

ISO

Clobetasol results in decreased expression of ARMCX4 mRNA

NCBI chr X:102,153,743...102,164,173
Ensembl chr X:102,153,800...102,164,633

G

ASH1 like histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of ASH1L mRNA

NCBI chr 2:176,644,393...176,780,848
Ensembl chr 2:176,644,924...176,780,847

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

ISO

Clobetasol results in increased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

aspartate beta-hydroxylase domain containing 2

increases expression

ISO

Clobetasol results in increased expression of ASPHD2 mRNA

NCBI chr12:49,908,539...49,919,060
Ensembl chr12:49,908,241...49,925,254

G

ASXL transcriptional regulator 3

decreases expression

ISO

Clobetasol results in decreased expression of ASXL3 mRNA

NCBI chr18:13,868,223...14,040,867
Ensembl chr18:13,868,674...14,037,373

G

autophagy related 13

increases expression

ISO

Clobetasol results in increased expression of ATG13 mRNA

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

autophagy related 4B, cysteine peptidase

increases expression

ISO

Clobetasol results in increased expression of ATG4B mRNA

NCBI chr 9:101,729,772...101,761,456
Ensembl chr 9:101,726,782...101,761,622

G

antioxidant 1 copper chaperone

increases expression

ISO

Clobetasol results in increased expression of ATOX1 mRNA

NCBI chr10:40,065,525...40,080,627
Ensembl chr10:40,065,527...40,080,585

G

ATPase phospholipid transporting 10B

decreases expression

ISO

Clobetasol results in decreased expression of ATP10B mRNA

NCBI chr10:27,996,729...28,252,801
Ensembl chr10:27,910,295...28,251,450

G

ATPase Na+/K+ transporting subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of ATP1A1 mRNA

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase Na+/K+ transporting subunit beta 2

increases expression

ISO

Clobetasol results in increased expression of ATP1B2 mRNA

NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708

G

ATP synthase F1 subunit alpha

increases expression

ISO

Clobetasol results in increased expression of ATP5F1A mRNA

NCBI chr18:73,567,537...73,575,473
Ensembl chr18:73,567,526...73,575,922

G

ATP synthase F1 subunit beta

increases expression

ISO

Clobetasol results in increased expression of ATP5F1B mRNA

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

ATP synthase membrane subunit c locus 2

increases expression

ISO

Clobetasol results in increased expression of ATP5MC2 mRNA

NCBI chr 7:135,669,847...135,680,839
Ensembl chr 7:135,669,848...135,678,231

G

ATP synthase membrane subunit f

increases expression

ISO

Clobetasol results in increased expression of ATP5MF mRNA

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATP synthase membrane subunit j

increases expression

ISO

Clobetasol results in increased expression of ATP5MJ mRNA

NCBI chr 6:136,839,890...136,845,640
Ensembl chr 1:177,906,475...177,907,045
Ensembl chr 1:177,906,475...177,907,045

G

ATP synthase peripheral stalk subunit d

increases expression

ISO

Clobetasol results in increased expression of ATP5PD mRNA

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATP synthase peripheral stalk subunit OSCP

increases expression

ISO

Clobetasol results in increased expression of ATP5PO mRNA

NCBI chr11:44,651,171...44,657,483
Ensembl chr11:44,651,173...44,657,520

G

ATPase H+ transporting V0 subunit B

increases expression

ISO

Clobetasol results in increased expression of ATP6V0B mRNA

NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:136,708,823...136,716,828

G

ATPase H+ transporting V0 subunit C

increases expression

ISO

Clobetasol results in increased expression of ATP6V0C mRNA

NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245

G

ATPase, H+ transporting V0 subunit e2

increases expression

ISO

Clobetasol results in increased expression of ATP6V0E2 mRNA

NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680

G

ATRX, chromatin remodeler

decreases expression

ISO

Clobetasol results in decreased expression of ATRX mRNA

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

ataxin 2

decreases expression

ISO

Clobetasol results in decreased expression of ATXN2 mRNA

NCBI chr12:40,413,657...40,509,895
Ensembl chr12:40,414,904...40,510,473

G

ataxin 7-like 3B

increases expression

ISO

Clobetasol results in increased expression of ATXN7L3B mRNA

NCBI chr 7:50,208,666...50,212,190
Ensembl chr 7:50,208,676...50,212,190

G

aurora kinase B

increases expression

ISO

Clobetasol results in increased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

beta-1,3-glucuronyltransferase 1

decreases expression

ISO

Clobetasol results in decreased expression of B3GAT1 mRNA

NCBI chr 8:33,362,791...33,390,446
Ensembl chr 8:33,363,048...33,390,443

G

beta-1,3-glucuronyltransferase 2

decreases expression

ISO

Clobetasol results in decreased expression of B3GAT2 mRNA

NCBI chr 9:33,663,482...33,746,466
Ensembl chr 9:33,663,482...33,746,466

G

BTB domain and CNC homolog 2

decreases expression

ISO

Clobetasol results in decreased expression of BACH2 mRNA

NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234

G

brain abundant, membrane attached signal protein 1

decreases expression

ISO

Clobetasol results in decreased expression of BASP1 mRNA

NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Clobetasol results in increased expression of BAX mRNA

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

branched chain ketoacid dehydrogenase kinase

increases expression

ISO

Clobetasol results in increased expression of BCKDK mRNA

NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:191,946,471...191,953,453

G

BCL6, transcription repressor

increases expression

ISO

Clobetasol results in increased expression of BCL6 mRNA

NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047

G

BAF chromatin remodeling complex subunit BCL7A

decreases expression

ISO

Clobetasol results in decreased expression of BCL7A mRNA

NCBI chr12:38,872,851...38,904,770
Ensembl chr12:38,872,851...38,904,770

G

BCL9, transcription coactivator

decreases expression

ISO

Clobetasol results in decreased expression of BCL9 mRNA

NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241

G

BCL6 co-repressor-like 1

decreases expression

ISO

Clobetasol results in decreased expression of BCORL1 mRNA

NCBI chr X:132,394,703...132,462,414
Ensembl chr X:132,397,069...132,461,976

G

BCR activator of RhoGEF and GTPase

decreases expression

ISO

Clobetasol results in decreased expression of BCR mRNA

NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333

G

BDP1 general transcription factor IIIB subunit

decreases expression

ISO

Clobetasol results in decreased expression of BDP1 mRNA

NCBI chr 2:33,112,518...33,204,270
Ensembl chr 2:33,112,518...33,204,241

G

basic helix-loop-helix family, member e40

increases expression

ISO

Clobetasol results in increased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

baculoviral IAP repeat-containing 6

decreases expression

ISO

Clobetasol results in decreased expression of BIRC6 mRNA

NCBI chr 6:26,474,843...26,668,275
Ensembl chr 6:26,474,843...26,668,507

G

bridge-like lipid transfer protein family member 3A

decreases expression

ISO

Clobetasol results in decreased expression of BLTP3A mRNA

NCBI chr20:5,912,033...5,956,404
Ensembl chr20:5,912,106...5,956,403

G

bone morphogenetic protein 7

increases expression

ISO

Clobetasol results in increased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

bone morphogenetic protein receptor type 2

decreases expression

ISO

Clobetasol results in decreased expression of BMPR2 mRNA

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:68,685,988...68,801,350

G

BCL2 family apoptosis regulator BOK

increases expression

ISO

Clobetasol results in increased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

BOP1 ribosomal biogenesis factor

increases expression

ISO

Clobetasol results in increased expression of BOP1 mRNA

NCBI chr 7:110,052,716...110,076,529
Ensembl chr 7:110,052,720...110,076,529

G

bora, aurora kinase A activator

decreases expression

ISO

Clobetasol results in decreased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:82,205,697...82,244,052

G

bromodomain containing 7

decreases expression

ISO

Clobetasol results in decreased expression of BRD7 mRNA

NCBI chr19:34,882,238...34,910,944
Ensembl chr19:34,882,304...34,910,944

G

BRICK1 subunit of SCAR/WAVE actin nucleating complex

increases expression

ISO

Clobetasol results in increased expression of BRK1 mRNA

NCBI chr 4:148,306,436...148,321,668
Ensembl chr 4:148,306,398...148,321,984

G

bromodomain and WD repeat domain containing 1

increases expression

ISO

Clobetasol results in increased expression of BRWD1 mRNA

NCBI chr11:48,756,174...48,853,692
Ensembl chr11:48,756,811...48,848,256

G

bassoon (presynaptic cytomatrix protein)

decreases expression

ISO

Clobetasol results in decreased expression of BSN mRNA

NCBI chr 8:117,663,447...117,754,412
Ensembl chr 8:117,670,334...117,754,412

G

BTB domain containing 2

increases expression

ISO

Clobetasol results in increased expression of BTBD2 mRNA

NCBI chr 7:9,710,392...9,726,032
Ensembl chr 7:9,712,269...9,726,032

G

BUB3 mitotic checkpoint protein

increases expression

ISO

Clobetasol results in increased expression of BUB3 mRNA

NCBI chr 1:195,760,532...195,771,140
Ensembl chr 1:195,758,105...195,791,028

G

complement C2

increases expression

ISO

Clobetasol results in increased expression of C2 mRNA

NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740

G

carbonic anhydrase 8

decreases expression

ISO

Clobetasol results in decreased expression of CAR8 mRNA

NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:26,102,813...26,199,796

G

calcineurin binding protein 1

decreases expression

ISO

Clobetasol results in decreased expression of CABIN1 mRNA

NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800

G

calreticulin

increases expression

ISO

Clobetasol results in increased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

cullin-associated and neddylation-dissociated 2 (putative)

decreases expression

ISO

Clobetasol results in decreased expression of CAND2 mRNA

NCBI chr 4:150,507,659...150,535,755
Ensembl chr 4:150,507,657...150,541,293

G

calpain 10

increases expression

ISO

Clobetasol results in increased expression of CAPN10 mRNA

NCBI chr 9:100,943,665...100,957,910
Ensembl chr 9:100,945,551...100,957,912

G

calpain 6

decreases expression

ISO

Clobetasol results in decreased expression of CAPN6 mRNA

NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178

G

capping actin protein of muscle Z-line subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of CAPZA1 mRNA

NCBI chr 2:195,008,035...195,053,100
Ensembl chr 2:195,008,039...195,053,100

G

cask-interacting protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CASKIN2 mRNA

NCBI chr10:101,526,131...101,540,362
Ensembl chr10:101,526,195...101,540,349

G

caspase 3

increases activity

ISO

Clobetasol results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

increases expression

ISO

Clobetasol results in increased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

carbonyl reductase 3

increases expression

ISO

Clobetasol results in increased expression of CBR3 mRNA

NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558

G

coiled-coil and C2 domain containing 1A

decreases expression

ISO

Clobetasol results in decreased expression of CC2D1A mRNA

NCBI chr19:40,916,587...40,931,702
Ensembl chr19:40,916,532...40,931,701

G

coiled-coil and C2 domain containing 2A

decreases expression

ISO

Clobetasol results in decreased expression of CC2D2A mRNA

NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331

G

coiled coil domain containing 88A

decreases expression

ISO

Clobetasol results in decreased expression of CCDC88A mRNA

NCBI chr14:107,304,654...107,456,104
Ensembl chr14:107,305,199...107,453,285

G

coiled-coil domain containing 88C

decreases expression

ISO

Clobetasol results in decreased expression of CCDC88C mRNA

NCBI chr 6:125,899,337...126,019,162
Ensembl chr 6:125,899,526...126,018,865

G

cellular communication network factor 2

increases expression

ISO

Clobetasol results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

copper chaperone for superoxide dismutase

increases expression

ISO

Clobetasol results in increased expression of CCS mRNA

NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260

G

chaperonin containing TCP1 subunit 2

increases expression

ISO

Clobetasol results in increased expression of CCT2 mRNA

NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:54,578,663...54,592,977

G

chaperonin containing TCP1 subunit 3

increases expression

ISO

Clobetasol results in increased expression of CCT3 mRNA

NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925

G

chaperonin containing TCP1 subunit 7

increases expression

ISO

Clobetasol results in increased expression of CCT7 mRNA

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973

G

CD109 molecule

increases expression

ISO

Clobetasol results in increased expression of CD109 mRNA

NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462

G

CD40 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD40 protein

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

Cd80 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD80 protein

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

Cd81 molecule

increases expression

ISO

Clobetasol results in increased expression of CD81 mRNA

NCBI chr 1:207,665,274...207,681,094
Ensembl chr 1:207,664,885...207,681,092

G

CD86 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

CDC42 binding protein kinase beta

decreases expression

ISO

Clobetasol results in decreased expression of CDC42BPB mRNA

NCBI chr 6:136,154,905...136,241,259
Ensembl chr 6:136,154,905...136,237,570

G

CDC42 effector protein 1

increases expression

ISO

Clobetasol results in increased expression of CDC42EP1 mRNA

NCBI chr 7:112,275,759...112,283,665
Ensembl chr 7:112,275,792...112,283,664

G

cell division cycle associated 7

increases expression

ISO

Clobetasol results in increased expression of CDCA7 mRNA

NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947

G

cadherin 13

increases expression

ISO

Clobetasol results in increased expression of CDH13 mRNA

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 4

decreases expression

ISO

Clobetasol results in decreased expression of CDH4 mRNA

NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020

G

cyclin-dependent kinase 5

increases expression

ISO

Clobetasol results in increased expression of CDK5 mRNA

NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:11,647,141...11,652,777

G

cyclin-dependent kinase-like 5

increases expression

ISO

Clobetasol results in increased expression of CDKL5 mRNA

NCBI chr X:37,566,320...37,796,766
Ensembl chr X:37,566,378...37,796,760

G

CDKN2A interacting protein N-terminal like

increases expression

ISO

Clobetasol results in increased expression of CDKN2AIPNL mRNA

NCBI chr10:36,731,983...36,741,500
Ensembl chr10:36,732,013...36,741,495

G

cerebellar degeneration-related protein 2

increases expression

ISO

Clobetasol results in increased expression of CDR2 mRNA

NCBI chr 1:184,934,128...184,959,036
Ensembl chr 1:184,934,129...184,968,863

G

CECR2, histone acetyl-lysine reader

decreases expression

ISO

Clobetasol results in decreased expression of CECR2 mRNA

NCBI chr 4:155,562,576...155,670,253
Ensembl chr 4:155,562,727...155,666,741

G

cadherin, EGF LAG seven-pass G-type receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of CELSR1 mRNA

NCBI chr 7:118,867,450...119,004,859
Ensembl chr 7:118,867,450...119,004,856

G

centromere protein E

decreases expression

ISO

Clobetasol results in decreased expression of CENPE mRNA

NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:226,300,798...226,369,636

G

centromere protein F

decreases expression

ISO

Clobetasol results in decreased expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centrosomal protein 131

decreases expression

ISO

Clobetasol results in decreased expression of CEP131 mRNA

NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797

G

centrosomal protein 350

decreases expression

ISO

Clobetasol results in decreased expression of CEP350 mRNA

NCBI chr13:70,573,597...70,714,673
Ensembl chr13:70,573,597...70,714,673

G

cofilin 1

increases expression

ISO

Clobetasol results in increased expression of CFL1 mRNA

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353

G

CF transmembrane conductance regulator

increases expression

ISO

Clobetasol results in increased expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

coiled-coil-helix-coiled-coil-helix domain containing 2

increases expression

ISO

Clobetasol results in increased expression of CHCHD2 mRNA

NCBI chr12:32,464,847...32,470,871
Ensembl chr12:32,464,824...32,470,871

G

chromodomain helicase DNA binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335

G

chromodomain helicase DNA binding protein 3

decreases expression

ISO

Clobetasol results in decreased expression of CHD3 mRNA

NCBI chr10:54,562,437...54,588,842
Ensembl chr10:54,562,437...54,588,810

G

chromodomain helicase DNA binding protein 7

decreases expression

ISO

Clobetasol results in decreased expression of CHD7 mRNA

NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734

G

chromodomain helicase DNA binding protein 8

decreases expression

ISO

Clobetasol results in decreased expression of CHD8 mRNA

NCBI chr15:27,379,285...27,438,959
Ensembl chr15:27,379,285...27,417,851

G

charged multivesicular body protein 7

increases expression

ISO

Clobetasol results in increased expression of CHMP7 mRNA

NCBI chr15:51,200,759...51,215,992
Ensembl chr15:51,201,298...51,215,992

G

carbohydrate sulfotransferase 2

increases expression

ISO

Clobetasol results in increased expression of CHST2 mRNA

NCBI chr 8:104,839,716...104,845,961
Ensembl chr 8:104,831,292...104,860,301

G

carbohydrate sulfotransferase 3

decreases expression

ISO

Clobetasol results in decreased expression of CHST3 mRNA

NCBI chr20:28,657,308...28,694,976
Ensembl chr20:28,657,308...28,694,526

G

cytosolic iron-sulfur assembly component 2B

increases expression

ISO

Clobetasol results in increased expression of CIAO2B mRNA

NCBI chr19:350,644...352,518
Ensembl chr19:350,653...352,518

G

cytokine induced apoptosis inhibitor 1

increases expression

ISO

Clobetasol results in increased expression of CIAPIN1 mRNA

NCBI chr19:10,185,955...10,199,120
Ensembl chr19:10,182,088...10,201,495

G

CDGSH iron sulfur domain 1

increases expression

ISO

Clobetasol results in increased expression of CISD1 mRNA

NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,254,187...17,271,042

G

creatine kinase B

increases expression

ISO

Clobetasol results in increased expression of CKB mRNA

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

CDC28 protein kinase regulatory subunit 1B

increases expression

ISO

Clobetasol results in increased expression of CKS1B mRNA

NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365

G

cytoplasmic linker associated protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CLASP2 mRNA

NCBI chr 8:122,555,532...122,736,934
Ensembl chr 8:122,555,524...122,737,587

G

CAP-GLY domain containing linker protein 3

decreases expression

ISO

Clobetasol results in decreased expression of CLIP3 mRNA

NCBI chr 1:94,674,492...94,690,643
Ensembl chr 1:94,674,661...94,690,642

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

increases expression

ISO

Clobetasol results in increased expression of CLPP mRNA

NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705

G

CLPTM1 regulator of GABA type A receptor forward trafficking

increases expression

ISO

Clobetasol results in increased expression of CLPTM1 mRNA

NCBI chr 1:88,417,447...88,449,047
Ensembl chr 1:88,417,447...88,449,446

G

CLPTM1-like

increases expression

ISO

Clobetasol results in increased expression of CLPTM1L mRNA

NCBI chr 1:31,496,094...31,512,148
Ensembl chr 1:31,496,094...31,512,077

G

citramalyl-CoA lyase

increases expression

ISO

Clobetasol results in increased expression of CLYBL mRNA

NCBI chr15:105,690,283...105,912,347
Ensembl chr15:105,690,295...105,912,345

G

cms1 ribosomal small subunit homolog

increases expression

ISO

Clobetasol results in increased expression of CMSS1 mRNA

NCBI chr11:56,403,620...56,701,751
Ensembl chr11:56,403,499...56,701,755

G

cytochrome C oxidase assembly factor 3

increases expression

ISO

Clobetasol results in increased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,720,456...86,721,440

G

collagen type XI alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264

G

collagen type XII alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL12A1 mRNA

NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:89,427,834...89,545,711

G

collagen type III alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 2 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL4A2 mRNA

NCBI chr16:84,749,672...84,885,520
Ensembl chr16:84,749,672...84,885,520

G

collagen type V alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type IX alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL9A1 mRNA

NCBI chr 9:34,081,364...34,164,552
Ensembl chr 9:34,003,905...34,164,543

G

COPI coat complex subunit beta 1

increases expression

ISO

Clobetasol results in increased expression of COPB1 mRNA

NCBI chr 1:177,838,751...177,876,688
Ensembl chr 1:177,838,752...177,872,840

G

COPI coat complex subunit epsilon

increases expression

ISO

Clobetasol results in increased expression of COPE mRNA

NCBI chr16:19,148,832...19,159,052
Ensembl chr16:19,148,832...19,159,212

G

COP9 signalosome subunit 8

increases expression

ISO

Clobetasol results in increased expression of COPS8 mRNA

NCBI chr 9:98,655,031...98,664,861
Ensembl chr 9:98,654,870...98,665,381

G

coactosin-like F-actin binding protein 1

increases expression

ISO

Clobetasol results in increased expression of COTL1 mRNA

NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840

G

cytochrome c oxidase assembly factor COX14

increases expression

ISO

Clobetasol results in increased expression of COX14 mRNA

NCBI chr 7:132,731,069...132,733,159
Ensembl chr 7:132,731,069...132,733,159

G

cytochrome c oxidase copper chaperone COX17

increases expression

ISO

Clobetasol results in increased expression of COX17 mRNA

NCBI chr11:75,906,245...75,912,036
Ensembl chr11:75,906,248...75,912,019

G

cytochrome c oxidase assembly factor COX19

increases expression

ISO

Clobetasol results in increased expression of COX19 mRNA

NCBI chr12:20,417,389...20,426,868
Ensembl chr12:20,417,341...20,426,868

G

cytochrome c oxidase subunit 5A

increases expression

ISO

Clobetasol results in increased expression of COX5A mRNA

NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:66,818,196...66,830,279

G

cytochrome c oxidase subunit 6A1

increases expression

ISO

Clobetasol results in increased expression of COX6A1 mRNA

NCBI chr12:46,922,709...46,925,762
Ensembl chr12:46,912,648...46,925,768

G

cytochrome c oxidase subunit 8A

increases expression

ISO

Clobetasol results in increased expression of COX8A mRNA

NCBI chr 1:213,831,302...213,833,623
Ensembl chr 1:213,831,298...213,833,623

G

carboxypeptidase E

increases expression

ISO

Clobetasol results in increased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

ciliogenesis and planar polarity effector complex subunit 1

decreases expression

ISO

Clobetasol results in decreased expression of CPLANE1 mRNA

NCBI chr 2:58,996,119...59,096,817
Ensembl chr 2:58,996,130...59,096,817

G

crumbs cell polarity complex component 2

decreases expression

ISO

Clobetasol results in decreased expression of CRB2 mRNA

NCBI chr 3:41,946,694...41,974,629
Ensembl chr 3:41,947,325...41,974,629

G

cAMP responsive element binding protein 3

increases expression

ISO

Clobetasol results in increased expression of CREB3 mRNA

NCBI chr 5:62,613,652...62,619,019
Ensembl chr 5:62,613,638...62,619,500

G

CREB binding protein

decreases expression

ISO

Clobetasol results in decreased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

cysteine-rich with EGF-like domains 1

increases expression

ISO

Clobetasol results in increased expression of CRELD1 mRNA

NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116

G

cysteine-rich with EGF-like domains 2

increases expression

ISO

Clobetasol results in increased expression of CRELD2 mRNA

NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:121,788,745...121,796,228

G

CREB regulated transcription coactivator 3

decreases expression

ISO

Clobetasol results in decreased expression of CRTC3 mRNA

NCBI chr 1:143,962,038...144,064,324
Ensembl chr 1:143,962,038...144,064,288

G

cryptochrome circadian regulator 1

increases expression

ISO

Clobetasol results in increased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

citrate synthase

increases expression

ISO

Clobetasol results in increased expression of CS mRNA

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine sulfinic acid decarboxylase

increases expression

ISO

Clobetasol results in increased expression of CSAD mRNA

NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581

G

cold shock domain containing C2

increases expression

ISO

Clobetasol results in increased expression of CSDC2 mRNA

NCBI chr 7:115,332,134...115,346,599
Ensembl chr 7:115,332,128...115,346,596

G

colony stimulating factor 2

decreases secretion

ISO

Clobetasol results in decreased secretion of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 2 alpha 1

increases expression

ISO

Clobetasol results in increased expression of CSNK2A1 mRNA

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

cysteine and glycine-rich protein 1

increases expression

ISO

Clobetasol results in increased expression of CSRP1 mRNA

NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139

G

cysteine and glycine-rich protein 2

increases expression

ISO

Clobetasol results in increased expression of CSRP2 mRNA

NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238

G

catenin alpha-like 1

decreases expression

ISO

Clobetasol results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:76,309,546...76,375,869
Ensembl chr 5:76,309,546...76,364,637

G

cathepsin B

increases expression

ISO

Clobetasol results in increased expression of CTSB mRNA

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cathepsin O

increases expression

ISO

Clobetasol results in increased expression of CTSO mRNA

NCBI chr 2:169,528,468...169,551,975
Ensembl chr 2:169,528,511...169,554,995

G

CUE domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of CUEDC1 mRNA

NCBI chr10:73,389,798...73,484,914
Ensembl chr10:73,389,841...73,483,749

G

cut-like homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of CUX2 mRNA

NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528

G

C-X-C motif chemokine ligand 12

increases expression

ISO

Clobetasol results in increased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

cytochrome c, somatic

increases expression

ISO

Clobetasol results in increased expression of CYCS mRNA

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

Clobetasol results in increased expression of CYP1A1 mRNA
Tretinoin inhibits the reaction [Clobetasol results in increased expression of CYP1A1 mRNA]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[Clobetasol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

ISO

Clobetasol results in increased expression of CYP3A5 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 51

increases expression

ISO

Clobetasol results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

dishevelled associated activator of morphogenesis 2

decreases expression

ISO

Clobetasol results in decreased expression of DAAM2 mRNA

NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671

G

defender against cell death 1

increases expression

ISO

Clobetasol results in increased expression of DAD1 mRNA

NCBI chr15:31,647,326...31,667,159
Ensembl chr15:31,647,326...31,667,287

G

DAZ associated protein 2

increases expression

ISO

Clobetasol results in increased expression of DAZAP2 mRNA

NCBI chr 7:133,593,503...133,599,044
Ensembl chr 7:133,593,512...133,599,047

G

DDB1 and CUL4 associated factor 12

increases expression

ISO

Clobetasol results in increased expression of DCAF12 mRNA

NCBI chr 5:61,256,353...61,278,155
Ensembl chr 5:61,256,353...61,278,119

G

doublecortin domain containing 2

decreases expression

ISO

Clobetasol results in decreased expression of DCDC2A mRNA

NCBI chr17:40,274,009...40,459,757
Ensembl chr17:40,274,009...40,458,790

G

dachsous cadherin-related 1

decreases expression

ISO

Clobetasol results in decreased expression of DCHS1 mRNA

NCBI chr 1:169,516,758...169,550,789
Ensembl chr 1:169,516,762...169,536,639

G

deoxycytidine kinase

increases expression

ISO

Clobetasol results in increased expression of DCK mRNA

NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,589,298...19,610,326

G

damage-specific DNA binding protein 1

increases expression

ISO

Clobetasol results in increased expression of DDB1 mRNA

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

D-dopachrome tautomerase

increases expression

ISO

Clobetasol results in increased expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121

G

delta(4)-desaturase, sphingolipid 1

increases expression

ISO

Clobetasol results in increased expression of DEGS1 mRNA

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

derlin 1

increases expression

ISO

Clobetasol results in increased expression of DERL1 mRNA

NCBI chr 7:91,293,963...91,316,639
Ensembl chr 7:91,258,382...91,316,678

G

diacylglycerol kinase kappa

decreases expression

ISO

Clobetasol results in decreased expression of DGKK mRNA

NCBI chr X:18,253,849...18,385,805
Ensembl chr X:18,256,463...18,385,640

G

24-dehydrocholesterol reductase

increases expression

ISO

Clobetasol results in increased expression of DHCR24 mRNA

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

7-dehydrocholesterol reductase

increases expression

ISO

Clobetasol results in increased expression of DHCR7 mRNA

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

dihydrofolate reductase

decreases expression

ISO

Clobetasol results in decreased expression of DHFR mRNA

NCBI chr 2:25,320,895...25,346,004

G

diablo, IAP-binding mitochondrial protein

decreases expression

ISO

Clobetasol results in decreased expression of DIABLO mRNA

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

death inducer-obliterator 1

decreases expression

ISO

Clobetasol results in decreased expression of DIDO1 mRNA

NCBI chr 3:188,150,100...188,203,445
Ensembl chr 3:188,150,100...188,194,823

G

DLG associated protein 4

decreases expression

ISO

Clobetasol results in decreased expression of DLGAP4 mRNA

NCBI chr 3:165,584,271...165,731,868
Ensembl chr 3:165,584,360...165,730,604

G

delta like canonical Notch ligand 3

increases expression

ISO

Clobetasol results in increased expression of DLL3 mRNA

NCBI chr 1:92,689,577...92,698,125
Ensembl chr 1:92,689,577...92,697,406

G

dynein, axonemal, assembly factor 3

increases expression

ISO

Clobetasol results in increased expression of DNAAF3 mRNA

NCBI chr 1:78,333,985...78,342,034
Ensembl chr 1:78,333,971...78,342,685

G

DnaJ heat shock protein family (Hsp40) member B11

increases expression

ISO

Clobetasol results in increased expression of DNAJB11 mRNA

NCBI chr11:91,656,334...91,672,800
Ensembl chr11:91,656,335...91,672,800

G

DnaJ heat shock protein family (Hsp40) member C3

increases expression

ISO

Clobetasol results in increased expression of DNAJC3 mRNA

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643

G

dynamin 3

decreases expression

ISO

Clobetasol results in decreased expression of DNM3 mRNA

NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

increases expression

ISO

Clobetasol results in increased expression of DNPH1 mRNA

NCBI chr 9:21,978,894...21,981,631
Ensembl chr 9:21,978,894...21,981,631

G

dihydropyrimidinase-like 2

increases expression

ISO

Clobetasol results in increased expression of DPYSL2 mRNA

NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065

G

dihydropyrimidinase-like 4

decreases expression

ISO

Clobetasol results in decreased expression of DPYSL4 mRNA

NCBI chr 1:203,312,646...203,328,523
Ensembl chr 1:203,311,694...203,328,523

G

dorsal inhibitory axon guidance protein

decreases expression

ISO

Clobetasol results in decreased expression of DRAXIN mRNA

NCBI chr 5:163,813,308...163,846,609
Ensembl chr 5:163,816,502...163,855,174

G

DS cell adhesion molecule

decreases expression

ISO

Clobetasol results in decreased expression of DSCAM mRNA

NCBI chr11:49,391,385...49,976,861
Ensembl chr11:49,347,531...49,976,238

G

dual specificity phosphatase 6

increases expression

ISO

Clobetasol results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dishevelled segment polarity protein 3

decreases expression

ISO

Clobetasol results in decreased expression of DVL3 mRNA

NCBI chr11:93,869,834...93,887,013
Ensembl chr11:93,869,834...93,886,903

G

dynein cytoplasmic 1 heavy chain 1

decreases expression

ISO

Clobetasol results in decreased expression of DYNC1H1 mRNA

NCBI chr 6:135,436,375...135,502,117
Ensembl chr 6:135,430,750...135,502,116

G

dynein light chain Tctex-type 1

increases expression

ISO

Clobetasol results in increased expression of DYNLT1B mRNA

NCBI chr 1:49,292,093...49,299,051
Ensembl chr 1:49,282,243...49,298,951

G

EBP, cholestenol delta-isomerase

increases expression

ISO

Clobetasol results in increased expression of EBP mRNA

NCBI chr X:16,971,372...16,977,782
Ensembl chr X:16,971,405...16,977,781

G

endothelial differentiation-related factor 1

increases expression

ISO

Clobetasol results in increased expression of EDF1 mRNA

NCBI chr 3:28,764,906...28,779,499

G

early endosome antigen 1

decreases expression

ISO

Clobetasol results in decreased expression of EEA1 mRNA

NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476

G

eukaryotic translation elongation factor 2

increases expression

ISO

Clobetasol results in increased expression of EEF2 mRNA

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544

G

eukaryotic translation initiation factor 2B subunit beta

increases expression

ISO

Clobetasol results in increased expression of EIF2B2 mRNA

NCBI chr 6:110,597,979...110,604,403
Ensembl chr 6:110,597,729...110,604,403

G

eukaryotic translation initiation factor 3, subunit G

increases expression

ISO

Clobetasol results in increased expression of EIF3G mRNA

NCBI chr 8:27,705,914...27,709,946
Ensembl chr 8:27,705,915...27,709,987

G

eukaryotic translation initiation factor 3, subunit I

increases expression

ISO

Clobetasol results in increased expression of EIF3I mRNA

NCBI chr 5:147,219,457...147,226,910
Ensembl chr 5:147,219,366...147,241,232

G

eukaryotic translation initiation factor 4A3

increases expression

ISO

Clobetasol results in increased expression of EIF4A3 mRNA

NCBI chr10:105,047,567...105,057,561
Ensembl chr10:105,047,568...105,058,207

G

eukaryotic translation initiation factor 4E binding protein 1

increases expression

ISO

Clobetasol results in increased expression of EIF4EBP1 mRNA

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 5B

decreases expression

ISO

Clobetasol results in decreased expression of EIF5B mRNA

NCBI chr 9:47,718,706...47,773,289
Ensembl chr 9:47,718,706...47,778,583

G

eukaryotic translation initiation factor 6

increases expression

ISO

Clobetasol results in increased expression of EIF6 mRNA

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

ELAV like RNA binding protein 3

decreases expression

ISO

Clobetasol results in decreased expression of ELAVL3 mRNA

NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659

G

extracellular leucine-rich repeat and fibronectin type III domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ELFN1 mRNA

NCBI chr12:19,773,911...19,839,375
Ensembl chr12:19,772,908...19,841,961

G

ELOVL fatty acid elongase 5

increases expression

ISO

Clobetasol results in increased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ER membrane protein complex subunit 4

increases expression

ISO

Clobetasol results in increased expression of EMC4 mRNA

NCBI chr 3:119,624,100...119,633,170
Ensembl chr 3:119,624,100...119,629,118

G

ER membrane protein complex subunit 7

increases expression

ISO

Clobetasol results in increased expression of EMC7 mRNA

NCBI chr 3:119,714,617...119,728,748
Ensembl chr 3:119,718,357...119,730,486

G

EMG1 N1-specific pseudouridine methyltransferase

increases expression

ISO

Clobetasol results in increased expression of EMG1 mRNA

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

ectonucleoside triphosphate diphosphohydrolase 6

increases expression

ISO

Clobetasol results in increased expression of ENTPD6 mRNA

NCBI chr 3:160,036,055...160,058,580
Ensembl chr 3:160,036,121...160,059,451

G

E1A binding protein p300

decreases expression

ISO

Clobetasol results in decreased expression of EP300 mRNA

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

erythrocyte membrane protein band 4.1

decreases expression

ISO

Clobetasol results in decreased expression of EPB41 mRNA

NCBI chr 5:149,394,080...149,548,178
Ensembl chr 5:149,394,096...149,543,540

G

ergosterol biosynthesis 28 homolog

increases expression

ISO

Clobetasol results in increased expression of ERG28 mRNA

NCBI chr 6:111,205,102...111,214,068
Ensembl chr 6:111,205,103...111,214,068

G

envoplakin

decreases expression

ISO

Clobetasol results in decreased expression of EVPL mRNA

NCBI chr10:101,957,107...101,973,656
Ensembl chr10:101,941,064...101,973,656

G

FA core complex associated protein 24

increases expression

ISO

Clobetasol results in increased expression of FAAP24 mRNA

NCBI chr 1:97,188,678...97,194,899
Ensembl chr 1:97,188,678...97,194,882

G

fatty acid binding protein 7

increases expression

ISO

Clobetasol results in increased expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

fatty acid desaturase 1

increases expression

ISO

Clobetasol results in increased expression of FADS1 mRNA

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615

G

fatty acid desaturase 2

increases expression

ISO

Clobetasol results in increased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

family with sequence similarity 184, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM184A mRNA

NCBI chr20:33,477,089...33,599,296
Ensembl chr20:33,477,089...33,599,293

G

family with sequence similarity 185, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM185A mRNA

NCBI chr 4:14,469,165...14,555,167
Ensembl chr 4:14,499,869...14,555,167

G

family with sequence similarity 193, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM193A mRNA

NCBI chr14:80,480,742...80,607,086
Ensembl chr14:80,480,742...80,607,024

G

Fas cell surface death receptor

increases expression

ISO

Clobetasol results in increased expression of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

fatty acid synthase

increases expression

ISO

Clobetasol results in increased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAT atypical cadherin 1

decreases expression

ISO

Clobetasol results in decreased expression of FAT1 mRNA

NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609

G

FAT atypical cadherin 3

decreases expression

ISO

Clobetasol results in decreased expression of FAT3 mRNA

NCBI chr 8:20,972,840...21,555,679
Ensembl chr 8:20,972,840...21,555,240

G

fibrillarin

increases expression

ISO

Clobetasol results in increased expression of FBL mRNA

NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506

G

F-box and leucine-rich repeat protein 18

decreases expression

ISO

Clobetasol results in decreased expression of FBXL18 mRNA

NCBI chr12:16,781,901...16,812,728
Ensembl chr12:16,789,665...16,814,240

G

farnesyl diphosphate farnesyl transferase 1

increases expression

ISO

Clobetasol results in increased expression of FDFT1 mRNA

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168

G

fasciculation and elongation protein zeta 1

decreases expression

ISO

Clobetasol results in decreased expression of FEZ1 mRNA

NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:44,733,300...44,784,097

G

fibronectin leucine rich transmembrane protein 2

decreases expression

ISO

Clobetasol results in decreased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

FLVCR choline and putative heme transporter 2

decreases expression

ISO

Clobetasol results in decreased expression of FLVCR2 mRNA

NCBI chr 6:111,139,352...111,203,345
Ensembl chr 6:111,139,295...111,203,345

G

formation of mitochondrial complex V assembly factor 1

increases expression

ISO

Clobetasol results in increased expression of FMC1 mRNA

NCBI chr 4:68,241,009...68,249,045
Ensembl chr 4:68,241,009...68,268,534

G

formin-like 2

decreases expression

ISO

Clobetasol results in decreased expression of FMNL2 mRNA

NCBI chr 3:57,758,236...58,033,832
Ensembl chr 3:57,758,191...58,033,831

G

formin binding protein 4

decreases expression

ISO

Clobetasol results in decreased expression of FNBP4 mRNA

NCBI chr 3:97,188,852...97,218,916
Ensembl chr 3:97,188,884...97,219,435

G

fibronectin type III domain containing 10

increases expression

ISO

Clobetasol results in increased expression of FNDC10 mRNA

NCBI chr 5:171,581,960...171,584,519
Ensembl chr 5:171,580,033...171,595,399

G

forkhead box K1

decreases expression

ISO

Clobetasol results in decreased expression of FOXK1 mRNA

NCBI chr12:17,223,599...17,288,564
Ensembl chr12:17,229,430...17,288,564

G

FAD-dependent oxidoreductase domain containing 1

increases expression

ISO

Clobetasol results in increased expression of FOXRED1 mRNA

NCBI chr 8:41,789,557...41,818,064
Ensembl chr 8:41,808,843...41,817,980

G

FERM domain containing 8

increases expression

ISO

Clobetasol results in increased expression of FRMD8 mRNA

NCBI chr 1:212,572,534...212,593,181
Ensembl chr 1:212,572,537...212,592,695

G

FERM and PDZ domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of FRMPD1 mRNA

NCBI chr 5:64,238,730...64,340,778
Ensembl chr 5:64,238,768...64,340,776

G

FRY microtubule binding protein

increases expression

ISO

Clobetasol results in increased expression of FRY mRNA

NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603

G

frizzled-related protein

increases expression

ISO

Clobetasol results in increased expression of FRZB mRNA

NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096

G

ferritin heavy chain 1

increases expression

ISO

Clobetasol results in increased expression of FTH1 mRNA

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

GABA type A receptor associated protein like 2

increases expression

ISO

Clobetasol results in increased expression of GABARAPL2 mRNA

NCBI chr19:56,819,826...56,830,662
Ensembl chr19:56,819,791...56,830,660

G

gamma-aminobutyric acid type B receptor subunit 2

decreases expression

ISO

Clobetasol results in decreased expression of GABBR2 mRNA

NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:65,743,073...66,083,695

G

galactokinase 1

increases expression

ISO

Clobetasol results in increased expression of GALK1 mRNA

NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,735,061...101,746,258

G

growth associated protein 43

decreases expression

ISO

Clobetasol results in decreased expression of GAP43 mRNA

NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797

G

glycyl-tRNA synthetase 1

increases expression

ISO

Clobetasol results in increased expression of GARS1 mRNA

NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876

G

glutamate-cysteine ligase, catalytic subunit

decreases expression

ISO

Clobetasol results in decreased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

GCN1 activator of EIF2AK4

decreases expression

ISO

Clobetasol results in decreased expression of GCN1 mRNA

NCBI chr12:46,652,273...46,715,119
Ensembl chr12:46,652,273...46,713,488

G

glycine cleavage system protein H

increases expression

ISO

Clobetasol results in increased expression of GCSH mRNA

NCBI chr19:61,944,850...61,955,607
Ensembl chr19:61,944,850...61,955,607

G

growth differentiation factor 11

decreases expression

ISO

Clobetasol results in decreased expression of GDF11 mRNA

NCBI chr 7:1,896,229...1,909,147
Ensembl chr 7:1,896,229...1,905,222

G

GDP dissociation inhibitor 1

increases expression

ISO

Clobetasol results in increased expression of GDI1 mRNA

NCBI chr X:157,238,900...157,245,562
Ensembl chr X:157,238,892...157,245,560

G

glycerophosphodiester phosphodiesterase domain containing 3

increases expression

ISO

Clobetasol results in increased expression of GDPD3 mRNA

NCBI chr 1:190,804,053...190,813,609
Ensembl chr 1:190,803,993...190,813,606

G

guided entry of tail-anchored proteins factor 3, ATPase

increases expression

ISO

Clobetasol results in increased expression of GET3 mRNA

NCBI chr19:40,034,675...40,043,064
Ensembl chr19:40,034,967...40,043,061

G

glutamine-fructose-6-phosphate transaminase 2

increases expression

ISO

Clobetasol results in increased expression of GFPT2 mRNA

NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419

G

glycosylated lysosomal membrane protein

increases expression

ISO

Clobetasol results in increased expression of GLMP mRNA

NCBI chr 2:176,092,098...176,095,688
Ensembl chr 2:176,091,839...176,097,208

G

glyoxalase 1

increases expression

ISO

Clobetasol results in increased expression of GLO1 mRNA

NCBI chr20:8,665,061...8,683,095
Ensembl chr20:8,665,061...8,683,191

G

glutaredoxin 3

increases expression

ISO

Clobetasol results in increased expression of GLRX3 mRNA

NCBI chr 1:201,671,410...201,701,722
Ensembl chr 1:201,671,481...201,701,717

G

glutaredoxin 5

increases expression

ISO

Clobetasol results in increased expression of GLRX5 mRNA

NCBI chr 6:129,752,902...129,763,278
Ensembl chr 6:129,752,840...129,763,278

G

glutamate-ammonia ligase

increases expression

ISO

Clobetasol results in increased expression of GLUL mRNA

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

ganglioside GM2 activator

increases expression

ISO

Clobetasol results in increased expression of GM2A mRNA

NCBI chr10:39,719,919...39,732,452
Ensembl chr10:39,719,938...39,732,451

G

germ cell-less 1, spermatogenesis associated

increases expression

ISO

Clobetasol results in increased expression of GMCL1 mRNA

NCBI chr 4:120,697,976...120,737,267
Ensembl chr 4:120,697,976...120,737,257

G

G protein subunit alpha 13

increases expression

ISO

Clobetasol results in increased expression of GNA13 mRNA

NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,836,444...94,874,968

G

G protein subunit alpha i3

increases expression

ISO

Clobetasol results in increased expression of GNAI3 mRNA

NCBI chr 2:198,430,920...198,468,874

G

G protein subunit beta 2

increases expression

ISO

Clobetasol results in increased expression of GNB2 mRNA

NCBI chr12:24,795,505...24,800,796
Ensembl chr12:24,795,827...24,800,796

G

golgin B1

decreases expression

ISO

Clobetasol results in decreased expression of GOLGB1 mRNA

NCBI chr11:77,348,573...77,406,165
Ensembl chr11:77,348,961...77,406,006

G

glutamic-oxaloacetic transaminase 1

increases expression

ISO

Clobetasol results in increased expression of GOT1 mRNA

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glycerol-3-phosphate dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of GPD1 mRNA

NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368

G

G protein-coupled estrogen receptor 1

increases expression

ISO

Clobetasol results in increased expression of GPER1 mRNA

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

glucose-6-phosphate isomerase

increases expression

ISO

Clobetasol results in increased expression of GPI1 mRNA

NCBI chr 1:95,965,389...95,996,932
Ensembl chr 1:95,965,396...95,993,261

G

G protein-coupled receptor 17

decreases expression

ISO

Clobetasol results in decreased expression of GPR17 mRNA

NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702

G

G protein-coupled receptor, class C, group 5, member B

increases expression

ISO

Clobetasol results in increased expression of GPRC5B mRNA

NCBI chr 1:182,748,247...182,772,711
Ensembl chr 1:182,748,247...182,772,757

G

glutathione peroxidase 1

increases expression

ISO

Clobetasol results in increased expression of GPX1 mRNA

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glyoxylate and hydroxypyruvate reductase

increases expression

ISO

Clobetasol results in increased expression of GRHPR mRNA

NCBI chr 5:64,029,856...64,039,287
Ensembl chr 5:64,022,368...64,039,276

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression

ISO

Clobetasol results in decreased expression of GRIK3 mRNA

NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873

G

glutamate ionotropic receptor NMDA type subunit associated protein 1

increases expression

ISO

Clobetasol results in increased expression of GRINA mRNA

NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:109,843,196...109,846,042

G

glutamate metabotropic receptor 3

decreases expression

ISO

Clobetasol results in decreased expression of GRM3 mRNA

NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764

G

glycogen synthase kinase 3 alpha

increases expression

ISO

Clobetasol results in increased expression of GSK3A mRNA

NCBI chr 1:89,943,669...89,953,514
Ensembl chr 1:89,943,669...89,953,593

G

glutathione-disulfide reductase

increases expression

ISO

Clobetasol results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase mu 2

increases expression

ISO

Clobetasol results in increased expression of GSTM5 mRNA

NCBI chr 2:198,312,179...198,316,962

G

glutathione S-transferase pi 1

increases expression

ISO

Clobetasol results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

GTP binding protein 1

increases expression

ISO

Clobetasol results in increased expression of GTPBP1 mRNA

NCBI chr 7:113,128,645...113,153,094
Ensembl chr 7:113,128,670...113,154,621

G

guanylate cyclase 1 soluble subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of GUCY1A1 mRNA

NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737

G

H1.0 linker histone

increases expression

ISO

Clobetasol results in increased expression of H1F0 mRNA

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H2A.J histone

increases expression

ISO

Clobetasol results in increased expression of H2AJ mRNA

NCBI chr 4:171,406,922...171,407,406
Ensembl chr 4:171,406,177...171,408,845

G

histidyl-tRNA synthetase 1

increases expression

ISO

Clobetasol results in increased expression of HARS1 mRNA

NCBI chr18:28,655,669...28,672,712
Ensembl chr18:28,655,671...28,672,712

G

heparin-binding EGF-like growth factor

decreases expression

ISO

Clobetasol results in decreased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

host cell factor C1

decreases expression

ISO

Clobetasol results in decreased expression of HCFC1 mRNA

NCBI chr X:156,839,100...156,864,132
Ensembl chr X:156,839,100...156,863,813

G

histone deacetylase 3

increases expression

ISO

Clobetasol results in increased expression of HDAC3 mRNA

NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025

G

HECT domain E3 ubiquitin protein ligase 4

decreases expression

ISO

Clobetasol results in decreased expression of HECTD4 mRNA

NCBI chr12:40,800,232...40,991,584
Ensembl chr12:40,843,770...40,991,798

G

hepatic and glial cell adhesion molecule

increases expression

ISO

Clobetasol results in increased expression of HEPACAM mRNA

NCBI chr 8:45,276,594...45,294,006
Ensembl chr 8:45,276,683...45,295,548

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

decreases expression

ISO

Clobetasol results in decreased expression of HERC1 mRNA

NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:75,796,357...75,965,347

G

huntingtin interacting protein 1 related

decreases expression

ISO

Clobetasol results in decreased expression of HIP1R mRNA

NCBI chr12:38,251,085...38,279,756
Ensembl chr12:38,251,086...38,279,654

G

HIVEP zinc finger 1

decreases expression

ISO

Clobetasol results in decreased expression of HIVEP1 mRNA

NCBI chr17:22,790,855...22,920,359
Ensembl chr17:22,790,855...22,917,196

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

ISO

Clobetasol results in increased expression of HMGCR mRNA

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

hook microtubule-tethering protein 3

decreases expression

ISO

Clobetasol results in decreased expression of HOOK3 mRNA

NCBI chr16:72,656,929...72,751,696
Ensembl chr16:72,657,019...72,764,071

G

homeo box A5

decreases expression

ISO

Clobetasol results in decreased expression of HOXA5 mRNA

NCBI chr 4:82,632,958...82,636,851
Ensembl chr 4:82,632,306...82,639,038

G

HR, lysine demethylase and nuclear receptor corepressor

decreases expression

ISO

Clobetasol results in decreased expression of HR mRNA

NCBI chr15:52,036,540...52,056,019
Ensembl chr15:52,036,540...52,056,015

G

heparan sulfate-glucosamine 3-sulfotransferase 1

increases expression

ISO

Clobetasol results in increased expression of HS3ST1 mRNA

NCBI chr14:75,398,101...75,429,628
Ensembl chr14:75,398,026...75,436,848

G

hydroxysteroid (17-beta) dehydrogenase 4

increases expression

ISO

Clobetasol results in increased expression of HSD17B4 mRNA

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

ISO

Clobetasol results in increased expression of HSD17B7 mRNA

NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754

G

heat shock protein family E (Hsp10) member 1

increases expression

ISO

Clobetasol results in increased expression of HSPE1 mRNA

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502

G

heparan sulfate proteoglycan 2

decreases expression

ISO

Clobetasol results in decreased expression of HSPG2 mRNA

NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:154,960,846...155,061,971

G

Huntingtin interacting protein K

increases expression

ISO

Clobetasol results in increased expression of HYPK mRNA

NCBI chr 3:128,888,709...128,890,089
Ensembl chr 3:128,888,717...128,891,405

G

intercellular adhesion molecule 1

decreases expression

ISO

Clobetasol results in decreased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

inhibitor of DNA binding 1

increases expression

ISO

Clobetasol results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 3

increases expression

ISO

Clobetasol results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

isocitrate dehydrogenase (NADP(+)) 2

increases expression

ISO

Clobetasol results in increased expression of IDH2 mRNA

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

isopentenyl-diphosphate delta isomerase 1

increases expression

ISO

Clobetasol results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

immediate early response 3 interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of IER3IP1 mRNA

NCBI chr18:72,749,976...72,761,060
Ensembl chr18:72,749,976...72,801,679

G

insulin-like growth factor binding protein 2

increases expression

ISO

Clobetasol results in increased expression of IGFBP2 mRNA

NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171

G

insulin-like growth factor binding protein 3

increases expression

ISO

Clobetasol results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

insulin-like growth factor binding protein 5

decreases expression

ISO

Clobetasol results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

immunoglobulin superfamily, member 10

decreases expression

ISO

Clobetasol results in decreased expression of IGSF10 mRNA

NCBI chr 2:145,725,868...145,754,850
Ensembl chr 2:145,725,878...145,754,579

G

immunoglobulin superfamily, member 9B

decreases expression

ISO

Clobetasol results in decreased expression of IGSF9B mRNA

NCBI chr 8:33,971,779...34,027,390
Ensembl chr 8:33,971,779...34,018,128

G

interleukin 1 alpha

decreases secretion

ISO

Clobetasol results in decreased secretion of IL1A protein

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Clobetasol results in decreased expression of IL2RA protein

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin enhancer binding factor 2

decreases expression

ISO

Clobetasol results in decreased expression of ILF2 mRNA

NCBI chr 2:178,256,927...178,268,773
Ensembl chr 2:178,248,585...178,268,920

G

IMP U3 small nucleolar ribonucleoprotein 3

increases expression

ISO

Clobetasol results in increased expression of IMP3 mRNA

NCBI chr 8:66,235,498...66,236,386

G

impact RWD domain protein

increases expression

ISO

Clobetasol results in increased expression of IMPACT mRNA

NCBI chr18:4,383,546...4,422,280
Ensembl chr18:4,383,575...4,422,278

G

inosine monophosphate dehydrogenase 2

increases expression

ISO

Clobetasol results in increased expression of IMPDH2 mRNA

NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873

G

INO80 complex ATPase subunit

decreases expression

ISO

Clobetasol results in decreased expression of INO80 mRNA

NCBI chr 3:126,822,280...126,919,532
Ensembl chr 3:126,822,280...126,919,532

G

insulin induced gene 1

increases expression

ISO

Clobetasol results in increased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778

G

integrator complex subunit 11

increases expression

ISO

Clobetasol results in increased expression of INTS11 mRNA

NCBI chr 5:171,761,370...171,779,883
Ensembl chr 5:171,761,371...171,779,883

G

integrator complex subunit 5

increases expression

ISO

Clobetasol results in increased expression of INTS5 mRNA

NCBI chr 1:215,218,012...215,222,790
Ensembl chr 1:215,218,017...215,223,240

G

IQ motif containing GTPase activating protein 2

decreases expression

ISO

Clobetasol results in decreased expression of IQGAP2 mRNA

NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:28,629,558...28,904,649

G

IQ motif and Sec7 domain ArfGEF 1

decreases expression

ISO

Clobetasol results in decreased expression of IQSEC1 mRNA

NCBI chr 4:124,725,917...125,045,351
Ensembl chr 4:124,725,917...125,045,550

G

insulin receptor substrate 2

decreases expression

ISO

Clobetasol results in decreased expression of IRS2 mRNA

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543

G

inosine triphosphatase

increases expression

ISO

Clobetasol results in increased expression of ITPA mRNA

NCBI chr 3:138,338,549...138,350,329
Ensembl chr 3:138,338,349...138,350,329

G

intersectin 1

decreases expression

ISO

Clobetasol results in decreased expression of ITSN1 mRNA

NCBI chr11:44,464,515...44,646,598
Ensembl chr11:44,513,186...44,646,598

G

isovaleryl-CoA dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of IVD mRNA

NCBI chr 3:126,305,584...126,326,016
Ensembl chr 3:126,305,364...126,328,160

G

interacts with SUPT6H, CTD assembly factor 1

decreases expression

ISO

Clobetasol results in decreased expression of IWS1 mRNA

NCBI chr18:23,969,352...24,011,560
Ensembl chr18:23,969,733...24,010,415

G

Janus kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of JAK1 mRNA

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

junctional adhesion molecule 3

increases expression

ISO

Clobetasol results in increased expression of JAM3 mRNA

NCBI chr 8:33,767,606...33,828,451
Ensembl chr 8:33,767,607...33,828,623

G

jumonji domain containing 1C

decreases expression

ISO

Clobetasol results in decreased expression of JMJD1C mRNA

NCBI chr20:21,330,990...21,508,580
Ensembl chr20:21,330,990...21,461,916

G

jumonji domain containing 8

increases expression

ISO

Clobetasol results in increased expression of JMJD8 mRNA

NCBI chr10:15,353,460...15,356,392
Ensembl chr10:15,353,475...15,356,393

G

junction mediating and regulatory protein, p53 cofactor

decreases expression

ISO

Clobetasol results in decreased expression of JMY mRNA

NCBI chr 2:26,401,047...26,465,959
Ensembl chr 2:26,409,969...26,465,649

G

Jupiter microtubule associated homolog 1

increases expression

ISO

Clobetasol results in increased expression of JPT1 mRNA

NCBI chr10:101,243,428...101,261,464
Ensembl chr10:101,243,424...101,261,469

G

KN motif and ankyrin repeat domains 4

decreases expression

ISO

Clobetasol results in decreased expression of KANK4 mRNA

NCBI chr 5:118,516,994...118,581,024
Ensembl chr 5:118,517,971...118,581,002

G

kazrin, periplakin interacting protein

decreases expression

ISO

Clobetasol results in decreased expression of KAZN mRNA

NCBI chr 5:159,675,803...160,666,084
Ensembl chr 5:159,675,803...160,664,154

G

potassium voltage-gated channel subfamily A member 2

decreases expression

ISO

Clobetasol results in decreased expression of KCNA2 mRNA

NCBI chr 2:197,392,746...197,406,606
Ensembl chr 2:197,392,698...197,407,519

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

increases expression

ISO

Clobetasol results in increased expression of KCNMB4 mRNA

NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281

G

potassium sodium-activated channel subfamily T member 1

increases expression

ISO

Clobetasol results in increased expression of KCNT1 mRNA

NCBI chr 3:29,081,071...29,136,902
Ensembl chr 3:29,081,321...29,134,768

G

potassium channel tetramerization domain containing 5

increases expression

ISO

Clobetasol results in increased expression of KCTD5 mRNA

NCBI chr10:13,583,781...13,609,762
Ensembl chr10:13,583,781...13,610,062

G

KDEL endoplasmic reticulum protein retention receptor 2

increases expression

ISO

Clobetasol results in increased expression of KDELR2 mRNA

NCBI chr12:16,252,424...16,270,737
Ensembl chr12:16,252,424...16,270,719

G

lysine demethylase 6B

decreases expression

ISO

Clobetasol results in decreased expression of KDM6B mRNA

NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610

G

KH RNA binding domain containing, signal transduction associated 1

decreases expression

ISO

Clobetasol results in decreased expression of KHDRBS1 mRNA

NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:147,347,904...147,373,448

G

kinesin family member 13A

decreases expression

ISO

Clobetasol results in decreased expression of KIF13A mRNA

NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760

G

kinesin family member 5A

decreases expression

ISO

Clobetasol results in decreased expression of KIF5A mRNA

NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:64,934,740...64,978,272

G

kirre like nephrin family adhesion molecule 2

increases expression

ISO

Clobetasol results in increased expression of KIRREL2 mRNA

NCBI chr 1:94,836,243...94,846,119
Ensembl chr 1:94,836,243...94,846,119

G

KLF transcription factor 9

increases expression

ISO

Clobetasol results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

lysine methyltransferase 2C

decreases expression

ISO

Clobetasol results in decreased expression of KMT2C mRNA

NCBI chr 4:10,353,698...10,755,965
Ensembl chr 4:10,353,735...10,568,620

G

lysine methyltransferase 2D

decreases expression

ISO

Clobetasol results in decreased expression of KMT2D mRNA

NCBI chr 7:131,859,696...131,901,032
Ensembl chr 7:131,859,696...131,900,072

G

lysine methyltransferase 2E

decreases expression

ISO

Clobetasol results in decreased expression of KMT2E mRNA

NCBI chr 4:12,550,570...12,655,329
Ensembl chr 4:12,550,570...12,619,721

G

kinetochore scaffold 1

decreases expression

ISO

Clobetasol results in decreased expression of KNL1 mRNA

NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774

G

keratinocyte associated protein 2

increases expression

ISO

Clobetasol results in increased expression of KRTCAP2 mRNA

NCBI chr 2:176,952,167...176,956,163
Ensembl chr 2:176,949,809...176,956,163

G

KTI12 chromatin associated

increases expression

ISO

Clobetasol results in increased expression of KTI12 mRNA

NCBI chr 5:128,829,751...128,831,273
Ensembl chr 5:128,826,844...128,834,910

G

laminin subunit alpha 1

decreases expression

ISO

Clobetasol results in decreased expression of LAMA1 mRNA

NCBI chr 9:115,139,548...115,263,620
Ensembl chr 9:115,139,548...115,264,251

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 1

increases expression

ISO

Clobetasol results in increased expression of LAMTOR1 mRNA

NCBI chr 1:165,684,001...165,689,698
Ensembl chr 1:165,684,091...165,703,178

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 5

increases expression

ISO

Clobetasol results in increased expression of LAMTOR5 mRNA

NCBI chr 2:197,588,242...197,593,598
Ensembl chr 2:197,588,242...197,593,598

G

lysosomal protein transmembrane 4 beta

increases expression

ISO

Clobetasol results in increased expression of LAPTM4B mRNA

NCBI chr 7:67,319,438...67,362,547
Ensembl chr 7:67,319,542...67,363,258

G

La ribonucleoprotein 1, translational regulator

decreases expression

ISO

Clobetasol results in decreased expression of LARP1 mRNA

NCBI chr10:42,691,833...42,746,816
Ensembl chr10:42,691,600...42,746,816

G

LBH regulator of WNT signaling pathway

increases expression

ISO

Clobetasol results in increased expression of LBH mRNA

NCBI chr 6:28,321,040...28,344,855
Ensembl chr 6:28,321,040...28,370,238

G

leukocyte receptor cluster member 8

decreases expression

ISO

Clobetasol results in decreased expression of LENG8 mRNA

NCBI chr 1:79,113,038...79,124,868
Ensembl chr 1:79,113,038...79,124,738

G

LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

increases expression

ISO

Clobetasol results in increased expression of LFNG mRNA

NCBI chr12:19,144,474...19,152,951
Ensembl chr12:19,124,662...19,152,918

G

galectin 1

increases expression

ISO

Clobetasol results in increased expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800

G

galectin-like

increases expression

ISO

Clobetasol results in increased expression of LGALSL mRNA

NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487

G

lin-52 DREAM MuvB core complex component

increases expression

ISO

Clobetasol results in increased expression of LIN52 mRNA

NCBI chr 6:109,829,896...109,927,122
Ensembl chr 6:109,830,131...109,925,310

G

lipopolysaccharide-induced TNF factor

increases expression

ISO

Clobetasol results in increased expression of LITAF mRNA

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930

G

lectin, mannose-binding 2

increases expression

ISO

Clobetasol results in increased expression of LMAN2 mRNA

NCBI chr17:9,274,362...9,294,950
Ensembl chr17:9,274,136...9,292,370

G

LIM and cysteine-rich domains 1

increases expression

ISO

Clobetasol results in increased expression of LMCD1 mRNA

NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875

G

lactoperoxidase

increases expression

ISO

Clobetasol results in increased expression of LPO mRNA

NCBI chr10:73,104,170...73,124,683
Ensembl chr10:73,104,188...73,123,456

G

LDL receptor related protein 1

decreases expression

ISO

Clobetasol results in decreased expression of LRP1 mRNA

NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196

G

LDL receptor related protein 2

increases expression

ISO

Clobetasol results in increased expression of LRP2 mRNA

NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535

G

leucine rich repeat containing 4B

decreases expression

ISO

Clobetasol results in decreased expression of LRRC4B mRNA

NCBI chr 1:104,058,558...104,092,831
Ensembl chr 1:104,072,128...104,093,298

G

leucine rich repeat transmembrane neuronal 2

decreases expression

ISO

Clobetasol results in decreased expression of LRRTM2 mRNA

NCBI chr18:27,091,919...27,096,967
Ensembl chr18:27,091,919...27,096,967

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

ISO

Clobetasol results in increased expression of LSM4 mRNA

NCBI chr16:18,789,466...18,795,164
Ensembl chr16:18,789,467...18,794,886

G

LSM8 homolog, U6 small nuclear RNA associated

increases expression

ISO

Clobetasol results in increased expression of LSM8 mRNA

NCBI chr 4:48,272,128...48,277,994
Ensembl chr 4:48,272,164...48,280,162

G

lymphocyte antigen 75

decreases expression

ISO

Clobetasol results in decreased expression of LY75 protein

NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878

G

mono-ADP ribosylhydrolase 1

increases expression

ISO

Clobetasol results in increased expression of MACROD1 mRNA

NCBI chr 1:213,675,413...213,831,571
Ensembl chr 1:213,675,406...213,816,348

G

MAF bZIP transcription factor K

increases expression

ISO

Clobetasol results in increased expression of MAFK mRNA

NCBI chr12:19,948,473...19,970,351
Ensembl chr12:19,948,476...19,959,192

G

MAGE family member E1

decreases expression

ISO

Clobetasol results in decreased expression of MAGEE1 mRNA

NCBI chr X:74,254,848...74,258,395
Ensembl chr X:74,254,958...74,258,371

G

MAGE family member H1

increases expression

ISO

Clobetasol results in increased expression of MAGEH1 mRNA

NCBI chr X:21,725,709...21,726,965
Ensembl chr X:21,718,669...21,727,219

G

mannosidase beta like

increases expression

ISO

Clobetasol results in increased expression of MANBAL mRNA

NCBI chr 3:166,455,067...166,484,652
Ensembl chr 3:166,455,066...166,487,431

G

mesencephalic astrocyte-derived neurotrophic factor

increases expression

ISO

Clobetasol results in increased expression of MANF mRNA

NCBI chr 8:116,427,053...116,430,259
Ensembl chr 8:116,427,048...116,429,910

G

microtubule-associated protein 1B

decreases expression

ISO

Clobetasol results in decreased expression of MAP1B mRNA

NCBI chr 2:32,551,423...32,644,471
Ensembl chr 2:32,551,423...32,657,094

G

microtubule-associated protein 1 light chain 3 beta

increases expression

ISO

Clobetasol results in increased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

microtubule-associated protein 2

decreases expression

ISO

Clobetasol results in decreased expression of MAP2 mRNA

NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459

G

mitogen activated protein kinase kinase 1

increases expression

ISO

Clobetasol results in increased expression of MAP2K1 mRNA

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen-activated protein kinase 8 interacting protein 2

increases expression

ISO

Clobetasol results in increased expression of MAPK8IP2 mRNA

NCBI chr 7:122,406,350...122,416,602
Ensembl chr 7:122,406,350...122,416,602

G

meiosis regulator and mRNA stability factor 1

decreases expression

ISO

Clobetasol results in decreased expression of MARF1 mRNA

NCBI chr10:1,395,271...1,439,974
Ensembl chr10:1,395,282...1,439,974

G

microtubule associated serine/threonine kinase family member 4

decreases expression

ISO

Clobetasol results in decreased expression of MAST4 mRNA

NCBI chr 2:35,627,190...36,219,090
Ensembl chr 2:35,627,190...36,218,832

G

minichromosome maintenance complex component 3 associated protein

decreases expression

ISO

Clobetasol results in decreased expression of MCM3AP mRNA

NCBI chr20:12,127,060...12,164,651
Ensembl chr20:12,127,060...12,164,651

G

mediator of DNA damage checkpoint 1

decreases expression

ISO

Clobetasol results in decreased expression of MDC1 mRNA

NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960

G

malate dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of MDH1 mRNA

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232

G

malate dehydrogenase 2

increases expression

ISO

Clobetasol results in increased expression of MDH2 mRNA

NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841

G

midasin AAA ATPase 1

decreases expression

ISO

Clobetasol results in decreased expression of MDN1 mRNA

NCBI chr 5:51,851,785...51,982,688
Ensembl chr 5:51,851,809...51,982,688

G

mitochondrial trans-2-enoyl-CoA reductase

increases expression

ISO

Clobetasol results in increased expression of MECR mRNA

NCBI chr 5:149,313,765...149,339,964
Ensembl chr 5:149,313,774...149,342,825

G

multiple EGF-like-domains 9

increases expression

ISO

Clobetasol results in increased expression of MEGF9 mRNA

NCBI chr 5:89,008,679...89,120,731
Ensembl chr 5:89,008,679...89,120,731

G

MER proto-oncogene, tyrosine kinase

increases expression

ISO

Clobetasol results in increased expression of MERTK mRNA

NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192

G

mesoderm development LRP chaperone

increases expression

ISO

Clobetasol results in increased expression of MESD mRNA

NCBI chr 1:147,275,904...147,289,134
Ensembl chr 1:147,275,396...147,289,134

G

methionyl aminopeptidase 1

increases expression

ISO

Clobetasol results in increased expression of METAP1 mRNA

NCBI chr 2:229,664,677...229,697,730
Ensembl chr 2:229,664,677...229,719,084

G

meteorin, glial cell differentiation regulator

increases expression

ISO

Clobetasol results in increased expression of METRN mRNA

NCBI chr10:15,321,200...15,323,218
Ensembl chr10:15,321,200...15,323,642

G

mex-3 RNA binding family member A

decreases expression

ISO

Clobetasol results in decreased expression of MEX3A mRNA

NCBI chr 2:176,287,900...176,297,369
Ensembl chr 2:176,287,900...176,297,369

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

ISO

Clobetasol results in increased expression of MFSD2A mRNA

NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916

G

MIA SH3 domain ER export factor 3

decreases expression

ISO

Clobetasol results in decreased expression of MIA3 mRNA

NCBI chr13:97,502,040...97,547,155
Ensembl chr13:97,494,275...97,543,587

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

decreases expression

ISO

Clobetasol results in decreased expression of MICAL3 mRNA

NCBI chr 4:155,824,941...156,025,003
Ensembl chr 4:155,824,946...156,005,238

G

marker of proliferation Ki-67

decreases expression

ISO

Clobetasol results in decreased expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

makorin, ring finger protein, 3

increases expression

ISO

Clobetasol results in increased expression of MKRN3 mRNA

NCBI chr 1:125,338,664...125,341,178
Ensembl chr 1:125,338,564...125,341,164

G

malectin

increases expression

ISO

Clobetasol results in increased expression of MLEC mRNA

NCBI chr12:47,118,918...47,133,598
Ensembl chr12:47,118,855...47,130,064

G

MLLT1, super elongation complex subunit

decreases expression

ISO

Clobetasol results in decreased expression of MLLT1 mRNA

NCBI chr 9:1,818,204...1,863,091
Ensembl chr 9:1,818,204...1,863,089

G

metabolism of cobalamin associated D

increases expression

ISO

Clobetasol results in increased expression of MMADHC mRNA

NCBI chr 3:55,117,832...55,135,735
Ensembl chr 3:55,117,833...55,135,851

G

mitochondrial pyruvate carrier 2

increases expression

ISO

Clobetasol results in increased expression of MPC2 mRNA

NCBI chr13:80,261,143...80,280,668
Ensembl chr13:80,259,727...80,280,668

G

mitochondrial ribosomal protein L14

increases expression

ISO

Clobetasol results in increased expression of MRPL14 mRNA

NCBI chr 9:22,800,286...22,812,711
Ensembl chr 9:22,795,744...22,812,855

G

mitochondrial ribosomal protein L34

increases expression

ISO

Clobetasol results in increased expression of MRPL34 mRNA

NCBI chr16:18,186,447...18,187,182
Ensembl chr16:18,185,306...18,187,181

G

mitochondrial ribosomal protein L46

increases expression

ISO

Clobetasol results in increased expression of MRPL46 mRNA

NCBI chr 1:142,108,266...142,117,030
Ensembl chr 1:142,106,531...142,117,030

G

mitochondrial ribosomal protein S14

increases expression

ISO

Clobetasol results in increased expression of MRPS14 mRNA

NCBI chr13:74,962,597...74,968,344
Ensembl chr13:74,962,515...74,970,975

G

mitochondrial ribosomal protein S26

increases expression

ISO

Clobetasol results in increased expression of MRPS26 mRNA

NCBI chr 3:138,222,324...138,223,987
Ensembl chr 3:138,222,165...138,223,987

G

mitochondrial ribosomal protein S27

increases expression

ISO

Clobetasol results in increased expression of MRPS27 mRNA

NCBI chr 2:32,474,178...32,542,741
Ensembl chr 2:32,473,965...32,542,738

G

methylsterol monooxygenase 1

increases expression

ISO

Clobetasol results in increased expression of MSMO1 mRNA

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445

G

moesin

increases expression

ISO

Clobetasol results in increased expression of MSN mRNA

NCBI chr X:65,005,546...65,073,512
Ensembl chr X:65,005,458...65,075,129

G

microtubule crosslinking factor 2

decreases expression

ISO

Clobetasol results in decreased expression of MTCL2 mRNA

NCBI chr 3:166,089,141...166,161,043
Ensembl chr 3:166,095,480...166,161,102

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases expression

ISO

Clobetasol results in increased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

mechanistic target of rapamycin kinase

decreases expression

ISO

Clobetasol results in decreased expression of MTOR mRNA

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

multivesicular body subunit 12B

decreases expression

ISO

Clobetasol results in decreased expression of MVB12B mRNA

NCBI chr 3:37,431,636...37,590,276
Ensembl chr 3:37,431,636...37,615,407

G

Max dimerization protein 3

increases expression

ISO

Clobetasol results in increased expression of MXD3 mRNA

NCBI chr17:9,306,552...9,310,278
Ensembl chr17:9,302,321...9,310,278

G

MYC binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325

G

myosin, heavy chain 9

decreases expression

ISO

Clobetasol results in decreased expression of MYH9 mRNA

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

myosin IXA

decreases expression

ISO

Clobetasol results in decreased expression of MYO9A mRNA

NCBI chr 8:69,044,853...69,248,094
Ensembl chr 8:69,044,885...69,245,231

G

nucleic acid binding protein 2

increases expression

ISO

Clobetasol results in increased expression of NABP2 mRNA

NCBI chr 7:1,415,491...1,421,113
Ensembl chr 7:1,415,492...1,422,682

G

neuron navigator 3

decreases expression

ISO

Clobetasol results in decreased expression of NAV3 mRNA

NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893

G

neural cell adhesion molecule 2

decreases expression

ISO

Clobetasol results in decreased expression of NCAM2 mRNA

NCBI chr11:33,591,748...34,078,788
Ensembl chr11:33,591,713...34,078,788

G

NCK-associated protein 5-like

decreases expression

ISO

Clobetasol results in decreased expression of NCKAP5L mRNA

NCBI chr 7:132,433,569...132,470,638
Ensembl chr 7:132,433,574...132,470,836

G

nucleolin

decreases expression

ISO

Clobetasol results in decreased expression of NCL mRNA

NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:94,446,682...94,456,083

G

nicalin

increases expression

ISO

Clobetasol results in increased expression of NCLN mRNA

NCBI chr 7:8,862,324...8,872,699
Ensembl chr 7:8,862,751...8,872,698

G

NDC1 transmembrane nucleoporin

increases expression

ISO

Clobetasol results in increased expression of NDC1 mRNA

NCBI chr 5:127,384,172...127,431,093
Ensembl chr 5:127,384,665...127,431,090

G

Nedd4 family interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of NDFIP1 mRNA

NCBI chr18:30,516,931...30,567,199
Ensembl chr18:30,516,981...30,568,471

G

NADH:ubiquinone oxidoreductase subunit A2

increases expression

ISO

Clobetasol results in increased expression of NDUFA2 mRNA

NCBI chr18:28,629,795...28,631,884
Ensembl chr18:28,629,795...28,631,884

G

NADH:ubiquinone oxidoreductase subunit A8

increases expression

ISO

Clobetasol results in increased expression of NDUFA8 mRNA

NCBI chr 3:39,783,479...39,799,507
Ensembl chr 3:39,783,479...39,799,507

G

NADH:ubiquinone oxidoreductase subunit A9

increases expression

ISO

Clobetasol results in increased expression of NDUFA9 mRNA

NCBI chr 4:161,345,398...161,374,188
Ensembl chr 4:161,345,400...161,375,025

G

NADH:ubiquinone oxidoreductase subunit B10

increases expression

ISO

Clobetasol results in increased expression of NDUFB10 mRNA

NCBI chr10:14,253,805...14,255,966
Ensembl chr10:14,253,805...14,255,966

G

NADH:ubiquinone oxidoreductase subunit B3

increases expression

ISO

Clobetasol results in increased expression of NDUFB3 mRNA

NCBI chr 9:67,623,417...67,633,629
Ensembl chr 9:67,623,614...67,633,613

G

NADH:ubiquinone oxidoreductase subunit B5

increases expression

ISO

Clobetasol results in increased expression of NDUFB5 mRNA

NCBI chr 2:117,447,605...117,461,943
Ensembl chr 2:117,447,035...117,461,590

G

NADH:ubiquinone oxidoreductase subunit B6

increases expression

ISO

Clobetasol results in increased expression of NDUFB6 mRNA

NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055

G

NADH:ubiquinone oxidoreductase subunit C1

increases expression

ISO

Clobetasol results in increased expression of NDUFC1 mRNA

NCBI chr 2:137,597,944...137,601,819
Ensembl chr 2:137,600,156...137,601,735

G

NADH:ubiquinone oxidoreductase subunit C2

increases expression

ISO

Clobetasol results in increased expression of NDUFC2 mRNA

NCBI chr 1:161,122,370...161,129,413
Ensembl chr 1:161,123,150...161,129,419

G

NADH:ubiquinone oxidoreductase core subunit S7

increases expression

ISO

Clobetasol results in increased expression of NDUFS7 mRNA

NCBI chr 7:10,103,226...10,110,862
Ensembl chr 7:10,103,227...10,110,691

G

NADH:ubiquinone oxidoreductase core subunit V1

increases expression

ISO

Clobetasol results in increased expression of NDUFV1 mRNA

NCBI chr 1:210,729,856...210,735,103
Ensembl chr 1:210,729,858...210,734,949

G

neural EGFL like 2

increases expression

ISO

Clobetasol results in increased expression of NELL2 mRNA

NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917

G

neuraminidase 1

increases expression

ISO

Clobetasol results in increased expression of NEU1 mRNA

NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383

G

neurofascin

decreases expression

ISO

Clobetasol results in decreased expression of NFASC mRNA

NCBI chr13:46,549,369...46,735,989
Ensembl chr13:46,549,369...46,736,139

G

neuroguidin

increases expression

ISO

Clobetasol results in increased expression of NGDN mRNA

NCBI chr15:32,459,898...32,467,260
Ensembl chr15:32,399,109...32,467,260

G

NHP2 ribonucleoprotein

increases expression

ISO

Clobetasol results in increased expression of NHP2 mRNA

NCBI chr10:36,378,020...36,381,362
Ensembl chr10:36,377,997...36,381,354

G

ninjurin 1

increases expression

ISO

Clobetasol results in increased expression of NINJ1 mRNA

NCBI chr17:15,659,208...15,668,115
Ensembl chr17:15,659,200...15,668,063

G

ninein-like

decreases expression

ISO

Clobetasol results in decreased expression of NINL mRNA

NCBI chr 3:160,208,757...160,275,077
Ensembl chr 3:160,196,883...160,275,108

G

notchless homolog 1

increases expression

ISO

Clobetasol results in increased expression of NLE1 mRNA

NCBI chr10:68,331,609...68,342,562
Ensembl chr10:68,331,609...68,340,386

G

neuroligin 2

decreases expression

ISO

Clobetasol results in decreased expression of NLGN2 mRNA

NCBI chr10:55,042,175...55,056,578
Ensembl chr10:55,043,185...55,056,578

G

NME/NM23 nucleoside diphosphate kinase 1

increases expression

ISO

Clobetasol results in increased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310

G

NME/NM23 nucleoside diphosphate kinase 4

increases expression

ISO

Clobetasol results in increased expression of NME4 mRNA

NCBI chr10:15,619,106...15,622,961
Ensembl chr10:15,619,106...15,623,098

G

NOP10 ribonucleoprotein

increases expression

ISO

Clobetasol results in increased expression of NOP10 mRNA

NCBI chr 3:119,521,255...119,522,340
Ensembl chr 3:119,521,255...119,522,340

G

NOP protein chaperone 1

increases expression

ISO

Clobetasol results in increased expression of NOPCHAP1 mRNA

NCBI chr 7:22,241,236...22,247,150
Ensembl chr 7:22,241,236...22,247,150

G

notch receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of NOTCH1 mRNA

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613

G

notch receptor 2

decreases expression

ISO

Clobetasol results in decreased expression of NOTCH2 mRNA

NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823

G

NOVA alternative splicing regulator 1

decreases expression

ISO

Clobetasol results in decreased expression of NOVA1 mRNA

NCBI chr 6:69,506,983...69,632,437
Ensembl chr 6:69,506,983...69,632,437

G

NPC intracellular cholesterol transporter 1

increases expression

ISO

Clobetasol results in increased expression of NPC1 mRNA

NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800

G

NPC intracellular cholesterol transporter 2

increases expression

ISO

Clobetasol results in increased expression of NPC2 mRNA

NCBI chr 6:110,128,325...110,149,245
Ensembl chr 6:110,128,325...110,150,004

G

nucleophosmin/nucleoplasmin, 3

increases expression

ISO

Clobetasol results in increased expression of NPM3 mRNA

NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:254,544,664...254,546,649

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 1, group D, member 2

decreases expression

ISO

Clobetasol results in decreased expression of NR1D2 mRNA

NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

ISO

Clobetasol results in increased activity of NR1I2 protein
[Clobetasol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 2, group F, member 1

decreases expression

ISO

Clobetasol results in decreased expression of NR2F1 mRNA

NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

increases expression

ISO

Clobetasol results in increased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220

G

neuronal vesicle trafficking associated 1

increases expression

ISO

Clobetasol results in increased expression of NSG1 mRNA

NCBI chr14:76,861,079...76,882,822
Ensembl chr14:76,860,746...76,883,390

G

NSE3 homolog, SMC5-SMC6 complex component

increases expression

ISO

Clobetasol results in increased expression of NSMCE3 mRNA

NCBI chr 1:127,812,572...127,813,899

G

5'-nucleotidase domain containing 2

increases expression

ISO

Clobetasol results in increased expression of NT5DC2 mRNA

NCBI chr16:6,328,925...6,336,978
Ensembl chr16:6,328,523...6,336,980

G

netrin 1

decreases expression

ISO

Clobetasol results in decreased expression of NTN1 mRNA

NCBI chr10:53,398,852...53,597,595
Ensembl chr10:53,398,852...53,584,060

G

NUBP iron-sulfur cluster assembly factor 2

increases expression

ISO

Clobetasol results in increased expression of NUBP2 mRNA

NCBI chr10:14,407,743...14,411,428
Ensembl chr10:14,407,745...14,411,600

G

nudix hydrolase 9

increases expression

ISO

Clobetasol results in increased expression of NUDT9 mRNA

NCBI chr14:5,980,042...5,997,998
Ensembl chr14:5,980,043...6,005,783

G

nucleoredoxin

increases expression

ISO

Clobetasol results in increased expression of NXN mRNA

NCBI chr10:61,607,557...61,745,807
Ensembl chr10:61,607,568...61,745,807

G

ornithine decarboxylase 1

increases expression

ISO

Clobetasol results in increased expression of ODC1 mRNA

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

olfactomedin 2

increases expression

ISO

Clobetasol results in increased expression of OLFM2 mRNA

NCBI chr 8:27,480,703...27,558,416
Ensembl chr 8:27,480,711...27,558,460

G

oligodendrocyte transcription factor 1

increases expression

ISO

Clobetasol results in increased expression of OLIG1 mRNA

NCBI chr11:44,000,450...44,002,592
Ensembl chr11:44,000,281...44,002,592

G

one cut homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of ONECUT2 mRNA

NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668

G

prolyl 4-hydroxylase subunit beta

increases expression

ISO

Clobetasol results in increased expression of P4HB mRNA

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

prolyl 4-hydroxylase, transmembrane

increases expression

ISO

Clobetasol results in increased expression of P4HTM mRNA

NCBI chr 8:118,153,158...118,172,199
Ensembl chr 8:118,153,158...118,171,002

G

poly(A) binding protein, cytoplasmic 1

decreases expression

ISO

Clobetasol results in decreased expression of PABPC1 mRNA

NCBI chr 7:69,662,513...69,674,806
Ensembl chr 7:69,663,068...69,675,050

G

presenilin associated, rhomboid-like

increases expression

ISO

Clobetasol results in increased expression of PARL mRNA

NCBI chr11:94,097,559...94,124,915
Ensembl chr11:94,097,934...94,148,287

G

poly (ADP-ribose) polymerase 1

decreases expression

ISO

Clobetasol results in decreased expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

PBX homeobox interacting protein 1

decreases expression

ISO

Clobetasol results in decreased expression of PBXIP1 mRNA

NCBI chr 2:177,154,056...177,167,810
Ensembl chr 2:177,154,101...177,167,328

G

protocadherin 10

decreases expression

ISO

Clobetasol results in decreased expression of PCDH10 mRNA

NCBI chr 2:130,553,432...130,619,591
Ensembl chr 2:130,553,425...130,613,407

G

protocadherin 17

decreases expression

ISO

Clobetasol results in decreased expression of PCDH17 mRNA

NCBI chr15:66,631,549...66,725,007
Ensembl chr15:66,633,142...66,722,105

G

protocadherin gamma subfamily A, 2

decreases expression

ISO

Clobetasol results in decreased expression of PCDHGA2 mRNA

NCBI chr18:29,745,189...29,919,095

G

protocadherin gamma subfamily C, 3

decreases expression

ISO

Clobetasol results in decreased expression of PCDHGC3 mRNA

NCBI chr18:29,884,245...29,919,095

G

PCF11 cleavage and polyadenylation factor subunit

increases expression

ISO

Clobetasol results in increased expression of PCF11 mRNA

NCBI chr 1:156,109,724...156,136,950
Ensembl chr 1:156,109,724...156,136,435

G

procollagen C-endopeptidase enhancer

increases expression

ISO

Clobetasol results in increased expression of PCOLCE mRNA

NCBI chr12:24,720,972...24,727,287
Ensembl chr12:24,720,936...24,727,287

G

prenylcysteine oxidase 1 like

increases expression

ISO

Clobetasol results in increased expression of PCYOX1L mRNA

NCBI chr18:57,420,971...57,431,632
Ensembl chr18:57,420,977...57,431,632

G

phosducin-like 3

increases expression

ISO

Clobetasol results in increased expression of PDCL3 mRNA

NCBI chr 9:48,730,083...48,738,554
Ensembl chr 9:48,723,767...48,739,529

G

protein disulfide isomerase family A, member 4

increases expression

ISO

Clobetasol results in increased expression of PDIA4 mRNA

NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191

G

protein disulfide isomerase family A, member 6

increases expression

ISO

Clobetasol results in increased expression of PDIA6 mRNA

NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091

G

pseudopodium-enriched atypical kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of PEAK1 mRNA

NCBI chr 8:65,501,068...65,715,768
Ensembl chr 8:65,505,043...65,715,111

G

phosphatidylethanolamine binding protein 1

increases expression

ISO

Clobetasol results in increased expression of PEBP1 mRNA

NCBI chr12:44,946,307...44,967,890
Ensembl chr12:44,963,675...44,971,780

G

prefoldin subunit 6

increases expression

ISO

Clobetasol results in increased expression of PFDN6 mRNA

NCBI chr20:4,947,844...4,949,318
Ensembl chr20:4,947,844...4,949,318

G

profilin 1

increases expression

ISO

Clobetasol results in increased expression of PFN1 mRNA

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611

G

phosphoglycerate mutase 1

increases expression

ISO

Clobetasol results in increased expression of PGAM1 mRNA

NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203

G

phosphogluconate dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of PGD mRNA

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

phosphoglycerate kinase 1

increases expression

ISO

Clobetasol results in increased expression of PGK1 mRNA

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959

G

prohibitin 1

increases expression

ISO

Clobetasol results in increased expression of PHB1 mRNA

NCBI chr10:81,102,043...81,114,815
Ensembl chr10:81,102,028...81,116,233

G

PHD finger protein 3

decreases expression

ISO

Clobetasol results in decreased expression of PHF3 mRNA

NCBI chr 9:40,559,929...40,632,096
Ensembl chr 9:40,559,929...40,632,056

G

PHD finger protein 5A

increases expression

ISO

Clobetasol results in increased expression of PHF5A mRNA

NCBI chr 7:115,258,609...115,265,174
Ensembl chr 7:115,258,609...115,265,174

G

phosphoglycerate dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

PHD and ring finger domains 1

decreases expression

ISO

Clobetasol results in decreased expression of PHRF1 mRNA

NCBI chr 1:205,763,264...205,796,478
Ensembl chr 1:205,763,549...205,801,557

G

phosphatidylinositol glycan anchor biosynthesis, class S

increases expression

ISO

Clobetasol results in increased expression of PIGS mRNA

NCBI chr10:63,720,568...63,735,255
Ensembl chr10:63,720,661...63,735,253

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta

decreases expression

ISO

Clobetasol results in decreased expression of PIK3C2B mRNA

NCBI chr13:47,046,866...47,107,733
Ensembl chr13:47,047,127...47,107,725

G

phosphoinositide-3-kinase regulatory subunit 1

increases expression

ISO

Clobetasol results in increased expression of PIK3R1 mRNA

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

Pim-3 proto-oncogene, serine/threonine kinase

increases expression

ISO

Clobetasol results in increased expression of PIM3 mRNA

NCBI chr 7:121,822,076...121,836,257
Ensembl chr 7:121,832,742...121,836,259

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

increases expression

ISO

Clobetasol results in increased expression of PIP4K2A mRNA

NCBI chr17:86,405,080...86,576,597
Ensembl chr17:86,405,081...86,576,430

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 2

increases expression

ISO

Clobetasol results in increased expression of PIP4P2 mRNA

NCBI chr 5:33,057,046...33,104,448
Ensembl chr 5:33,056,684...33,104,451

G

pyruvate kinase M1/2

increases expression

ISO

Clobetasol results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipase C, gamma 2

decreases expression

ISO

Clobetasol results in decreased expression of PLCG2 mRNA

NCBI chr19:62,456,196...62,592,684
Ensembl chr19:62,453,259...62,592,684

G

polo-like kinase 2

increases expression

ISO

Clobetasol results in increased expression of PLK2 mRNA

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1

increases expression

ISO

Clobetasol results in increased expression of PLOD1 mRNA

NCBI chr 5:163,623,847...163,650,737
Ensembl chr 5:163,623,848...163,651,110

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

increases expression

ISO

Clobetasol results in increased expression of PLOD3 mRNA

NCBI chr12:25,313,070...25,323,631
Ensembl chr12:25,313,072...25,323,631

G

phospholipid transfer protein

increases expression

ISO

Clobetasol results in increased expression of PLTP mRNA

NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:173,994,162...174,012,505

G

plexin A1

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA1 mRNA

NCBI chr 4:123,295,165...123,340,132
Ensembl chr 4:123,297,244...123,340,428

G

plexin A2

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA2 mRNA

NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453

G

plexin A4

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA4 mRNA

NCBI chr 4:61,687,483...62,129,467
Ensembl chr 4:61,687,510...62,129,445

G

plexin C1

decreases expression

ISO

Clobetasol results in decreased expression of PLXNC1 mRNA

NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:31,276,978...31,431,092

G

plexin D1

decreases expression

ISO

Clobetasol results in decreased expression of PLXND1 mRNA

NCBI chr 4:150,675,377...150,715,706
Ensembl chr 4:150,675,377...150,715,566

G

RNA polymerase I and III subunit C

increases expression

ISO

Clobetasol results in increased expression of POLR1C mRNA

NCBI chr 9:22,233,318...22,237,430
Ensembl chr 9:22,233,305...22,237,428

G

RNA polymerase I and III subunit D

increases expression

ISO

Clobetasol results in increased expression of POLR1D mRNA

NCBI chr12:13,084,505...13,118,069
Ensembl chr12:13,084,512...13,095,627

G

RNA polymerase II subunit A

decreases expression

ISO

Clobetasol results in decreased expression of POLR2A mRNA

NCBI chr10:54,951,162...54,977,179
Ensembl chr10:54,951,162...54,977,179

G

RNA polymerase II subunit I

increases expression

ISO

Clobetasol results in increased expression of POLR2I mRNA

NCBI chr 1:94,610,976...94,612,413
Ensembl chr 1:94,610,942...94,613,000

G

RNA polymerase II, I and III subunit L

increases expression

ISO

Clobetasol results in increased expression of POLR2L mRNA

NCBI chr 1:205,999,607...206,001,615
Ensembl chr19:8,341,868...8,342,071

G

RNA polymerase III subunit H

increases expression

ISO

Clobetasol results in increased expression of POLR3H mRNA

NCBI chr 7:115,309,571...115,319,881
Ensembl chr 7:115,309,589...115,319,915

G

RNA polymerase III subunit K

increases expression

ISO

Clobetasol results in increased expression of POLR3K mRNA

NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:189,360,171...189,366,697

G

peptidylprolyl isomerase E

increases expression

ISO

Clobetasol results in increased expression of PPIE mRNA

NCBI chr 5:140,691,285...140,704,347
Ensembl chr 5:140,683,801...140,740,767

G

peptidylprolyl isomerase like 1

increases expression

ISO

Clobetasol results in increased expression of PPIL1 mRNA

NCBI chr20:7,303,919...7,323,962
Ensembl chr20:7,303,922...7,318,781

G

protein phosphatase, Mg2+/Mn2+ dependent, 1K

increases expression

ISO

Clobetasol results in increased expression of PPM1K mRNA

NCBI chr 4:88,942,226...88,969,139
Ensembl chr 4:88,942,386...88,969,136

G

protein phosphatase methylesterase 1

increases expression

ISO

Clobetasol results in increased expression of PPME1 mRNA

NCBI chr 1:164,080,242...164,127,261
Ensembl chr 1:164,080,242...164,127,220

G

protein phosphatase 1 catalytic subunit alpha

increases expression

ISO

Clobetasol results in increased expression of PPP1CA mRNA

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193

G

protein phosphatase 1 catalytic subunit beta

increases expression

ISO

Clobetasol results in increased expression of PPP1CB mRNA

NCBI chr 6:29,681,099...29,712,835
Ensembl chr 6:29,681,100...29,712,924

G

protein phosphatase 1, regulatory (inhibitor) subunit 14B

increases expression

ISO

Clobetasol results in increased expression of PPP1R14B mRNA

NCBI chr 1:213,594,416...213,596,527
Ensembl chr12:21,088,517...21,101,431
Ensembl chr 1:21,088,517...21,101,431

G

protein phosphatase 1, regulatory subunit 26

decreases expression

ISO

Clobetasol results in decreased expression of PPP1R26 mRNA

NCBI chr 3:32,179,686...32,188,069
Ensembl chr 3:32,177,235...32,188,264

G

protein phosphatase 1, regulatory subunit 35

increases expression

ISO

Clobetasol results in increased expression of PPP1R35 mRNA

NCBI chr12:24,552,709...24,556,040

G

protein phosphatase 1, regulatory subunit 3C

increases expression

ISO

Clobetasol results in increased expression of PPP1R3C mRNA

NCBI chr 1:243,873,524...243,878,527
Ensembl chr 1:243,871,704...243,878,835

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

ISO

Clobetasol results in increased expression of PPP2R1A mRNA

NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:69,213,038...69,238,242

G

protein phosphatase 4, catalytic subunit

increases expression

ISO

Clobetasol results in increased expression of PPP4C mRNA

NCBI chr 1:190,823,447...190,830,247
Ensembl chr 1:190,823,486...190,830,168

G

protein phosphatase 5, catalytic subunit

increases expression

ISO

Clobetasol results in increased expression of PPP5C mRNA

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950

G

PEAK1 related kinase activating pseudokinase 1

decreases expression

ISO

Clobetasol results in decreased expression of PRAG1 mRNA

NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532

G

peroxiredoxin 1

increases expression

ISO

Clobetasol results in increased expression of PRDX1 mRNA

NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504

G

peroxiredoxin 2

increases expression

ISO

Clobetasol results in increased expression of PRDX2 mRNA

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006

G

peroxiredoxin 3

increases expression

ISO

Clobetasol results in increased expression of PRDX3 mRNA

NCBI chr 1:269,987,691...270,000,111
Ensembl chr 1:269,987,685...270,000,300

G

peroxiredoxin 5

increases expression

ISO

Clobetasol results in increased expression of PRDX5 mRNA

NCBI chr 1:213,529,042...213,532,787
Ensembl chr 1:213,529,035...213,533,020

G

protein kinase C, alpha

decreases expression

ISO

Clobetasol results in decreased expression of PRKCA mRNA

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

protein kinase C, beta

decreases expression

ISO

Clobetasol results in decreased expression of PRKCB mRNA

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

proline-rich basic protein 1

decreases expression

ISO

Clobetasol results in decreased expression of PROB1 mRNA

NCBI chr18:27,516,599...27,521,443
Ensembl chr18:27,516,332...27,523,808

G

phosphoribosyl pyrophosphate synthetase 2

increases expression

ISO

Clobetasol results in increased expression of PRPS2 mRNA

NCBI chr X:30,592,845...30,630,127
Ensembl chr X:30,593,019...30,630,126

G

proline rich 12

decreases expression

ISO

Clobetasol results in decreased expression of PRR12 mRNA

NCBI chr 1:104,646,492...104,670,454
Ensembl chr 1:104,646,492...104,670,454

G

proline-rich coiled-coil 2B

decreases expression

ISO

Clobetasol results in decreased expression of PRRC2B mRNA

NCBI chr 3:35,831,017...35,916,854
Ensembl chr 3:35,863,046...35,916,854

G

proline-rich coiled-coil 2C

decreases expression

ISO

Clobetasol results in decreased expression of PRRC2C mRNA

NCBI chr13:77,537,226...77,606,926
Ensembl chr13:77,537,814...77,607,001

G

prune homolog 2 with BCH domain

increases expression

ISO

Clobetasol results in increased expression of PRUNE2 mRNA

NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592

G

proteasome 20S subunit alpha 2

increases expression

ISO

Clobetasol results in increased expression of PSMA2 mRNA

NCBI chr17:55,250,054...55,260,441
Ensembl chr17:55,247,442...55,339,673

G

proteasome 20S subunit alpha 5

increases expression

ISO

Clobetasol results in increased expression of PSMA5 mRNA

NCBI chr 2:198,584,502...198,607,867
Ensembl chr 2:198,584,505...198,607,867

G

proteasome 20S subunit alpha 6

increases expression

ISO

Clobetasol results in increased expression of PSMA6 mRNA

NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:78,500,736...78,531,717

G

proteasome 20S subunit beta 3

increases expression

ISO

Clobetasol results in increased expression of PSMB3 mRNA

NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883

G

proteasome 20S subunit beta 4

increases expression

ISO

Clobetasol results in increased expression of PSMB4 mRNA

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

proteasome 20S subunit beta 5

increases expression

ISO

Clobetasol results in increased expression of PSMB5 mRNA

NCBI chr15:32,042,784...32,047,379
Ensembl chr15:32,042,787...32,047,379

G

proteasome 20S subunit beta 7

increases expression

ISO

Clobetasol results in increased expression of PSMB7 mRNA

NCBI chr 3:42,767,500...42,827,470
Ensembl chr 3:42,767,501...42,827,601

G

proteasome 26S subunit, ATPase 5

increases expression

ISO

Clobetasol results in increased expression of PSMC5 mRNA

NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921

G

proteasome 26S subunit, non-ATPase 13

increases expression

ISO

Clobetasol results in increased expression of PSMD13 mRNA

NCBI chr 1:205,394,248...205,406,525
Ensembl chr 1:205,393,746...205,411,651

G

proteasome 26S subunit, non-ATPase 6

increases expression

ISO

Clobetasol results in increased expression of PSMD6 mRNA

NCBI chr15:13,532,675...13,542,682
Ensembl chr15:13,532,675...13,542,682

G

phosphoserine phosphatase

increases expression

ISO

Clobetasol results in increased expression of PSPH mRNA

NCBI chr12:32,527,091...32,541,182
Ensembl chr12:32,519,269...32,541,180

G

polypyrimidine tract binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of PTBP2 mRNA

NCBI chr 2:210,497,610...210,558,497
Ensembl chr 2:210,497,706...210,558,291

G

pentatricopeptide repeat domain 2

increases expression

ISO

Clobetasol results in increased expression of PTCD2 mRNA

NCBI chr 2:32,446,441...32,474,114
Ensembl chr 2:32,446,182...32,474,285

G

phosphatidylserine synthase 2

increases expression

ISO

Clobetasol results in increased expression of PTDSS2 mRNA

NCBI chr 1:205,671,024...205,695,556
Ensembl chr 1:205,671,041...205,695,553

G

prostaglandin E synthase 2

increases expression

ISO

Clobetasol results in increased expression of PTGES2 mRNA

NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:36,088,246...36,097,694

G

prostaglandin F2 receptor inhibitor

increases expression

ISO

Clobetasol results in increased expression of PTGFRN mRNA

NCBI chr 2:191,158,166...191,233,432
Ensembl chr 2:191,158,166...191,234,115

G

protein phosphatase 2 phosphatase activator

increases expression

ISO

Clobetasol results in increased expression of PTPA mRNA

NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772

G

protein tyrosine phosphatase, receptor type, F

decreases expression

ISO

Clobetasol results in decreased expression of PTPRF mRNA

NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426

G

protein tyrosine phosphatase, receptor type, S

decreases expression

ISO

Clobetasol results in decreased expression of PTPRS mRNA

NCBI chr 9:1,332,558...1,394,161
Ensembl chr 9:1,332,559...1,394,093

G

PTTG1 interacting protein

increases expression

ISO

Clobetasol results in increased expression of PTTG1IP mRNA

NCBI chr20:11,029,608...11,047,395
Ensembl chr20:11,029,608...11,046,909

G

peroxisomal membrane protein 2

increases expression

ISO

Clobetasol results in increased expression of PXMP2 mRNA

NCBI chr12:52,053,951...52,064,283
Ensembl chr12:52,053,788...52,064,283

G

pyrroline-5-carboxylate reductase 2

increases expression

ISO

Clobetasol results in increased expression of PYCR2 mRNA

NCBI chr13:95,158,236...95,162,030
Ensembl chr13:95,158,183...95,162,029

G

quinoid dihydropteridine reductase

increases expression

ISO

Clobetasol results in increased expression of QDPR mRNA

NCBI chr14:69,882,776...69,896,378
Ensembl chr14:69,882,612...69,896,379

G

glutamine and serine rich 1

decreases expression

ISO

Clobetasol results in decreased expression of QSER1 mRNA

NCBI chr 3:111,592,377...111,658,825
Ensembl chr 3:111,595,171...111,657,103

G

R3H domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of R3HDM1 mRNA

NCBI chr13:42,148,281...42,286,311
Ensembl chr13:42,148,290...42,286,311

G

RAB1A, member RAS oncogene family

increases expression

ISO

Clobetasol results in increased expression of RAB1A mRNA

NCBI chr14:98,623,582...98,648,766
Ensembl chr14:98,623,635...98,661,582

G

RAB, member RAS oncogene family-like 6

decreases expression

ISO

Clobetasol results in decreased expression of RABL6 mRNA

NCBI chr 3:28,800,802...28,826,722
Ensembl chr 3:28,800,802...28,826,722

G

Ras association (RalGDS/AF-6) and pleckstrin homology domains 1

decreases expression

ISO

Clobetasol results in decreased expression of RAPH1 mRNA

NCBI chr 9:69,397,272...69,484,174
Ensembl chr 9:69,401,517...69,484,019

G

ribonucleoprotein, PTB-binding 2

increases expression

ISO

Clobetasol results in increased expression of RAVER2 mRNA

NCBI chr 5:120,796,807...120,898,281
Ensembl chr 5:120,800,126...120,895,825

G

RB binding protein 4, chromatin remodeling factor

increases expression

ISO

Clobetasol results in increased expression of RBBP4 mRNA

NCBI chr 5:146,940,207...146,959,501
Ensembl chr 5:146,922,611...146,959,501

G

RB binding protein 6, ubiquitin ligase

decreases expression

ISO

Clobetasol results in decreased expression of RBBP6 mRNA

NCBI chr 1:186,934,563...186,966,852
Ensembl chr 1:186,934,938...186,966,852

G

RNA binding motif protein 15B

decreases expression

ISO

Clobetasol results in decreased expression of RBM15B mRNA

NCBI chr 8:116,422,309...116,425,374
Ensembl chr 8:116,421,540...116,425,940

G

regulator of chromosome condensation 2

increases expression

ISO

Clobetasol results in increased expression of RCC2 mRNA

NCBI chr 5:158,277,476...158,300,294
Ensembl chr 5:158,277,476...158,300,294

G

receptor accessory protein 5

increases expression

ISO

Clobetasol results in increased expression of REEP5 mRNA

NCBI chr18:26,219,528...26,257,505
Ensembl chr18:26,219,530...26,250,660

G

arginine-glutamic acid dipeptide repeats

decreases expression

ISO

Clobetasol results in decreased expression of RERE mRNA

NCBI chr 5:166,048,770...166,380,559
Ensembl chr 5:166,048,844...166,380,558

G

REV3 like, DNA directed polymerase zeta catalytic subunit

decreases expression

ISO

Clobetasol results in decreased expression of REV3L mRNA

NCBI chr20:44,686,482...44,844,668
Ensembl chr20:44,686,940...44,844,668

G

required for excision 1-B domain containing

increases expression

ISO

Clobetasol results in increased expression of REX1BD mRNA

NCBI chr16:18,956,023...18,958,494
Ensembl chr16:18,955,969...18,958,494

G

refilin B

increases expression

ISO

Clobetasol results in increased expression of RFLNB mRNA

NCBI chr10:61,391,947...61,398,224
Ensembl chr10:61,390,659...61,398,224

G

regulatory factor X, 7

decreases expression

ISO

Clobetasol results in decreased expression of RFX7 mRNA

NCBI chr 8:82,134,747...82,219,898
Ensembl chr 8:82,134,747...82,219,898

G

Ras homolog, mTORC1 binding

increases expression

ISO

Clobetasol results in increased expression of RHEB mRNA

NCBI chr 4:11,012,173...11,053,860
Ensembl chr 4:11,012,643...11,053,931

G

ras homolog family member T2

increases expression

ISO

Clobetasol results in increased expression of RHOT2 mRNA

NCBI chr10:15,363,467...15,369,263
Ensembl chr10:15,361,726...15,369,006

G

ring finger protein 145

increases expression

ISO

Clobetasol results in increased expression of RNF145 mRNA

NCBI chr10:29,507,779...29,552,153
Ensembl chr10:29,507,772...29,552,151

G

ring finger protein 168

decreases expression

ISO

Clobetasol results in decreased expression of RNF168 mRNA

NCBI chr11:81,991,352...82,013,306
Ensembl chr11:81,991,360...82,013,306

G

ring finger protein 187

increases expression

ISO

Clobetasol results in increased expression of RNF187 mRNA

NCBI chr10:44,209,080...44,214,979
Ensembl chr10:44,202,332...44,215,470

G

ring finger protein 5

increases expression

ISO

Clobetasol results in increased expression of RNF5 mRNA

NCBI chr20:4,150,032...4,152,593
Ensembl chr20:4,150,138...4,152,591

G

Ro60, Y RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of RO60 mRNA

NCBI chr13:58,049,838...58,070,828
Ensembl chr13:58,049,858...58,076,264

G

roundabout guidance receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of ROBO1 mRNA

NCBI chr11:24,067,869...25,108,694
Ensembl chr11:24,067,878...25,108,694

G

Rho-associated coiled-coil containing protein kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of ROCK1 mRNA

NCBI chr18:1,387,360...1,509,218
Ensembl chr18:1,387,360...1,509,147

G

ribosomal protein L12

increases expression

ISO

Clobetasol results in increased expression of RPL12 mRNA

NCBI chr 3:36,661,940...36,664,314
Ensembl chr 3:36,661,939...36,664,306

G

ribosomal protein L13

increases expression

ISO

Clobetasol results in increased expression of RPL13 mRNA

NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059

G

ribosomal protein L13A

decreases expression

ISO

Clobetasol results in decreased expression of RPL13A mRNA

NCBI chr 1:104,746,223...104,748,975
Ensembl chr 1:104,746,223...104,748,914

G

ribosomal protein L14

increases expression

ISO

Clobetasol results in increased expression of RPL14 mRNA

NCBI chr 8:129,163,620...129,166,745
Ensembl chr 8:129,163,317...129,167,459

G

ribosomal protein L18

increases expression

ISO

Clobetasol results in increased expression of RPL18 mRNA

NCBI chr 1:105,325,269...105,327,911
Ensembl chr 1:105,325,250...105,327,910

G

ribosomal protein L24

increases expression

ISO

Clobetasol results in increased expression of RPL24 mRNA

NCBI chr11:58,122,997...58,128,405
Ensembl chr11:58,122,997...58,128,405

G

ribosomal protein L27

increases expression

ISO

Clobetasol results in increased expression of RPL27 mRNA

NCBI chr10:86,875,758...86,879,457
Ensembl chr10:86,876,024...86,879,441

G

ribosomal protein L37A

increases expression

ISO

Clobetasol results in increased expression of RPL37A mRNA

NCBI chr 9:81,748,091...81,750,174
Ensembl chr 9:81,748,103...81,751,975

G

ribosomal protein L39

increases expression

ISO

Clobetasol results in increased expression of RPL39 mRNA

NCBI chr X:121,192,901...121,195,896
Ensembl chr 7:31,721,884...31,722,039
Ensembl chr15:31,721,884...31,722,039
Ensembl chr X:31,721,884...31,722,039

G

ribosomal protein L8

increases expression

ISO

Clobetasol results in increased expression of RPL8 mRNA

NCBI chr 7:110,506,815...110,509,106
Ensembl chr 7:110,506,800...110,509,103
Ensembl chr 3:110,506,800...110,509,103

G

ribosomal protein L9

increases expression

ISO

Clobetasol results in increased expression of RPL9 mRNA

NCBI chr14:43,247,536...43,250,784
Ensembl chr14:43,247,588...43,250,782
Ensembl chr 1:43,247,588...43,250,782

G

ribosomal protein lateral stalk subunit P0

increases expression

ISO

Clobetasol results in increased expression of RPLP0 mRNA

NCBI chr12:46,715,121...46,718,390
Ensembl chr12:46,715,124...46,718,422

G

ribophorin II

increases expression

ISO

Clobetasol results in increased expression of RPN2 mRNA

NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:166,362,049...166,409,922

G

ribonuclease P/MRP subunit p25 like

increases expression

ISO

Clobetasol results in increased expression of RPP25L mRNA

NCBI chr 5:61,674,299...61,675,844
Ensembl chr 5:61,672,199...61,675,168

G

ribosomal protein S11

increases expression

ISO

Clobetasol results in increased expression of RPS11 mRNA

NCBI chr 1:104,742,153...104,744,261
Ensembl chr 1:104,742,155...104,744,337

G

ribosomal protein S14

affects expression

ISO

Clobetasol affects the expression of RPS14 mRNA

NCBI chr18:56,492,010...56,503,092
Ensembl chr18:56,498,245...56,503,091

G

ribosomal protein S15a

increases expression

ISO

Clobetasol results in increased expression of RPS15A mRNA

NCBI chr 1:181,854,396...181,861,330
Ensembl chr 1:181,854,396...181,861,201

G

ribosomal protein S18

increases expression

ISO

Clobetasol results in increased expression of RPS18 mRNA

NCBI chr20:4,933,741...4,937,423
Ensembl chr20:4,917,095...4,937,423

G

ribosomal protein S27-like

increases expression

ISO

Clobetasol results in increased expression of RPS27L mRNA

NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130
Ensembl chr 8:33,713,661...33,714,130

G

ribosomal protein S5

increases expression

ISO

Clobetasol results in increased expression of RPS5 mRNA

NCBI chr 1:82,610,965...82,615,262
Ensembl chr 1:82,610,965...82,615,262

G

ribosomal protein S8

increases expression

ISO

Clobetasol results in increased expression of RPS8 mRNA

NCBI chr 5:135,866,941...135,869,511
Ensembl chr 5:135,866,941...135,869,548

G

remodeling and spacing factor 1

decreases expression

ISO

Clobetasol results in decreased expression of RSF1 mRNA

NCBI chr 1:161,303,596...161,426,326
Ensembl chr 1:161,303,660...161,420,290

G

ribosomal L24 domain containing 1

increases expression

ISO

Clobetasol results in increased expression of RSL24D1 mRNA

NCBI chr 8:82,733,627...82,742,632
Ensembl chr 8:82,733,649...82,744,497

G

RT1 class II, locus DMa

increases expression

ISO

Clobetasol results in increased expression of H2-DMA mRNA

NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335

G

RNA 2',3'-cyclic phosphate and 5'-OH ligase

increases expression

ISO

Clobetasol results in increased expression of RTCB mRNA

NCBI chr 7:19,795,393...19,814,875
Ensembl chr 7:19,795,393...19,814,875

G

retrotransposon Gag like 5

decreases expression

ISO

Clobetasol results in decreased expression of RTL5 mRNA

NCBI chr X:71,223,914...71,228,713
Ensembl chr X:71,221,371...71,232,653

G

reticulon 4 interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of RTN4IP1 mRNA

NCBI chr20:48,964,903...49,004,235
Ensembl chr20:48,964,816...49,006,456

G

RuvB-like AAA ATPase 2

increases expression

ISO

Clobetasol results in increased expression of RUVBL2 mRNA

NCBI chr 1:105,038,487...105,051,851
Ensembl chr 1:105,038,174...105,051,720

G

ryanodine receptor 3

decreases expression

ISO

Clobetasol results in decreased expression of RYR3 mRNA

NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677

G

S100 calcium binding protein A10

increases expression

ISO

Clobetasol results in increased expression of S100A10 mRNA

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103

G

SAC3 domain containing 1

increases expression

ISO

Clobetasol results in increased expression of SAC3D1 mRNA

NCBI chr 1:212,843,463...212,845,842
Ensembl chr 1:212,843,463...212,845,883

G

spalt-like transcription factor 1

decreases expression

ISO

Clobetasol results in decreased expression of SALL1 mRNA

NCBI chr19:34,179,316...34,196,278
Ensembl chr19:34,181,078...34,196,278

G

sterile alpha motif domain containing 4B

decreases expression

ISO

Clobetasol results in decreased expression of SAMD4B mRNA

NCBI chr 1:92,816,955...92,855,243
Ensembl chr 1:92,809,800...92,841,393

G

SAMM50 sorting and assembly machinery component

increases expression

ISO

Clobetasol results in increased expression of SAMM50 mRNA

NCBI chr 7:117,197,460...117,221,668
Ensembl chr 7:117,197,381...117,224,581

G

S-adenosylmethionine sensor upstream of mTORC1

increases expression

ISO

Clobetasol results in increased expression of SAMTOR mRNA

NCBI chr 4:42,847,720...42,911,546
Ensembl chr 4:42,836,172...42,917,567

G

Sin3A associated protein 18

increases expression

ISO

Clobetasol results in increased expression of SAP18 mRNA

NCBI chr15:36,058,784...36,063,089
Ensembl chr10:87,156,914...87,158,257
Ensembl chr15:87,156,914...87,158,257

G

Sin3A associated protein 30

increases expression

ISO

Clobetasol results in increased expression of SAP30 mRNA

NCBI chr16:37,758,494...37,763,825
Ensembl chr16:37,757,656...37,763,823

G

secretion associated, Ras related GTPase 1A

increases expression

ISO

Clobetasol results in increased expression of SAR1A mRNA

NCBI chr20:30,166,310...30,178,718
Ensembl chr20:30,166,334...30,178,710

G

secretion associated, Ras related GTPase 1B

increases expression

ISO

Clobetasol results in increased expression of SAR1B mRNA

NCBI chr10:36,525,365...36,555,009
Ensembl chr10:36,519,384...36,555,005

G

store-operated calcium entry-associated regulatory factor

increases expression

ISO

Clobetasol results in increased expression of SARAF mRNA

NCBI chr16:64,720,404...64,738,653
Ensembl chr16:64,720,418...64,738,653

G

SAM and SH3 domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of SASH1 mRNA

NCBI chr 1:4,940,207...5,238,777
Ensembl chr 1:4,940,207...5,238,530

G

strawberry notch homolog 2

decreases expression

ISO

Clobetasol results in decreased expression of SBNO2 mRNA

NCBI chr 7:10,256,221...10,300,175
Ensembl chr 7:10,253,248...10,300,176

G

SR-related CTD-associated factor 11

decreases expression

ISO

Clobetasol results in decreased expression of SCAF11 mRNA

NCBI chr 7:129,450,872...129,503,280
Ensembl chr 7:129,417,955...129,503,280

G

stearoyl-CoA desaturase

increases expression

ISO

Clobetasol results in increased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

stimulator of chondrogenesis 1

increases expression

ISO

Clobetasol results in increased expression of SCRG1 mRNA

NCBI chr16:37,770,739...37,799,010
Ensembl chr16:37,770,739...37,799,010

G

syndecan 4

increases expression

ISO

Clobetasol results in increased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670

G

stromal cell derived factor 2

increases expression

ISO

Clobetasol results in increased expression of SDF2 mRNA

NCBI chr10:63,638,634...63,649,109
Ensembl chr10:63,638,634...63,649,108

G

stromal cell-derived factor 2-like 1

increases expression

ISO

Clobetasol results in increased expression of SDF2L1 mRNA

NCBI chr11:97,376,878...97,379,120
Ensembl chr11:97,376,878...97,379,120

G

succinate dehydrogenase complex flavoprotein subunit A

increases expression

ISO

Clobetasol results in increased expression of SDHA mRNA

NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:30,764,590...30,790,121

G

succinate dehydrogenase complex subunit C

increases expression

ISO

Clobetasol results in increased expression of SDHC mRNA

NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044

G

sidekick cell adhesion molecule 2

decreases expression

ISO

Clobetasol results in decreased expression of SDK2 mRNA

NCBI chr10:99,324,047...99,601,683
Ensembl chr10:99,324,047...99,601,683

G

SEC11 homolog A, signal peptidase complex subunit

increases expression

ISO

Clobetasol results in increased expression of SEC11A mRNA

NCBI chr 1:144,290,680...144,318,658
Ensembl chr 1:144,284,497...144,324,009

G

SEC13 homolog, nuclear pore and COPII coat complex component

increases expression

ISO

Clobetasol results in increased expression of SEC13 mRNA

NCBI chr 4:148,433,344...148,446,735
Ensembl chr 4:148,433,349...148,446,755

G

SEC61 translocon subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of SEC61A1 mRNA

NCBI chr 4:122,530,785...122,545,141
Ensembl chr 4:122,530,789...122,545,141

G

SEC61 translocon subunit beta

increases expression

ISO

Clobetasol results in increased expression of SEC61B mRNA

NCBI chr 5:66,569,184...66,577,394
Ensembl chr 5:66,569,196...66,580,028

G

SEL1L family member 3

increases expression

ISO

Clobetasol results in increased expression of SEL1L3 mRNA

NCBI chr14:61,988,350...62,095,542
Ensembl chr14:61,988,346...62,095,542

G

selenium binding protein 1

increases expression

ISO

Clobetasol results in increased expression of SELENBP1 mRNA

NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:185,183,004...185,194,295

G

selenoprotein K

increases expression

ISO

Clobetasol results in increased expression of SELENOK mRNA

NCBI chr16:5,158,601...5,167,183
Ensembl chr16:5,158,621...5,168,512

G

serine incorporator 5

increases expression

ISO

Clobetasol results in increased expression of SERINC5 mRNA

NCBI chr 2:25,581,952...25,685,403
Ensembl chr 2:25,581,951...25,685,403

G

serpin family E member 2

increases expression

ISO

Clobetasol results in increased expression of SERPINE2 mRNA

NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202

G

SET binding protein 1

decreases expression

ISO

Clobetasol results in decreased expression of SETBP1 mRNA

NCBI chr18:74,465,616...74,827,455
Ensembl chr18:74,465,616...74,827,455

G

SET domain containing 1A, histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of SETD1A mRNA

NCBI chr 1:191,818,752...191,842,167
Ensembl chr 1:191,818,752...191,842,160

G

SET domain containing 2, histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of SETD2 mRNA

NCBI chr 8:119,390,207...119,475,863
Ensembl chr 8:119,390,207...119,475,863

G

splicing factor 3b, subunit 3

increases expression

ISO

Clobetasol results in increased expression of SF3B3 mRNA

NCBI chr19:55,692,124...55,729,640
Ensembl chr19:55,692,126...55,729,621

G

small G protein signaling modulator 2

decreases expression

ISO

Clobetasol results in decreased expression of SGSM2 mRNA

NCBI chr10:60,216,556...60,258,199
Ensembl chr10:60,216,556...60,257,817

G

SH3 domain binding glutamate-rich protein like 3

increases expression

ISO

Clobetasol results in increased expression of SH3BGRL3 mRNA

NCBI chr 5:151,637,897...151,639,270
Ensembl chr 5:151,637,674...151,639,395

G

SH3-domain binding protein 4

decreases expression

ISO

Clobetasol results in decreased expression of SH3BP4 mRNA

NCBI chr 9:97,107,877...97,186,878
Ensembl chr 9:97,107,877...97,186,878

G

SH3 domain containing 19

decreases expression

ISO

Clobetasol results in decreased expression of SH3D19 mRNA

NCBI chr 2:173,654,234...173,814,030
Ensembl chr 2:173,654,420...173,814,025

G

shisa family member 3

increases expression

ISO

Clobetasol results in increased expression of SHISA3 mRNA

NCBI chr14:40,917,563...40,922,135
Ensembl chr14:40,917,564...40,922,135

G

solute carrier family 10 member 6

increases expression

ISO

Clobetasol results in increased expression of SLC10A6 mRNA

NCBI chr14:6,385,348...6,407,532
Ensembl chr14:6,385,537...6,408,894

G

solute carrier family 11 member 2

increases expression

ISO

Clobetasol results in increased expression of SLC11A2 mRNA

NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:133,381,878...133,418,941

G

solute carrier family 12, member 9

increases expression

ISO

Clobetasol results in increased expression of SLC12A9 mRNA

NCBI chr12:25,005,741...25,022,628
Ensembl chr12:25,005,738...25,022,607

G

solute carrier family 25 member 11

increases expression

ISO

Clobetasol results in increased expression of SLC25A11 mRNA

NCBI chr10:55,856,209...55,859,060
Ensembl chr10:55,855,979...55,859,060

G

solute carrier family 25 member 18

increases expression

ISO

Clobetasol results in increased expression of SLC25A18 mRNA

NCBI chr 4:155,672,939...155,693,549
Ensembl chr 4:155,673,169...155,693,548

G

solute carrier family 25 member 29

increases expression

ISO

Clobetasol results in increased expression of SLC25A29 mRNA

NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:133,506,331...133,517,827

G

solute carrier family 25 member 3

increases expression

ISO

Clobetasol results in increased expression of SLC25A3 mRNA

NCBI chr 7:27,499,164...27,506,685
Ensembl chr 7:27,499,165...27,506,309

G

solute carrier family 25 member 33

increases expression

ISO

Clobetasol results in increased expression of SLC25A33 mRNA

NCBI chr 5:165,478,070...165,518,186
Ensembl chr 5:165,478,072...165,502,973

G

solute carrier family 25, member 39

increases expression

ISO

Clobetasol results in increased expression of SLC25A39 mRNA

NCBI chr10:87,862,630...87,867,626
Ensembl chr10:87,862,631...87,866,973

G

solute carrier family 25 member 4

increases expression

ISO

Clobetasol results in increased expression of SLC25A4 mRNA

NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700

G

solute carrier family 25 member 5

increases expression

ISO

Clobetasol results in increased expression of SLC25A5 mRNA

NCBI chr X:120,897,616...120,900,683
Ensembl chr X:120,897,563...120,900,688

G

solute carrier family 2 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 35 member A1

increases expression

ISO

Clobetasol results in increased expression of SLC35A1 mRNA

NCBI chr 5:54,021,896...54,044,677
Ensembl chr 5:54,021,896...54,044,677

G

solute carrier family 38, member 2

increases expression

ISO

Clobetasol results in increased expression of SLC38A2 mRNA

NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619

G

solute carrier family 39 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC39A1 mRNA

NCBI chr 2:178,001,052...178,006,689
Ensembl chr 2:178,001,119...178,006,689

G

solute carrier family 44, member 5

increases expression

ISO

Clobetasol results in increased expression of SLC44A5 mRNA

NCBI chr 2:245,570,875...245,866,369
Ensembl chr 2:245,570,829...245,867,780

G

solute carrier family 48 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC48A1 mRNA

NCBI chr 7:130,794,233...130,802,119
Ensembl chr 7:130,794,245...130,803,022

G

solute carrier family 6 member 1

decreases expression

ISO

Clobetasol results in decreased expression of SLC6A1 mRNA

NCBI chr 4:149,004,447...149,037,840
Ensembl chr 4:149,004,635...149,037,839

G

solute carrier family 6 member 9

increases expression

ISO

Clobetasol results in increased expression of SLC6A9 mRNA

NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172

G

solute carrier family 7 member 5

increases expression

ISO

Clobetasol results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

slit guidance ligand 3

increases expression

ISO

Clobetasol results in increased expression of SLIT3 mRNA

NCBI chr10:20,075,929...20,660,704
Ensembl chr10:20,076,021...20,660,704

G

SLX4 structure-specific endonuclease subunit

decreases expression

ISO

Clobetasol results in decreased expression of SLX4 mRNA

NCBI chr10:12,032,131...12,055,685
Ensembl chr10:12,033,048...12,055,650

G

small integral membrane protein 7

increases expression

ISO

Clobetasol results in increased expression of SMIM7 mRNA

NCBI chr16:17,308,466...17,312,384
Ensembl chr16:17,308,395...17,312,371

G

staphylococcal nuclease and tudor domain containing 1

increases expression

ISO

Clobetasol results in increased expression of SND1 mRNA

NCBI chr 4:58,060,689...58,459,926
Ensembl chr 4:58,060,640...58,459,925

G

sushi, nidogen and EGF-like domains 1

decreases expression

ISO

Clobetasol results in decreased expression of SNED1 mRNA

NCBI chr 9:101,221,497...101,281,401
Ensembl chr 9:101,221,530...101,281,401

G

small nuclear ribonucleoprotein U11/U12 subunit 25

increases expression

ISO

Clobetasol results in increased expression of SNRNP25 mRNA

NCBI chr10:15,924,932...15,928,279
Ensembl chr10:15,924,940...15,928,252

G

small nuclear ribonucleoprotein U5 subunit 40

increases expression

ISO

Clobetasol results in increased expression of SNRNP40 mRNA

NCBI chr 5:147,984,758...148,017,932
Ensembl chr 5:147,984,656...148,018,725

G

small nuclear ribonucleoprotein polypeptides B and B1

increases expression

ISO

Clobetasol results in increased expression of SNRPB mRNA

NCBI chr 3:137,824,870...137,832,479
Ensembl chr 3:137,824,683...137,832,515

G

small nuclear ribonucleoprotein D2 polypeptide

increases expression

ISO

Clobetasol results in increased expression of SNRPD2 mRNA

NCBI chr 1:87,926,030...87,929,259
Ensembl chr 1:87,926,048...87,933,339
Ensembl chr20:87,926,048...87,933,339

G

sorting nexin 17

increases expression

ISO

Clobetasol results in increased expression of SNX17 mRNA

NCBI chr 6:30,897,500...30,902,972
Ensembl chr 6:30,897,501...30,902,972

G

sine oculis binding protein homolog

decreases expression

ISO

Clobetasol results in decreased expression of SOBP mRNA

NCBI chr20:48,064,445...48,243,607
Ensembl chr20:48,064,445...48,243,607

G

SON DNA and RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of SON mRNA

NCBI chr11:44,336,818...44,409,127
Ensembl chr11:44,377,976...44,409,127

G

SRY-box transcription factor 11

decreases expression

ISO

Clobetasol results in decreased expression of SOX11 mRNA

NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691

G

SRY-box transcription factor 4

decreases expression

ISO

Clobetasol results in decreased expression of SOX4 mRNA

NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024

G

SRY-box transcription factor 6

decreases expression

ISO

Clobetasol results in decreased expression of SOX6 mRNA

NCBI chr 1:179,157,678...179,769,243
Ensembl chr 1:179,163,566...179,711,727

G

SRY-box transcription factor 9

decreases expression

ISO

Clobetasol results in decreased expression of SOX9 mRNA

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

signal peptidase complex subunit 2

increases expression

ISO

Clobetasol results in increased expression of SPCS2 mRNA

NCBI chr 1:163,575,842...163,595,269
Ensembl chr 1:163,575,842...163,595,271

G

sperm antigen with calponin homology and coiled-coil domains 1

decreases expression

ISO

Clobetasol results in decreased expression of SPECC1 mRNA

NCBI chr10:47,138,351...47,412,311
Ensembl chr10:47,138,398...47,412,319

G

SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2

increases expression

ISO

Clobetasol results in increased expression of SPOCK2 mRNA

NCBI chr20:28,580,262...28,607,198
Ensembl chr20:28,580,226...28,608,409

G

sprouty RTK signaling antagonist 4

increases expression

ISO

Clobetasol results in increased expression of SPRY4 mRNA

NCBI chr18:30,687,633...30,702,546
Ensembl chr18:30,687,039...30,704,173

G

SPRY domain containing 4

increases expression

ISO

Clobetasol results in increased expression of SPRYD4 mRNA

NCBI chr 7:1,217,984...1,222,231
Ensembl chr 7:1,218,122...1,219,942

G

spectrin, beta, non-erythrocytic 1

decreases expression

ISO

Clobetasol results in decreased expression of SPTBN1 mRNA

NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836

G

spectrin, beta, non-erythrocytic 2

decreases expression

ISO

Clobetasol results in decreased expression of SPTBN2 mRNA

NCBI chr 1:211,432,373...211,473,016
Ensembl chr 1:211,432,373...211,473,306

G

serine palmitoyltransferase, small subunit A

increases expression

ISO

Clobetasol results in increased expression of SPTSSA mRNA

NCBI chr 6:77,879,931...77,891,344
Ensembl chr 6:77,879,941...77,891,403

G

Snf2-related CREBBP activator protein

decreases expression

ISO

Clobetasol results in decreased expression of SRCAP mRNA

NCBI chr 1:191,554,043...191,607,096
Ensembl chr 1:191,554,043...191,604,265

G

SRC kinase signaling inhibitor 1

decreases expression

ISO

Clobetasol results in decreased expression of SRCIN1 mRNA

NCBI chr10:82,999,295...83,066,359
Ensembl chr10:82,991,033...83,067,419

G

SLIT-ROBO Rho GTPase activating protein 3

decreases expression

ISO

Clobetasol results in decreased expression of SRGAP3 mRNA

NCBI chr 4:147,391,082...147,626,407
Ensembl chr 4:147,395,880...147,625,713

G

spermidine synthase

increases expression

ISO

Clobetasol results in increased expression of SRM mRNA

NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705

G

SRP receptor subunit alpha

increases expression

ISO

Clobetasol results in increased expression of SRPRA mRNA

NCBI chr 8:41,818,199...41,824,292
Ensembl chr 8:41,818,229...41,824,280

G

sulfiredoxin 1

increases expression

ISO

Clobetasol results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

SS18 like 2

increases expression

ISO

Clobetasol results in increased expression of SS18L2 mRNA

NCBI chr 8:130,252,774...130,255,388
Ensembl chr 8:130,252,782...130,257,367

G

signal sequence receptor subunit 3

increases expression

ISO

Clobetasol results in increased expression of SSR3 mRNA

NCBI chr 2:151,915,101...151,935,162
Ensembl chr 2:151,906,149...151,935,170

G

steroidogenic acute regulatory protein

decreases expression

ISO

Clobetasol results in decreased expression of STAR mRNA

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

StAR-related lipid transfer domain containing 4

increases expression

ISO

Clobetasol results in increased expression of STARD4 mRNA

NCBI chr18:25,088,831...25,104,172
Ensembl chr18:25,091,255...25,104,172

G

StAR-related lipid transfer domain containing 9

decreases expression

ISO

Clobetasol results in decreased expression of STARD9 mRNA

NCBI chr 3:128,034,866...128,150,493
Ensembl chr 3:128,034,908...128,127,402

G

stathmin 3

increases expression

ISO

Clobetasol results in increased expression of STMN3 mRNA

NCBI chr 3:188,794,358...188,802,494
Ensembl chr 3:188,794,358...188,802,873

G

stonin 2

decreases expression

ISO

Clobetasol results in decreased expression of STON2 mRNA

NCBI chr 6:116,291,898...116,441,391
Ensembl chr 6:116,298,198...116,407,092

G

STIP1 homology and U-box containing protein 1

increases expression

ISO

Clobetasol results in increased expression of STUB1 mRNA

NCBI chr10:15,355,278...15,357,559
Ensembl chr10:15,355,279...15,357,559

G

SUB1 regulator of transcription

increases expression

ISO

Clobetasol results in increased expression of SUB1 mRNA

NCBI chr 2:62,735,379...62,747,545
Ensembl chr 2:62,732,736...62,747,679

G

SUN domain containing ossification factor

decreases expression

ISO

Clobetasol results in decreased expression of SUCO mRNA

NCBI chr13:76,726,095...76,791,174
Ensembl chr13:76,726,859...76,791,174

G

SPT6 homolog, histone chaperone and transcription elongation factor

decreases expression

ISO

Clobetasol results in decreased expression of SUPT6 mRNA

NCBI chr10:63,601,990...63,638,851
Ensembl chr10:63,601,993...63,638,851

G

surfeit 4

increases expression

ISO

Clobetasol results in increased expression of SURF4 mRNA

NCBI chr 3:30,646,435...30,659,641
Ensembl chr 3:30,638,299...30,661,390

G

spectrin repeat containing nuclear envelope protein 1

decreases expression

ISO

Clobetasol results in decreased expression of SYNE1 mRNA

NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

ISO

Clobetasol results in decreased expression of SYNE2 mRNA

NCBI chr 6:100,272,729...100,586,364
Ensembl chr 6:100,272,729...100,583,723

G

synergin, gamma

decreases expression

ISO

Clobetasol results in decreased expression of SYNRG mRNA

NCBI chr10:69,346,154...69,428,714
Ensembl chr10:69,322,114...69,428,714

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of TAB2 mRNA

NCBI chr 1:4,195,400...4,245,485
Ensembl chr 1:4,195,400...4,245,485

G

transgelin 2

increases expression

ISO

Clobetasol results in increased expression of TAGLN2 mRNA

NCBI chr13:87,499,350...87,506,328
Ensembl chr13:87,499,394...87,506,330

G

TAO kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of TAOK1 mRNA

NCBI chr10:62,871,198...62,989,049
Ensembl chr10:62,871,198...62,957,595

G

transcription activation suppressor family member 2

decreases expression

ISO

Clobetasol results in decreased expression of TASOR2 mRNA

NCBI chr17:71,504,656...71,559,878
Ensembl chr17:71,504,822...71,559,035

G

tubulin folding cofactor C

increases expression

ISO

Clobetasol results in increased expression of TBCC mRNA

NCBI chr 9:21,596,472...21,597,660
Ensembl chr 9:21,595,615...21,597,842

G

tubulin folding cofactor D

increases expression

ISO

Clobetasol results in increased expression of TBCD mRNA

NCBI chr10:107,215,626...107,372,398
Ensembl chr10:107,215,633...107,372,402

G

transcriptional and immune response regulator

increases expression

ISO

Clobetasol results in increased expression of TCIM mRNA

NCBI chr16:74,298,344...74,299,637
Ensembl chr16:74,298,344...74,299,636

G

TEF transcription factor, PAR bZIP family member

decreases expression

ISO

Clobetasol results in decreased expression of TEF mRNA

NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:115,193,282...115,221,928

G

TEN1 subunit of CST complex

increases expression

ISO

Clobetasol results in increased expression of TEN1 mRNA

NCBI chr10:101,930,212...101,951,932
Ensembl chr10:101,930,222...101,953,979

G

TIA1 cytotoxic granule-associated RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of TIA1 mRNA

NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665

G

translocase of inner mitochondrial membrane 10

increases expression

ISO

Clobetasol results in increased expression of TIMM10 mRNA

NCBI chr 3:90,315,048...90,318,613
Ensembl chr 3:90,315,092...90,318,614

G

translocase of inner mitochondrial membrane 13

increases expression

ISO

Clobetasol results in increased expression of TIMM13 mRNA

NCBI chr 7:9,459,490...9,460,849
Ensembl chr 7:9,459,582...9,460,862

G

translocase of inner mitochondrial membrane 8A1

increases expression

ISO

Clobetasol results in increased expression of TIMM8A1 mRNA

NCBI chr X:102,011,206...102,015,444
Ensembl chr X:102,011,206...102,015,444

G

TIMP metallopeptidase inhibitor 4

increases expression

ISO

Clobetasol results in increased expression of TIMP4 mRNA

NCBI chr 4:149,978,667...149,985,350
Ensembl chr 4:149,978,685...149,985,452

G

talin 1

decreases expression

ISO

Clobetasol results in decreased expression of TLN1 mRNA

NCBI chr 5:62,583,730...62,613,687
Ensembl chr 5:62,583,731...62,613,687

G

TM2 domain containing 2

increases expression

ISO

Clobetasol results in increased expression of TM2D2 mRNA

NCBI chr16:73,719,331...73,724,853
Ensembl chr16:73,719,332...73,724,981

G

transmembrane p24 trafficking protein 3

increases expression

ISO

Clobetasol results in increased expression of TMED3 mRNA

NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:99,121,361...99,129,215

G

transmembrane p24 trafficking protein 4

increases expression

ISO

Clobetasol results in increased expression of TMED4 mRNA

NCBI chr14:85,338,980...85,343,577
Ensembl chr14:85,338,980...85,343,577

G

transmembrane protein 101

increases expression

ISO

Clobetasol results in increased expression of TMEM101 mRNA

NCBI chr10:87,605,300...87,609,053
Ensembl chr10:87,605,300...87,608,999

G

transmembrane protein 109

increases expression

ISO

Clobetasol results in increased expression of TMEM109 mRNA

NCBI chr 1:216,944,516...216,955,091
Ensembl chr 1:216,944,519...216,955,138

G

transmembrane protein 128

increases expression

ISO

Clobetasol results in increased expression of TMEM128 mRNA

NCBI chr14:76,751,848...76,761,576
Ensembl chr14:76,752,603...76,772,217

G

transmembrane protein 131

decreases expression

ISO

Clobetasol results in decreased expression of TMEM131 mRNA

NCBI chr 9:46,512,328...46,658,624
Ensembl chr 9:46,512,328...46,658,481

G

transmembrane protein 135

increases expression

ISO

Clobetasol results in increased expression of TMEM135 mRNA

NCBI chr 1:152,418,929...152,692,405
Ensembl chr 1:152,418,930...152,633,717

G

transmembrane protein 151B

decreases expression

ISO

Clobetasol results in decreased expression of TMEM151B mRNA

NCBI chr 9:22,953,881...22,961,726
Ensembl chr 9:22,953,881...22,961,726

G

transmembrane protein 160

increases expression

ISO

Clobetasol results in increased expression of TMEM160 mRNA

NCBI chr 1:86,292,582...86,295,290
Ensembl chr 1:86,292,753...86,297,780

G

transmembrane protein 179

increases expression

ISO

Clobetasol results in increased expression of TMEM179 mRNA

NCBI chr 6:137,390,422...137,401,438
Ensembl chr 6:137,390,423...137,401,438

G

transmembrane protein 208

increases expression

ISO

Clobetasol results in increased expression of TMEM208 mRNA

NCBI chr19:50,113,494...50,116,210
Ensembl chr19:50,113,510...50,124,153

G

transmembrane protein 229A

increases expression

ISO

Clobetasol results in increased expression of TMEM229A mRNA

NCBI chr 4:54,405,822...54,410,802
Ensembl chr 4:54,399,867...54,412,225

G

transmembrane protein 256

increases expression

ISO

Clobetasol results in increased expression of TMEM256 mRNA

NCBI chr10:55,056,959...55,058,869
Ensembl chr10:55,056,760...55,058,862

G

transmembrane protein 35A

increases expression

ISO

Clobetasol results in increased expression of TMEM35A mRNA

NCBI chr X:101,796,623...101,807,471
Ensembl chr X:101,796,623...101,807,470

G

transmembrane protein 43

increases expression

ISO

Clobetasol results in increased expression of TMEM43 mRNA

NCBI chr 4:125,534,844...125,549,986
Ensembl chr 4:125,534,813...125,549,988

G

transmembrane protein 50B

increases expression

ISO

Clobetasol results in increased expression of TMEM50B mRNA

NCBI chr11:44,290,805...44,323,650
Ensembl chr11:44,290,807...44,323,607

G

transmembrane protein 59

increases expression

ISO

Clobetasol results in increased expression of TMEM59 mRNA

NCBI chr 5:127,191,320...127,212,436
Ensembl chr 5:127,191,030...127,217,531

G

transmembrane protein 97

increases expression

ISO

Clobetasol results in increased expression of TMEM97 mRNA

NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818

G

tumor necrosis factor

decreases secretion

ISO

Clobetasol results in decreased secretion of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 1A

increases expression

ISO

Clobetasol results in increased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

tenascin R

decreases expression

ISO

Clobetasol results in decreased expression of TNR mRNA

NCBI chr13:74,285,141...74,706,174
Ensembl chr13:74,507,366...74,701,115

G

trinucleotide repeat containing 18

decreases expression

ISO

Clobetasol results in decreased expression of TNRC18 mRNA

NCBI chr12:16,868,930...16,965,224
Ensembl chr12:16,868,978...16,965,217

G

transducer of ERBB2, 2

increases expression

ISO

Clobetasol results in increased expression of TOB2 mRNA

NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:115,239,895...115,258,155

G

toll interacting protein

increases expression

ISO

Clobetasol results in increased expression of TOLLIP mRNA

NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988

G

triosephosphate isomerase 1

increases expression

ISO

Clobetasol results in increased expression of TPI1 mRNA

NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:159,301,562...159,305,413

G

translocated promoter region, nuclear basket protein

decreases expression

ISO

Clobetasol results in decreased expression of TPR mRNA

NCBI chr13:64,974,419...65,037,604
Ensembl chr13:64,974,419...65,037,602

G

taperin

increases expression

ISO

Clobetasol results in increased expression of TPRN mRNA

NCBI chr 3:28,474,322...28,481,800
Ensembl chr 3:28,473,620...28,482,117

G

transformer 2 alpha

decreases expression

ISO

Clobetasol results in decreased expression of TRA2A mRNA

NCBI chr 4:79,551,699...79,570,621
Ensembl chr 4:79,551,542...79,570,619

G

TP53 regulated inhibitor of apoptosis 1

increases expression

ISO

Clobetasol results in increased expression of TRIAP1 mRNA

NCBI chr12:46,928,273...46,930,766
Ensembl chr12:46,928,273...46,930,766

G

TLR4 interactor with leucine-rich repeats

decreases expression

ISO

Clobetasol results in decreased expression of TRIL mRNA

NCBI chr 4:84,252,781...84,257,626
Ensembl chr 4:84,239,028...84,260,209

G

tripartite motif-containing 35

increases expression

ISO

Clobetasol results in increased expression of TRIM35 mRNA

NCBI chr15:44,669,222...44,685,766
Ensembl chr15:44,656,322...44,685,765

G

tripartite motif-containing 67

decreases expression

ISO

Clobetasol results in decreased expression of TRIM67 mRNA

NCBI chr19:69,659,857...69,703,290
Ensembl chr19:69,661,777...69,698,805

G

trio Rho guanine nucleotide exchange factor

decreases expression

ISO

Clobetasol results in decreased expression of TRIO mRNA

NCBI chr 2:80,235,485...80,531,824
Ensembl chr 2:80,235,485...80,531,612

G

tRNA methyltransferase 10B

increases expression

ISO

Clobetasol results in increased expression of TRMT10B mRNA

NCBI chr 5:64,344,491...64,368,175
Ensembl chr 5:64,344,545...64,368,172

G

transformation/transcription domain-associated protein

decreases expression

ISO

Clobetasol results in decreased expression of TRRAP mRNA

NCBI chr12:14,851,758...14,941,444
Ensembl chr12:14,851,758...14,941,407

G

TSC22 domain family, member 1

decreases expression

ISO

Clobetasol results in decreased expression of TSC22D1 mRNA

NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322

G

TSC22 domain family, member 3

increases expression

ISO

Clobetasol results in increased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

TSC22 domain family, member 4

increases expression

ISO

Clobetasol results in increased expression of TSC22D4 mRNA

NCBI chr12:24,575,948...24,588,806
Ensembl chr12:24,567,176...24,587,894

G

translin

increases expression

ISO

Clobetasol results in increased expression of TSN mRNA

NCBI chr13:31,917,133...31,930,069
Ensembl chr13:31,919,231...31,930,417

G

tetraspanin 13

increases expression

ISO

Clobetasol results in increased expression of TSPAN13 mRNA

NCBI chr 6:58,466,051...58,492,804
Ensembl chr 6:58,465,684...58,492,819

G

tetraspanin 3

increases expression

ISO

Clobetasol results in increased expression of TSPAN3 mRNA

NCBI chr 8:65,442,100...65,465,961
Ensembl chr 8:65,442,101...65,465,844

G

tetraspanin 31

increases expression

ISO

Clobetasol results in increased expression of TSPAN31 mRNA

NCBI chr 7:64,774,881...64,783,534
Ensembl chr 7:64,774,910...64,777,726

G

tau tubulin kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of TTBK1 mRNA

NCBI chr 9:21,990,973...22,035,961
Ensembl chr 9:21,990,973...22,035,961

G

tetratricopeptide repeat domain 17

decreases expression

ISO

Clobetasol results in decreased expression of TTC17 mRNA

NCBI chr 3:100,718,820...100,829,464
Ensembl chr 3:100,718,827...100,829,129

G

tetratricopeptide repeat domain 28

decreases expression

ISO

Clobetasol results in decreased expression of TTC28 mRNA

NCBI chr12:51,002,816...51,443,461
Ensembl chr12:51,005,089...51,443,531

G

tubulin tyrosine ligase like 12

increases expression

ISO

Clobetasol results in increased expression of TTLL12 mRNA

NCBI chr 7:116,612,609...116,631,244
Ensembl chr 7:116,612,609...116,631,577

G

TUB bipartite transcription factor

decreases expression

ISO

Clobetasol results in decreased expression of TUB mRNA

NCBI chr 1:172,386,772...172,465,791
Ensembl chr 1:172,382,197...172,465,790

G

tubulin, alpha 1A

increases expression

ISO

Clobetasol results in increased expression of TUBA1A mRNA

NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035

G

tubulin, alpha 1B

increases expression

ISO

Clobetasol results in increased expression of TUBA1B mRNA

NCBI chr 7:131,969,606...131,972,587
Ensembl chr 7:131,968,770...131,996,035

G

tubulin, alpha 1C

increases expression

ISO

Clobetasol results in increased expression of TUBA1C mRNA

NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311

G

tubulin, beta 2A class IIa

increases expression

ISO

Clobetasol results in increased expression of TUBB2A mRNA

NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838

G

tubulin, beta 5 class I

increases expression

ISO

Clobetasol results in increased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

taxilin beta

decreases expression

ISO

Clobetasol results in decreased expression of TXLNB mRNA

NCBI chr 1:14,224,647...14,269,837
Ensembl chr 1:14,195,329...14,269,835

G

thioredoxin-like 1

increases expression

ISO

Clobetasol results in increased expression of TXNL1 mRNA

NCBI chr18:59,397,275...59,428,072
Ensembl chr18:59,398,535...59,435,518

G

tRNA-yW synthesizing protein 5

increases expression

ISO

Clobetasol results in increased expression of TYW5 mRNA

NCBI chr 9:66,455,364...66,473,446
Ensembl chr 9:66,455,370...66,473,446

G

UBA domain containing 2

increases expression

ISO

Clobetasol results in increased expression of UBAC2 mRNA

NCBI chr15:105,366,776...105,514,435
Ensembl chr15:105,366,697...105,514,444

G

UBA-like domain containing 2

increases expression

ISO

Clobetasol results in increased expression of UBALD2 mRNA

NCBI chr10:102,161,370...102,165,952
Ensembl chr10:102,160,866...102,168,041

G

ubiquitin-conjugating enzyme E2G 2

increases expression

ISO

Clobetasol results in increased expression of UBE2G2 mRNA

NCBI chr20:10,983,322...11,005,060
Ensembl chr20:10,983,325...11,005,187

G

ubiquitin family domain containing 1

increases expression

ISO

Clobetasol results in increased expression of UBFD1 mRNA

NCBI chr 1:186,057,267...186,068,832
Ensembl chr 1:186,057,123...186,066,103

G

ubiquitin-like 5

increases expression

ISO

Clobetasol results in increased expression of UBL5 mRNA

NCBI chr 8:27,457,738...27,461,458

G

ubiquitin protein ligase E3 component n-recognin 4

decreases expression

ISO

Clobetasol results in decreased expression of UBR4 mRNA

NCBI chr 5:156,919,029...157,027,127
Ensembl chr 5:156,919,085...157,027,127

G

ubiquitin protein ligase E3 component n-recognin 7

increases expression

ISO

Clobetasol results in increased expression of UBR7 mRNA

NCBI chr 6:127,663,454...127,683,302
Ensembl chr 6:127,663,447...127,694,390

G

UBX domain protein 4

decreases expression

ISO

Clobetasol results in decreased expression of UBXN4 mRNA

NCBI chr13:42,292,346...42,324,928
Ensembl chr13:42,292,528...42,326,143

G

uncoupling protein 2

increases expression

ISO

Clobetasol results in increased expression of UCP2 mRNA

NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743

G

unc-80 homolog, NALCN channel complex subunit

decreases expression

ISO

Clobetasol results in decreased expression of UNC80 mRNA

NCBI chr 9:75,461,618...75,639,849
Ensembl chr 9:75,461,599...75,639,842

G

ubiquinol-cytochrome c reductase complex assembly factor 2

increases expression

ISO

Clobetasol results in increased expression of UQCC2 mRNA

NCBI chr20:5,204,682...5,217,080
Ensembl chr17:12,088,037...12,088,606
Ensembl chr20:12,088,037...12,088,606

G

ubiquinol-cytochrome c reductase, complex III subunit X

increases expression

ISO

Clobetasol results in increased expression of UQCR10 mRNA

NCBI chr14:83,789,657...83,791,914
Ensembl chr14:83,789,658...83,791,914

G

ubiquinol-cytochrome c reductase core protein 1

increases expression

ISO

Clobetasol results in increased expression of UQCRC1 mRNA

NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:118,468,200...118,479,964

G

ubiquitin specific peptidase 34

decreases expression

ISO

Clobetasol results in decreased expression of USP34 mRNA

NCBI chr14:101,487,110...101,677,519
Ensembl chr14:101,487,153...101,678,632

G

ubiquitin specific peptidase 54

increases expression

ISO

Clobetasol results in increased expression of USP54 mRNA

NCBI chr15:3,706,013...3,806,935
Ensembl chr15:3,741,311...3,806,932

G

UTP14A small subunit processome component

decreases expression

ISO

Clobetasol results in decreased expression of UTP14A mRNA

NCBI chr X:132,317,163...132,342,524
Ensembl chr X:132,317,159...132,342,523

G

utrophin

decreases expression

ISO

Clobetasol results in decreased expression of UTRN mRNA

NCBI chr 1:8,541,061...9,044,487
Ensembl chr 1:8,542,798...9,044,487

G

vasohibin 1

increases expression

ISO

Clobetasol results in increased expression of VASH1 mRNA

NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689

G

vascular cell adhesion molecule 1

decreases expression

ISO

Clobetasol results in decreased expression of VCAM1 mRNA

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

voltage-dependent anion channel 1

increases expression

ISO

Clobetasol results in increased expression of VDAC1 mRNA

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

G

voltage-dependent anion channel 2

increases expression

ISO

Clobetasol results in increased expression of VDAC2 mRNA

NCBI chr15:2,512,214...2,526,105
Ensembl chr15:2,512,216...2,532,229

G

vimentin

increases expression

ISO

Clobetasol results in increased expression of VIM mRNA

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vitamin K epoxide reductase complex, subunit 1

increases expression

ISO

Clobetasol results in increased expression of VKORC1 mRNA

NCBI chr 1:191,932,969...191,935,490

G

vacuolar protein sorting 13 homolog B

decreases expression

ISO

Clobetasol results in decreased expression of VPS13B mRNA

NCBI chr 7:68,436,996...69,013,574
Ensembl chr 7:68,443,655...69,013,574

G

VPS37B subunit of ESCRT-I

decreases expression

ISO

Clobetasol results in decreased expression of VPS37B mRNA

NCBI chr12:38,220,973...38,249,935
Ensembl chr12:38,220,959...38,249,935

G

vexin

decreases expression

ISO

Clobetasol results in decreased expression of VXN mRNA

NCBI chr 5:14,442,040...14,467,500
Ensembl chr 5:14,442,040...14,467,500

G

WASP family member 1

decreases expression

ISO

Clobetasol results in decreased expression of WASF1 mRNA

NCBI chr20:45,908,458...45,956,118
Ensembl chr20:45,908,750...45,955,640

G

WW domain binding protein 2

increases expression

ISO

Clobetasol results in increased expression of WBP2 mRNA

NCBI chr10:101,811,308...101,819,766
Ensembl chr10:101,812,321...101,819,770

G

WD repeat and FYVE domain containing 3

decreases expression

ISO

Clobetasol results in decreased expression of WDFY3 mRNA

NCBI chr14:7,873,946...8,115,002
Ensembl chr14:7,911,151...8,114,993

G

WD repeat domain 26

decreases expression

ISO

Clobetasol results in decreased expression of WDR26 mRNA

NCBI chr13:95,462,017...95,503,826
Ensembl chr13:95,462,020...95,503,738

G

WD repeat domain 46

increases expression

ISO

Clobetasol results in increased expression of WDR46 mRNA

NCBI chr20:4,939,721...4,947,619
Ensembl chr20:4,939,732...4,947,741

G

wolframin ER transmembrane glycoprotein

increases expression

ISO

Clobetasol results in increased expression of WFS1 mRNA

NCBI chr14:78,035,205...78,059,718
Ensembl chr14:78,034,864...78,060,459

G

WAS/WASL interacting protein family, member 2

decreases expression

ISO

Clobetasol results in decreased expression of WIPF2 mRNA

NCBI chr10:84,317,305...84,357,862
Ensembl chr10:84,317,334...84,356,123

G

Wnt family member 7A

decreases expression

ISO

Clobetasol results in decreased expression of WNT7A mRNA

NCBI chr 4:125,420,276...125,466,149
Ensembl chr 4:125,420,276...125,466,149

G

WSC domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of WSCD1 mRNA

NCBI chr10:56,884,404...56,924,013
Ensembl chr10:56,884,583...56,924,013

G

WT1 associated protein

decreases expression

ISO

Clobetasol results in decreased expression of WTAP mRNA

NCBI chr 1:50,070,973...50,096,074
Ensembl chr 1:50,070,769...50,096,072

G

WW and C2 domain containing 2

decreases expression

ISO

Clobetasol results in decreased expression of WWC2 mRNA

NCBI chr16:50,991,096...51,154,529
Ensembl chr16:50,991,096...51,154,526

G

Yip1 interacting factor homolog A, membrane trafficking protein

increases expression

ISO

Clobetasol results in increased expression of YIF1A mRNA

NCBI chr 1:211,823,921...211,828,437
Ensembl chr 1:211,824,273...211,828,802

G

Yip1 domain family, member 3

increases expression

ISO

Clobetasol results in increased expression of YIPF3 mRNA

NCBI chr 9:22,227,867...22,233,177
Ensembl chr 9:22,227,871...22,233,177

G

YLP motif containing 1

decreases expression

ISO

Clobetasol results in decreased expression of YLPM1 mRNA

NCBI chr 6:110,373,371...110,449,578
Ensembl chr 6:110,373,686...110,449,578

G

yippee-like 4

decreases expression

ISO

Clobetasol results in decreased expression of YPEL4 mRNA

NCBI chr 3:90,222,060...90,227,395
Ensembl chr 3:90,222,803...90,227,381

G

YTH N6-methyladenosine RNA binding protein C1

decreases expression

ISO

Clobetasol results in decreased expression of YTHDC1 mRNA

NCBI chr14:21,540,276...21,570,724
Ensembl chr14:21,540,278...21,570,769

G

YY1 transcription factor

decreases expression

ISO

Clobetasol results in decreased expression of YY1 mRNA

NCBI chr 6:133,471,615...133,500,875
Ensembl chr 6:133,471,562...133,497,257

G

zinc finger, BED-type containing 6

decreases expression

ISO

Clobetasol results in decreased expression of ZBED6 mRNA

NCBI chr13:47,659,269...47,665,540
Ensembl chr13:47,658,667...47,668,221

G

zinc finger CCCH-type containing 7B

decreases expression

ISO

Clobetasol results in decreased expression of ZC3H7B mRNA

NCBI chr 7:115,142,245...115,190,513
Ensembl chr 7:115,142,420...115,190,513

G

zinc finger CCHC-type containing 14

decreases expression

ISO

Clobetasol results in decreased expression of ZCCHC14 mRNA

NCBI chr19:66,582,800...66,627,136
Ensembl chr19:66,582,800...66,627,136

G

zinc finger, C3H1-type containing

decreases expression

ISO

Clobetasol results in decreased expression of ZFC3H1 mRNA

NCBI chr 7:52,894,417...52,950,755
Ensembl chr 7:52,894,172...52,950,758

G

zinc finger homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX2 mRNA

NCBI chr15:32,501,755...32,541,720
Ensembl chr15:32,503,115...32,535,085

G

zinc finger homeobox 3

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX3 mRNA

NCBI chr19:52,789,146...53,795,664
Ensembl chr19:53,551,488...53,795,664

G

zinc finger homeobox 4

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX4 mRNA

NCBI chr 2:98,131,996...98,321,070
Ensembl chr 2:98,131,996...98,315,469

G

zinc finger protein 282

decreases expression

ISO

Clobetasol results in decreased expression of ZFP282 mRNA

NCBI chr 4:78,215,940...78,241,193
Ensembl chr 4:78,215,898...78,241,192

G

zinc finger protein 316

decreases expression

ISO

Clobetasol results in decreased expression of ZFP316 mRNA

NCBI chr12:16,408,032...16,427,427
Ensembl chr12:16,408,464...16,427,427

G

zinc finger protein 334

decreases expression

ISO

Clobetasol results in decreased expression of ZFP334 mRNA

NCBI chr 3:174,531,835...174,544,374
Ensembl chr 3:174,533,517...174,544,400

G

zinc finger protein 423

decreases expression

ISO

Clobetasol results in decreased expression of ZFP423 mRNA

NCBI chr19:35,282,149...35,580,775
Ensembl chr19:35,282,110...35,580,773

G

zinc finger protein 462

decreases expression

ISO

Clobetasol results in decreased expression of ZFP462 mRNA

NCBI chr 5:74,465,383...74,606,020
Ensembl chr 5:74,468,643...74,606,020

G

zinc finger protein 488

decreases expression

ISO

Clobetasol results in decreased expression of ZFP488 mRNA

NCBI chr16:9,289,286...9,299,928
Ensembl chr16:9,280,322...9,300,400

G

zinc finger protein 57

increases expression

ISO

Clobetasol results in increased expression of ZFP57 mRNA

NCBI chr20:1,526,565...1,546,480
Ensembl chr20:1,527,961...1,535,041

G

zinc finger protein 592

decreases expression

ISO

Clobetasol results in decreased expression of ZFP592 mRNA

NCBI chr 1:144,355,227...144,411,686
Ensembl chr 1:144,361,654...144,411,684

G

zinc finger protein 609

decreases expression

ISO

Clobetasol results in decreased expression of ZFP609 mRNA

NCBI chr 8:75,109,676...75,243,045
Ensembl chr 8:75,109,676...75,213,086

G

zinc finger protein 638

decreases expression

ISO

Clobetasol results in decreased expression of ZFP638 mRNA

NCBI chr 4:117,913,528...118,032,644
Ensembl chr 4:117,913,545...118,032,643

G

zinc finger protein 706

increases expression

ISO

Clobetasol results in increased expression of ZFP706 mRNA

NCBI chr 7:70,050,960...70,059,588
Ensembl chr 7:70,052,534...70,059,159

G

zinc finger with KRAB and SCAN domains 3

decreases expression

ISO

Clobetasol results in decreased expression of ZKSCAN3 mRNA

NCBI chr17:47,912,816...47,928,553
Ensembl chr17:47,912,912...47,928,551

G

zinc finger ZZ-type and EF-hand domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ZZEF1 mRNA

NCBI chr10:57,911,728...58,049,412
Ensembl chr10:57,911,728...58,049,412

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases secretion

ISO

Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
increases activity

ISO

Hydrocortisone promotes the reaction [ABCC3 protein affects the transport of calcein AM]
Hydrocortisone results in increased expression of ABCC3 mRNA
Hydrocortisone results in increased activity of ABCC3 protein

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

acetyl-CoA carboxylase alpha

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of ACACA mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

atypical chemokine receptor 1

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ACKR1 mRNA]

NCBI chr13:88,314,735...88,316,354
Ensembl chr13:88,293,188...88,317,807

G

ATP citrate lyase

increases expression

ISO

Hydrocortisone results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

acyl-CoA synthetase long-chain family member 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

actinin alpha 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

ADAM metallopeptidase domain 12

decreases expression

ISO

Hydrocortisone results in decreased expression of ADAM12 mRNA

NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552

G

adhesion G protein-coupled receptor E5

decreases expression

ISO

Hydrocortisone results in decreased expression of ADGRE5 mRNA

NCBI chr19:41,302,687...41,332,183
Ensembl chr19:41,303,213...41,324,641

G

adhesion G protein-coupled receptor G1

decreases expression

ISO

Hydrocortisone results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

alpha-fetoprotein

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

angiotensinogen

decreases expression
increases secretion

ISO

Hydrocortisone results in decreased expression of AGT protein
AGT protein results in increased secretion of Hydrocortisone

PMID:7473517 PMID:28235592

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

aldo-keto reductase family 1, member D1

increases reduction
multiple interactions

ISO

AKR1D1 protein results in increased reduction of Hydrocortisone
AKR1D1 protein alternative form results in increased reduction of Hydrocortisone; AKR1D1 protein results in increased reduction of Hydrocortisone
[AKR1D1 protein alternative form results in increased reduction of Hydrocortisone] which results in increased chemical synthesis of 5-dihydrocortisol

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

AKT serine/threonine kinase 1

decreases phosphorylation

EXP

Hydrocortisone results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

AKT serine/threonine kinase 2

decreases expression

ISO

Hydrocortisone results in decreased expression of AKT2 mRNA

PMID:31075344 PMID:32535229

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420

G

albumin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldolase, fructose-bisphosphate A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

anti-Mullerian hormone receptor type 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA

NCBI chr 7:135,454,517...135,470,183
Ensembl chr 7:135,457,922...135,471,104

G

annexin A1

multiple interactions
increases expression

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ANXA1 mRNA]

PMID:25763180 PMID:34480604

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

apolipoprotein A1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein B

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

androgen receptor

affects activity
affects binding
multiple interactions

ISO
EXP

Hydrocortisone affects the activity of AR protein
Hydrocortisone binds to AR protein
Hydrocortisone binds to AR protein mutant form
Hydrocortisone binds to and results in increased activity of AR protein; Hydrocortisone binds to and results in increased activity of AR protein mutant form

PMID:11956172 PMID:12676605 PMID:14565775 PMID:15084347

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginase 1

increases expression
multiple interactions

EXP

Hydrocortisone results in increased expression of ARG1 mRNA
Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

achaete-scute family bHLH transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA

NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231

G

basic helix-loop-helix ARNT like 1

decreases expression

ISO

Hydrocortisone results in decreased expression of BMAL1 mRNA

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

bone morphogenetic protein 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA

NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA

NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485

G

caspase 3

increases activity
multiple interactions

ISO
EXP

Hydrocortisone results in increased activity of CASP3 protein
Hydrocortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]

PMID:15086553 PMID:15755911

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

decreases expression
multiple interactions

ISO
EXP

Hydrocortisone results in decreased expression of CCL2 protein
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]

PMID:20116850 PMID:25851902

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Hydrocortisone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Hydrocortisone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

CD14 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD40 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD40 protein

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

Cd80 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD80 protein

PMID:15086553 PMID:15241357

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

CD86 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD86 protein

PMID:15086553 PMID:15241357

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

cell division cycle 20

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cadherin 10

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA

NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332

G

cadherin 5

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of CDH5 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CDH5 protein]

NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822

G

CEA cell adhesion molecule 6

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA

NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:89,544,400...89,562,552

G

CCAAT/enhancer binding protein alpha

multiple interactions
increases expression

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
Hydrocortisone results in increased expression of CEBPA mRNA; Hydrocortisone results in increased expression of CEBPA protein

PMID:30528684 PMID:30776459 PMID:32535229 PMID:33476690

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

affects expression
multiple interactions

ISO

Hydrocortisone affects the expression of CEBPB mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of CEBPB mRNA]

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

cell death-inducing DFFA-like effector c

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA

NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806

G

collagen type I alpha 1 chain

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type III alpha 1 chain

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type VII alpha 1 chain

decreases expression

ISO

Hydrocortisone results in decreased expression of COL7A1 mRNA

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439

G

carnitine palmitoyltransferase 1A

decreases expression

ISO

Hydrocortisone results in decreased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

corticotropin releasing hormone

increases abundance

ISO

CRH protein results in increased abundance of Hydrocortisone

PMID:8888355 PMID:20570051

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

cryptochrome circadian regulator 1

increases expression

ISO

Hydrocortisone results in increased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

crystallin, alpha B

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

citrate synthase

decreases activity
multiple interactions

EXP

Hydrocortisone results in decreased activity of CS protein
Dactinomycin inhibits the reaction [Hydrocortisone results in decreased activity of CS protein]

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

colony stimulating factor 2

decreases secretion
multiple interactions

ISO

Hydrocortisone results in decreased secretion of CSF2 protein
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]

PMID:10460758 PMID:15086553

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

catenin beta 1

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of CTNNB1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CTNNB1 protein]

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression
multiple interactions
affects expression

ISO

Hydrocortisone results in decreased expression of CYP11A1 mRNA; Hydrocortisone results in decreased expression of CYP11A1 protein
HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]
Hydrocortisone affects the expression of CYP11A1 mRNA

PMID:30528684 PMID:34454011

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases chemical synthesis
multiple interactions
affects metabolic processing

ISO

CYP11B1 protein results in increased chemical synthesis of Hydrocortisone
3',4'-dimethoxyflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; alpha-naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; beta-Naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]
CYP11B1 protein affects the metabolism of Hydrocortisone

PMID:16030167 PMID:16054388 PMID:19900470 PMID:22172629

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
decreases expression

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
Hydrocortisone results in decreased expression of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 26, subfamily b, polypeptide 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA

NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:118,599,356...118,616,176

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP2B1 mRNA; Hydrocortisone results in increased expression of CYP2B1 protein

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

ISO

CYP2D6 gene SNP affects the reaction [Ethylenethiourea affects the abundance of Hydrocortisone]

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP2E1 mRNA; Hydrocortisone results in increased expression of CYP2E1 protein

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression

ISO

Hydrocortisone results in decreased expression of CYP2S1 mRNA

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
affects metabolic processing
multiple interactions
affects hydroxylation
increases metabolic processing

EXP
ISO

Hydrocortisone results in increased expression of CYP3A2 mRNA
CYP3A4 protein affects the metabolism of Hydrocortisone
CYP3A4 promoter mutant form inhibits the reaction [Hydrocortisone results in increased expression of CYP3A4 mRNA]; kaempferol inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]; Quercetin inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]
CYP3A4 protein affects the hydroxylation of Hydrocortisone
CYP3A4 protein results in increased metabolism of Hydrocortisone

PMID:2271712 PMID:10476907 PMID:11907490 PMID:12505310 PMID:15025748 More...

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP3A23-3A1 mRNA; Hydrocortisone results in increased expression of CYP3A23-3A1 protein

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of CYP3A5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA

PMID:23223499 PMID:34480604

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 4, subfamily a, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP4A1 mRNA

NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:134,360,111...134,374,231

G

DCC netrin 1 receptor

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA

NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541

G

decorin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

doublecortin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA

NCBI chr X:112,227,455...112,370,291
Ensembl chr X:112,227,455...112,304,161

G

dehydrogenase/reductase 9

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA

NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:74,555,606...74,581,376

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

desmoglein 1

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:11,948,098...11,980,455
Ensembl chr18:11,949,488...11,980,451

G

dual specificity phosphatase 1

increases expression

ISO

Hydrocortisone results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

EBF transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA

NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702

G

EBF transcription factor 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA

NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305

G

endothelial cell surface expressed chemotaxis and apoptosis regulator

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA

NCBI chr18:27,583,791...27,593,184
Ensembl chr18:27,583,195...27,593,195

G

epidermal growth factor

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]

PMID:17805209 PMID:34480604

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

egl-9 family hypoxia-inducible factor 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA

NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015

G

ELAV like RNA binding protein 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA

NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659

G

ELAV like RNA binding protein 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA

NCBI chr 5:130,285,418...130,429,106
Ensembl chr 5:130,285,418...130,429,096

G

empty spiracles homeobox 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA

NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671

G

erythropoietin

increases expression

ISO

Hydrocortisone results in increased expression of EPO protein

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

ERBB receptor feedback inhibitor 1

increases expression

EXP

Hydrocortisone results in increased expression of ERRFI1 mRNA

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

estrogen receptor 1

multiple interactions

ISO

Hydrocortisone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

fatty acid binding protein 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid binding protein 4

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fumarylacetoacetate hydrolase

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA

NCBI chr 1:147,957,931...147,980,708
Ensembl chr 1:147,957,935...147,981,046

G

Fas cell surface death receptor

multiple interactions
increases expression

ISO

[HIV Envelope Protein gp120 co-treated with Hydrocortisone] results in increased expression of FAS mRNA; Hydrocortisone promotes the reaction [Mitoxantrone results in increased expression of FAS]
Hydrocortisone results in increased expression of FAS protein

PMID:9676859 PMID:11075952 PMID:15086553

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

fatty acid synthase

multiple interactions
increases expression

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

F-box protein 32

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

fibrinogen beta chain

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 7

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA

NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328

G

fibroblast growth factor 9

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA

NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926

G

FKBP prolyl isomerase 5

increases expression

ISO

Hydrocortisone results in increased expression of FKBP5 mRNA

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

filaggrin

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of FLG mRNA
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

NCBI chr 2:181,583,801...181,596,464
Ensembl chr 2:181,583,808...181,595,968

G

fibronectin leucine rich transmembrane protein 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA

NCBI chr 3:148,448,115...148,461,458
Ensembl chr 3:148,439,354...148,461,650

G

Fms related receptor tyrosine kinase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750

G

forkhead box D3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA

NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786

G

forkhead box G1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA

NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392

G

forkhead box O1

increases expression

ISO

Hydrocortisone results in increased expression of FOXO1 mRNA

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

GATA binding protein 6

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA

NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,458,253...2,492,322

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

EXP
ISO

Hydrocortisone results in increased expression of GCLC mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA

PMID:10978506 PMID:34480604

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

growth hormone 1

increases expression

ISO

Hydrocortisone results in increased expression of GH1 protein

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

glyceronephosphate O-acyltransferase

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of GNPAT mRNA]

NCBI chr19:69,719,707...69,746,244
Ensembl chr19:69,719,394...69,746,244

G

G protein-coupled receptor 183

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA

NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977

G

glutathione peroxidase 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616

G

glutamate ionotropic receptor AMPA type subunit 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679

G

glutathione S-transferase alpha 1

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of GSTA1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; Hydrocortisone results in increased expression of and results in increased activity of GSTA1 protein

PMID:11297599 PMID:34480604

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

glutathione S-transferase alpha 2

multiple interactions
decreases expression
increases expression

EXP
ISO

Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of GSTA2 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA
Hydrocortisone results in decreased expression of GSTA2 mRNA
Hydrocortisone results in increased expression of GSTA2 mRNA

PMID:10476907 PMID:11502894 PMID:22606287 PMID:34480604

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase omega 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA

NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167

G

glutathione S-transferase pi 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

guanylate cyclase 1 soluble subunit alpha 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA

NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737

G

hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)

increases expression

ISO

Hydrocortisone results in increased expression of H6PD mRNA

NCBI chr 5:165,717,456...165,753,158
Ensembl chr 5:165,721,654...165,753,125

G

heart and neural crest derivatives expressed 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA

NCBI chr16:37,928,145...37,931,488
Ensembl chr16:37,928,145...37,931,488

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

histone deacetylase 1

multiple interactions
increases expression

ISO

HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

hes family bHLH transcription factor 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA

NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021

G

hepatocyte growth factor

decreases expression

ISO

Hydrocortisone results in decreased expression of HGF protein

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

homeobox A1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA

NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209

G

homeobox A2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA

NCBI chr 4:82,593,389...82,597,589
Ensembl chr 4:82,593,389...82,595,692

G

homeo box A5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA

NCBI chr 4:82,632,958...82,636,851
Ensembl chr 4:82,632,306...82,639,038

G

homeo box B3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA

NCBI chr10:81,786,001...81,810,655
Ensembl chr10:81,795,882...81,809,628

G

homeo box D4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA

NCBI chr 3:80,021,886...80,041,462
Ensembl chr 3:80,036,900...80,038,948

G

homeobox D8

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA

NCBI chr 3:80,015,223...80,017,789
Ensembl chr 3:80,014,735...80,018,765

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
affects expression
increases oxidation
affects response to substance
increases chemical synthesis
increases expression
increases activity
affects oxidation

ISO
EXP

[HSD11B1 protein results in increased metabolism of Ketosteroids] which results in increased chemical synthesis of Hydrocortisone; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; Mifepristone affects the reaction [Hydrocortisone affects the expression of HSD11B1 mRNA]; perfluorooctane sulfonic acid inhibits the reaction [Hydrocortisone results in increased expression of HSD11B1]
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein
HSD11B1 protein results in increased chemical synthesis of Hydrocortisone
Hydrocortisone results in increased expression of HSD11B1; Hydrocortisone results in increased expression of HSD11B1 mRNA; Hydrocortisone results in increased expression of HSD11B1 protein
Hydrocortisone results in increased activity of HSD11B1 protein

PMID:16054388 PMID:16751407 PMID:17761898 PMID:20410225 PMID:22178014 More...

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

affects binding
decreases expression
increases oxidation
multiple interactions
increases metabolic processing

ISO

HSD11B2 protein binds to Hydrocortisone
Hydrocortisone results in decreased expression of HSD11B2 mRNA; Hydrocortisone results in decreased expression of HSD11B2 protein
HSD11B2 protein results in increased oxidation of Hydrocortisone
[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HSD11B2 mRNA]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Hydrocortisone]
HSD11B2 protein results in increased metabolism of Hydrocortisone

PMID:22273746 PMID:22796344 PMID:26859423 PMID:30528684

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

affects binding

ISO

Hydrocortisone binds to HSD3B1 protein

NCBI chr 2:188,858,574...188,864,694

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

multiple interactions

ISO

[galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Hydrocortisone

NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
Hydrocortisone results in decreased expression of ICAM1 protein

PMID:9150321 PMID:15086553 PMID:15358673

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon-induced protein 44

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon beta 1

multiple interactions
decreases secretion

ISO

IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]; Mitotane promotes the reaction [IFNB1 protein results in decreased secretion of Hydrocortisone]

NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487

G

interferon gamma

multiple interactions

ISO

[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IFNG protein]

PMID:15663561 PMID:29594315

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 1

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]
Hydrocortisone results in decreased expression of IGF1 mRNA; Hydrocortisone results in decreased expression of IGF1 protein

PMID:30528684 PMID:31075344 PMID:32535229

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

affects expression
multiple interactions

ISO

Hydrocortisone affects the expression of IGF1R mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of IGF1R mRNA]

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor 2

multiple interactions
increases secretion

ISO

IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

insulin-like growth factor binding protein 5

decreases expression

ISO

Hydrocortisone results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

insulin-like growth factor binding protein 7

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA

NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620

G

interleukin 10

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]

PMID:29777833 PMID:33476690

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 17A

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 1 alpha

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of IL1A mRNA
Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]

PMID:18722610 PMID:21980503

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases abundance
decreases expression
multiple interactions

ISO
EXP

IL1B protein results in increased abundance of Hydrocortisone
Hydrocortisone results in decreased expression of IL1B mRNA
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]

PMID:10460758 PMID:12548226 PMID:25851902 PMID:29594315 PMID:33476690

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 2

multiple interactions

ISO

[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]

PMID:29594315 PMID:29777833

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Hydrocortisone results in decreased expression of IL2RA protein

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 4

decreases expression

ISO

Hydrocortisone results in decreased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IL5 protein]
Hydrocortisone results in decreased expression of IL5 protein

PMID:7988651 PMID:15663561

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

decreases secretion
decreases expression

ISO

Hydrocortisone results in decreased secretion of IL6 protein
Hydrocortisone results in decreased expression of IL6 protein

PMID:12682474 PMID:16255036

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions
increases expression

ISO

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Octreotide inhibits the reaction [Hydrocortisone results in increased expression of INS protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:7473517 PMID:7792821 PMID:7917157 PMID:33476690

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

ISL LIM homeobox 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA

NCBI chr 2:49,813,618...49,823,442
Ensembl chr 2:49,813,618...49,823,442

G

integrin subunit alpha 10

increases expression

ISO

Hydrocortisone results in increased expression of ITGA10 mRNA

NCBI chr 2:186,871,711...186,891,012
Ensembl chr 2:186,871,711...186,891,012

G

integrin subunit alpha 5

increases expression

ISO

Hydrocortisone results in increased expression of ITGA5 mRNA

NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:136,358,097...136,381,305

G

involucrin

decreases expression

ISO

Hydrocortisone results in decreased expression of IVL mRNA

NCBI chr 2:180,842,307...180,854,646
Ensembl chr 2:180,842,307...180,846,578

G

Kelch-like ECH-associated protein 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

kallikrein 1

increases export

ISO

Hydrocortisone results in increased export of KLK1 protein

NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:103,779,164...103,783,270

G

kallikrein 1-related peptidase C10

increases expression

ISO

Hydrocortisone results in increased expression of KLK3 protein

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin 1

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT1 mRNA]

NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537

G

keratin 10

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT10 mRNA]

NCBI chr10:84,834,865...84,839,160
Ensembl chr10:84,834,840...84,839,160

G

LCK proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA

NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267

G

low density lipoprotein receptor

multiple interactions
decreases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of LDLR mRNA]

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

lymphoid enhancer binding factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929

G

loricrin cornified envelope precursor protein

decreases expression

ISO

Hydrocortisone results in decreased expression of LORICRIN mRNA

NCBI chr 2:180,253,674...180,256,572
Ensembl chr 2:180,253,674...180,256,572

G

lipoprotein lipase

multiple interactions

ISO

Hydrocortisone results in decreased activity of and results in decreased expression of LPL protein

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

lumican

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA

NCBI chr 7:34,245,323...34,252,510
Ensembl chr 7:34,245,360...34,252,508

G

lymphocyte antigen 75

decreases expression

ISO

Hydrocortisone results in decreased expression of LY75 protein

NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878

G

MAF bZIP transcription factor G

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA

NCBI chr10:106,401,633...106,410,159

G

monoamine oxidase A

increases expression

ISO

Hydrocortisone results in increased expression of MAOA mRNA

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631

G

mitogen activated protein kinase kinase kinase 7

decreases expression

ISO

Hydrocortisone results in decreased expression of MAP3K7 mRNA

NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012

G

muscular LMNA-interacting protein

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA

NCBI chr 8:86,815,491...87,085,117
Ensembl chr 8:86,814,798...87,082,408

G

matrix metallopeptidase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 9

multiple interactions

ISO

Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

myelin protein zero-like 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA

NCBI chr13:80,385,454...80,422,315
Ensembl chr13:80,385,456...80,422,390

G

metallothionein 1A

increases expression

EXP

Hydrocortisone results in increased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

myosin, light chain 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA

NCBI chr10:89,949,733...89,985,308
Ensembl chr10:89,949,404...89,985,308

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO
EXP

[Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein; Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]

PMID:22606287 PMID:33476690

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

multiple interactions
increases expression

ISO

[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of NFKBIA mRNA]

PMID:25763180 PMID:33476690

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nitric oxide synthase 2

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

natriuretic peptide A

increases expression
decreases secretion

ISO

Hydrocortisone results in increased expression of NPPA protein
NPPA protein results in decreased secretion of Hydrocortisone

PMID:2434734 PMID:2931268 PMID:7473517

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

neuropeptide Y

affects expression

ISO

Hydrocortisone affects the expression of NPY protein

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

EXP
ISO

Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NQO1 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 mRNA]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA

PMID:22606287 PMID:34480604

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 2, group F, member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA

NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA

NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects localization
increases activity
affects binding
increases phosphorylation
decreases expression
affects abundance
increases expression

ISO
EXP

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; [Hydrocortisone co-treated with Progesterone] results in increased expression of NR3C1 mRNA; [Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Atrazine inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bifenthrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A analog inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol AF inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol AF inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol Z inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol Z inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; croneton inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Hydrocortisone binds to and affects the activity of NR3C1 protein; Hydrocortisone binds to and results in increased activity of NR3C1 protein; Hydrocortisone results in increased expression of and affects the localization of NR3C1 protein; Methoxychlor inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone affects the localization of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein alternative form inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein alternative form]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Pesticides inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Polybrominated Biphenyls metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; resmethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Soil Pollutants inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Thiram inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; tributyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; tris(1,3-dichloro-2-propyl)phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
NR3C1 protein binds to Hydrocortisone
Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]
Hydrocortisone results in increased phosphorylation of NR3C1 protein
Hydrocortisone results in decreased expression of NR3C1 mRNA; Hydrocortisone results in decreased expression of NR3C1 protein
Fluoxetine promotes the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
Hydrocortisone analog binds to NR3C1 protein
NR3C1 gene polymorphism affects the abundance of Hydrocortisone
Hydrocortisone results in increased expression of NR3C1; Hydrocortisone results in increased expression of NR3C1 mRNA

PMID:926113 PMID:1597467 PMID:11956172 PMID:12871829 PMID:15362971 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions
increases activity

ISO

[Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased abundance of Hydrocortisone
Hydrocortisone results in increased activity of NR3C2 protein

PMID:15362971 PMID:15780662 PMID:16566900

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

nuclear receptor subfamily 6, group A, member 1

decreases expression

ISO

Hydrocortisone results in decreased expression of NR6A1 mRNA

NCBI chr 3:42,904,832...43,094,622
Ensembl chr 3:42,904,832...43,092,951

G

occludin

increases expression

ISO

Hydrocortisone results in increased expression of OCLN mRNA

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

oxytocin/neurophysin I prepropeptide

affects abundance

ISO

OXT protein affects the abundance of Hydrocortisone

NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594

G

progestagen associated endometrial protein

increases metabolic processing

ISO

PAEP protein modified form results in increased metabolism of Hydrocortisone

NCBI chr 3:28,929,252...28,932,592

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases activity
increases expression

EXP

3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; bifenthrin inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dactinomycin inhibits the reaction [Hydrocortisone results in increased activity of PCK1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]

PMID:6476976 PMID:26647222

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

proliferating cell nuclear antigen

decreases expression

ISO

Hydrocortisone results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphodiesterase 1A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA

NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212

G

period circadian regulator 1

increases expression

ISO

Hydrocortisone results in increased expression of PER1 mRNA

NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211

G

phospholamban

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA

NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241

G

patatin-like phospholipase domain containing 2

decreases expression

ISO

Hydrocortisone results in decreased expression of PNPLA2 mRNA

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

proopiomelanocortin

increases response to substance
multiple interactions
increases abundance
increases secretion

ISO

POMC protein results in increased susceptibility to Hydrocortisone
Lead inhibits the reaction [POMC protein modified form results in increased secretion of Hydrocortisone]; Melatonin inhibits the reaction [POMC protein results in increased abundance of Hydrocortisone]
POMC protein results in increased secretion of Hydrocortisone

PMID:1321309 PMID:3015460 PMID:9881897 PMID:11082157 PMID:21332028 More...

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

POU class 5 homeobox 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor delta

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

prolactin

multiple interactions

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

prune homolog 2 with BCH domain

decreases expression

ISO

Hydrocortisone results in decreased expression of PRUNE2 mRNA

NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO
EXP

Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]
Hydrocortisone results in increased expression of PTGS2 protein
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PTGS2 protein]

PMID:17805209 PMID:18650268

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RAP1A, member of RAS oncogene family

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of RAP1A mRNA
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAP1A mRNA]

NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808

G

Rap guanine nucleotide exchange factor 3

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAPGEF3 mRNA]

NCBI chr 7:130,754,883...130,777,303
Ensembl chr 7:130,754,871...130,777,668

G

retinoic acid receptor, alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:84,389,622...84,425,160

G

RB binding protein 7, chromatin remodeling factor

affects response to substance

ISO

RBBP7 protein affects the susceptibility to Hydrocortisone

NCBI chr X:35,544,873...35,563,030
Ensembl chr X:35,544,873...35,563,030

G

RNA binding motif protein 20

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA

NCBI chr 1:262,671,311...262,912,551
Ensembl chr 1:262,688,978...262,891,364

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

decreases expression

ISO

Hydrocortisone results in decreased expression of REN protein

PMID:7473517 PMID:15743397

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

RAR-related orphan receptor A

increases expression

ISO

Hydrocortisone results in increased expression of RORA mRNA

NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730

G

RRAD, Ras related glycolysis inhibitor and calcium channel regulator

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA

NCBI chr19:360,581...363,874
Ensembl chr19:360,973...363,871

G

scavenger receptor class B, member 1

multiple interactions
decreases expression

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SCARB1 mRNA]

PMID:31075344 PMID:34480604

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

sodium channel epithelial 1 subunit alpha

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1A mRNA

NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405

G

sodium channel epithelial 1 subunit beta

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1B mRNA

NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049

G

sodium channel epithelial 1 subunit gamma

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1G mRNA

NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097

G

semaphorin 3C

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA

NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740

G

serpin family A member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA

NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:128,619,382...128,660,703

G

serpin family B member 1A

multiple interactions

EXP
ISO

Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1A protein modified form
Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form

NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,799,415...31,808,166

G

serpin family C member 1

increases expression

ISO

Hydrocortisone results in increased expression of SERPINC1 protein

NCBI chr13:75,790,558...75,804,826
Ensembl chr13:75,790,546...75,817,643

G

splicing factor 1

multiple interactions
decreases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SF1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590

G

secreted frizzled-related protein 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA

NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079

G

surfactant protein B

increases expression

ISO

Hydrocortisone results in increased expression of SFTPB mRNA

NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646

G

surfactant protein C

increases expression

ISO

Hydrocortisone results in increased expression of SFTPC mRNA

NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475

G

SH3-domain binding protein 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA

NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,589,877...6,655,211

G

sirtuin 1

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of SIRT1 mRNA
NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

solute carrier family 22 member 2

multiple interactions

ISO

Hydrocortisone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 23 member 2

multiple interactions

ISO

Hydrocortisone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid]

NCBI chr 3:139,755,583...139,913,304
Ensembl chr 3:139,755,584...139,847,343

G

solute carrier family 5 member 5

multiple interactions

ISO

1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] affects the localization of SLC5A5 protein]; 1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased expression of SLC5A5 protein]; Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin affects the localization of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin results in increased expression of SLC5A5 protein]

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

SRY-box transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA

NCBI chr16:83,837,689...83,841,703
Ensembl chr16:83,802,160...83,841,775

G

SRY-box transcription factor 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

serine palmitoyltransferase, small subunit B

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA

NCBI chr 2:156,432,509...156,461,936
Ensembl chr 2:156,432,512...156,460,909

G

sequestosome 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of SREBF1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

sulfiredoxin 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

steroidogenic acute regulatory protein

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of STAR mRNA; Hydrocortisone results in decreased expression of STAR protein
Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of STAR mRNA]

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

stathmin 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA

NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335

G

tyrosine aminotransferase

multiple interactions
increases expression
increases activity

ISO
EXP

Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; o-Aminoazotoluene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]
Hydrocortisone results in increased expression of TAT mRNA
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Methyldimethylaminoazobenzene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]

PMID:6120038 PMID:16267830 PMID:22465009 PMID:26647222

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

T-box transcription factor 19

decreases abundance

ISO

TBX19 gene mutant form results in decreased abundance of Hydrocortisone

NCBI chr13:79,983,935...80,016,219
Ensembl chr13:79,983,935...80,007,023

G

T-box transcription factor 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA

NCBI chr10:71,177,082...71,186,275
Ensembl chr10:71,177,082...71,186,275

G

transferrin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:33476690 PMID:34480604

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transcription factor AP-2 alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transcription factor AP-2 beta

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA

NCBI chr 9:29,282,703...29,312,568
Ensembl chr 9:29,282,825...29,312,568

G

transforming growth factor, beta 1

multiple interactions

EXP
ISO

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA

PMID:17434272 PMID:33476690

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transglutaminase 1

multiple interactions
increases expression

ISO

[Hydrocortisone co-treated with sodium arsenate] results in increased expression of TGM1 mRNA; [Hydrocortisone co-treated with sodium arsenite] results in increased expression of TGM1 mRNA; sodium arsenate inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]; sodium arsenite inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]

NCBI chr15:33,160,985...33,175,632
Ensembl chr15:33,160,987...33,174,463

G

tight junction protein 1

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of TJP1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of TJP1 protein]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

toll-like receptor 2

increases expression

ISO

Hydrocortisone results in increased expression of TLR2 mRNA

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

toll-like receptor 4

decreases expression

ISO

Hydrocortisone results in decreased expression of TLR4 mRNA

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

transmembrane 4 L six family member 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA

NCBI chr 2:143,720,220...143,771,283
Ensembl chr 2:143,720,267...143,771,227

G

tumor necrosis factor

decreases secretion
multiple interactions
decreases expression

ISO

Hydrocortisone results in decreased secretion of TNF protein
Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the expression of TNF mRNA]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Hydrocortisone results in decreased expression of TNF mRNA

PMID:9150321 PMID:10100995 PMID:15086553 PMID:21980503 PMID:26481333 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

trehalase

decreases activity

ISO

Hydrocortisone results in decreased activity of TREH protein

NCBI chr 8:53,886,946...53,901,113
Ensembl chr 8:53,886,946...53,900,335

G

TSC22 domain family, member 3

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]
3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cobaltous chloride results in increased abundance of Cobalt] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cupric chloride results in increased abundance of Copper] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [lead nitrate results in increased abundance of Lead] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [stannous chloride results in increased abundance of Tin] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [zinc chloride results in increased abundance of Zinc] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; resmethrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]

PMID:25763180 PMID:26647222 PMID:29957541

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

transthyretin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:12,216,732...12,225,969

G

thioredoxin reductase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

urocortin 2

increases abundance

ISO

UCN2 protein results in increased abundance of Hydrocortisone

NCBI chr 8:118,516,111...118,517,660
Ensembl chr 8:118,483,364...118,517,439

G

uncoupling protein 1

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420

G

UDP glucuronosyltransferase family 2 member A3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA

NCBI chr14:20,851,970...20,869,974
Ensembl chr14:20,851,969...20,869,973

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

EXP

Hydrocortisone results in increased expression of UGT2B1 mRNA

NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331

G

vascular cell adhesion molecule 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]

PMID:10100995 PMID:15358673 PMID:34480604

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [Nickel results in increased expression of VEGFA protein]
Hydrocortisone results in decreased expression of VEGFA protein

PMID:9390328 PMID:17549480 PMID:20116850

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vestigial-like family member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA

NCBI chr X:140,016,938...140,036,348

G

von Willebrand factor

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of VWF mRNA]

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757

G

zinc finger AN1-type containing 2A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA

NCBI chr12:20,275,435...20,286,513
Ensembl chr12:20,275,450...20,286,513

G

zinc finger protein 36

increases expression

ISO

Hydrocortisone results in increased expression of ZFP36 mRNA

NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

[Calcitriol co-treated with Cortisone] results in decreased expression of ADIPOQ mRNA

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

aldo-keto reductase family 1, member D1

multiple interactions

ISO

[AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

caspase 3

multiple interactions

EXP

Cortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

increases expression

ISO

Cortisone results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

dehydrogenase/reductase 7

increases reduction

ISO

DHRS7 protein results in increased reduction of Cortisone

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744

G

fatty acid binding protein 4

increases expression
multiple interactions

ISO

Cortisone results in increased expression of FABP4 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

glutamate-ammonia ligase

increases activity

EXP

Cortisone results in increased activity of GLUL protein

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
increases expression
increases reduction
affects response to substance
increases metabolic processing
affects metabolic processing

ISO
EXP

[Calcitriol co-treated with Cortisone] results in increased expression of HSD11B1 mRNA; [HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
Cortisone results in increased expression of HSD11B1 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of and results in increased activity of HSD11B1 protein]; Cortisone results in increased expression of and results in increased activity of HSD11B1 protein
[HSD11B1 protein affects the susceptibility to Cortisone] which results in decreased activity of NFE2L2 protein; [HSD11B1 protein co-treated with Cortisone] results in decreased expression of NQO1 mRNA; Cortisone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA]
HSD11B1 protein results in increased metabolism of Cortisone
HSD11B1 protein affects the metabolism of Cortisone

PMID:16054388 PMID:16751407 PMID:19918113 PMID:21315688 PMID:22606287 More...

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

increases chemical synthesis
multiple interactions

ISO

HSD11B2 protein results in increased chemical synthesis of Cortisone
[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]

PMID:22796344 PMID:26859423

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

interleukin 1 beta

multiple interactions
decreases expression

ISO

perfluorooctane sulfonic acid inhibits the reaction [Cortisone results in decreased expression of IL1B]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression
multiple interactions

ISO

Cortisone results in decreased expression of IL6
perfluorooctane sulfonic acid inhibits the reaction [Cortisone results in decreased expression of IL6]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO
EXP

[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
[HSD11B1 protein affects the susceptibility to Cortisone] which results in decreased activity of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nitric oxide synthase 2

increases expression

ISO

Cortisone results in increased expression of NOS2 protein

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

EXP

[HSD11B1 protein co-treated with Cortisone] results in decreased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 3, group C, member 1

affects binding
multiple interactions
increases activity

ISO

Cortisone binds to NR3C1 protein
[Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
Cortisone results in increased activity of NR3C1 protein

PMID:15705660 PMID:15780662 PMID:22606287

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Cortisone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

ISO

2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

increases expression

ISO

Cortisone results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

serum/glucocorticoid regulated kinase 1

increases expression
multiple interactions

EXP

Cortisone results in increased expression of SGK1 mRNA
Phenylephrine promotes the reaction [Cortisone results in increased expression of SGK1 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cortisone results in increased expression of SGK1 mRNA]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

solute carrier family 22 member 2

multiple interactions

ISO

Cortisone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 2 member 4

increases expression
multiple interactions

ISO

Cortisone results in increased expression of SLC2A4 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of SLC2A4 mRNA]

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

tumor necrosis factor

increases expression

ISO

Cortisone results in increased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

ISO

[Cyproterone co-treated with Albuterol] results in decreased expression of CYP19A1

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

Cyproterone results in increased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

growth regulating estrogen receptor binding 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of GREB1 mRNA]

NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126

G

MYB proto-oncogene like 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of MYBL1 mRNA]

NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588

G

serum/glucocorticoid regulated kinase 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of SGK1 mRNA]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone results in decreased expression of A2M mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of A2M mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of A2M mRNA
Dexamethasone results in increased expression of A2M mRNA

PMID:12971794 PMID:25047013 PMID:28628672

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

arylacetamide deacetylase

decreases expression

ISO

Dexamethasone results in decreased expression of AADAC mRNA

NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:146,313,279...146,324,525

G

adipogenesis associated, Mth938 domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AAMDC mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of AAMDC mRNA

NCBI chr 1:161,273,205...161,303,253
Ensembl chr 1:161,262,347...161,299,340

G

angio-associated, migratory cell protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AAMP mRNA

NCBI chr 9:83,312,519...83,318,325
Ensembl chr 9:83,312,519...83,318,325

G

alanyl-tRNA synthetase 1

decreases expression

ISO

Dexamethasone results in decreased expression of AARS1 mRNA

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497

G

4-aminobutyrate aminotransferase

increases expression

ISO

Dexamethasone results in increased expression of ABAT mRNA

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of ABCA1 mRNA
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ABCA1 mRNA]
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ABCA1 mRNA

PMID:16054899 PMID:20032058 PMID:25932594

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 6

increases expression

ISO

Dexamethasone results in increased expression of ABCA6 mRNA

NCBI chr10:95,642,026...95,711,535
Ensembl chr10:95,641,900...95,710,899

G

ATP binding cassette subfamily B member 11

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of ABCB11 mRNA
[Dexamethasone co-treated with Ibuprofen] results in increased expression of ABCB11 mRNA

PMID:19118567 PMID:20888898 PMID:29222744 PMID:32599024

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
decreases expression
decreases activity
increases secretion
affects response to substance

ISO
EXP

[Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; ABCB1 gene polymorphism affects the reaction [Dexamethasone results in decreased secretion of IFNG protein]; ABCB1 gene polymorphism affects the reaction [Dexamethasone results in decreased secretion of IL2 protein]; ABCB1 gene polymorphism affects the reaction [Dexamethasone results in decreased secretion of IL4 protein]; ABCB1 gene polymorphism affects the reaction [Dexamethasone results in decreased secretion of TNF protein]; Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Dexamethasone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Dexamethasone]
Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCB1A mRNA]
Dexamethasone results in increased expression of ABCB1 protein; Dexamethasone results in increased expression of ABCB1A mRNA; Dexamethasone results in increased expression of ABCB1A protein
Dexamethasone results in decreased expression of ABCB1 mRNA; Dexamethasone results in decreased expression of ABCB1A mRNA
Dexamethasone results in increased expression of ABCB1 mRNA
Dexamethasone results in decreased activity of ABCB1 protein
ABCB1 gene polymorphism affects the susceptibility to Dexamethasone

PMID:12387747 PMID:15205389 PMID:16321374 PMID:17015168 PMID:17324141 More...

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of ABCB1B mRNA
Dexamethasone results in increased expression of ABCB1B mRNA; Dexamethasone results in increased expression of ABCB1B protein
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCB1B mRNA]

PMID:15205389 PMID:17324141 PMID:19958760 PMID:22733784

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily B member 4

increases expression

EXP

Dexamethasone results in increased expression of ABCB4 mRNA

PMID:12429353 PMID:19118567

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily B member 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ABCB9 mRNA

NCBI chr12:38,146,659...38,192,862
Ensembl chr12:38,159,904...38,192,860

G

ATP binding cassette subfamily C member 1

multiple interactions
increases expression

EXP
ISO

Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC1 mRNA]
Dexamethasone results in increased expression of ABCC1 mRNA

PMID:15205389 PMID:22185406

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression
decreases expression

EXP
ISO

Testosterone inhibits the reaction [Dexamethasone results in increased expression of ABCC2 mRNA]
Dexamethasone results in increased expression of ABCC2 mRNA; Dexamethasone results in increased expression of ABCC2 protein
Dexamethasone results in decreased expression of ABCC2 mRNA

PMID:12429353 PMID:15102944 PMID:15258109 PMID:15908472 PMID:19118567 More...

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
decreases expression
affects expression
increases activity

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ABCC3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABCC3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ABCC3 mRNA; Dexamethasone promotes the reaction [ABCC3 protein affects the transport of calcein AM]
Dexamethasone results in increased expression of ABCC3 mRNA; Dexamethasone results in increased expression of ABCC3 protein
Dexamethasone results in decreased expression of ABCC3 mRNA; Dexamethasone results in decreased expression of ABCC3 protein
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC3 mRNA]
Dexamethasone affects the expression of ABCC3 mRNA
Dexamethasone results in increased activity of ABCC3 protein

PMID:15102944 PMID:15205389 PMID:15908472 PMID:15979871 PMID:17522070 More...

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

decreases expression

EXP

Dexamethasone results in decreased expression of ABCC4 mRNA; Dexamethasone results in decreased expression of ABCC4 protein

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily C member 6

affects expression
decreases expression

EXP

Dexamethasone affects the expression of ABCC6 mRNA
Dexamethasone results in decreased expression of ABCC6 mRNA

PMID:15102944 PMID:16260000

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

ATP binding cassette subfamily D member 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ABCD2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ABCD2 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCD2 mRNA]

PMID:22185406 PMID:25047013 PMID:28628672

NCBI chr 7:124,142,597...124,191,202
Ensembl chr 7:124,142,595...124,191,202

G

ATP binding cassette subfamily F member 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

ISO
EXP

Dexamethasone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dexamethasone results in decreased expression of ABCG2 mRNA

PMID:15365089 PMID:20607812

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

abhydrolase domain containing 1

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of ABHD1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ABHD1 mRNA]

NCBI chr 6:31,142,476...31,147,464
Ensembl chr 6:31,142,476...31,147,464

G

abhydrolase domain containing 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ABHD11 mRNA

NCBI chr12:27,318,739...27,322,016
Ensembl chr12:27,318,749...27,321,970

G

abhydrolase domain containing 14A

increases expression

ISO

Dexamethasone results in increased expression of ABHD14A mRNA

NCBI chr 8:115,957,853...115,965,697
Ensembl chr 8:115,957,858...115,965,697

G

abhydrolase domain containing 17C, depalmitoylase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ABHD17C mRNA

NCBI chr 1:147,493,755...147,534,715
Ensembl chr 1:147,493,753...147,534,715

G

abhydrolase domain containing 2, acylglycerol lipase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABHD2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ABHD2 mRNA

NCBI chr 1:142,626,748...142,707,892
Ensembl chr 1:142,626,732...142,712,674

G

abhydrolase domain containing 5, lysophosphatidic acid acyltransferase

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ABHD5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ABHD5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ABHD5 mRNA

PMID:25047013 PMID:28628672

NCBI chr 8:130,877,834...130,903,947
Ensembl chr 8:130,877,703...130,903,947

G

abl-interactor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ABI2 mRNA

NCBI chr 9:69,321,072...69,490,630
Ensembl chr 9:69,321,150...69,490,597

G

ABI family, member 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ABI3 mRNA

NCBI chr10:81,266,571...81,277,561
Ensembl chr10:81,266,571...81,277,561

G

ABI family member 3 binding protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ABI3BP mRNA

NCBI chr11:57,381,282...57,597,989
Ensembl chr11:57,381,422...57,598,120

G

ABL proto-oncogene 2, non-receptor tyrosine kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABL2 mRNA

NCBI chr13:71,223,902...71,319,770
Ensembl chr13:71,224,019...71,389,775

G

actin binding LIM protein family, member 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ABLIM2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ABLIM2 mRNA

NCBI chr14:79,090,046...79,214,986
Ensembl chr14:79,090,923...79,214,972

G

actin-binding Rho activating protein

affects expression

ISO

Dexamethasone affects the expression of ABRA mRNA

NCBI chr 7:74,855,008...74,859,076
Ensembl chr 7:74,855,007...74,859,076

G

ABRA C-terminal like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ABRACL mRNA

NCBI chr 1:14,474,802...14,484,992
Ensembl chr 1:14,474,803...14,485,055

G

acetyl-CoA acyltransferase 2

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [Roscovitine co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA

PMID:23428407 PMID:34323617

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACACA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased phosphorylation of ACACA protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACACA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACACA protein; [Acrylamide co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased phosphorylation of ACACA protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein co-treated with Quercetin] results in increased phosphorylation of ACACA protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of ACACA protein; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of ACACA mRNA]; Ivermectin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACACA protein]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACACA mRNA]; rotenoisin A promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of ACACA protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased phosphorylation of ACACA protein]; thermozymocidin inhibits the reaction [Dexamethasone results in increased expression of ACACA mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]

PMID:18586010 PMID:23428407 PMID:25559859 PMID:30409764 PMID:30446312 More...

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acetyl-CoA carboxylase beta

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACACB mRNA
[bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACACB mRNA; [bisphenol A metabolite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACACB mRNA; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of ACACB mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ACACB mRNA

PMID:25047013 PMID:28628672 PMID:30665118 PMID:31053639

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214

G

acyl-CoA dehydrogenase family, member 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ACAD8 mRNA

NCBI chr 8:33,641,420...33,665,542
Ensembl chr 8:33,641,420...33,665,542

G

acyl-CoA dehydrogenase family, member 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAD9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA

NCBI chr 2:120,871,329...120,894,306
Ensembl chr 2:120,871,227...120,894,709

G

acyl-CoA dehydrogenase, long chain

decreases expression

ISO

Dexamethasone results in decreased expression of ACADL protein

NCBI chr 9:75,783,689...75,822,077
Ensembl chr 9:75,783,689...75,822,164

G

acyl-CoA dehydrogenase medium chain

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ACADM mRNA
Dexamethasone results in decreased expression of ACADM protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACADM mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACADM mRNA

PMID:17522070 PMID:23428407 PMID:24848799 PMID:33567340

NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864

G

acyl-CoA dehydrogenase, very long chain

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACADVL mRNA

NCBI chr10:55,231,558...55,236,786
Ensembl chr10:55,231,440...55,236,750

G

aggrecan

multiple interactions
decreases expression
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAN mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAN mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ACAN mRNA; [TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of ACAN mRNA]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]; Resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ACAN mRNA]]
Dexamethasone results in decreased expression of ACAN mRNA; Dexamethasone results in decreased expression of ACAN protein
Dexamethasone results in increased expression of ACAN mRNA

PMID:17502159 PMID:21351055 PMID:25047013 PMID:26526931 PMID:27608943 More...

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779

G

acetyl-CoA acetyltransferase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAT1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ACAT1 mRNA

NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:62,876,003...62,905,042

G

acetyl-CoA acetyltransferase 2

increases expression

ISO

Dexamethasone results in increased expression of ACAT2 mRNA

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095

G

acyl-CoA binding domain containing 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACBD5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ACBD5 mRNA

NCBI chr17:90,114,250...90,156,286
Ensembl chr17:90,114,375...90,156,286

G

acyl-CoA binding domain containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ACBD7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACBD7 mRNA

NCBI chr17:79,813,106...79,821,254
Ensembl chr17:79,813,106...79,818,448

G

angiotensin I converting enzyme

increases expression
multiple interactions
decreases activity

EXP
ISO

Dexamethasone results in increased expression of ACE mRNA; Dexamethasone results in increased expression of ACE protein
diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of ACE protein]; Enalapril inhibits the reaction [Dexamethasone results in increased expression of ACE protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of ACE protein]]
Dexamethasone results in decreased activity of ACE protein
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of ACE mRNA]; [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of ACE protein]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of ACE mRNA]

PMID:1659346 PMID:9498404 PMID:15932931 PMID:22733784 PMID:30940551 More...

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

angiotensin converting enzyme 2

decreases expression

ISO

Dexamethasone results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

acetylcholinesterase

increases activity
multiple interactions

EXP

Dexamethasone results in increased activity of ACHE protein
[Dexamethasone co-treated with Ascorbic Acid] results in increased expression of ACHE mRNA; [Dexamethasone co-treated with Ascorbic Acid] results in increased expression of and results in increased activity of ACHE protein; Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]; Melatonin inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Melatonin inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]

PMID:21986892 PMID:27019979

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

apoptotic chromatin condensation inducer 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACIN1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACIN1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ACIN1 mRNA

NCBI chr15:32,072,121...32,117,004
Ensembl chr15:32,072,123...32,117,166

G

atypical chemokine receptor 3

decreases expression

ISO

Dexamethasone results in decreased expression of ACKR3 mRNA

NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214

G

ATP citrate lyase

decreases expression

EXP

Dexamethasone results in decreased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

aconitase 1

increases expression

ISO

Dexamethasone results in increased expression of ACO1 mRNA

NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600

G

aconitase 2

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ACO2 mRNA
Dexamethasone results in decreased expression of ACO2 protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ACO2 mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACO2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of ACO2 mRNA]

PMID:20032058 PMID:23428407 PMID:24848799 PMID:33567340

NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892

G

acyl-CoA thioesterase 1

increases expression

ISO

Dexamethasone results in increased expression of ACOT1 mRNA

NCBI chr 6:109,367,274...109,375,268
Ensembl chr 6:109,367,268...109,380,749

G

acyl-CoA thioesterase 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACOT11 mRNA

NCBI chr 5:126,756,255...126,804,526
Ensembl chr 5:126,756,255...126,804,507

G

acyl-CoA thioesterase 7

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ACOT7 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACOT7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACOT7 mRNA

PMID:14618091 PMID:28628672

NCBI chr 5:167,969,284...168,062,033
Ensembl chr 5:167,968,895...168,062,033

G

acyl-CoA oxidase 1

decreases expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone results in decreased expression of ACOX1 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACOX1 mRNA; [Dexamethasone co-treated with Ibuprofen] results in increased expression of ACOX1 mRNA
Dexamethasone results in increased expression of ACOX1 mRNA

PMID:12971794 PMID:21041162 PMID:23428407 PMID:29222744

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136

G

acyl-CoA oxidase 2

decreases expression

ISO

Dexamethasone results in decreased expression of ACOX2 mRNA

NCBI chr15:19,090,820...19,122,392
Ensembl chr15:19,090,926...19,122,392

G

acid phosphatase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACP4 mRNA

NCBI chr 1:103,872,922...103,888,418
Ensembl chr 1:103,872,922...103,881,156

G

acid phosphatase 5, tartrate resistant

multiple interactions
increases activity
increases expression

ISO
EXP

[Thalidomide co-treated with Dexamethasone] results in decreased expression of ACP5 protein
Dexamethasone results in increased activity of ACP5 protein
Alendronate inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]; caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]
Dexamethasone results in increased expression of ACP5 mRNA

PMID:16079895 PMID:21041162 PMID:27387537 PMID:28363435

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

acyl-CoA synthetase family member 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACSF2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ACSF2 mRNA

PMID:25047013 PMID:28628672

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase long-chain family member 1

multiple interactions
increases expression
decreases expression

ISO
EXP

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ACSL1 mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACSL1 mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACSL1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACSL1 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACSL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACSL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ACSL1 mRNA
Dexamethasone results in increased expression of ACSL1 mRNA
Dexamethasone results in decreased expression of ACSL1 mRNA

PMID:16054899 PMID:17522070 PMID:23428407 PMID:25047013 PMID:28628672

NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023

G

acyl-CoA synthetase long-chain family member 4

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACSL4 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ACSL4 mRNA]

PMID:16054899 PMID:20032058

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase long-chain family member 5

increases expression

ISO

Dexamethasone results in increased expression of ACSL5 mRNA

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

acyl-CoA synthetase short-chain family member 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACSS2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ACSS2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTA2 mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of and results in increased phosphorylation of ACTA2 protein]; Tetrachlorodibenzodioxin promotes the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTA2 mRNA]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; PTPN1 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; PTPN1 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]; SENP2 protein promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; NLRC5 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; NLRC5 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]; SIRT1 protein promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]
Dexamethasone results in decreased expression of ACTA2 mRNA

PMID:14618091 PMID:16054899 PMID:26435214 PMID:26739621 PMID:26806094 More...

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTB mRNA; Tetrachlorodibenzodioxin promotes the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTB mRNA]

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, alpha, cardiac muscle 1

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTC1 mRNA; Tetrachlorodibenzodioxin promotes the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTC1 mRNA]

NCBI chr 3:121,266,291...121,271,827
Ensembl chr 3:121,266,291...121,271,827

G

actin gamma 2, smooth muscle

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ACTG2 mRNA
Dexamethasone results in increased expression of ACTG2 mRNA

PMID:16054899 PMID:22733784

NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295

G

actinin, alpha 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACTN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACTN1 mRNA

PMID:22733784 PMID:28628672

NCBI chr 6:104,731,485...104,826,312
Ensembl chr 6:104,731,485...104,826,172

G

actinin alpha 2

increases expression

ISO

Dexamethasone results in increased expression of ACTN2 mRNA

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

actin related protein 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR1A mRNA

NCBI chr 1:255,179,241...255,199,009
Ensembl chr 1:255,179,242...255,199,459

G

actin related protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR2 mRNA

NCBI chr14:98,500,119...98,535,092
Ensembl chr14:98,500,138...98,541,998

G

actin related protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACTR3 mRNA

NCBI chr13:39,353,413...39,396,509
Ensembl chr13:39,353,079...39,396,711

G

actin related protein 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR6 mRNA

NCBI chr 7:26,037,574...26,058,362
Ensembl chr 7:26,037,574...26,060,604

G

activin A receptor type 1C

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACVR1C mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACVR1C mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ACVR1C mRNA

PMID:25047013 PMID:28628672

NCBI chr 3:63,224,322...63,301,252
Ensembl chr 3:63,227,559...63,301,205

G

activin A receptor like type 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ACVRL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ACVRL1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305

G

adenosine deaminase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293

G

ADAM metallopeptidase domain 10

multiple interactions

EXP

[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]

NCBI chr 8:80,226,862...80,358,728
Ensembl chr 8:80,226,674...80,361,600

G

ADAM metallopeptidase domain 12

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADAM12 mRNA

NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552

G

ADAM metallopeptidase domain 15

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADAM15 mRNA

NCBI chr 2:177,052,363...177,062,879
Ensembl chr 2:177,052,363...177,062,849

G

ADAM metallopeptidase domain 17

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ADAM17 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA

PMID:14618091 PMID:28628672

NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344

G

ADAM metallopeptidase domain 19

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ADAM19 mRNA

NCBI chr10:30,992,713...31,084,455
Ensembl chr10:30,992,754...31,084,455

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADAMTS1 mRNA
Dexamethasone results in increased expression of ADAMTS1 mRNA

PMID:16054899 PMID:22733784 PMID:25047013

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

ADAM metallopeptidase with thrombospondin type 1 motif, 16

decreases expression

ISO

Dexamethasone results in decreased expression of ADAMTS16 mRNA

NCBI chr 1:34,258,899...34,388,952
Ensembl chr 1:34,258,899...34,388,952

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

decreases expression

ISO

Dexamethasone results in decreased expression of ADAMTS4 mRNA

NCBI chr13:86,203,011...86,212,500
Ensembl chr13:86,202,642...86,212,514

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

decreases expression

ISO

Dexamethasone results in decreased expression of ADAMTS6 mRNA

NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ADAMTS9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADAMTS9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADAMTS9 mRNA

PMID:25047013 PMID:28628672

NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876

G

ADAMTS-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADAMTSL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ADAMTSL1 mRNA

NCBI chr 5:105,010,471...105,965,792
Ensembl chr 5:105,010,464...105,964,394

G

adenosine deaminase, RNA-specific, B1

increases expression

ISO

Dexamethasone results in increased expression of ADARB1 mRNA

NCBI chr20:11,222,171...11,350,416
Ensembl chr20:11,222,164...11,350,415

G

adenylate cyclase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ADCY1 mRNA

NCBI chr14:86,125,119...86,234,459
Ensembl chr14:86,124,850...86,261,075

G

adenylate cyclase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADCY3 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of ADCY3 mRNA; [rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of ADCY3 mRNA

PMID:28628672 PMID:29288687

NCBI chr 6:32,819,602...32,923,174
Ensembl chr 6:32,843,961...32,923,173

G

adenylate cyclase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADCY4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADCY4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ADCY4 mRNA

NCBI chr15:33,236,201...33,252,070
Ensembl chr15:33,236,208...33,252,026

G

adenylate cyclase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADCY6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADCY6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ADCY6 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of ADCY6 mRNA

PMID:28628672 PMID:29288687

NCBI chr 7:131,621,860...131,642,923
Ensembl chr 7:131,621,860...131,642,770

G

adenylate cyclase 7

decreases expression

ISO

Dexamethasone results in decreased expression of ADCY7 mRNA

NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743

G

adenylate cyclase 8

multiple interactions

ISO

[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of ADCY8 mRNA

NCBI chr 7:98,306,434...98,555,687
Ensembl chr 7:98,306,464...98,555,038

G

adducin 3

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ADD3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADD3 mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:262,152,722...262,260,504
Ensembl chr 1:262,154,996...262,260,504

G

adhesion G protein-coupled receptor A3

decreases expression

ISO

Dexamethasone results in decreased expression of ADGRA3 mRNA

NCBI chr14:65,085,418...65,188,949
Ensembl chr14:65,087,380...65,188,959

G

adhesion G protein-coupled receptor D1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADGRD1 mRNA

NCBI chr12:33,124,981...33,239,778
Ensembl chr12:33,125,915...33,272,509

G

adhesion G protein-coupled receptor F5

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA

NCBI chr 9:25,014,861...25,128,045
Ensembl chr 9:25,018,277...25,121,237

G

adhesion G protein-coupled receptor L2

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ADGRL2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA

PMID:14618091 PMID:28628672

NCBI chr 2:240,356,176...240,987,246
Ensembl chr 2:240,356,177...240,855,933

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of ADH1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADH1C mRNA
Dexamethasone results in increased expression of ADH1C mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ADH1 mRNA]

PMID:20032058 PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291

G

alcohol dehydrogenase 4 (class II), pi polypeptide

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADH4 mRNA

NCBI chr 2:229,622,092...229,640,120
Ensembl chr 2:229,622,095...229,641,879

G

alcohol dehydrogenase, iron containing, 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADHFE1 mRNA

NCBI chr 5:14,488,784...14,515,405
Ensembl chr 5:14,488,788...14,515,835

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression

ISO
EXP

2,2',4,4',5-brominated diphenyl ether promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased secretion of ADIPOQ protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA; [quinoxyfen co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased secretion of ADIPOQ protein; [Roscovitine co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased secretion of ADIPOQ protein; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of ADIPOQ mRNA; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of and results in decreased secretion of ADIPOQ protein; [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of ADIPOQ mRNA; [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of ADIPOQ protein; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased secretion of ADIPOQ protein; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased secretion of ADIPOQ protein; bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]]; dibutyldichlorotin inhibits the reaction [Dexamethasone results in increased expression of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Ethanol inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased secretion of ADIPOQ protein]; GHRL protein inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased secretion of ADIPOQ protein]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein]; Palmitic Acid inhibits the reaction [[sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased secretion of ADIPOQ protein]; Rosiglitazone promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; tributyltin promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; triphenyltin chloride inhibits the reaction [Dexamethasone results in increased expression of ADIPOQ protein]
Dexamethasone results in increased expression of ADIPOQ mRNA; Dexamethasone results in increased expression of ADIPOQ protein
17 alpha-Hydroxyprogesterone Caproate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; 17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; 2-chloro-5-nitrobenzanilide promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of ADIPOQ mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of ADIPOQ protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of ADIPOQ mRNA; avobenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; avobenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; bisphenol A promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; BQ 610 affects the reaction [sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; butylparaben promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Dicamba inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; Diethylhexyl Phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Equilin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Melengestrol Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Mifepristone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Norethindrone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Norgestrel inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; octocrylene inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; octocrylene promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; octocrylene promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; oxybenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; oxybenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ protein]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Pertussis Toxin promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; RES 701-1 affects the reaction [sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; sodium arsenite affects the reaction [Pertussis Toxin promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; Spironolactone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; T 0070907 affects the reaction [avobenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; T 0070907 inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; T 0070907 inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; thiocarbohydrazide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; tributyltin promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ protein]; tributyltin promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; tributyltin promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]

PMID:16054899 PMID:19186324 PMID:19853017 PMID:22197818 PMID:22956630 More...

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

adiponectin receptor 2

multiple interactions

ISO

Dexamethasone promotes the reaction [rosiglitazone results in increased activity of ADIPOR2 promoter]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADIPOR2 mRNA

PMID:16609881 PMID:23428407

NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666

G

adrenomedullin

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ADM mRNA
Dexamethasone results in increased expression of ADM mRNA

PMID:16054899 PMID:19853017 PMID:22733784 PMID:25047013

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

2-aminoethanethiol dioxygenase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADO mRNA

NCBI chr20:21,043,694...21,044,862
Ensembl chr20:21,043,317...21,048,483

G

adenosine A2B receptor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADORA2B mRNA

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

adenosine A3 receptor

increases expression

EXP

Dexamethasone results in increased expression of ADORA3 mRNA; Dexamethasone results in increased expression of ADORA3 protein

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

ADP-dependent glucokinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADPGK mRNA

NCBI chr 8:68,595,194...68,623,179
Ensembl chr 8:68,595,248...68,623,178

G

adrenoceptor alpha 1B

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ADRA1B mRNA; Dexamethasone results in increased expression of ADRA1B protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADRA1B mRNA

PMID:10229127 PMID:28628672

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

increases expression

ISO

Dexamethasone results in increased expression of ADRA1D mRNA; Dexamethasone results in increased expression of ADRA1D protein

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

adrenoceptor alpha 2A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADRA2A mRNA

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871

G

adrenoceptor alpha 2C

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ADRA2C mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ADRA2C mRNA

PMID:25047013 PMID:28628672

NCBI chr14:79,695,514...79,697,476
Ensembl chr14:79,694,995...79,706,656

G

adrenoceptor beta 2

increases expression
increases activity
decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of ADRB2 mRNA
Dexamethasone results in increased activity of ADRB2 protein
Dexamethasone results in decreased expression of ADRB2 mRNA
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADRB2 mRNA
Mifepristone inhibits the reaction [Dexamethasone results in increased expression of ADRB2 mRNA]

PMID:9032216 PMID:9074950 PMID:16054899 PMID:21804312

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

adrenoceptor beta 3

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ADRB3 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of ADRB3 mRNA; [mangiferin co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADRB3 protein; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADRB3 mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ADRB3 protein

PMID:10725275 PMID:29288687 PMID:32417366

NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420

G

adenylosuccinate synthase 1

decreases expression

ISO

Dexamethasone results in decreased expression of ADSS1 protein

NCBI chr 6:137,500,549...137,523,087
Ensembl chr 6:137,501,001...137,523,086

G

actin filament associated protein 1-like 1

increases expression

ISO

Dexamethasone results in increased expression of AFAP1L1 mRNA

NCBI chr18:57,454,120...57,514,584
Ensembl chr18:57,454,121...57,514,480

G

ALF transcription elongation factor 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of AFF1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AFF1 mRNA

PMID:22733784 PMID:28628672

NCBI chr14:6,165,864...6,328,848
Ensembl chr14:6,169,562...6,328,879

G

ALF transcription elongation factor 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AFF4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFF4 mRNA

NCBI chr10:37,998,319...38,080,580
Ensembl chr10:37,999,579...38,080,580

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AFG3L2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFG3L2 mRNA

NCBI chr18:63,224,163...63,269,000
Ensembl chr18:63,224,163...63,269,000

G

aftiphilin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AFTPH mRNA

NCBI chr14:99,072,761...99,127,006
Ensembl chr14:99,072,761...99,126,727

G

aspartylglucosaminidase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of AGA mRNA

NCBI chr16:45,191,215...45,249,537
Ensembl chr16:45,223,339...45,249,551

G

ArfGAP with FG repeats 2

increases expression

ISO

Dexamethasone results in increased expression of AGFG2 mRNA

NCBI chr12:24,649,008...24,692,069
Ensembl chr12:24,649,038...24,685,197

G

argonaute RISC catalytic component 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AGO2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AGO2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AGO2 mRNA

NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:106,918,125...106,993,980

G

argonaute RISC catalytic component 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AGO3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AGO3 mRNA

NCBI chr 5:143,913,957...143,998,746
Ensembl chr 5:143,926,501...143,998,737

G

1-acylglycerol-3-phosphate O-acyltransferase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AGPAT1 mRNA

NCBI chr20:4,140,565...4,149,531
Ensembl chr20:4,140,565...4,150,445

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of AGPAT2 mRNA
Dexamethasone results in increased expression of AGPAT2 mRNA

PMID:23428407 PMID:25047013

NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:29,814,924...29,826,581

G

1-acylglycerol-3-phosphate O-acyltransferase 3

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of AGPAT3 mRNA; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of AGPAT3 mRNA]
Dexamethasone results in increased expression of AGPAT3 mRNA

PMID:23428407 PMID:31053639

NCBI chr20:10,330,650...10,415,026
Ensembl chr20:10,394,465...10,410,632

G

1-acylglycerol-3-phosphate O-acyltransferase 4

decreases expression

ISO

Dexamethasone results in decreased expression of AGPAT4 mRNA

NCBI chr 1:51,075,081...51,181,548
Ensembl chr 1:51,075,081...51,180,976

G

alkylglycerone phosphate synthase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AGPS mRNA

NCBI chr 3:81,154,599...81,253,099
Ensembl chr 3:81,154,604...81,258,277

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA

NCBI chr 6:58,435,908...58,456,678
Ensembl chr 6:58,435,908...58,456,677

G

agrin

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of AGRN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AGRN mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539

G

angiotensinogen

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA; [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of AGT mRNA; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; ICI 118551 inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]]; Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]; Propranolol inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]
[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone co-treated with bisphenol AF] results in increased expression of AGT mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of AGT mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AGT mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AGT mRNA
Dexamethasone results in increased expression of AGT mRNA
Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha]; Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of Dinoprostone]

PMID:4030047 PMID:6421564 PMID:7843740 PMID:16054899 PMID:19853017 More...

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

angiotensin II receptor, type 1a

multiple interactions
increases expression
affects expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AGTR1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AGTR1 mRNA
Dexamethasone results in increased expression of AGTR1A mRNA; Dexamethasone results in increased expression of AGTR1A protein
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of AGTR1A protein]
diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of AGTR1 protein]; Enalapril inhibits the reaction [Dexamethasone results in increased expression of AGTR1 protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of AGTR1 protein]]
Dexamethasone affects the expression of AGTR1 mRNA
Dexamethasone results in increased expression of AGTR1 protein; Dexamethasone results in increased expression of AGTR1A mRNA

PMID:23935943 PMID:28628672 PMID:30359671 PMID:30940551 PMID:32494933

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

angiotensin II receptor, type 2

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of AGTR2 mRNA; Dexamethasone results in decreased expression of AGTR2 protein
[Dexamethasone co-treated with Lithium Chloride co-treated with Pilocarpine] affects the expression of AGTR2 mRNA; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of GDNF mRNA]; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of INS1 mRNA]; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of INS2 mRNA]; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of NPHS1 mRNA]; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of NPHS2 mRNA]; AGTR2 protein inhibits the reaction [Dexamethasone results in decreased expression of RET mRNA]; Dexamethasone promotes the reaction [NR3C1 protein binds to AGTR2 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of AGTR2 mRNA]; trichostatin A inhibits the reaction [Dexamethasone results in decreased expression of AGTR2 mRNA]

PMID:30359671 PMID:32494933 PMID:32791177

NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745

G

adenosylhomocysteinase-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AHCYL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930

G

AHNAK nucleoprotein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AHNAK mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHNAK mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AHNAK mRNA

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675

G

AHNAK nucleoprotein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AHNAK2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHNAK2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AHNAK2 mRNA

NCBI chr 6:137,648,867...137,697,580
Ensembl chr 6:137,652,537...137,675,546

G

aryl hydrocarbon receptor

multiple interactions
affects localization
increases degradation
affects binding
decreases expression
increases expression

ISO
EXP

[2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide co-treated with Dexamethasone] affects the localization of AHR protein; Dexamethasone inhibits the reaction [AHR protein results in increased expression of CYP1A1]; Dexamethasone inhibits the reaction [Benzo(a)pyrene results in increased expression of AHR mRNA]; Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AHR protein]; Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]; Dexamethasone promotes the reaction [IL1B protein affects the localization of AHR protein]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of AHR mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of AHR protein]
Dexamethasone affects the localization of AHR protein
Dexamethasone results in increased degradation of AHR protein
Dexamethasone binds to AHR protein
Dexamethasone results in increased expression of AHR mRNA
Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]]
Dexamethasone results in increased expression of AHR mRNA; Dexamethasone results in increased expression of AHR protein
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of AHR mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of AHR mRNA]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin binds to AHR protein]]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of AHR mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of AHR mRNA]
Dexamethasone results in decreased expression of AHR mRNA; Dexamethasone results in decreased expression of AHR protein

PMID:9804617 PMID:10478797 PMID:16054899 PMID:17552871 PMID:17690134 More...

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

activator of Hsp90 ATPase activity 1

increases expression

ISO

Dexamethasone results in increased expression of AHSA1 mRNA

NCBI chr 6:112,644,287...112,652,290
Ensembl chr 6:112,644,479...112,655,595

G

activator of HSP90 ATPase homolog 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHSA2 mRNA

NCBI chr14:101,677,447...101,688,706
Ensembl chr14:101,677,447...101,686,923

G

alpha-2-HS-glycoprotein

increases response to substance

ISO

AHSG gene polymorphism results in increased susceptibility to Dexamethasone

NCBI chr11:91,625,975...91,632,583
Ensembl chr11:91,625,975...91,634,039

G

axin interactor, dorsalization associated

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AIDA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AIDA mRNA

NCBI chr13:97,471,931...97,499,531
Ensembl chr13:97,471,604...97,499,535

G

allograft inflammatory factor 1-like

increases expression

ISO

Dexamethasone results in increased expression of AIF1L mRNA

NCBI chr 3:35,627,239...35,651,793
Ensembl chr 3:35,627,239...35,651,793

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions
increases activity

ISO
EXP

Dexamethasone inhibits the reaction [Puromycin Aminonucleoside affects the localization of AIFM1 protein]
Dexamethasone results in increased activity of AIFM1 protein

PMID:15987750 PMID:16403471

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

AIF family member 2

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of AIFM2 mRNA
Dexamethasone results in increased expression of AIFM2 mRNA

PMID:24848799 PMID:25047013

NCBI chr20:30,195,781...30,222,014
Ensembl chr20:30,193,829...30,220,957

G

androgen-induced 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of AIG1 mRNA

NCBI chr 1:9,866,546...10,089,454
Ensembl chr 1:9,866,548...10,089,155

G

aryl-hydrocarbon receptor-interacting protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AIP mRNA

NCBI chr 1:210,837,473...210,848,691
Ensembl chr 1:210,836,755...210,848,634

G

adenylate kinase 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AK1 mRNA
Dexamethasone results in decreased expression of AK1 protein

PMID:28628672 PMID:33567340

NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757

G

adenylate kinase 2

increases expression

ISO

Dexamethasone results in increased expression of AK2 mRNA

NCBI chr 5:146,609,469...146,649,008
Ensembl chr 5:146,630,445...146,650,610

G

adenylate kinase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AK3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AK3 mRNA

NCBI chr 1:236,151,012...236,178,689
Ensembl chr 1:236,151,012...236,178,183

G

adenylate kinase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AK4 mRNA

NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401

G

A-kinase anchoring protein 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKAP10 mRNA

NCBI chr10:47,044,819...47,108,153
Ensembl chr10:47,044,819...47,108,203

G

A-kinase anchoring protein 11

decreases expression

ISO

Dexamethasone results in decreased expression of AKAP11 mRNA

NCBI chr15:60,320,839...60,365,480
Ensembl chr15:60,320,839...60,365,335

G

A-kinase anchoring protein 12

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of AKAP12 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AKAP12 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKAP12 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AKAP12 mRNA

PMID:16054899 PMID:28628672

NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557

G

A-kinase anchoring protein 7

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA

NCBI chr 1:21,906,503...22,168,663
Ensembl chr 1:21,906,676...22,037,090

G

akirin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AKIRIN1 mRNA

NCBI chr 5:141,274,174...141,289,617
Ensembl chr 5:141,274,175...141,289,575

G

aldo-keto reductase family 1 member A1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKR1A1 mRNA

NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035

G

aldo-keto reductase family 1 member B1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AKR1B1 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of AKR1B1 mRNA
Dexamethasone results in decreased expression of AKR1B1 protein

PMID:24848799 PMID:28628672 PMID:33567340

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1, member B7

multiple interactions

EXP

Dexamethasone inhibits the reaction [Freund's Adjuvant results in increased expression of AKR1B7 mRNA]

NCBI chr 4:64,043,901...64,083,751
Ensembl chr 4:64,020,686...64,064,909

G

aldo-keto reductase family 1, member C1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AKR1C1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AKR1C1 mRNA
Dexamethasone results in increased expression of AKR1C1 mRNA

PMID:25047013 PMID:28628672

NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247

G

aldo-keto reductase family 1, member C3

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of AKR1C3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AKR1C3 mRNA

PMID:25047013 PMID:28628672

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

aldo-keto reductase family 1 member C8

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of AKR1CL mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of AKR1CL mRNA]

NCBI chr17:71,091,398...71,117,985
Ensembl chr17:71,083,080...71,117,957

G

AKT serine/threonine kinase 1

decreases phosphorylation
decreases expression
multiple interactions
increases expression

ISO
EXP

Dexamethasone results in decreased phosphorylation of AKT1 protein
Dexamethasone results in decreased expression of AKT1 mRNA
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein]
Dexamethasone results in increased expression of AKT1 mRNA
Dexamethasone results in decreased expression of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [echinacoside inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of AKT1 protein; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of AKT1 mRNA; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased phosphorylation of AKT1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of AKT1 protein; Dexamethasone affects the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of AKT1 protein]; Dexamethasone inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of AKT1 protein]; echinacoside inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of AKT1 mRNA]; PIK3R1 mutant form inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Dexamethasone affects the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; PIK3R1 protein affects the reaction [Dexamethasone results in decreased expression of AKT1 protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of AKT1 protein]
[Dexamethasone co-treated with beta-hydroxyisovaleric acid] results in increased phosphorylation of AKT1 protein; Dexamethasone inhibits the reaction [Hydrogen Sulfide results in decreased phosphorylation of AKT1 protein]; INS1 protein inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; Mifepristone inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]

PMID:15187100 PMID:15576458 PMID:18467435 PMID:20181797 PMID:22733784 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

AKT serine/threonine kinase 2

multiple interactions
decreases expression

ISO
EXP

Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA]
Dexamethasone inhibits the reaction [SMAD5 protein binds to AKT2 gene]

PMID:20079400 PMID:20462044 PMID:35148621

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420

G

5'-aminolevulinate synthase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ALAS1 mRNA

NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642

G

albumin

multiple interactions
increases expression
decreases expression
increases secretion

ISO
EXP

Dexamethasone inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; Dexamethasone inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; Dexamethasone inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein]
Dexamethasone results in increased expression of ALB mRNA; Dexamethasone results in increased expression of ALB protein
Dexamethasone results in decreased expression of ALB protein
Dexamethasone results in increased secretion of ALB protein

PMID:10380089 PMID:14676436 PMID:15965953 PMID:16908450 PMID:27427493

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

activated leukocyte cell adhesion molecule

increases expression

ISO

Dexamethasone results in increased expression of ALCAM mRNA

NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876

G

aldehyde dehydrogenase 16 family, member A1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ALDH16A1 mRNA

NCBI chr 1:104,763,200...104,776,270
Ensembl chr 1:104,763,055...104,776,270

G

aldehyde dehydrogenase 18 family, member A1

decreases expression

ISO

Dexamethasone results in decreased expression of ALDH18A1 mRNA

NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:249,325,082...249,357,383

G

aldehyde dehydrogenase 1 family, member A1

affects expression

EXP

Dexamethasone affects the expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member A2

increases expression

ISO

Dexamethasone results in increased expression of ALDH1A2 mRNA

NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883

G

aldehyde dehydrogenase 1 family, member A3

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ALDH1A3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ALDH1A3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALDH1A3 mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777

G

aldehyde dehydrogenase 1 family, member B1

affects expression
increases expression

EXP
ISO

Dexamethasone affects the expression of ALDH1B1 mRNA
Dexamethasone results in increased expression of ALDH1B1 mRNA

PMID:15102944 PMID:17998271

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

aldehyde dehydrogenase 1 family, member L1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ALDH1L1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ALDH1L1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 4:124,617,182...124,663,674
Ensembl chr 4:124,617,217...124,664,704

G

aldehyde dehydrogenase 1 family, member L2

decreases expression

ISO

Dexamethasone results in decreased expression of ALDH1L2 mRNA

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398

G

aldehyde dehydrogenase 2 family member

increases expression

ISO

Dexamethasone results in increased expression of ALDH2 mRNA

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

aldehyde dehydrogenase 3 family, member A1

decreases expression

ISO

Dexamethasone results in decreased expression of ALDH3A1 mRNA

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151

G

aldehyde dehydrogenase 4 family, member A1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ALDH4A1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ALDH4A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALDH4A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ALDH4A1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:157,163,189...157,188,673
Ensembl chr 5:157,162,945...157,188,673

G

aldehyde dehydrogenase 8 family, member A1

increases expression

ISO

Dexamethasone results in increased expression of ALDH8A1 mRNA

NCBI chr 1:18,003,507...18,022,952
Ensembl chr 1:18,003,514...18,023,883

G

aldolase, fructose-bisphosphate A

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ALDOA mRNA
Dexamethasone results in increased expression of ALDOA mRNA

PMID:17522070 PMID:28628672

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

aldolase, fructose-bisphosphate C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ALDOC mRNA

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ALG14 mRNA

NCBI chr 2:212,053,008...212,130,136
Ensembl chr 2:212,044,969...212,130,140

G

ALG3, alpha-1,3- mannosyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ALG3 mRNA

NCBI chr11:93,804,859...93,810,403
Ensembl chr11:93,804,891...93,812,060

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ALOX12B mRNA

NCBI chr10:54,361,898...54,373,776
Ensembl chr10:54,361,898...54,373,776

G

arachidonate 5-lipoxygenase

multiple interactions

EXP

Dexamethasone inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein]

NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126

G

arachidonate 5-lipoxygenase activating protein

increases expression

ISO

Dexamethasone results in increased expression of ALOX5AP mRNA

NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038

G

alpha-kinase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ALPK1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ALPK1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ALPK1 mRNA

NCBI chr 2:218,801,425...218,924,013
Ensembl chr 2:218,780,189...218,921,646

G

alpha-kinase 2

increases expression

ISO

Dexamethasone results in increased expression of ALPK2 mRNA

NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985

G

alkaline phosphatase, biomineralization associated

multiple interactions
decreases expression
increases expression

ISO
EXP

[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with 1,25-dihydroxyvitamin D] inhibits the reaction [WNT3A protein results in increased expression of ALPL protein]; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ALPL mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA]
Dexamethasone results in decreased expression of ALPL mRNA; Dexamethasone results in decreased expression of ALPL protein
Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of ALPL mRNA]; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of ALPL protein]; caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of ALPL protein]
Dexamethasone results in increased expression of ALPL mRNA
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ALPL mRNA; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]

PMID:15270777 PMID:26424790 PMID:26492236 PMID:27608943 PMID:28363435 More...

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

ALS2 C-terminal like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ALS2CL mRNA

NCBI chr 8:119,746,498...119,762,824
Ensembl chr 8:119,743,248...119,762,843

G

Aly/REF export factor

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ALYREF mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALYREF mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ALYREF mRNA

PMID:21041162 PMID:28628672

NCBI chr10:106,369,750...106,373,395
Ensembl chr10:106,369,750...106,373,395

G

anti-Mullerian hormone

decreases secretion

EXP

Dexamethasone results in decreased secretion of AMH protein

NCBI chr 7:9,557,451...9,559,867
Ensembl chr 7:9,557,451...9,559,867

G

adhesion molecule with Ig like domain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of AMIGO2 mRNA

NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218

G

adhesion molecule with Ig like domain 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AMIGO3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AMIGO3 mRNA

NCBI chr 8:117,620,499...117,622,025
Ensembl chr 8:117,616,629...117,626,577

G

angiomotin like 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AMOTL2 mRNA

NCBI chr 8:112,182,060...112,198,032
Ensembl chr 8:112,181,863...112,198,030

G

adenosine monophosphate deaminase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AMPD2 mRNA

NCBI chr 2:198,395,767...198,408,514
Ensembl chr 2:198,395,768...198,408,796

G

adenosine monophosphate deaminase 3

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of AMPD3 mRNA
apicidin inhibits the reaction [Dexamethasone results in increased expression of AMPD3 mRNA]; trichostatin A inhibits the reaction [Dexamethasone results in increased expression of AMPD3 mRNA]; Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of AMPD3 mRNA]
Testosterone inhibits the reaction [Dexamethasone results in increased expression of AMPD3 mRNA]

PMID:14618091 PMID:20032058 PMID:22733784 PMID:23946490 PMID:29229235

NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608

G

amphiphysin

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of AMPH mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AMPH mRNA

PMID:25047013 PMID:28628672

NCBI chr17:50,435,018...50,678,583
Ensembl chr17:50,435,018...50,678,501

G

aminomethyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AMT mRNA

NCBI chr 8:117,859,700...117,866,692
Ensembl chr 8:117,860,345...117,866,803

G

amylase 2a3

decreases expression

EXP

Dexamethasone results in decreased expression of AMY2A3 mRNA

NCBI chr 2:204,005,840...204,014,412
Ensembl chr 2:204,005,840...204,014,413

G

amylase 2a5

increases expression

ISO

Dexamethasone results in increased expression of AMY2A5 mRNA

NCBI chr 2:203,949,578...203,958,111

G

anaphase promoting complex subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of ANAPC1 mRNA

NCBI chr 3:136,303,350...136,383,464
Ensembl chr 3:136,303,413...136,383,464

G

anaphase promoting complex subunit 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANAPC10 mRNA

NCBI chr19:45,057,278...45,109,882
Ensembl chr19:45,029,546...45,109,882

G

angiopoietin 1

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ANGPT1 mRNA

PMID:16997883 PMID:28628672

NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696

G

angiopoietin-like 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ANGPTL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANGPTL1 mRNA

PMID:25047013 PMID:28628672

NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818

G

angiopoietin-like 4

increases expression
increases response to substance
decreases expression
multiple interactions
affects response to substance

ISO
EXP

Dexamethasone results in increased expression of ANGPTL4 mRNA
ANGPTL4 gene mutant form results in increased susceptibility to Dexamethasone
Dexamethasone results in decreased expression of ANGPTL4 mRNA
Dexamethasone inhibits the reaction [Freund's Adjuvant results in decreased expression of ANGPTL4 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of ANGPTL4 mRNA]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of ANGPTL4 mRNA; [ANGPTL4 gene mutant form results in increased susceptibility to Dexamethasone] which results in decreased expression of FASN mRNA; [ANGPTL4 gene mutant form results in increased susceptibility to Dexamethasone] which results in decreased expression of MLXIPL mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ANGPTL4 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ANGPTL4 mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of ACACA mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of ACACB mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of AGPAT3 mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of CD36 mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of LPIN1 mRNA]; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of MLXIPL mRNA alternative form]; ANGPTL4 gene mutant form promotes the reaction [Dexamethasone results in decreased expression of SREBF1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ANGPTL4 mRNA]
ANGPTL4 affects the susceptibility to Dexamethasone

PMID:16054899 PMID:19628874 PMID:20032058 PMID:21149847 PMID:22733784 More...

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

angiopoietin like 7

increases expression

ISO

Dexamethasone results in increased expression of ANGPTL7 mRNA

NCBI chr 5:164,215,223...164,220,408
Ensembl chr 5:164,215,223...164,220,584

G

ankyrin 1

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of ANK1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of ANK1 mRNA]

NCBI chr16:75,578,824...75,757,464
Ensembl chr16:75,578,824...75,757,464

G

ankyrin 3

increases expression

ISO

Dexamethasone results in increased expression of ANK3 mRNA

NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,601,826...19,084,879

G

ankyrin repeat and FYVE domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ANKFY1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ANKFY1 mRNA

NCBI chr10:57,810,781...57,882,495
Ensembl chr10:57,810,781...57,882,495

G

ankyrin repeat and MYND domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKMY2 mRNA

NCBI chr 6:58,616,251...58,657,634
Ensembl chr 6:58,615,243...58,657,685

G

ankyrin repeat domain 1

decreases expression

ISO

Dexamethasone results in decreased expression of ANKRD1 mRNA

NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751

G

ankyrin repeat domain containing 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ANKRD11 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKRD11 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ANKRD11 mRNA

NCBI chr19:67,848,836...68,007,491
Ensembl chr19:67,848,844...68,007,491

G

ankyrin repeat domain 12

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ANKRD12 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKRD12 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:113,030,127...113,134,816
Ensembl chr 9:113,030,919...113,134,762

G

ankyrin repeat domain 13a

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANKRD13A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANKRD13A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ANKRD13A mRNA

NCBI chr12:47,458,828...47,488,959
Ensembl chr12:47,458,831...47,489,312

G

ankyrin repeat domain 13B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ANKRD13B mRNA

NCBI chr10:62,817,791...62,836,456
Ensembl chr10:62,817,778...62,836,635

G

ankyrin repeat domain 24

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANKRD24 mRNA

NCBI chr 7:8,712,720...8,731,910
Ensembl chr 7:8,712,722...8,731,910

G

ankyrin repeat domain 37

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ANKRD37 mRNA

NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545

G

ankyrin repeat domain 49

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANKRD49 mRNA

NCBI chr 8:19,908,968...19,913,656
Ensembl chr 8:19,908,973...19,913,656

G

ankyrin repeat domain 53

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ANKRD53 mRNA

NCBI chr 4:117,804,702...117,810,650
Ensembl chr 4:117,804,548...117,810,645

G

ankyrin repeat and sterile alpha motif domain containing 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ANKS1A mRNA

NCBI chr20:5,965,421...6,118,875
Ensembl chr20:5,965,028...6,118,875

G

ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKZF1 mRNA

NCBI chr 9:84,136,862...84,143,830
Ensembl chr 9:84,136,862...84,145,091

G

ANTXR cell adhesion molecule 1

decreases expression

ISO

Dexamethasone results in decreased expression of ANTXR1 mRNA

NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892

G

ANTXR cell adhesion molecule 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANTXR2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANTXR2 mRNA

NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168

G

annexin A1

multiple interactions
affects response to substance
increases phosphorylation
increases localization
increases expression

ISO
EXP

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Dexamethasone results in increased phosphorylation of ANXA1 protein]; ANXA1 protein inhibits the reaction [Dexamethasone results in decreased susceptibility to CXCL8 protein]; Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]]; Mifepristone inhibits the reaction [Dexamethasone results in increased localization of ANXA1 protein modified form]; Mifepristone inhibits the reaction [Dexamethasone results in increased phosphorylation of and results in increased expression of ANXA1 protein]
ANXA1 protein affects the susceptibility to Dexamethasone
ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan]
Dexamethasone results in increased expression of ANXA1 protein

PMID:7522859 PMID:10807665 PMID:12475898 PMID:15472012

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

annexin A10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ANXA10 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANXA10 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ANXA10 mRNA

NCBI chr16:32,505,025...32,571,961
Ensembl chr16:32,467,126...32,571,961

G

annexin A11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANXA11 mRNA

NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839

G

annexin A3

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ANXA3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANXA3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ANXA3 mRNA

PMID:16054899 PMID:28628672

NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849

G

annexin A4

increases expression

ISO

Dexamethasone results in increased expression of ANXA4 mRNA

PMID:22733784 PMID:25047013

NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:120,741,750...120,798,513

G

annexin A6

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ANXA6 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ANXA6 mRNA
Dexamethasone results in increased expression of ANXA6 mRNA

PMID:16054899 PMID:25047013 PMID:28628672

NCBI chr10:39,602,106...39,657,183
Ensembl chr10:39,602,106...39,657,359

G

annexin A8

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA

NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,403,353...9,418,310

G

amine oxidase, copper containing 3

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of AOC3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AOC3 mRNA

PMID:25047013 PMID:28628672

NCBI chr10:86,773,018...86,780,961

G

aldehyde oxidase 1

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of AOX1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AOX1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of AOX1 mRNA]

PMID:20032058 PMID:25047013 PMID:28628672

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

adaptor related protein complex 1 subunit beta 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AP1B1 mRNA

NCBI chr14:84,093,529...84,144,835
Ensembl chr14:84,093,559...84,144,892

G

adaptor related protein complex 1 subunit gamma 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP1G1 mRNA

NCBI chr19:54,654,101...54,740,586
Ensembl chr19:54,620,807...54,740,586

G

adaptor related protein complex 1 subunit gamma 2

increases expression

ISO

Dexamethasone results in increased expression of AP1G2 mRNA

NCBI chr15:32,541,528...32,549,392
Ensembl chr15:32,541,528...32,549,280

G

adaptor related protein complex 1 subunit sigma 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of AP1S2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of AP1S2 mRNA

NCBI chr X:34,204,601...34,230,819
Ensembl chr X:34,204,603...34,228,529

G

adaptor related protein complex 2 subunit alpha 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP2A1 mRNA

NCBI chr 1:104,520,789...104,550,655
Ensembl chr 1:104,520,792...104,550,655

G

adaptor related protein complex 3 subunit beta 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AP3B2 mRNA

NCBI chr 1:144,821,819...144,854,533
Ensembl chr 1:144,821,819...144,854,432

G

adaptor related protein complex 3 subunit mu 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of AP3M2 mRNA

NCBI chr16:75,908,459...75,937,915
Ensembl chr16:75,920,084...75,937,923

G

adaptor related protein complex 3 subunit sigma 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP3S1 mRNA

NCBI chr18:41,649,321...41,718,221
Ensembl chr18:41,648,796...41,767,641

G

adaptor related protein complex 3 subunit sigma 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP3S2 mRNA

NCBI chr 1:143,228,131...143,268,573
Ensembl chr 1:143,228,135...143,268,573

G

adaptor related protein complex 5 subunit beta 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AP5B1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AP5B1 mRNA

NCBI chr 1:212,305,612...212,309,643
Ensembl chr 1:212,305,604...212,309,629

G

APC down-regulated 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of APCDD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of APCDD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of APCDD1 protein; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT1 protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT10B protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT3A protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of APCDD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of APCDD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of APCDD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of APCDD1 mRNA
Dexamethasone results in increased expression of APCDD1 mRNA

PMID:16054899 PMID:25047013 PMID:28242765 PMID:28628672

NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356

G

APC down-regulated 1 like

decreases expression

ISO

Dexamethasone results in decreased expression of APCDD1L mRNA

NCBI chr 3:183,000,504...183,076,628
Ensembl chr 3:183,000,521...183,076,339

G

acylaminoacyl-peptide hydrolase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of APEH mRNA

NCBI chr 8:117,652,390...117,661,502
Ensembl chr 8:117,652,393...117,661,711

G

apelin

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of APLN mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of APLN mRNA]

PMID:19853017 PMID:20032058

NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246

G

adipocyte plasma membrane associated protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of APMAP mRNA

NCBI chr 3:159,869,451...159,897,727
Ensembl chr 3:159,869,451...159,897,726

G

apolipoprotein A1

affects expression
multiple interactions
increases expression

EXP

Dexamethasone affects the expression of APOA1 mRNA
[fenofibric acid co-treated with Dexamethasone] results in increased expression of APOA1 mRNA; fenofibric acid inhibits the reaction [Dexamethasone results in increased expression of APOA1 mRNA]

PMID:7556148 PMID:11328961 PMID:15102944

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein A4

affects expression
increases expression

EXP

Dexamethasone affects the expression of APOA4 mRNA
Dexamethasone results in increased expression of APOA4 mRNA

PMID:11328961 PMID:15102944

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164

G

apolipoprotein B

increases expression
affects expression

EXP

Dexamethasone results in increased expression of APOB protein
Dexamethasone affects the expression of APOB mRNA; Dexamethasone affects the expression of APOB protein

PMID:15965953 PMID:32234517

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein B mRNA editing enzyme catalytic subunit 1

increases expression

ISO

Dexamethasone results in increased expression of APOBEC1 mRNA

NCBI chr 4:157,472,879...157,500,496
Ensembl chr 4:157,472,868...157,498,909

G

apolipoprotein C1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of APOC1 mRNA

NCBI chr 1:88,475,018...88,479,052
Ensembl chr 1:88,474,663...88,478,155

G

apolipoprotein C3

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of APOC3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]
pirinixic acid inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]

PMID:11162775 PMID:20032058

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679

G

apolipoprotein D

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of APOD mRNA

NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263

G

apolipoprotein E

increases expression

ISO

Dexamethasone results in increased expression of APOE mRNA

PMID:21041162 PMID:25047013

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855

G

apolipoprotein L9a

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of APOL9A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of APOL4 mRNA

PMID:22733784 PMID:28628672

NCBI chr 7:111,021,452...111,030,380
Ensembl chr 7:111,021,453...111,028,213

G

apolipoprotein O

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of APOO mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of APOO mRNA

NCBI chr X:63,151,736...63,256,696
Ensembl chr X:63,151,814...63,256,690

G

amyloid beta precursor protein

multiple interactions

EXP

[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA; [APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA; [APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein; [APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form; [APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; Huang Qi results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of APPL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of APPL1 mRNA

NCBI chr16:2,125,234...2,173,457
Ensembl chr16:2,125,234...2,173,421

G

aquaporin 1

decreases expression

ISO

Dexamethasone results in decreased expression of AQP1 mRNA

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression

ISO

Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]]
Dexamethasone results in increased expression of AQP3 mRNA; Dexamethasone results in increased expression of AQP3 protein

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

aquaporin 5

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of AQP5 mRNA
Dexamethasone inhibits the reaction [bisphenol A results in decreased expression of AQP5 protein]

PMID:22733784 PMID:26283537

NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062

G

aquaporin 7

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of AQP7 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of AQP7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AQP7 mRNA

PMID:14618091 PMID:19853017 PMID:25047013 PMID:28628672

NCBI chr 5:60,968,495...60,982,618
Ensembl chr 5:60,967,558...60,982,618

G

androgen receptor

affects activity
multiple interactions
affects binding
decreases expression

ISO
EXP

Dexamethasone affects the activity of AR protein
Dexamethasone inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Dexamethasone inhibits the reaction [Metribolone results in increased activity of AR protein]
Dexamethasone binds to AR protein
Dexamethasone results in decreased expression of AR mRNA
[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]; bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]]
Dexamethasone binds to AR protein mutant form

PMID:11956172 PMID:14565775 PMID:15084347 PMID:18324785 PMID:19681914 More...

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

A-Raf proto-oncogene, serine/threonine kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ARAF mRNA; Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]]

PMID:10807665 PMID:28628672

NCBI chr X:3,780,932...3,845,919
Ensembl chr X:3,780,932...3,792,611

G

amphiregulin

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of AREG mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of AREG mRNA

PMID:12837037 PMID:28628672

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

ARF GTPase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARF1 mRNA

NCBI chr10:44,497,543...44,513,994

G

ADP-ribosylation factor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARL17B mRNA

NCBI chr10:89,367,843...89,389,644
Ensembl chr10:89,368,044...89,389,651

G

ARF GTPase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARF3 mRNA

NCBI chr 7:131,765,039...131,792,075
Ensembl chr 7:131,750,672...131,770,123

G

arginase 2

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of ARG2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ARG2 mRNA]

PMID:14618091 PMID:20032058

NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375

G

arginine and glutamate rich 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARGLU1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARGLU1 mRNA

NCBI chr16:87,455,097...87,479,148
Ensembl chr16:87,455,113...87,479,148

G

Rho GTPase activating protein 10

increases expression

ISO

Dexamethasone results in increased expression of ARHGAP10 mRNA

PMID:17998272 PMID:22733784

NCBI chr19:47,352,783...47,614,532
Ensembl chr19:47,352,276...47,614,531

G

Rho GTPase activating protein 20

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ARHGAP20 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ARHGAP20 mRNA

PMID:25047013 PMID:28628672

NCBI chr 8:60,970,480...61,055,199
Ensembl chr 8:60,970,475...61,055,198

G

Rho GTPase activating protein 22

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ARHGAP22 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARHGAP22 mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr16:8,480,222...8,637,823
Ensembl chr16:8,479,956...8,637,822

G

Rho GTPase activating protein 29

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARHGAP29 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARHGAP29 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARHGAP29 mRNA

NCBI chr 2:212,744,626...212,816,710
Ensembl chr 2:212,755,803...212,986,729

G

Rho GTPase activating protein 30

increases expression

ISO

Dexamethasone results in increased expression of ARHGAP30 mRNA

NCBI chr13:86,354,448...86,376,552
Ensembl chr13:86,354,547...86,376,888

G

Rho GTPase activating protein 39

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ARHGAP39 mRNA

NCBI chr 7:110,326,918...110,419,500
Ensembl chr 7:110,326,918...110,419,460

G

Rho GTPase activating protein 45

decreases expression

ISO

Dexamethasone results in decreased expression of ARHGAP45 mRNA

NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890

G

Rho GTPase activating protein 5

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ARHGAP5 mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ARHGAP5 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ARHGAP5 mRNA]

NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636

G

Rho GTPase activating protein 6

increases expression

ISO

Dexamethasone results in increased expression of ARHGAP6 mRNA

NCBI chr X:28,525,912...29,062,344
Ensembl chr X:28,525,917...29,061,244

G

Rho guanine nucleotide exchange factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARHGEF1 mRNA

NCBI chr 1:89,626,884...89,648,823
Ensembl chr 1:89,628,266...89,649,067

G

Rho/Rac guanine nucleotide exchange factor 2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ARHGEF2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ARHGEF2 mRNA

PMID:22733784 PMID:28628672

NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646

G

Rho guanine nucleotide exchange factor 28

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARHGEF28 mRNA

NCBI chr 2:30,998,292...31,294,757
Ensembl chr 2:30,998,295...31,294,853

G

Cdc42 guanine nucleotide exchange factor 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARHGEF9 mRNA

NCBI chr X:63,929,168...64,087,267
Ensembl chr X:63,929,176...64,087,104

G

AT-rich interaction domain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARID2 mRNA

NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187

G

AT-rich interaction domain 5A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ARID5A mRNA

NCBI chr 9:46,030,513...46,058,729
Ensembl chr 9:46,030,548...46,045,363

G

AT-rich interaction domain 5B

increases expression

ISO

Dexamethasone results in increased expression of ARID5B mRNA

NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686

G

ariadne RBR E3 ubiquitin protein ligase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARIH2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARIH2 mRNA

NCBI chr 8:118,175,267...118,234,425
Ensembl chr 8:118,175,267...118,234,284

G

ARF like GTPase 2 binding protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL2BP mRNA

NCBI chr19:10,342,895...10,352,529
Ensembl chr19:10,342,895...10,352,514

G

ARF like GTPase 4C

decreases expression

ISO

Dexamethasone results in decreased expression of ARL4C mRNA

NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772

G

ARF like GTPase 6 interacting protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL6IP4 mRNA

NCBI chr12:38,140,566...38,142,711
Ensembl chr12:38,140,550...38,142,724

G

ARF like GTPase 8A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL8A mRNA

NCBI chr13:49,137,632...49,146,633
Ensembl chr13:49,137,632...49,146,633

G

armadillo repeat containing 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ARMC9 mRNA

NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589

G

armadillo repeat containing, X-linked 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ARMCX1 mRNA

NCBI chr X:102,192,225...102,196,130
Ensembl chr X:102,192,015...102,199,115

G

aryl hydrocarbon receptor nuclear translocator

increases expression

EXP

Dexamethasone results in increased expression of ARNT mRNA

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

aryl hydrocarbon receptor nuclear translocator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARNT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ARNT2 mRNA

NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997

G

actin related protein 2/3 complex, subunit 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARPC1B mRNA

NCBI chr12:14,595,939...14,609,501
Ensembl chr12:14,595,678...14,609,504

G

actin related protein 2/3 complex, subunit 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC3 mRNA

NCBI chr12:39,833,569...39,847,436
Ensembl chr12:39,833,569...39,847,436

G

actin related protein 2/3 complex, subunit 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ARPC5 mRNA

NCBI chr13:67,454,379...67,463,288
Ensembl chr13:67,437,027...67,463,283

G

actin related protein 2/3 complex, subunit 5-like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ARPC5L mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA

NCBI chr 3:43,169,518...43,177,224
Ensembl chr 3:43,169,462...43,177,240
Ensembl chr 9:43,169,462...43,177,240

G

cAMP regulated phosphoprotein 21

decreases expression

ISO

Dexamethasone results in decreased expression of ARPP21 mRNA

NCBI chr 8:120,912,964...121,077,586
Ensembl chr 8:120,912,970...121,031,357

G

arrestin domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ARRDC2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARRDC2 mRNA

NCBI chr16:18,635,883...18,640,019
Ensembl chr16:18,635,883...18,640,158

G

arylsulfatase G

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARSG mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ARSG mRNA

NCBI chr10:94,912,094...95,063,021
Ensembl chr10:94,913,152...95,042,447

G

ADP-ribosyltransferase 1

multiple interactions
increases expression

EXP
ISO

Testosterone inhibits the reaction [Dexamethasone results in increased expression of ART1 mRNA]

PMID:20032058 PMID:22733784

NCBI chr 1:165,890,032...165,899,154
Ensembl chr 1:165,890,086...165,899,146

G

ADP-ribosyltransferase 3

increases expression

ISO

Dexamethasone results in increased expression of ART3 mRNA

NCBI chr14:15,921,540...16,003,764
Ensembl chr14:15,921,395...15,949,806

G

ADP-ribosyltransferase 5

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of ART5 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ART5 mRNA]

PMID:20032058 PMID:22733784

NCBI chr 1:165,885,344...165,895,306
Ensembl chr 1:165,885,280...165,895,306

G

artemin

decreases expression

ISO

Dexamethasone results in decreased expression of ARTN mRNA

NCBI chr 5:136,750,188...136,755,645
Ensembl chr 5:136,750,188...136,753,457

G

N-acylsphingosine amidohydrolase 2

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of ASAH2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of ASAH2 mRNA]

NCBI chr 1:239,278,994...239,386,598
Ensembl chr 1:239,278,994...239,382,024

G

ankyrin repeat and SOCS box-containing 1

decreases expression

ISO

Dexamethasone results in decreased expression of ASB1 mRNA

NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907

G

ankyrin repeat and SOCS box-containing 2

increases expression

ISO

Dexamethasone results in increased expression of ASB2 mRNA

NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASB7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ASB7 mRNA

NCBI chr 1:129,621,462...129,677,788
Ensembl chr 1:129,635,330...129,677,505

G

activating signal cointegrator 1 complex subunit 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ASCC3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ASCC3 mRNA

NCBI chr20:55,089,430...55,372,374
Ensembl chr20:55,255,503...55,372,374

G

acid sensing ion channel subunit 1

decreases expression

EXP

Dexamethasone results in decreased expression of ASIC1 mRNA

NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832

G

acid sensing ion channel subunit 2

decreases expression

EXP

Dexamethasone results in decreased expression of ASIC2 mRNA

NCBI chr10:66,368,308...67,438,237
Ensembl chr10:66,368,310...66,636,245

G

acid sensing ion channel subunit 3

decreases expression

EXP

Dexamethasone results in decreased expression of ASIC3 mRNA

NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:11,652,946...11,657,367

G

argininosuccinate lyase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ASL mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASL mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ASL mRNA

NCBI chr12:32,295,779...32,313,257
Ensembl chr12:32,295,633...32,317,261

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

Dexamethasone results in decreased expression of ASNS mRNA

PMID:22733784 PMID:25047013

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

aspartoacylase

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ASPA mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ASPA mRNA
Dexamethasone results in increased expression of ASPA mRNA

PMID:24848799 PMID:25047013 PMID:28628672

NCBI chr10:58,390,204...58,443,790
Ensembl chr10:58,379,410...58,443,769

G

aspartate-beta-hydroxylase

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ASPH mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ASPH mRNA

PMID:22733784 PMID:28628672

NCBI chr 5:27,398,933...27,611,519
Ensembl chr 5:27,398,949...27,611,215

G

asporin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ASPN mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ASPN mRNA

NCBI chr17:15,286,338...15,310,567
Ensembl chr17:15,287,065...15,310,632

G

aspartic peptidase, retroviral-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ASPRV1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ASPRV1 mRNA

NCBI chr 4:120,634,793...120,636,265
Ensembl chr 4:120,634,793...120,636,260

G

ASPSCR1 tether for SLC2A4, UBX domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ASPSCR1 mRNA

NCBI chr10:106,450,600...106,488,231
Ensembl chr10:106,450,567...106,488,579

G

asparaginase and isoaspartyl peptidase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ASRGL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASRGL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ASRGL1 mRNA

NCBI chr 1:215,436,180...215,456,188
Ensembl chr 1:215,435,218...215,456,198

G

argininosuccinate synthase 1

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of ASS1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of ASS1 mRNA]

PMID:20032058 PMID:25047013

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627

G

ASXL transcriptional regulator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASXL2 mRNA

NCBI chr 6:32,090,497...32,234,487
Ensembl chr 6:32,145,607...32,227,851

G

ATPase family, AAA domain containing 2

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of ATAD2 mRNA

NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238

G

ATPase family, AAA domain containing 2B

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ATAD2B mRNA

NCBI chr 6:33,646,075...33,789,532
Ensembl chr 6:33,646,075...33,789,532

G

ATCAY kinesin light chain interacting caytaxin

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of ATCAY mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of ATCAY mRNA]

NCBI chr 7:9,138,485...9,162,249
Ensembl chr 7:9,138,587...9,163,370

G

activating transcription factor 3

decreases expression

ISO

Dexamethasone results in decreased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ATF4 mRNA
Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 mRNA]

PMID:22733784 PMID:27660012

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

activating transcription factor 5

decreases expression

ISO

Dexamethasone results in decreased expression of ATF5 mRNA

PMID:22733784 PMID:25047013

NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183

G

activating transcription factor 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATF6 mRNA

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033

G

autophagy related 14

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of ATG14 protein
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Dexamethasone results in increased expression of ATG14 protein]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of ATG14 protein]

NCBI chr15:23,275,457...23,306,817
Ensembl chr15:23,275,457...23,306,815

G

autophagy related 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ATG5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ATG5 mRNA

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

autophagy related 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ATG7 mRNA

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

atlastin GTPase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ATL3 mRNA

NCBI chr 1:214,110,127...214,151,098
Ensembl chr 1:214,109,702...214,152,510

G

atos homolog A

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ATOSA mRNA
Dexamethasone results in increased expression of ATOSA mRNA

PMID:22733784 PMID:28628672

NCBI chr 8:84,575,360...84,653,103
Ensembl chr 8:84,575,370...84,653,091

G

ATPase 13A3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ATP13A3 mRNA

NCBI chr11:83,860,725...83,946,899
Ensembl chr11:83,870,218...83,944,662

G

ATPase Na+/K+ transporting subunit alpha 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ATP1A2 mRNA

NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911

G

ATPase Na+/K+ transporting subunit beta 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP1B2 mRNA

NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708

G

ATPase Na+/K+ transporting subunit beta 3

increases expression

ISO

Dexamethasone results in increased expression of ATP1B3 mRNA

NCBI chr 8:105,789,824...105,821,151
Ensembl chr 8:65,253,361...65,254,304
Ensembl chr 8:65,253,361...65,254,304

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

increases expression
decreases expression

EXP
ISO

Dexamethasone results in increased expression of ATP2A1 mRNA
Dexamethasone results in decreased expression of ATP2A1 protein

PMID:14618091 PMID:33567340

NCBI chr 1:190,457,198...190,475,410
Ensembl chr 1:190,457,198...190,475,423

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions
increases expression

ISO

Dexamethasone promotes the reaction [Lipopolysaccharides results in increased expression of ATP2A2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP2A2 mRNA
Dexamethasone results in increased expression of ATP2A2 mRNA

PMID:22185406 PMID:28628672

NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934

G

ATPase plasma membrane Ca2+ transporting 4

increases expression

ISO

Dexamethasone results in increased expression of ATP2B4 mRNA

NCBI chr13:47,708,157...47,807,389
Ensembl chr13:47,711,121...47,758,876

G

ATP synthase F1 subunit alpha

increases expression
multiple interactions
decreases expression

ISO

Dexamethasone results in increased expression of ATP5F1A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP5F1A mRNA
Dexamethasone results in decreased expression of ATP5F1A protein

PMID:25047013 PMID:28628672 PMID:33567340

NCBI chr18:73,567,537...73,575,473
Ensembl chr18:73,567,526...73,575,922

G

ATP synthase F1 subunit beta

decreases expression

ISO

Dexamethasone results in decreased expression of ATP5F1B protein

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

ATP synthase F1 subunit delta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ATP5F1D mRNA

NCBI chr 7:10,211,260...10,218,989
Ensembl chr 7:10,211,262...10,216,583

G

ATP synthase membrane subunit f

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP5MF mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ATP5MF mRNA

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATPase H+ transporting accessory protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6AP1 mRNA

NCBI chr X:157,231,243...157,238,323
Ensembl chr X:157,225,327...157,238,323

G

ATPase H+ transporting accessory protein 1 like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ATP6AP1L mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP6AP1L mRNA

NCBI chr 2:23,772,724...23,814,913
Ensembl chr 2:23,772,745...23,814,618

G

ATPase H+ transporting accessory protein 2

decreases expression

ISO

Dexamethasone results in decreased expression of ATP6AP2 mRNA

NCBI chr X:12,856,708...12,883,670
Ensembl chr X:12,855,859...12,905,875

G

ATPase H+ transporting V0 subunit a1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP6V0A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ATP6V0A1 mRNA

NCBI chr10:86,436,089...86,490,185
Ensembl chr10:86,436,141...86,490,181

G

ATPase H+ transporting V0 subunit B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6V0B mRNA

NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:136,708,823...136,716,828

G

ATPase H+ transporting V0 subunit D1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6V0D1 mRNA

NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395

G

ATPase H+ transporting V1 subunit H

decreases expression

ISO

Dexamethasone results in decreased expression of ATP6V1H mRNA

NCBI chr 5:19,176,849...19,282,516
Ensembl chr 5:19,176,849...19,282,516

G

ataxin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ATXN2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ATXN2 mRNA

NCBI chr12:40,413,657...40,509,895
Ensembl chr12:40,414,904...40,510,473

G

ataxin 7-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ATXN7L1 mRNA

NCBI chr 6:55,487,309...55,709,751
Ensembl chr 6:55,649,362...55,701,996

G

arginine vasopressin

multiple interactions
decreases expression
increases activity

EXP

Dexamethasone inhibits the reaction [AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha]; Dexamethasone inhibits the reaction [AVP protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [Phenylephrine results in increased secretion of AVP protein]; Enalapril promotes the reaction [Dexamethasone results in increased activity of AVP protein]; Hexamethonium promotes the reaction [Dexamethasone results in increased activity of AVP protein]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of AVP mRNA]

PMID:2271928 PMID:3346065 PMID:4030047 PMID:32445661

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522

G

alpha-2-glycoprotein 1, zinc-binding

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of AZGP1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AZGP1 mRNA

PMID:19853017 PMID:28628672

NCBI chr12:22,044,685...22,051,248
Ensembl chr12:22,044,751...22,053,020

G

antizyme inhibitor 2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of AZIN2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:146,568,187...146,594,777
Ensembl chr 5:146,565,437...146,594,777

G

beta-2 microglobulin

decreases expression
increases expression

ISO

Dexamethasone results in decreased expression of B2M protein
Dexamethasone results in increased expression of B2M mRNA

PMID:3047540 PMID:21041162

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

beta-1,3-N-acetylgalactosaminyltransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of B3GALNT2 mRNA

NCBI chr17:56,030,409...56,072,952
Ensembl chr17:56,030,409...56,072,952

G

Beta-1,3-galactosyltransferase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of B3GALT4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GALT4 mRNA

NCBI chr20:4,937,974...4,939,549
Ensembl chr20:4,937,674...4,939,885

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA

NCBI chr14:101,009,682...101,034,507
Ensembl chr14:100,967,131...101,043,412

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA

NCBI chr11:94,645,480...94,657,584
Ensembl chr11:94,645,480...94,660,514

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of B3GNT9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of B3GNT9 mRNA

PMID:22733784 PMID:28628672

NCBI chr19:50,039,649...50,042,206
Ensembl chr19:50,030,866...50,043,339

G

beta-1,4-galactosyltransferase 1

decreases expression

ISO

Dexamethasone results in decreased expression of B4GALT1 mRNA

NCBI chr 5:60,731,601...60,778,456
Ensembl chr 5:60,731,602...60,778,445

G

beta-1,4-galactosyltransferase 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of B4GALT5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B4GALT5 mRNA

NCBI chr 3:176,437,073...176,453,001
Ensembl chr 3:176,437,073...176,488,978

G

beta-1,4-galactosyltransferase 6

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of B4GALT6 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of B4GALT6 mRNA]

NCBI chr18:12,233,350...12,290,204
Ensembl chr18:12,233,351...12,290,204

G

beta-1,4-galactosyltransferase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B4GALT7 mRNA

NCBI chr17:9,023,667...9,032,742
Ensembl chr17:9,023,618...9,032,745

G

BPTF associated chromatin complex component 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BACC1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BACC1 mRNA

NCBI chr10:55,450,648...55,453,409
Ensembl chr10:55,450,250...55,453,311

G

beta-secretase 1

multiple interactions

EXP

[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; Huang Qi inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918

G

BCL2-associated agonist of cell death

decreases phosphorylation
increases phosphorylation
multiple interactions
increases expression

ISO

Dexamethasone results in decreased phosphorylation of BAD protein
Dexamethasone results in increased phosphorylation of BAD protein
Mifepristone inhibits the reaction [Dexamethasone results in decreased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BAD mRNA]; MK 2206 inhibits the reaction [Dexamethasone results in increased phosphorylation of BAD protein]; naringin inhibits the reaction [Dexamethasone results in increased phosphorylation of BAD protein]

PMID:16644695 PMID:30878453

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BAG cochaperone 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BAG2 mRNA

NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752

G

BAG cochaperone 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BAG4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BAG4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BAG4 mRNA

NCBI chr16:72,991,407...73,008,620
Ensembl chr16:72,991,362...73,013,273

G

BAG cochaperone 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BAG5 mRNA

NCBI chr 6:136,589,623...136,593,278
Ensembl chr 6:136,584,741...136,598,492

G

BAG cochaperone 6

decreases expression

ISO

Dexamethasone results in decreased expression of BAG6 mRNA

NCBI chr20:3,680,607...3,693,329
Ensembl chr20:3,680,607...3,693,329

G

BAR/IMD domain containing adaptor protein 2 like 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BAIAP2L2 mRNA

NCBI chr 7:112,704,798...112,731,691
Ensembl chr 7:112,704,682...112,731,127

G

BCL2-antagonist/killer 1

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of BAK1 mRNA; Dexamethasone results in increased expression of BAK1 protein
fludarabine inhibits the reaction [Dexamethasone results in increased expression of BAK1 protein]

PMID:19428934 PMID:30506661

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BMP and activin membrane-bound inhibitor

decreases expression

ISO

Dexamethasone results in decreased expression of BAMBI mRNA

NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247

G

brain abundant, membrane attached signal protein 1

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of BASP1 mRNA]

NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [echinacoside inhibits the reaction [Dexamethasone results in increased expression of BAX protein]]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in decreased expression of BAX protein; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of BAX mRNA]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of BAX protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BAX protein]; echinacoside inhibits the reaction [Dexamethasone results in increased expression of BAX protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of BAX protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BAX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BAX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BAX mRNA
Dexamethasone results in increased expression of BAX mRNA; Dexamethasone results in increased expression of BAX protein
Dexamethasone inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; fludarabine inhibits the reaction [Dexamethasone results in increased expression of BAX protein]

PMID:9790906 PMID:11751460 PMID:15987750 PMID:19080409 PMID:23935943 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

bromodomain adjacent to zinc finger domain, 2A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BAZ2A mRNA

NCBI chr 7:1,107,377...1,145,507
Ensembl chr 7:1,107,796...1,145,507

G

Bcl-2 binding component 3

increases expression
decreases expression

ISO

Dexamethasone results in increased expression of BBC3 mRNA
Dexamethasone results in decreased expression of BBC3 mRNA

PMID:22733784 PMID:25047013

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

BBSome interacting protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BBIP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBIP1 mRNA

NCBI chr 1:262,950,459...262,964,410
Ensembl chr 1:262,950,462...262,964,394

G

bublin coiled coil protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBLN mRNA

NCBI chr 3:36,072,325...36,075,070
Ensembl chr 3:36,072,328...36,075,093

G

basal body orientation factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BBOF1 mRNA

NCBI chr 6:109,786,363...109,812,153
Ensembl chr 6:109,786,363...109,812,147

G

Bardet-Biedl syndrome 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBS1 mRNA

NCBI chr 1:211,614,195...211,633,504
Ensembl chr 1:211,615,533...211,633,468

G

Bardet-Biedl syndrome 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BBS7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBS7 mRNA

NCBI chr 2:121,362,884...121,402,473
Ensembl chr 2:121,362,885...121,402,473

G

B-cell receptor-associated protein 31

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCAP31 mRNA

NCBI chr X:156,548,911...156,581,002
Ensembl chr X:156,548,911...156,579,371

G

BCAS3, microtubule associated cell migration factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCAS3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCAS3 mRNA

NCBI chr10:70,711,084...71,170,492
Ensembl chr10:70,711,525...71,170,803

G

branched chain amino acid transaminase 1

decreases expression

ISO

Dexamethasone results in decreased expression of BCAT1 mRNA

NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288

G

branched chain amino acid transaminase 2

increases expression

ISO

Dexamethasone results in increased expression of BCAT2 mRNA

NCBI chr 1:105,175,157...105,196,474
Ensembl chr 1:105,176,977...105,196,463

G

BCDIN3 domain containing RNA methyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCDIN3D mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BCDIN3D mRNA

NCBI chr 7:132,484,404...132,488,998
Ensembl chr 7:132,484,431...132,488,998

G

butyrylcholinesterase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCHE mRNA

NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760

G

BCL2, apoptosis regulator

multiple interactions
decreases response to substance
increases expression
decreases expression
increases response to substance

ISO
EXP

[Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BCL2 mRNA; [oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 mRNA; [oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 protein; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BCL2]; Mycophenolic Acid inhibits the reaction [BCL2 protein results in decreased susceptibility to Dexamethasone]
Dexamethasone results in increased expression of BCL2 mRNA
Dexamethasone results in decreased expression of BCL2 mRNA; Dexamethasone results in decreased expression of BCL2 protein
Dexamethasone results in increased expression of BCL2 protein
Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2 protein]; fludarabine inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [echinacoside inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of BCL2 protein; BCL2 gene inhibits the reaction [Dexamethasone results in decreased activity of CAT protein]; BCL2 gene inhibits the reaction [Dexamethasone results in decreased activity of NQO1 protein]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of BCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; echinacoside inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of BCL2 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]
Dexamethasone results in increased expression of BCL2; Dexamethasone results in increased expression of BCL2 protein
BCL2 protein results in increased susceptibility to Dexamethasone

PMID:7517174 PMID:10200551 PMID:11319611 PMID:11751460 PMID:15867202 More...

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCL2-related protein A1

increases expression

ISO

Dexamethasone results in increased expression of BCL2A1B mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890

G

Bcl2-like 1

multiple interactions
decreases expression
increases expression
increases stability

ISO
EXP

Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 mRNA]; Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2L1 protein]; Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein]; Dexamethasone inhibits the reaction [Dactinomycin results in increased expression of BCL2L1 protein]; Dexamethasone inhibits the reaction [Dichlororibofuranosylbenzimidazole results in increased expression of BCL2L1 protein]
Dexamethasone results in decreased expression of BCL2L1 protein
Dexamethasone results in increased expression of BCL2L1 mRNA
Dexamethasone results in increased expression of BCL2L1 mRNA alternative form; Dexamethasone results in increased expression of BCL2L1 protein alternative form
Dexamethasone results in increased expression of BCL2L1 mRNA alternative form; Dexamethasone results in increased expression of BCL2L1 protein; Dexamethasone results in increased expression of BCL2L1 protein alternative form
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BCL2L1 protein]; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BCL2L1 protein; Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein]
Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]; Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2L1 protein]; Doxorubicin inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein]; fludarabine inhibits the reaction [Dexamethasone results in decreased expression of BCL2L1 protein]; Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BCL2L1 protein]
Dexamethasone results in increased stability of BCL2L1 mRNA

PMID:9326359 PMID:10200566 PMID:11319611 PMID:15388240 PMID:15804364 More...

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 11

increases response to substance
increases expression
multiple interactions
increases phosphorylation

ISO

BCL2L11 protein results in increased susceptibility to Dexamethasone
Dexamethasone results in increased expression of BCL2L11 mRNA alternative form; Dexamethasone results in increased expression of BCL2L11 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L11 mRNA; GSTM1 protein inhibits the reaction [Dexamethasone results in increased phosphorylation of BCL2L11 protein]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of BCL2L11 protein]

PMID:12782123 PMID:14996839 PMID:17953376 PMID:18515658 PMID:20067466 More...

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

Bcl2-like 13

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L13 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA

NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158

G

Bcl2-like 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of BCL2L2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L2 mRNA

PMID:21041162 PMID:28628672

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379

G

BCL3, transcription coactivator

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of BCL3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of BCL3 mRNA]

PMID:20032058 PMID:25047013

NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368

G

BCL6, transcription repressor

decreases expression

ISO

Dexamethasone results in decreased expression of BCL6 mRNA

NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047

G

BAF chromatin remodeling complex subunit BCL7A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL7A mRNA

NCBI chr12:38,872,851...38,904,770
Ensembl chr12:38,872,851...38,904,770

G

BAF chromatin remodeling complex subunit BCL7B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL7B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL7B mRNA

NCBI chr12:27,133,412...27,146,631
Ensembl chr12:27,133,412...27,146,636

G

BCL2-associated transcription factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BCLAF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BCLAF1 mRNA

NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:16,914,118...16,936,801

G

BCR activator of RhoGEF and GTPase

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of BCR mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of BCR mRNA]

NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333

G

3-hydroxybutyrate dehydrogenase 1

increases expression

ISO

Dexamethasone results in increased expression of BDH1 mRNA

NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636

G

3-hydroxybutyrate dehydrogenase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BDH2 mRNA

NCBI chr 2:226,376,346...226,397,010
Ensembl chr 2:226,376,356...226,397,006

G

bradykinin receptor B1

multiple interactions
decreases expression

EXP
ISO

Dexamethasone inhibits the reaction [KNG1 protein binds to and results in increased activity of BDKRB1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BDKRB1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BDKRB1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of BDKRB1 mRNA
Dexamethasone results in decreased expression of BDKRB1 mRNA

PMID:11159707 PMID:25047013 PMID:28628672

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

brain-derived neurotrophic factor

decreases expression
multiple interactions
decreases acetylation

ISO
EXP

Dexamethasone results in decreased expression of BDNF mRNA; Dexamethasone results in decreased expression of BDNF protein
BDNF protein inhibits the reaction [Dexamethasone results in decreased expression of SLC17A7 mRNA]; BDNF protein inhibits the reaction [Dexamethasone results in decreased expression of SLC1A1 mRNA]; BDNF protein inhibits the reaction [Dexamethasone results in increased expression of GAD1 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]; Dexamethasone promotes the reaction [HDAC2 protein binds to BDNF promoter]; Dexamethasone promotes the reaction [NR3C1 protein binds to BDNF promoter]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]]; Mifepristone inhibits the reaction [Dexamethasone results in decreased acetylation of BDNF exon]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of BDNF mRNA]; romidepsin inhibits the reaction [Dexamethasone results in decreased acetylation of BDNF exon]; romidepsin inhibits the reaction [Dexamethasone results in decreased expression of BDNF mRNA]

PMID:15215491 PMID:25047013 PMID:29111458 PMID:30628712 PMID:31518422

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

beclin 1

multiple interactions

ISO

[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BECN1 protein
Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of BECN1 protein]

PMID:23111315 PMID:38729284

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

bestrophin 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of BEST1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BEST1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BEST1 mRNA

PMID:22733784 PMID:28628672

NCBI chr 1:216,054,395...216,071,012
Ensembl chr 1:216,054,395...216,070,974

G

bestrophin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BEST2 mRNA

NCBI chr19:40,047,191...40,053,216
Ensembl chr19:40,047,191...40,053,216

G

brain expressed X-linked 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BEX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BEX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BEX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of BEX1 mRNA

NCBI chr X:103,811,458...103,812,986
Ensembl chr X:103,808,935...103,812,092

G

bone gamma-carboxyglutamate protein

multiple interactions
decreases expression

ISO
EXP

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BGLAP mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased secretion of BGLAP protein; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
Dexamethasone results in decreased expression of BGLAP mRNA; Dexamethasone results in decreased expression of BGLAP protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of BGLAP mRNA]; protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; XAV939 inhibits the reaction [protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of BGLAP mRNA]]; XAV939 inhibits the reaction [protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]]
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA; [Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]]

PMID:12510807 PMID:19216230 PMID:23111315 PMID:25932594 PMID:26492236 More...

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

biglycan

decreases expression

ISO

Dexamethasone results in decreased expression of BGN mRNA

NCBI chr X:156,348,633...156,360,797
Ensembl chr X:156,348,615...156,360,799

G

basic helix-loop-helix family, member e40

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of BHLHE40 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BHLHE40 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BHLHE40 mRNA

PMID:22733784 PMID:28628672

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

basic helix-loop-helix family, member e41

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of BHLHE41 mRNA]

NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355

G

betaine-homocysteine S-methyltransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BHMT2 mRNA

NCBI chr 2:26,630,502...26,647,450
Ensembl chr 2:26,630,510...26,651,326

G

BicC family RNA binding protein 1

decreases expression

ISO

Dexamethasone results in decreased expression of BICC1 mRNA

NCBI chr20:17,448,745...17,685,887
Ensembl chr20:17,448,765...17,685,885

G

BICRA like chromatin remodeling complex associated protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BICRAL mRNA

NCBI chr 9:21,597,886...21,682,985
Ensembl chr 9:21,597,855...21,682,983

G

baculoviral IAP repeat-containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BIRC2 mRNA; Dexamethasone inhibits the reaction [TNF protein results in decreased expression of BIRC2 protein]

PMID:11399663 PMID:28628672

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

baculoviral IAP repeat-containing 3

multiple interactions
increases expression

ISO
EXP

Dexamethasone inhibits the reaction [TNF protein results in decreased expression of BIRC3 protein]
Dexamethasone results in increased expression of BIRC3 mRNA; Dexamethasone results in increased expression of BIRC3 protein
Testosterone inhibits the reaction [Dexamethasone results in increased expression of BIRC3 mRNA]

PMID:9374718 PMID:11399663 PMID:12782123 PMID:16144937 PMID:20032058

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

baculoviral IAP repeat-containing 5

affects expression
multiple interactions

ISO

Dexamethasone affects the expression of BIRC5
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BIRC5 protein]; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BIRC5 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BIRC5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BIRC5 mRNA; [PDCD5 protein co-treated with Dexamethasone] results in decreased expression of BIRC5; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BIRC5]

PMID:20693715 PMID:21244764 PMID:28628672 PMID:29704545

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

basic, immunoglobulin-like variable motif containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BIVM mRNA

NCBI chr 9:53,760,885...53,797,125
Ensembl chr 9:53,761,331...53,797,118

G

B-cell linker

increases expression

ISO

Dexamethasone results in increased expression of BLNK mRNA

NCBI chr 1:249,703,064...249,770,533
Ensembl chr 1:249,703,072...249,770,533

G

basic helix-loop-helix ARNT like 1

affects expression
multiple interactions

ISO

Dexamethasone affects the expression of BMAL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BMAL1 mRNA

PMID:23251369 PMID:28628672 PMID:29040059

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

Bcl2 modifying factor

decreases expression

ISO

Dexamethasone results in decreased expression of BMF mRNA

NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258

G

BMI1 proto-oncogene, polycomb ring finger

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BMI1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BMI1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BMI1 mRNA

NCBI chr17:86,240,683...86,250,044
Ensembl chr17:86,243,491...86,250,024

G

bone morphogenetic protein 1

increases expression

EXP

Dexamethasone results in increased expression of BMP1 mRNA

NCBI chr15:51,961,310...52,005,597
Ensembl chr15:51,961,310...52,005,485

G

bone morphogenetic protein 2

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of ACAN mRNA]; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of COL2A1 mRNA]; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of GREM1 mRNA]; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of SOST mRNA]; Dexamethasone promotes the reaction [BMP2 protein results in increased expression of SOX9 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]
Dexamethasone results in decreased expression of BMP2 mRNA; Dexamethasone results in decreased expression of BMP2 protein
Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]

PMID:15268896 PMID:17502159 PMID:22940495 PMID:23111315 PMID:26492236 More...

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

BMP-2 inducible kinase

multiple interactions
decreases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BMP2K mRNA
Dexamethasone results in decreased expression of BMP2K mRNA

PMID:28628672 PMID:38971901

NCBI chr14:12,785,169...12,882,676
Ensembl chr14:12,785,169...12,882,657

G

bone morphogenetic protein 4

multiple interactions
affects expression

ISO

Dexamethasone inhibits the reaction [BMP4 protein results in increased expression of GREM1 mRNA]; Dexamethasone inhibits the reaction [BMP4 protein results in increased expression of SOST mRNA]
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of BMP4 mRNA
Dexamethasone affects the expression of BMP4 mRNA

PMID:15268896 PMID:16054899 PMID:21277400

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

bone morphogenetic protein 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BMP6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BMP6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BMP6 mRNA; Dexamethasone inhibits the reaction [BMP6 protein results in increased expression of GREM1 mRNA]; Dexamethasone inhibits the reaction [BMP6 protein results in increased expression of SOST mRNA]

PMID:15268896 PMID:28628672

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

bone morphogenetic protein 7

multiple interactions

ISO

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of BMP7 mRNA

PMID:29288687 PMID:33091441

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

bone morphogenetic protein 8a

decreases response to substance
increases expression

ISO

BMP8A results in decreased susceptibility to Dexamethasone
Dexamethasone results in increased expression of BMP8A mRNA; Dexamethasone results in increased expression of BMP8A protein

PMID:21277400 PMID:22733784

NCBI chr 5:140,874,942...140,902,881
Ensembl chr 5:140,874,503...140,902,881

G

BMP-binding endothelial regulator

increases expression
decreases expression

ISO
EXP

Dexamethasone results in increased expression of BMPER mRNA
Dexamethasone results in decreased expression of BMPER mRNA

PMID:22733784 PMID:38971901

NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359

G

bone morphogenetic protein receptor type 1A

multiple interactions
decreases expression

EXP
ISO

Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BMPR1A mRNA
Dexamethasone results in decreased expression of BMPR1A mRNA; Dexamethasone results in decreased expression of BMPR1A protein

PMID:27387537 PMID:28628672 PMID:38971901

NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861

G

bone morphogenetic protein receptor type 1B

decreases expression

EXP

Dexamethasone results in decreased expression of BMPR1B mRNA

NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311

G

bone morphogenetic protein receptor type 2

decreases expression

EXP

Dexamethasone results in decreased expression of BMPR2 mRNA

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:68,685,988...68,801,350

G

BMS1 ribosome biogenesis factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BMS1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BMS1 mRNA

NCBI chr 4:153,230,471...153,267,437
Ensembl chr 4:153,230,471...153,267,429

G

basonuclin zinc finger protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BNC1 mRNA

NCBI chr 1:145,326,881...145,352,534
Ensembl chr 1:145,326,892...145,353,510

G

basonuclin zinc finger protein 2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of BNC2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BNC2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BNC2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428

G

BCL2 interacting protein 3

increases expression
decreases expression

ISO

Dexamethasone results in increased expression of BNIP3 mRNA
Dexamethasone results in decreased expression of BNIP3 mRNA

PMID:21041162 PMID:25047013

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

biorientation of chromosomes in cell division 1-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BOD1L1 mRNA

NCBI chr14:73,320,880...73,375,662
Ensembl chr14:73,320,832...73,375,658

G

BCL2 family apoptosis regulator BOK

increases expression

ISO

Dexamethasone results in increased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

bolA family member 3

increases expression

ISO

Dexamethasone results in increased expression of BOLA3 mRNA

NCBI chr 4:117,411,044...117,420,491
Ensembl chr 4:117,410,680...117,420,491

G

BLOC-1 related complex subunit 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BORCS5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BORCS5 mRNA

NCBI chr 4:169,190,025...169,272,335
Ensembl chr 4:169,204,528...169,271,819

G

BLOC-1 related complex subunit 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BORCS6 mRNA

NCBI chr10:54,259,349...54,261,203
Ensembl chr10:54,256,949...54,261,387

G

3'(2'), 5'-bisphosphate nucleotidase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BPNT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BPNT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BPNT2 mRNA

NCBI chr 5:22,573,241...22,600,126
Ensembl chr 5:22,570,165...22,600,126

G

bromodomain containing 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BRD10 mRNA

NCBI chr 1:236,904,520...236,984,414
Ensembl chr 1:236,904,520...236,983,923

G

bromodomain containing 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BRD3 mRNA

NCBI chr 3:31,173,332...31,227,749
Ensembl chr 3:31,173,332...31,227,629

G

bromodomain containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BRD7 mRNA

NCBI chr19:34,882,238...34,910,944
Ensembl chr19:34,882,304...34,910,944

G

bromodomain containing 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BRD9 mRNA

NCBI chr 1:31,158,546...31,185,812
Ensembl chr 1:31,158,546...31,186,125

G

biogenesis of ribosomes BRX1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BRIX1 mRNA

NCBI chr 2:61,177,769...61,188,647
Ensembl chr 2:61,177,771...61,188,647

G

BRO1 domain and CAAX motif containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BROX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BROX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BROX mRNA

NCBI chr13:97,451,736...97,471,598
Ensembl chr13:97,451,737...97,471,519

G

bone marrow stromal cell antigen 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BST1 mRNA

NCBI chr14:71,466,179...71,482,671
Ensembl chr14:71,466,180...71,482,647

G

B-TFIID TATA-box binding protein associated factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BTAF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BTAF1 mRNA

NCBI chr 1:244,065,728...244,156,457
Ensembl chr 1:244,065,743...244,156,457

G

BTB domain containing 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BTBD6 mRNA

NCBI chr 6:137,879,202...137,881,662
Ensembl chr 6:137,879,162...137,881,652

G

BTB domain containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BTBD7 mRNA

NCBI chr 6:127,685,185...127,774,947
Ensembl chr 6:127,688,421...127,737,222

G

biotinidase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BTD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of BTD mRNA

NCBI chr16:6,869,448...6,900,711
Ensembl chr16:6,869,291...6,901,410

G

BTG anti-proliferation factor 1

increases expression
multiple interactions
decreases expression

ISO

Dexamethasone results in increased expression of BTG1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BTG1 mRNA
Dexamethasone results in decreased expression of BTG1 mRNA

PMID:12782123 PMID:21041162 PMID:28628672

NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406

G

BTG anti-proliferation factor 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of BTG2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BTG2 mRNA

PMID:12782123 PMID:28628672

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690

G

butyrophilin-like 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BTNL2 mRNA

NCBI chr20:4,492,100...4,505,932
Ensembl chr20:4,492,111...4,505,932

G

beta-transducin repeat containing E3 ubiquitin protein ligase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of BTRC mRNA

NCBI chr 1:254,159,085...254,324,819
Ensembl chr 1:254,159,124...254,328,357

G

BUB3 mitotic checkpoint protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of BUB3 mRNA

NCBI chr 1:195,760,532...195,771,140
Ensembl chr 1:195,758,105...195,791,028

G

similar to human chromosome 5 open reading frame 15

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C5ORF15 mRNA

NCBI chr10:37,064,889...37,077,493
Ensembl chr10:37,064,728...37,077,493

G

similar to human chromosome 22 open reading frame 39

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C22ORF39 mRNA

NCBI chr11:95,660,135...95,665,750
Ensembl chr11:95,663,881...95,664,588

G

similar to human chromosome 3 open reading frame 38

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of C3ORF38 mRNA

NCBI chr11:15,930,504...15,935,152
Ensembl chr11:15,783,138...15,935,152

G

similar to human chromosome 1 open reading frame 21

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of C1ORF21 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF21 mRNA

PMID:25047013 PMID:28628672

NCBI chr13:66,540,245...66,749,631
Ensembl chr13:66,540,245...66,659,684

G

similar to chromosome 2 open reading frame 76

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of C2ORF76 mRNA

NCBI chr13:33,801,523...33,889,430
Ensembl chr13:33,802,243...33,877,384

G

similar to human chromosome 14 open reading frame 93

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C14ORF93 mRNA

NCBI chr15:32,007,591...32,034,337
Ensembl chr15:32,007,595...32,034,289

G

C1GALT1-specific chaperone 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of C1GALT1C1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1GALT1C1 mRNA

PMID:25047013 PMID:28628672

NCBI chr X:122,243,736...122,248,217
Ensembl chr X:122,234,454...122,248,422

G

similar to human chromosome 19 open reading frame 12

increases expression

ISO

Dexamethasone results in increased expression of C19ORF12 mRNA

NCBI chr 1:100,010,280...100,023,907
Ensembl chr 1:100,010,323...100,023,903

G

similar to human chromosome 19 open reading frame 18

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of C19ORF18 mRNA

NCBI chr 1:82,094,513...82,122,109
Ensembl chr 1:82,098,305...82,122,119

G

similar to human chromosome 9 open reading frame 85

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of C9ORF85 mRNA

NCBI chr 1:228,562,621...228,624,472
Ensembl chr 1:228,564,731...228,624,278

G

complement C1q A chain

increases expression

ISO

Dexamethasone results in increased expression of C1QA mRNA

NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732

G

C1q and TNF related 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1QTNF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1QTNF1 mRNA

NCBI chr10:104,159,021...104,180,253
Ensembl chr10:104,158,886...104,180,251

G

C1q and TNF related 3

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of C1QTNF3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of C1QTNF3 mRNA]

NCBI chr 2:61,644,225...61,666,640
Ensembl chr 2:61,644,276...61,666,559

G

C1q and TNF related 5

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of C1QTNF5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1QTNF5 mRNA

PMID:22733784 PMID:28628672

NCBI chr 8:53,347,754...53,349,912
Ensembl chr 8:53,347,711...53,349,912

G

C1q and TNF related 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1QTNF6 mRNA

NCBI chr 7:111,958,348...111,964,948
Ensembl chr 7:111,958,350...111,966,871

G

complement C1r

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1R mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1R mRNA

NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:159,098,918...159,109,714

G

complement C1s

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1S mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1S mRNA

NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736

G

similar to human chromosome 6 open reading frame 136

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C6ORF136 mRNA

NCBI chr20:2,862,567...2,866,756
Ensembl chr20:2,862,478...2,866,754

G

similar to human chromosome 6 open reading frame 89

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C6ORF89 mRNA

NCBI chr20:7,324,105...7,368,482
Ensembl chr20:7,324,129...7,363,666

G

C2 calcium-dependent domain containing 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of C2CD2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C2CD2 mRNA

PMID:25047013 PMID:28628672

NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016

G

similar to human chromosome 1 open reading frame 54

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF54 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1ORF54 mRNA

NCBI chr 2:186,113,922...186,124,637
Ensembl chr 2:186,113,922...186,124,335

G

complement C3

multiple interactions
increases expression

EXP
ISO

Dexamethasone promotes the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA]
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of C3 protein]
Dexamethasone results in increased expression of C3 mRNA

PMID:11566438 PMID:21041162 PMID:22733784 PMID:33140555

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

similar to human chromosome 9 open reading frame 50

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of C9ORF50 mRNA

NCBI chr 3:34,477,535...34,484,791
Ensembl chr 3:34,478,508...34,484,805

G

complement C4A (Rodgers blood group)

multiple interactions
increases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in increased expression of C4A mRNA]

NCBI chr20:4,010,306...4,024,707

G

similar to human chromosome 2 open reading frame 68

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C2ORF68 mRNA

NCBI chr 4:105,960,543...105,966,509
Ensembl chr 4:105,960,751...105,966,508

G

complement C5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C5 mRNA; Dexamethasone analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein]

PMID:18776917 PMID:28628672

NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:38,668,174...38,759,468

G

similar to human chromosome 1 open reading frame 159

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1ORF159 mRNA

NCBI chr 5:171,983,700...172,001,373
Ensembl chr 5:171,983,936...172,001,373

G

similar to human chromosome 1 open reading frame 167

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C1ORF167 mRNA

NCBI chr 5:163,770,495...163,788,791

G

similar to human chromosome 8 open reading frame 34

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of C8ORF34 mRNA

NCBI chr 5:12,021,000...12,560,212
Ensembl chr 5:12,021,007...12,559,772

G

complement C6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of C6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of C6 mRNA

NCBI chr 2:55,573,596...55,648,857
Ensembl chr 2:55,573,653...55,649,120

G

similar to human chromosome 11 open reading frame 54

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BKGD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BKGD mRNA

NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811

G

similar to human chromosome 11 open reading frame 71

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C11ORF71 mRNA

NCBI chr 8:57,735,075...57,735,489
Ensembl chr 8:57,734,900...57,738,597

G

similar to human chromosome 15 open reading frame 39

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C15ORF39 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of C15ORF39 mRNA

NCBI chr 8:66,542,269...66,551,835
Ensembl chr 8:66,542,269...66,554,782

G

similar to human chromosome 6 open reading frame 132

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of C6ORF132 mRNA

NCBI chr 9:21,022,482...21,058,942
Ensembl chr 9:21,023,092...21,059,125

G

carbonic anhydrase 12

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CA12 mRNA; Dexamethasone inhibits the reaction [Genistein results in increased expression of CA12 mRNA]; fulvestrant promotes the reaction [Dexamethasone inhibits the reaction [Genistein results in increased expression of CA12 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Genistein results in increased expression of CA12 mRNA]]; NR3C1 mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Genistein results in increased expression of CA12 mRNA]]
Dexamethasone results in increased expression of CA12 mRNA

PMID:25136773 PMID:28628672

NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465

G

carbonic anhydrase 3

decreases expression

ISO

Dexamethasone results in decreased expression of CA3 protein; Dexamethasone results in decreased expression of CAR3 mRNA

PMID:22733784 PMID:33567340

NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524

G

carbonic anhydrase 4

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CA4 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CA4 mRNA]

NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916

G

Cdk5 and Abl enzyme substrate 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CABLES1 mRNA

NCBI chr18:3,349,681...3,455,956
Ensembl chr18:3,351,652...3,455,956

G

calcium binding protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CABP4 mRNA

NCBI chr 1:210,857,223...210,872,431
Ensembl chr 1:210,858,133...210,862,632

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

ISO

[Dexamethasone co-treated with Genistein] results in increased expression of CACNA1I mRNA

NCBI chr 7:113,716,266...113,827,670
Ensembl chr 7:113,716,266...113,827,670

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CACNA2D1 mRNA

NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147

G

calcium voltage-gated channel auxiliary subunit alpha2delta 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CACNA2D4 mRNA

NCBI chr 4:154,080,877...154,197,369
Ensembl chr 4:154,080,877...154,193,778

G

calcium voltage-gated channel auxiliary subunit beta 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CACNB3 mRNA

NCBI chr 7:131,663,810...131,676,085
Ensembl chr 7:131,662,545...131,676,085

G

carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAD mRNA

NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297

G

calbindin 1

decreases expression

EXP

Dexamethasone results in decreased expression of CALB1 mRNA

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

calbindin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CALB2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CALB2 mRNA

NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952

G

calcitonin-related polypeptide alpha

decreases response to substance
decreases expression
multiple interactions

ISO
EXP

CALCA protein results in decreased susceptibility to Dexamethasone
Dexamethasone results in decreased expression of CALCA mRNA
Dexamethasone inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]

PMID:11588175 PMID:14729435 PMID:16222118

NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529

G

calcium homeostasis modulator family member 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CALHM5 mRNA

NCBI chr20:26,609,400...26,615,478
Ensembl chr20:26,609,400...26,615,478

G

calmodulin-like 4

multiple interactions

ISO

[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CALML4 mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CALML4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CALML4 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CALML4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CALML4 mRNA

PMID:16054899 PMID:28628672

NCBI chr 8:72,218,870...72,230,650
Ensembl chr 8:72,218,613...72,230,650

G

calumenin

increases expression

EXP

Dexamethasone results in increased expression of CALU mRNA

NCBI chr 4:58,914,456...58,941,957
Ensembl chr 4:58,914,421...58,941,956

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CAMK2D mRNA

NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:217,698,551...217,960,276

G

calcium/calmodulin-dependent protein kinase IV

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CAMK4 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CAMK4 mRNA]

NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,857,146...25,077,193

G

cathelicidin antimicrobial peptide

multiple interactions

ISO

[Dexamethasone co-treated with Genistein] results in increased expression of CAMP mRNA

NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998

G

calmodulin regulated spectrin-associated protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAMSAP1 mRNA

NCBI chr 3:29,144,318...29,206,382
Ensembl chr 3:29,144,318...29,204,184

G

calmodulin regulated spectrin-associated protein family, member 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAMSAP2 mRNA

NCBI chr13:50,274,950...50,354,298
Ensembl chr13:50,274,950...50,354,298

G

calcium activated nucleotidase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CANT1 mRNA

NCBI chr10:104,135,676...104,148,854
Ensembl chr10:104,135,682...104,148,698

G

calpain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of CAPN1 mRNA

NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:212,705,222...212,729,445

G

calpain 2

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CAPN2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CAPN2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CAPN2 mRNA]

PMID:20032058 PMID:21041162 PMID:28628672

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

calpain 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CAPN3 mRNA

NCBI chr 3:127,860,002...127,913,677
Ensembl chr 3:127,861,589...127,911,638

G

calpain 6

decreases expression

ISO

Dexamethasone results in decreased expression of CAPN6 mRNA

NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178

G

calpain, small subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAPNS1 mRNA

NCBI chr 1:94,572,083...94,582,332
Ensembl chr 1:94,572,083...94,583,368

G

calpain, small subunit 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAPNS2 mRNA

NCBI chr19:30,277,324...30,278,266

G

caprin family member 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CAPRIN2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAPRIN2 mRNA

NCBI chr 4:183,537,935...183,592,162
Ensembl chr 4:183,537,430...183,592,809

G

calcyphosine 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CAPS2 mRNA

NCBI chr 7:49,467,320...49,525,465
Ensembl chr 7:49,464,885...49,525,465

G

carbonic anhydrase 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CA2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CA2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CA2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CA2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064

G

caspase recruitment domain family, member 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CARD10 mRNA

NCBI chr 7:112,210,944...112,252,044
Ensembl chr 7:112,210,776...112,239,806

G

caspase recruitment domain family, member 14

increases expression

ISO

Dexamethasone results in increased expression of CARD14 mRNA

NCBI chr10:105,064,941...105,100,132
Ensembl chr10:105,064,941...105,100,132

G

caspase recruitment domain family, member 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CARD6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CARD6 mRNA

NCBI chr 2:55,921,832...55,934,388
Ensembl chr 2:55,921,832...55,934,363

G

calcium regulated heat stable protein 1

decreases expression

ISO

Dexamethasone results in decreased expression of CARHSP1 mRNA

NCBI chr10:7,453,602...7,467,218
Ensembl chr10:7,452,978...7,467,770

G

cysteinyl-tRNA synthetase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CARS1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CARS1 mRNA

NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407

G

cysteinyl-tRNA synthetase 2, mitochondrial

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CARS2 mRNA

NCBI chr16:84,649,617...84,689,254
Ensembl chr16:84,645,627...84,690,192

G

caspase 1

multiple interactions
increases cleavage
increases expression

ISO
EXP

Dexamethasone inhibits the reaction [TNF protein results in increased expression of CASP1 mRNA]
Dexamethasone results in increased cleavage of CASP1 protein
PPARG protein inhibits the reaction [Dexamethasone results in increased cleavage of CASP1 protein]
[Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of CASP1 protein]; [Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of CASP1 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]
Dexamethasone results in increased expression of CASP1 mRNA

PMID:11397893 PMID:21041162 PMID:22733784 PMID:30102002 PMID:32687258 More...

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 2

decreases expression

EXP
ISO

Dexamethasone results in decreased expression of CASP2 mRNA

PMID:14618091 PMID:21041162

NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022

G

caspase 3

decreases activity
increases cleavage
increases activity
multiple interactions
decreases expression
increases expression

ISO
EXP

Dexamethasone results in decreased activity of CASP3 protein
Dexamethasone results in increased cleavage of CASP3 protein
Dexamethasone results in increased activity of CASP3 protein
[afuresertib co-treated with pomalidomide co-treated with Dexamethasone] results in increased cleavage of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [GCS-100 co-treated with Dexamethasone] results in increased activity of CASP3 protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CASP3 mRNA; [PDCD5 protein co-treated with Dexamethasone] results in increased expression of CASP3; Dexamethasone inhibits the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Dexamethasone promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased cleavage of CASP3 protein]; Dexamethasone promotes the reaction [Gold results in increased activity of CASP3 protein]; Dexamethasone promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Dexamethasone promotes the reaction [Silver results in increased activity of CASP3 protein]; Dexamethasone results in increased cleavage of and results in increased activity of CASP3 protein; FAS protein inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]; Ginkgo biloba extract inhibits the reaction [Dexamethasone results in increased expression of CASP3 protein]; isocoumarin NM-3 promotes the reaction [Dexamethasone results in increased activity of CASP3 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [TNFSF10 protein results in increased activity of CASP3 protein]]
Dexamethasone results in decreased expression of CASP3 mRNA
Active Hexose Correlated Compound inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]; caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]; Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]; Dexamethasone inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Dexamethasone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Dexamethasone inhibits the reaction [Doxorubicin results in increased cleavage of and results in increased activity of CASP3 protein]; Dexamethasone inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]; Dexamethasone results in increased cleavage of and results in increased activity of CASP3 protein; Dexamethasone results in increased expression of and results in increased cleavage of CASP3 protein; fludarabine inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]]; Ubiquinone inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [echinacoside inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]]; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]; CDKN1A protein affects the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CASP3 mRNA]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CASP3 protein]; Dexamethasone inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; echinacoside inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; Mifepristone inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]; MK 2206 inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; Spermine inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]

PMID:10200566 PMID:10919278 PMID:11137978 PMID:11319611 PMID:11399061 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

increases expression

ISO

Dexamethasone results in increased expression of CASP4 mRNA

PMID:21041162 PMID:22733784

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 6

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CASP6 mRNA
Dexamethasone results in decreased expression of CASP6 mRNA

PMID:21041162 PMID:28628672

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 7

multiple interactions

EXP
ISO

Dexamethasone inhibits the reaction [TGFB1 protein results in increased activity of CASP7 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CASP7 mRNA

PMID:15388240 PMID:28628672

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

multiple interactions
increases response to substance
increases activity

ISO
EXP

[afuresertib co-treated with pomalidomide co-treated with Dexamethasone] results in increased cleavage of CASP8 protein; [Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Dexamethasone; Dexamethasone inhibits the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [TNFSF10 protein results in increased activity of CASP8 protein]]
CASP8 protein results in increased susceptibility to Dexamethasone
[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]; [benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]]; CASP8 protein promotes the reaction [Dexamethasone results in increased expression of TSC22D3 protein]; lactacystin inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]]; Spermine inhibits the reaction [Dexamethasone results in increased activity of CASP8 protein]
Dexamethasone inhibits the reaction [TGFB1 protein results in increased activity of CASP8 protein]

PMID:11399061 PMID:15388240 PMID:15576458 PMID:17070682 PMID:20671745 More...

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 8 associated protein 2

decreases expression

ISO

Dexamethasone results in decreased expression of CASP8AP2 mRNA

NCBI chr 5:51,809,366...51,848,633
Ensembl chr 5:51,810,972...51,848,632

G

caspase 9

increases cleavage
increases activity
multiple interactions
decreases expression

ISO
EXP

Dexamethasone results in increased cleavage of CASP9 protein
Dexamethasone results in increased activity of CASP9 protein
Dexamethasone inhibits the reaction [TGFB1 protein results in increased activity of CASP9 protein]; fludarabine inhibits the reaction [Dexamethasone results in increased cleavage of CASP9 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [echinacoside inhibits the reaction [Dexamethasone results in increased cleavage of CASP9 protein]]; echinacoside inhibits the reaction [Dexamethasone results in increased cleavage of CASP9 protein]; Spermine inhibits the reaction [Dexamethasone results in increased activity of CASP9 protein]
isocoumarin NM-3 promotes the reaction [Dexamethasone results in increased activity of CASP9 protein]
Dexamethasone results in decreased expression of CASP9 mRNA

PMID:11399061 PMID:11734450 PMID:15388240 PMID:15574755 PMID:15576458 More...

Ensembl chr 5:159,391,188...159,409,648

G

calsequestrin 2

affects expression

ISO

Dexamethasone affects the expression of CASQ2 mRNA

NCBI chr 2:192,214,556...192,270,821
Ensembl chr 2:192,214,537...192,270,820

G

catalase

multiple interactions
increases expression
decreases activity
increases activity
decreases expression

ISO
EXP

[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CAT mRNA; BCL2 gene inhibits the reaction [Dexamethasone results in decreased activity of CAT protein]; Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of CAT protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Dexamethasone inhibits the reaction [Paraquat results in increased activity of CAT protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CAT mRNA
Dexamethasone results in increased expression of CAT mRNA
Dexamethasone results in increased expression of CAT protein
[Dexamethasone co-treated with ciprofibrate] results in increased expression of CAT protein; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT protein]; Dexamethasone inhibits the reaction [Oleic Acid results in increased activity of CAT protein]
Dexamethasone results in increased activity of CAT protein
Dexamethasone results in decreased expression of CAT mRNA

PMID:10590836 PMID:11114198 PMID:15353912 PMID:15895680 PMID:15965953 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

caveolin 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CAV1 mRNA; [octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein; [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein]
[Dexamethasone results in increased expression of CAV1 protein] which results in decreased susceptibility to VEGFA protein
Dexamethasone results in increased expression of CAV1 mRNA; Dexamethasone results in increased expression of CAV1 protein

PMID:14984747 PMID:16054899 PMID:23426970 PMID:25047013

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

caveolin 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CAV2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAV2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425

G

caveolae associated protein 1

increases expression

ISO

Dexamethasone results in increased expression of CAVIN1 mRNA

NCBI chr10:86,384,401...86,398,240
Ensembl chr10:86,384,401...86,396,383

G

caveolae associated protein 2

multiple interactions
increases expression

ISO

apicidin inhibits the reaction [Dexamethasone results in increased expression of CAVIN2 mRNA]; Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of CAVIN2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CAVIN2 mRNA

PMID:23946490 PMID:28628672

NCBI chr 9:57,794,007...57,806,024
Ensembl chr 9:57,794,019...57,806,024

G

CACN subunit beta associated regulatory protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CBARP mRNA

NCBI chr 7:10,217,314...10,225,855
Ensembl chr 7:10,217,328...10,225,854

G

Cbl proto-oncogene B

increases expression

ISO

Dexamethasone results in increased expression of CBLB; Dexamethasone results in increased expression of CBLB mRNA

NCBI chr11:62,058,829...62,225,904
Ensembl chr11:62,061,653...62,225,778

G

Cbl proto-oncogene like 1

decreases expression

ISO

Dexamethasone results in decreased expression of CBLL1 mRNA

NCBI chr 6:53,798,712...53,812,890
Ensembl chr 6:53,798,712...53,813,880

G

carbonyl reductase 1

decreases expression

ISO

Dexamethasone results in decreased expression of CBR1 mRNA

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104

G

chromobox 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CBX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CBX1 mRNA

NCBI chr10:82,266,746...82,286,431
Ensembl chr10:82,266,759...82,287,242

G

chromobox 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CBX7 mRNA

NCBI chr 7:113,341,030...113,358,716
Ensembl chr 7:113,341,030...113,358,346

G

chromobox 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CBX8 mRNA

NCBI chr10:104,793,062...104,795,500
Ensembl chr10:104,793,062...104,795,500

G

coiled-coil and C2 domain containing 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CC2D1A mRNA

NCBI chr19:40,916,587...40,931,702
Ensembl chr19:40,916,532...40,931,701

G

cell division cycle and apoptosis regulator 1

increases expression

ISO

Dexamethasone results in increased expression of CCAR1 mRNA

NCBI chr20:31,228,624...31,271,233
Ensembl chr20:31,228,624...31,271,227

G

coiled-coil domain containing 107

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCDC107 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC107 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CCDC107 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:62,545,273...62,548,711
Ensembl chr 5:62,544,714...62,548,709

G

coiled-coil domain containing 117

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC117 mRNA

NCBI chr14:84,614,282...84,623,648
Ensembl chr14:84,614,283...84,624,087

G

coiled-coil domain containing 120

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC120 mRNA

NCBI chr X:17,437,219...17,443,716
Ensembl chr X:17,425,624...17,444,717

G

coiled-coil domain containing 121

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC121 mRNA

NCBI chr 6:30,690,831...30,693,437
Ensembl chr 6:30,690,831...30,693,437

G

coiled-coil domain containing 127

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC127 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC127 mRNA

NCBI chr 1:30,757,010...30,764,473
Ensembl chr 1:30,757,010...30,764,473

G

coiled-coil domain containing 136

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC136 mRNA

NCBI chr 4:58,963,196...58,992,962
Ensembl chr 4:58,962,908...58,992,975

G

coiled-coil domain containing 137

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC137 mRNA

NCBI chr10:106,229,099...106,235,502
Ensembl chr10:106,229,099...106,235,502

G

coiled-coil domain containing 146

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC146 mRNA

NCBI chr 4:14,554,966...14,703,801
Ensembl chr 4:14,554,966...14,703,799

G

coiled-coil domain containing 167

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC167 mRNA

NCBI chr20:7,768,425...7,783,181
Ensembl chr20:7,753,072...7,783,181

G

coiled-coil domain containing 177

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC177 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC177 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CCDC177 mRNA

NCBI chr 6:106,135,827...106,142,413
Ensembl chr 6:106,134,333...106,144,441

G

coiled coil domain containing 28B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC28B mRNA

NCBI chr 5:147,246,627...147,251,629
Ensembl chr 5:147,246,628...147,251,629

G

coiled-coil domain containing 47

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCDC47 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC47 mRNA

NCBI chr10:91,630,101...91,648,626
Ensembl chr10:91,630,106...91,648,626

G

coiled-coil domain containing 59

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC59 mRNA

NCBI chr 7:43,029,272...43,035,655
Ensembl chr 7:43,029,272...43,035,655

G

coiled-coil domain containing 61

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC61 mRNA

NCBI chr 1:87,665,541...87,685,732
Ensembl chr 1:87,665,541...87,685,732

G

coiled-coil domain containing 69

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCDC69 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC69 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CCDC69 mRNA

PMID:25047013 PMID:28628672

NCBI chr10:39,673,984...39,701,080
Ensembl chr10:39,673,985...39,700,579

G

coiled-coil domain containing 71-like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CCDC71L mRNA

NCBI chr 6:54,687,474...54,691,566
Ensembl chr 6:54,617,540...55,014,344

G

coiled-coil domain containing 77

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC77 mRNA

NCBI chr 4:155,206,402...155,238,235
Ensembl chr 4:155,193,275...155,239,207

G

coiled-coil domain containing 85A

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCDC85A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCDC85A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC85A mRNA

PMID:25047013 PMID:28628672

NCBI chr14:106,327,580...106,560,205
Ensembl chr14:106,327,580...106,560,165

G

coiled-coil domain containing 86

decreases expression

ISO

Dexamethasone results in decreased expression of CCDC86 mRNA

NCBI chr 1:217,015,059...217,021,439
Ensembl chr 1:217,014,848...217,021,468

G

coiled-coil domain containing 88C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCDC88C mRNA

NCBI chr 6:125,899,337...126,019,162
Ensembl chr 6:125,899,526...126,018,865

G

cholecystokinin B receptor

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CCKBR mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CCKBR mRNA]

NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745

G

C-C motif chemokine ligand 11

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCL11 mRNA
Dexamethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CCL11 mRNA]
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 protein]

PMID:21041162 PMID:27568862 PMID:31751647

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 12

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCL12 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCL13 mRNA

PMID:21041162 PMID:28628672

NCBI chr10:67,567,876...67,569,426
Ensembl chr10:67,567,876...67,569,426

G

C-C motif chemokine ligand 17

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CCL17 mRNA; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL17 mRNA; TNF protein inhibits the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL17 mRNA]
Dexamethasone results in increased expression of CCL17 mRNA

PMID:16054899 PMID:21041162 PMID:23503329

NCBI chr19:10,208,120...10,218,340
Ensembl chr19:10,208,120...10,209,895

G

C-C motif chemokine ligand 19

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCL19 mRNA
[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL19 mRNA; TNF protein inhibits the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL19 mRNA]

PMID:21041162 PMID:23503329

NCBI chr 5:61,759,220...61,761,164
Ensembl chr 5:61,759,220...61,772,022

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO
EXP

15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; [Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCL2 mRNA; Dexamethasone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Dexamethasone inhibits the reaction [Mitomycin results in increased expression of CCL2 mRNA]; Dexamethasone inhibits the reaction [Mitomycin results in increased secretion of CCL2 protein]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] affects the susceptibility to Ethanol] which results in increased secretion of CCL2 protein; [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] affects the susceptibility to GHRL protein] which results in increased secretion of CCL2 protein; [Amiodarone co-treated with Dexamethasone] results in increased expression of CCL2 mRNA; [Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCL2 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCL2 mRNA]; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL2 mRNA; Dexamethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CCL2 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCL2 mRNA]; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL2 mRNA]
Dexamethasone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
Dexamethasone results in increased expression of CCL2 mRNA

PMID:15187150 PMID:16054899 PMID:16997883 PMID:18234956 PMID:19255438 More...

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 20

multiple interactions

ISO
EXP

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL20 mRNA; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL20 mRNA]
Dexamethasone inhibits the reaction [IL1B protein results in increased expression of CCL20 mRNA]; Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CCL20 protein]

PMID:23503329 PMID:25851902

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

C-C motif chemokine ligand 24

multiple interactions

ISO

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL24 mRNA

NCBI chr12:26,737,423...26,741,420
Ensembl chr12:26,737,439...26,750,924

G

C-C motif chemokine ligand 25

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CCL25 mRNA
[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL25 mRNA

PMID:21041162 PMID:23503329

NCBI chr12:7,505,231...7,514,402
Ensembl chr12:7,505,235...7,514,385

G

C-C motif chemokine ligand 26

multiple interactions

ISO

Dexamethasone inhibits the reaction [IL4 protein results in increased expression of CCL26 protein]

NCBI chr12:26,745,972...26,750,924

G

C-C motif chemokine ligand 27

multiple interactions

ISO

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCL27 mRNA

NCBI chr 5:61,737,261...61,744,375
Ensembl chr 5:61,737,261...61,743,522

G

C-C motif chemokine ligand 3

multiple interactions
decreases expression

ISO

Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]]
Dexamethasone results in decreased expression of CCL3 protein
Dexamethasone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]

PMID:16880258 PMID:21880982 PMID:27568862 PMID:36416909

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

multiple interactions

ISO

Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 protein]

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

ISO
EXP

Dexamethasone inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]
Dexamethasone results in increased expression of CCL5 mRNA
Dexamethasone inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Dexamethasone inhibits the reaction [[CCL5 protein co-treated with Calcimycin] results in increased expression of ALOX5 protein]
[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL5 mRNA; Dexamethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CCL5 mRNA]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of CCL5 protein]

PMID:10495789 PMID:16908450 PMID:18083043 PMID:21041162 PMID:23503329 More...

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

C-C motif chemokine ligand 7

multiple interactions
decreases expression

ISO

[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCL7 mRNA; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL7 mRNA; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CCL7 mRNA]
Dexamethasone results in decreased expression of CCL7 mRNA

PMID:16054899 PMID:22733784 PMID:23503329

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947

G

C-C motif chemokine ligand 9

increases expression

ISO

Dexamethasone results in increased expression of CCL6 mRNA

NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877

G

cellular communication network factor 1

increases expression

ISO

Dexamethasone results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression

ISO

Dexamethasone results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CCN3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CCN3 mRNA

NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581

G

cellular communication network factor 4

decreases expression

ISO

Dexamethasone results in decreased expression of CCN4 mRNA

NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:100,534,505...100,563,094

G

cellular communication network factor 5

multiple interactions

ISO

[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCN5 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCN5 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCN5 mRNA]

NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062

G

cyclin A2

decreases expression
multiple interactions
increases expression

ISO

Dexamethasone results in decreased expression of CCNA2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CCNA2 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNA2 protein; silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNA2 protein]
Dexamethasone results in increased expression of CCNA2 mRNA

PMID:21041162 PMID:23137833 PMID:25559859 PMID:28628672

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

decreases expression
increases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CCNB1 mRNA
Dexamethasone results in increased expression of CCNB1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CCNB1 mRNA]

PMID:20032058 PMID:23137833

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNC mRNA

NCBI chr 5:40,063,589...40,081,731
Ensembl chr 5:40,063,623...40,093,370

G

cyclin D1

multiple interactions
decreases expression
increases expression
increases ubiquitination
increases degradation

ISO
EXP

bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of CCND1 protein]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein]
Dexamethasone results in decreased expression of CCND1 mRNA; Dexamethasone results in decreased expression of CCND1 protein
Dexamethasone results in increased expression of CCND1 mRNA
Dexamethasone results in increased ubiquitination of CCND1 protein
Dexamethasone results in increased degradation of CCND1 protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased degradation of CCND1 protein]; Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CCND1 mRNA]
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCND1 protein]; 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CCND1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCND1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCND1 mRNA; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CCND1 protein; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; dorsomorphin inhibits the reaction [14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CCND1 protein]]; naringin inhibits the reaction [Dexamethasone results in increased expression of CCND1 mRNA]; protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCND1 protein]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]

PMID:12971794 PMID:14618091 PMID:15489888 PMID:16054899 PMID:16707792 More...

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D2

decreases expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone results in decreased expression of CCND2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCND2 mRNA
Dexamethasone results in decreased expression of CCND2 mRNA; Dexamethasone results in decreased expression of CCND2 protein
Dexamethasone results in increased expression of CCND2 mRNA

PMID:14618091 PMID:19428934 PMID:21041162 PMID:28628672

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

cyclin D3

decreases expression

ISO

Dexamethasone results in decreased expression of CCND3 mRNA

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

cyclin E1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CCNE1 mRNA
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNE1 protein]; 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CCNE1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNE1 protein; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CCNE1 protein; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNE1 protein]

PMID:21041162 PMID:24646949 PMID:27475717 PMID:30248417

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cyclin G1

increases expression

EXP

Dexamethasone results in increased expression of CCNG1 mRNA

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766

G

cyclin I

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CCNI mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNI mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCNI mRNA

NCBI chr14:15,164,047...15,186,885
Ensembl chr14:15,164,095...15,186,885

G

cyclin J

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CCNJ mRNA

NCBI chr 1:249,608,991...249,626,798
Ensembl chr 1:249,608,969...249,626,794

G

cyclin L2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNL2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CCNL2 mRNA

NCBI chr 5:171,698,951...171,711,037
Ensembl chr 5:171,699,689...171,711,231

G

C-C motif chemokine receptor 3

decreases expression

ISO

Dexamethasone results in decreased expression of CCR3 protein

NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:132,463,788...132,511,593

G

C-C motif chemokine receptor 4

increases expression

ISO

Dexamethasone results in increased expression of CCR4 mRNA

NCBI chr 8:123,054,505...123,060,244
Ensembl chr 8:123,054,324...123,077,642

G

C-C motif chemokine receptor 7

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CCR7 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CCR7 mRNA; Dexamethasone inhibits the reaction [Particulate Matter results in increased expression of CCR7 protein]

PMID:21041162 PMID:28463086 PMID:28628672

NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501

G

C-C motif chemokine receptor 9

increases expression
decreases expression

ISO

Dexamethasone results in increased expression of CCR9 mRNA
Dexamethasone results in decreased expression of CCR9 mRNA

PMID:17998272 PMID:21041162

NCBI chr 8:132,273,581...132,287,651
Ensembl chr 8:132,273,544...132,287,883

G

chaperonin containing TCP1 subunit 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCT4 mRNA

NCBI chr14:101,193,057...101,205,935
Ensembl chr14:101,192,772...101,205,770

G

chaperonin containing TCP1 subunit 8

decreases expression

ISO

Dexamethasone results in decreased expression of CCT8 mRNA

NCBI chr11:40,196,619...40,208,328
Ensembl chr11:40,196,619...40,208,328

G

CD14 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD14 protein

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD151 molecule (Raph blood group)

increases expression

ISO

Dexamethasone results in increased expression of CD151 mRNA

NCBI chr 1:205,994,300...205,998,307
Ensembl chr 1:205,994,738...205,998,784

G

CD163 molecule

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CD163 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD163 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA

PMID:17410599 PMID:28628672

NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:158,770,749...158,804,146

G

Cd2 molecule

decreases expression

ISO

Dexamethasone results in decreased expression of CD2 mRNA

NCBI chr 2:191,399,510...191,412,659
Ensembl chr 2:191,399,510...191,413,665

G

CD22 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD22 mRNA

NCBI chr 1:95,243,785...95,270,430
Ensembl chr 1:95,244,868...95,259,730

G

CD24 molecule

increases expression
decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CD24 mRNA
Dexamethasone results in decreased expression of CD24A mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CD24 mRNA]

PMID:14618091 PMID:20032058 PMID:21041162

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD27 molecule

decreases expression

ISO

Dexamethasone results in decreased expression of CD27 mRNA

NCBI chr 4:159,716,932...159,721,823
Ensembl chr 4:159,716,935...159,721,823

G

CD274 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD274 mRNA

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951

G

Cd28 molecule

multiple interactions
decreases expression

ISO

[Dexamethasone co-treated with CD28 protein] results in increased expression of NFKBIA mRNA; Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of IFNG protein]; Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of IL2 protein]; Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]; Mifepristone inhibits the reaction [[Dexamethasone co-treated with CD28 protein] results in increased expression of NFKBIA mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of IFNG protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of IL2 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [CD28 protein results in increased secretion of TNF protein]]
Dexamethasone results in decreased expression of CD28 mRNA

PMID:20363256 PMID:21041162

NCBI chr 9:69,660,316...69,689,192
Ensembl chr 9:69,545,326...69,689,192

G

Cd2 (cytoplasmic tail) binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CD2BP2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD2BP2 mRNA

NCBI chr 1:191,239,899...191,244,395
Ensembl chr 1:191,239,901...191,243,398

G

CD302 molecule

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CD302 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CD302 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD302 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CD302 mRNA

PMID:25047013 PMID:28628672

NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737

G

CD36 molecule

increases expression
multiple interactions
affects expression

ISO
EXP

Dexamethasone results in increased expression of CD36 mRNA; Dexamethasone results in increased expression of CD36 protein
Dexamethasone promotes the reaction [NR3C1 protein binds to CD36 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CD36 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CD36 protein]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CD36 mRNA]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CD36 protein]
Dexamethasone inhibits the reaction [Freund's Adjuvant results in increased expression of CD36 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of CD36 mRNA]
Dexamethasone affects the expression of CD36 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CD36 mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CD36 mRNA; ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of CD36 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein binds to CD36 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CD36 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CD36 protein]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CD36 mRNA]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CD36 protein]

PMID:10614771 PMID:14618091 PMID:15102944 PMID:20032058 PMID:21041162 More...

NCBI chr 4:18,209,088...18,302,142

G

CD38 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD38 mRNA

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

CD3 delta subunit of T-cell receptor complex

decreases expression

ISO

Dexamethasone results in decreased expression of CD3D mRNA

NCBI chr 8:54,184,573...54,190,112
Ensembl chr 8:54,175,155...54,196,722

G

CD3 epsilon subunit of T-cell receptor complex

decreases expression

ISO

Dexamethasone results in decreased expression of CD3E mRNA

NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876

G

CD3 gamma subunit of T-cell receptor complex

decreases expression

ISO

Dexamethasone results in decreased expression of CD3G mRNA

NCBI chr 8:54,177,572...54,184,087
Ensembl chr 8:54,177,977...54,183,918

G

Cd4 molecule

multiple interactions
decreases expression

ISO

Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of CD4 protein]
Dexamethasone results in decreased expression of CD4 mRNA

PMID:11408767 PMID:20363256 PMID:21041162

NCBI chr 4:159,355,147...159,381,636
Ensembl chr 4:159,356,337...159,381,461

G

CD40 molecule

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CD40 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CD40 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]

PMID:21041162 PMID:22185406 PMID:28628672

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

Cd5 molecule

decreases expression

ISO

Dexamethasone results in decreased expression of CD5 mRNA

NCBI chr 1:216,790,245...216,811,209
Ensembl chr 1:216,790,245...216,811,209

G

CD52 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD52 mRNA

NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086

G

Cd53 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD53 mRNA

PMID:12782123 PMID:21041162

NCBI chr 2:197,040,369...197,087,925
Ensembl chr 2:197,040,369...197,218,593

G

CD55 molecule (Cromer blood group)

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

CD59b molecule

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CD59 mRNA

NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:110,914,091...110,935,310

G

Cd6 molecule

decreases expression

ISO

Dexamethasone results in decreased expression of CD6 mRNA

NCBI chr 1:216,867,767...216,906,642
Ensembl chr 1:216,867,771...216,879,432

G

Cd68 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD68 protein
Dexamethasone results in increased expression of CD68 mRNA

PMID:10614771 PMID:21041162

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

Cd69 molecule

increases expression
decreases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CD69 mRNA
Dexamethasone results in decreased expression of CD69 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CD69 mRNA]

PMID:12782123 PMID:21041162 PMID:22185406

NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509

G

Cd7 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD7 mRNA

NCBI chr10:106,802,373...106,805,269
Ensembl chr10:106,802,383...106,805,294

G

Cd72 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD72 mRNA

NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:62,493,161...62,500,519

G

CD74 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD74 mRNA

NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410

G

Cd81 molecule

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CD81 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD81 mRNA

PMID:21041162 PMID:28628672

NCBI chr 1:207,665,274...207,681,094
Ensembl chr 1:207,664,885...207,681,092

G

CD83 molecule

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CD83 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CD83 mRNA; Dexamethasone inhibits the reaction [Particulate Matter results in increased expression of CD83 protein]

PMID:21041162 PMID:28463086 PMID:28628672

NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047

G

CD8 subunit alpha

decreases expression

ISO

Dexamethasone results in decreased expression of CD8A mRNA

NCBI chr 4:104,924,116...104,928,353
Ensembl chr 4:104,900,833...104,928,358

G

CD8 subunit beta

decreases expression

ISO

Dexamethasone results in decreased expression of CD8B1 mRNA

NCBI chr 4:104,870,911...104,886,838
Ensembl chr 4:104,870,893...104,886,868

G

CD9 molecule

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CD9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CD9 mRNA

NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444

G

CD93 molecule

increases expression

ISO

Dexamethasone results in increased expression of CD93 mRNA

NCBI chr 3:156,345,019...156,351,537
Ensembl chr 3:156,345,019...156,351,537

G

CD99 molecule (Xg blood group)

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CD99 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of CD99 mRNA

NCBI chr20:56,000,494...56,005,140

G

cytidine deaminase

increases activity

ISO

Dexamethasone results in increased activity of CDA protein

NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541

G

cell division cycle 34, ubiquitin conjugating enzyme

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CDC34 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDC34 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CDC34 mRNA

NCBI chr 7:10,668,209...10,674,206
Ensembl chr 7:10,668,210...10,674,526

G

cell division cycle 37-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDC37L1 mRNA

NCBI chr 1:236,118,630...236,147,527
Ensembl chr 1:236,118,555...236,207,079

G

cell division cycle 40

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CDC40 mRNA

NCBI chr20:45,855,739...45,908,239
Ensembl chr20:45,855,739...45,907,978

G

cell division cycle 42

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDC42 mRNA
Dexamethasone results in decreased expression of CDC42 mRNA

PMID:16054899 PMID:29111458

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:154,839,631...154,876,627

G

CDC42 binding protein kinase beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDC42BPB mRNA

NCBI chr 6:136,154,905...136,241,259
Ensembl chr 6:136,154,905...136,237,570

G

CDC42 effector protein 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CDC42EP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CDC42EP2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:212,631,317...212,640,231
Ensembl chr 1:212,629,881...212,640,234

G

CDC42 effector protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDC42EP4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDC42EP4 mRNA

NCBI chr10:99,271,750...99,298,551
Ensembl chr10:99,267,540...99,300,168

G

CDC42 small effector 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDC42SE1 mRNA

NCBI chr 2:185,494,692...185,502,519
Ensembl chr 2:185,496,547...185,502,514

G

cell division cycle associated 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CDCA2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA2 mRNA

NCBI chr15:46,071,360...46,117,524
Ensembl chr15:46,071,360...46,116,639

G

cell division cycle associated 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDCA4 mRNA

NCBI chr 6:137,713,390...137,722,652
Ensembl chr 6:137,713,051...137,722,580

G

cell division cycle associated 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CDCA5 mRNA

NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:212,804,014...212,821,309

G

cell division cycle associated 7

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CDCA7 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CDCA7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA7 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CDCA7 mRNA]

PMID:20032058 PMID:28628672

NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947

G

cell division cycle associated 7 like

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CDCA7L mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA7L mRNA

PMID:22733784 PMID:28628672

NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843

G

cadherin 1

multiple interactions
decreases expression

ISO
EXP

Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Particulate Matter] results in decreased expression of CDH1 protein]; Dexamethasone inhibits the reaction [Bleomycin results in decreased expression of CDH1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in decreased expression of CDH1 protein]
Dexamethasone inhibits the reaction [Particulate Matter results in decreased expression of CDH1 protein]
Dexamethasone results in decreased expression of CDH1 mRNA

PMID:28300665 PMID:28694203 PMID:35335934 PMID:36790081

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 13

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDH13 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDH13 mRNA]
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CDH13 mRNA]

PMID:16054899 PMID:20032058

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CDH2 mRNA
Dexamethasone inhibits the reaction [Particulate Matter results in increased expression of CDH2 protein]
Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Particulate Matter] results in increased expression of CDH2 protein]

PMID:25047013 PMID:35335934

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cadherin-related family member 1

decreases expression

ISO

Dexamethasone results in decreased expression of CDHR1 mRNA

NCBI chr16:12,863,696...12,883,579
Ensembl chr16:12,863,696...12,883,579

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDIPT mRNA

NCBI chr 1:191,013,632...191,017,943
Ensembl chr 1:191,013,463...191,017,971

G

cyclin-dependent kinase 1

decreases expression
increases expression

EXP
ISO

Dexamethasone results in decreased expression of CDK1 mRNA
Dexamethasone results in increased expression of CDK1 mRNA

PMID:14618091 PMID:23137833

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 14

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CDK14 mRNA

NCBI chr 4:29,619,237...30,213,651
Ensembl chr 4:29,621,217...30,213,651

G

cyclin dependent kinase 2

multiple interactions
decreases expression
increases expression
decreases activity

ISO
EXP

Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA]; Dexamethasone inhibits the reaction [CDK2 protein binds to CDKN1A protein]
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK2 protein]; 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK2 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK2 protein; [Acrylamide co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK2 protein; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK2 protein; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK2 protein]; dorsomorphin inhibits the reaction [14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CDK2 protein]]
Dexamethasone results in increased expression of CDK2 mRNA
Dexamethasone inhibits the reaction [CDK2 protein results in increased phosphorylation of RB1 protein]
Dexamethasone results in decreased expression of CDK2 mRNA; Dexamethasone results in decreased expression of CDK2 protein; Dexamethasone results in decreased expression of CDK2 protein modified form
Dexamethasone results in decreased activity of CDK2 protein

PMID:9442036 PMID:12800980 PMID:19428934 PMID:21041162 PMID:23137833 More...

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase 4

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CDK4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDK4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CDK4 mRNA
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK4 protein]; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK4 protein

PMID:21041162 PMID:24646949 PMID:28628672

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

CDK5 regulatory subunit associated protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDK5RAP3 mRNA

NCBI chr10:82,390,845...82,402,814
Ensembl chr10:82,390,845...82,400,001

G

cyclin-dependent kinase 6

multiple interactions

ISO

14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK6 protein]; 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK6 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CDK6 protein; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CDK6 protein; dorsomorphin inhibits the reaction [14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CDK6 protein]]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDK6 mRNA

PMID:24646949 PMID:28628672 PMID:30248417

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CDK7 mRNA

NCBI chr 2:33,574,623...33,599,485
Ensembl chr 2:33,574,623...33,599,485

G

cyclin-dependent kinase 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CDK9 mRNA

NCBI chr 3:36,394,168...36,399,016
Ensembl chr 3:36,394,169...36,399,528

G

cyclin-dependent kinase-like 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CDKL3 mRNA

NCBI chr10:36,755,413...36,850,197
Ensembl chr10:36,764,377...36,878,660

G

cyclin-dependent kinase inhibitor 1A

increases expression
decreases stability
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of CDKN1A mRNA; Dexamethasone results in increased expression of CDKN1A protein
Dexamethasone results in decreased stability of CDKN1A protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased expression of and affects the localization of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased stability of CDKN1A protein]; [Acrylamide co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1A protein; CDKN1A protein affects the reaction [Dexamethasone affects the expression of NFE2L2 protein]; CDKN1A protein affects the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; CDKN1A protein affects the reaction [Dexamethasone results in increased expression of HMOX1 protein]; Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Dexamethasone results in decreased expression of and affects the localization of CDKN1A protein; IGF1 protein inhibits the reaction [Dexamethasone results in decreased expression of and affects the localization of CDKN1A protein]; IGF1 protein inhibits the reaction [Dexamethasone results in decreased stability of CDKN1A protein]
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CDKN1A mRNA]
Dexamethasone inhibits the reaction [CDK2 protein binds to CDKN1A protein]

PMID:9442036 PMID:12800980 PMID:18395440 PMID:20032058 PMID:21041162 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

increases expression
decreases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of CDKN1B mRNA; Dexamethasone results in increased expression of CDKN1B protein
Dexamethasone results in decreased expression of CDKN1B mRNA; Dexamethasone results in decreased expression of CDKN1B protein
[Polyribonucleotides results in decreased expression of MIR17 mRNA] inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B mRNA]; [Polyribonucleotides results in decreased expression of MIR17 mRNA] inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B protein]; Dexamethasone inhibits the reaction [FOXL2 protein binds to CDKN1B promoter]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDKN1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDKN1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CDKN1B mRNA; [Polyribonucleotides results in decreased expression of MIR17 mRNA] inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B mRNA]; [Polyribonucleotides results in decreased expression of MIR17 mRNA] inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B protein]; Dexamethasone inhibits the reaction [FOXL2 protein binds to CDKN1B promoter]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of CDKN1B protein]
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in decreased expression of CDKN1B protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1B protein; [Acrylamide co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1B protein; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in decreased expression of CDKN1B protein; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1B protein]

PMID:19428934 PMID:24646949 PMID:25559859 PMID:28628672 PMID:30409764 More...

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 1C

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CDKN1C mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDKN1C mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CDKN1C mRNA

PMID:21041162 PMID:22064387 PMID:28628672

NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498

G

cyclin-dependent kinase inhibitor 2C

increases expression

ISO

Dexamethasone results in increased expression of CDKN2C mRNA

NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891

G

cyclin dependent kinase inhibitor 2D

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDKN2D mRNA
Dexamethasone results in decreased expression of CDKN2D mRNA

PMID:21041162 PMID:28628672

NCBI chr 8:28,108,036...28,110,809
Ensembl chr 8:28,108,044...28,110,809

G

cyclin-dependent kinase inhibitor 3

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CDKN3 mRNA]

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

cysteine dioxygenase type 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDO1 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDO1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDO1 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CDO1 mRNA
Dexamethasone results in increased expression of CDO1 mRNA

PMID:16054899 PMID:25047013 PMID:28628672

NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891

G

cell adhesion associated, oncogene regulated

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CDON mRNA
[HDAC1 protein co-treated with HDAC2 protein] affects the reaction [Dexamethasone results in decreased expression of CDON mRNA]; apicidin inhibits the reaction [Dexamethasone results in decreased expression of CDON mRNA]; HDAC3 protein affects the reaction [Dexamethasone results in decreased expression of CDON mRNA]; Valproic Acid inhibits the reaction [Dexamethasone results in decreased expression of CDON mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDON mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDON mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CDON mRNA

PMID:22733784 PMID:27645313 PMID:28628672

NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345

G

cerebellar degeneration-related protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDR2 mRNA

NCBI chr 1:184,934,128...184,959,036
Ensembl chr 1:184,934,129...184,968,863

G

CDP-diacylglycerol synthase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CDS2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDS2 mRNA

NCBI chr 3:139,967,870...140,006,459
Ensembl chr 3:139,967,742...140,009,201

G

corneodesmosin

decreases expression

ISO

Dexamethasone results in decreased expression of CDSN mRNA

NCBI chr20:3,184,142...3,188,962
Ensembl chr20:3,183,808...3,188,962

G

carnitine deficiency-associated gene expressed in ventricle 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDV3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CDV3 mRNA

NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:112,813,952...112,826,056

G

CEA cell adhesion molecule 1

increases expression

EXP

Dexamethasone results in increased expression of CEACAM1 mRNA

NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798

G

CEA cell adhesion molecule 20

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEACAM20 mRNA

NCBI chr 1:88,750,010...88,771,679
Ensembl chr 1:88,750,000...88,772,779

G

CEA cell adhesion molecule 6

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA

NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:89,544,400...89,562,552

G

CCAAT/enhancer binding protein alpha

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CEBPA mRNA; Dexamethasone results in increased expression of CEBPA protein
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of CEBPA mRNA]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Bismuth affects the susceptibility to [INS protein co-treated with Dexamethasone co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine]] which results in decreased expression of CEBPA mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CEBPA protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] affects the expression of CEBPA mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]
(+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein]; (+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; (+)-JQ1 compound inhibits the reaction [Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of CEBPA mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] affects the expression of CEBPA protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; [Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; andrographolide affects the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPA mRNA]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Ivermectin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; IWR-1 compound inhibits the reaction [Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]]; JMJD6 mutant form inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein]; Palmitic Acid promotes the reaction [[sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA protein]; Quercetin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Rosiglitazone promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; sodium arsenite inhibits the reaction [[INS1 protein co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]; sodium arsenite promotes the reaction [[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]

PMID:9543393 PMID:11101056 PMID:11812925 PMID:12837037 PMID:15965953 More...

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

multiple interactions
decreases expression
increases expression

EXP
ISO

2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine inhibits the reaction [Dexamethasone results in increased expression of CEBPB mRNA]; [Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; CEBPB protein inhibits the reaction [PPARA protein inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA]]; Dexamethasone inhibits the reaction [CEBPB protein results in increased expression of GSTA2 mRNA]; Dexamethasone results in increased localization of and results in increased activity of CEBPB protein; Quercetin promotes the reaction [Dexamethasone results in increased expression of CEBPB protein]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of CEBPB mRNA]
Dexamethasone results in decreased expression of CEBPB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CEBPB mRNA; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPB mRNA
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] promotes the reaction [CREB1 protein binds to CEBPB promoter]]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CEBPB protein]; 2,2',4,4',5-brominated diphenyl ether promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPB protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPB mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] promotes the reaction [CREB1 protein binds to CEBPB promoter]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of and results in increased phosphorylation of CEBPB protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPB mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CEBPB protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein; [INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPB protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPB mRNA; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CEBPB protein]; andrographolide affects the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPB mRNA]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of and results in increased phosphorylation of CEBPB protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; dorsomorphin inhibits the reaction [rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPB protein]]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; ITGB1 protein promotes the reaction [ST6GAL1 protein inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPB mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPB protein]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; ST6GAL1 protein inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]
Dexamethasone results in increased expression of CEBPB mRNA; Dexamethasone results in increased expression of CEBPB protein

PMID:14568882 PMID:15661831 PMID:15870285 PMID:15965953 PMID:16054899 More...

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

multiple interactions
increases expression

ISO
EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPD mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD protein; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CEBPD mRNA]

PMID:16054899 PMID:20032058 PMID:30903904 PMID:33412187 PMID:34302803

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

CUGBP, Elav-like family member 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CELF1 mRNA

NCBI chr 3:97,380,407...97,455,253
Ensembl chr 3:97,380,424...97,452,791

G

CUGBP, Elav-like family member 2

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA]
Dexamethasone results in increased expression of CELF2 mRNA

PMID:16054899 PMID:25047013

NCBI chr17:75,813,928...76,639,300
Ensembl chr17:75,813,704...76,636,362

G

cadherin, EGF LAG seven-pass G-type receptor 3

decreases expression

ISO

Dexamethasone results in decreased expression of CELSR3 mRNA

NCBI chr 8:118,409,136...118,438,593
Ensembl chr 8:118,409,136...118,436,847

G

cell migration inducing hyaluronidase 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CEMIP mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEMIP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CEMIP mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:147,316,052...147,471,552
Ensembl chr 1:147,316,052...147,471,768

G

cell migration inducing hyaluronidase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEMIP2 mRNA

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:228,757,466...228,832,906

G

centrosomal AT-AC splicing factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CENATAC mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CENATAC mRNA

NCBI chr 8:53,632,777...53,639,661
Ensembl chr 8:53,632,044...53,639,650

G

cell cycle exit and neuronal differentiation 1

increases expression

ISO

Dexamethasone results in increased expression of CEND1 mRNA

NCBI chr 1:205,954,713...205,957,710
Ensembl chr 1:205,953,197...205,957,944

G

centromere protein A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein F

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CENPF mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centromere protein O

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CENPO mRNA

NCBI chr 6:32,923,127...32,937,879
Ensembl chr 6:32,908,025...32,937,853

G

centromere protein T

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CENPT mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CENPT mRNA

NCBI chr19:50,644,548...50,651,048
Ensembl chr19:50,634,368...50,651,037

G

centromere protein U

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CENPU mRNA

NCBI chr16:52,448,446...52,471,662
Ensembl chr16:52,425,096...52,471,662

G

centromere protein W

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CENPW mRNA

NCBI chr 1:29,353,939...29,359,109
Ensembl chr 1:29,353,970...29,359,109

G

centromere protein X

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CENPX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CENPX mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CENPX mRNA

NCBI chr10:106,489,796...106,492,637
Ensembl chr10:106,489,796...106,492,637

G

centrosomal protein 112

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CEP112 mRNA

NCBI chr10:93,865,630...94,332,679
Ensembl chr10:93,865,699...94,332,680

G

centrosomal protein 131

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP131 mRNA

NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797

G

centrosomal protein 135

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP135 mRNA

NCBI chr14:31,884,774...31,950,050
Ensembl chr14:31,884,781...31,950,050

G

centrosomal protein 164

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CEP164 mRNA

NCBI chr 8:54,967,621...55,031,264
Ensembl chr 8:54,967,621...55,031,206

G

centrosomal protein 170B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEP170B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP170B mRNA

NCBI chr 6:137,602,707...137,627,750
Ensembl chr 6:137,602,707...137,627,750

G

centrosomal protein 19

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CEP19 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CEP19 mRNA

NCBI chr11:82,182,868...82,192,134
Ensembl chr11:82,182,868...82,192,032

G

centrosomal protein 250

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP250 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CEP250 mRNA

NCBI chr 3:164,931,033...164,976,210
Ensembl chr 3:164,931,066...164,976,210

G

centrosomal protein 290

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEP290 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CEP290 mRNA

NCBI chr 7:37,196,765...37,285,955
Ensembl chr 7:37,196,783...37,285,955

G

centrosomal protein 41

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CEP41 mRNA

NCBI chr 4:60,238,602...60,279,670
Ensembl chr 4:60,239,539...60,254,419

G

centrosomal protein 63

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CEP63 mRNA

NCBI chr 8:112,041,586...112,093,061
Ensembl chr 8:112,041,594...112,084,646

G

carboxylesterase 1D

increases expression
multiple interactions
decreases expression

ISO
EXP

Dexamethasone results in increased expression of CES1 mRNA; Dexamethasone results in increased expression of CES1 protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CES1D mRNA
Dexamethasone results in decreased expression of CES1D mRNA
Dexamethasone results in decreased expression of CES1 mRNA; Dexamethasone results in decreased expression of CES1 protein

PMID:10640517 PMID:22429928 PMID:24848799 PMID:25047013

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carboxylesterase 2H

affects expression
increases expression
decreases expression
multiple interactions

EXP
ISO

Dexamethasone affects the expression of CES2 mRNA
Dexamethasone results in increased expression of CES2 mRNA; Dexamethasone results in increased expression of CES2 protein
Dexamethasone results in decreased expression of CES2 mRNA; Dexamethasone results in decreased expression of CES2 protein
Dexamethasone promotes the reaction [CES2 protein results in increased hydrolysis of Methylprednisolone Hemisuccinate]

PMID:10640517 PMID:15102944 PMID:15794950

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

carboxylesterase 3a

decreases expression

EXP

Dexamethasone results in decreased expression of CES3 mRNA; Dexamethasone results in decreased expression of CES3 protein

NCBI chr19:49,902,312...49,910,484

G

centrin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CETN2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CETN2 mRNA

NCBI chr X:155,812,212...155,817,186
Ensembl chr X:155,812,003...155,817,744

G

centrin 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CETN3 mRNA

NCBI chr 2:13,817,760...13,837,502
Ensembl chr 2:13,824,803...13,837,502

G

cilia and flagella associated protein 410

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CFAP410 mRNA

NCBI chr20:10,687,506...10,694,366
Ensembl chr20:10,687,506...10,694,366

G

complement factor B

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CFB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CFB mRNA

PMID:21041162 PMID:28628672

NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740

G

complement factor D

decreases expression
multiple interactions
increases expression

ISO

Dexamethasone results in decreased expression of CFD mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CFD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CFD mRNA
Dexamethasone results in increased expression of CFD mRNA
(+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CFD mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CFD mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CFD mRNA
Dexamethasone results in increased expression of CFD protein

PMID:17998272 PMID:19853017 PMID:23428407 PMID:24418828 PMID:25047013 More...

NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:10,463,775...10,465,572

G

cofilin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CFL1 mRNA

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353

G

cofilin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CFL2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CFL2 mRNA

NCBI chr 6:78,090,843...78,094,888
Ensembl chr 6:78,090,843...78,094,888

G

CASP8 and FADD-like apoptosis regulator

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CFLAR; Dexamethasone results in increased expression of CFLAR mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CFLAR mRNA; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CFLAR]

PMID:21244764 PMID:25047013 PMID:28628672

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

cholesterol 25-hydroxylase

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CH25H mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CH25H mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CH25H mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CH25H mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 1:241,428,048...241,429,366
Ensembl chr 1:241,331,619...241,431,190

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

decreases expression

ISO

Dexamethasone results in decreased expression of CHAC1 mRNA

PMID:22733784 PMID:25047013

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

chromatin assembly factor 1 subunit B

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of CHAF1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHAF1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHAF1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CHAF1B mRNA

PMID:26424790 PMID:28628672

NCBI chr11:46,670,560...46,690,739
Ensembl chr11:46,670,630...46,690,733

G

choline O-acetyltransferase

decreases expression

EXP

Dexamethasone results in decreased expression of CHAT protein

NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,663,665...7,723,416

G

coiled-coil-helix-coiled-coil-helix domain containing 10

increases expression

ISO

Dexamethasone results in increased expression of CHCHD10 mRNA

NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,277...12,745,677

G

coiled-coil-helix-coiled-coil-helix domain containing 7

increases expression

ISO

Dexamethasone results in increased expression of CHCHD7 mRNA

NCBI chr 5:21,754,719...21,759,274
Ensembl chr 5:21,754,719...21,759,274

G

chromodomain helicase DNA binding protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CHD1 mRNA

NCBI chr 1:65,334,905...65,402,270
Ensembl chr 1:65,335,218...65,401,280

G

chromodomain helicase DNA binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335

G

chromodomain helicase DNA binding protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CHD4 mRNA

NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866

G

chromodomain helicase DNA binding protein 7

increases expression

ISO

Dexamethasone results in increased expression of CHD7 mRNA

NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734

G

chromodomain helicase DNA binding protein 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHD8 mRNA

NCBI chr15:27,379,285...27,438,959
Ensembl chr15:27,379,285...27,417,851

G

chromodomain helicase DNA binding protein 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHD9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CHD9 mRNA

NCBI chr19:32,114,379...32,337,488
Ensembl chr19:32,115,920...32,319,042

G

chitinase 3 like 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CHI3L1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHI3L1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CHI3L1 mRNA

PMID:16357325 PMID:25047013 PMID:28628672

NCBI chr13:48,193,839...48,201,822
Ensembl chr13:48,193,800...48,201,825

G

cysteine-rich hydrophobic domain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHIC2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CHIC2 mRNA

NCBI chr14:33,511,839...33,546,181
Ensembl chr14:33,511,535...33,548,558

G

chitinase domain containing 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with IL4 protein] results in increased expression of CHID1 mRNA; [Dexamethasone co-treated with IL4 protein] results in increased expression of CHID1 protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CHID1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHID1 mRNA; IFNG protein inhibits the reaction [[Dexamethasone co-treated with IL4 protein] results in increased expression of CHID1 mRNA]
Dexamethasone results in increased expression of CHID1 mRNA

PMID:16357325 PMID:28628672

NCBI chr 1:206,024,059...206,059,259
Ensembl chr 1:205,998,801...206,059,227

G

choline kinase beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHKB mRNA

NCBI chr 7:122,380,592...122,385,102
Ensembl chr 7:122,380,594...122,383,949

G

charged multivesicular body protein 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHMP1A mRNA

NCBI chr19:68,146,672...68,154,952
Ensembl chr19:68,146,672...68,154,952

G

charged multivesicular body protein 4B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHMP4B mRNA

NCBI chr 3:163,631,054...163,671,569
Ensembl chr 3:163,631,054...163,671,569

G

chordin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CHRD mRNA

NCBI chr11:93,676,400...93,685,584
Ensembl chr11:93,676,400...93,685,278

G

chordin-like 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CHRDL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CHRDL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHRDL1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CHRDL1 mRNA

PMID:25047013 PMID:28628672

NCBI chr X:111,685,864...111,789,684
Ensembl chr X:111,685,866...111,789,661

G

cholinergic receptor, muscarinic 4

multiple interactions

ISO

Dexamethasone inhibits the reaction [Ovalbumin results in decreased expression of CHRM4 mRNA]

NCBI chr 3:98,349,080...98,356,821
Ensembl chr 3:98,348,650...98,358,771

G

cholinergic receptor nicotinic delta subunit

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of CHRND mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CHRND mRNA]

NCBI chr 9:95,310,316...95,318,734
Ensembl chr 9:95,310,298...95,318,745

G

carbohydrate sulfotransferase 14

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CHST14 mRNA

NCBI chr 3:126,370,348...126,372,405
Ensembl chr 3:126,370,348...126,372,777

G

carbohydrate sulfotransferase 15

increases expression

ISO

Dexamethasone results in increased expression of CHST15 mRNA

NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444

G

carbohydrate sulfotransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CHST2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CHST2 mRNA

NCBI chr 8:104,839,716...104,845,961
Ensembl chr 8:104,831,292...104,860,301

G

carbohydrate sulfotransferase 6

decreases expression

ISO

Dexamethasone results in decreased expression of CHST6 mRNA

NCBI chr19:56,769,991...56,790,276
Ensembl chr19:56,769,967...56,790,306

G

chondroitin sulfate synthase 1

decreases expression

ISO

Dexamethasone results in decreased expression of CHSY1 mRNA

NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:129,100,041...129,161,081

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

ISO

Dexamethasone inhibits the reaction [TNF protein results in increased activity of CHUK protein]

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

cytosolic iron-sulfur assembly component 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CIAO3 mRNA

NCBI chr10:15,300,403...15,309,467
Ensembl chr10:15,300,471...15,309,468

G

calcium and integrin binding family member 2

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CIB2 mRNA]

NCBI chr 8:63,826,410...63,843,301
Ensembl chr 8:63,826,411...63,843,277

G

cell death-inducing DFFA-like effector a

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CIDEA mRNA
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone co-treated with bisphenol AF] results in increased expression of CIDEA mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of CIDEA mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CIDEA mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of CIDEA mRNA; [mangiferin co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CIDEA mRNA; [Roscovitine co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEA mRNA; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of CIDEA mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CIDEA mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEA mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CIDEA mRNA]

PMID:19853017 PMID:20032058 PMID:24848799 PMID:29288687 PMID:31596606 More...

NCBI chr18:63,164,817...63,190,384
Ensembl chr18:63,164,099...63,190,382

G

cell death-inducing DFFA-like effector c

multiple interactions
increases expression

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of CIDEC mRNA; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of CIDEC mRNA
Dexamethasone results in increased expression of CIDEC mRNA
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA

PMID:19853017 PMID:23086663 PMID:25047013 PMID:28628672 PMID:34323617

NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806

G

cartilage intermediate layer protein

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CILP mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CILP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CILP mRNA

PMID:25047013 PMID:28628672

NCBI chr 8:74,671,696...74,687,420
Ensembl chr 8:74,671,534...74,687,409

G

cyclin-dependent kinase 2-interacting protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CINP mRNA

NCBI chr 6:135,698,477...135,720,798
Ensembl chr 6:135,706,793...135,720,689

G

cold inducible RNA binding protein

decreases expression

ISO

Dexamethasone results in decreased expression of CIRBP mRNA

NCBI chr 7:10,184,515...10,189,623

G

cytokine inducible SH2-containing protein

increases expression

ISO

Dexamethasone results in increased expression of CISH mRNA

NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986

G

Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1

multiple interactions
decreases expression

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA]
Dexamethasone results in decreased expression of CITED1 mRNA

PMID:28189605 PMID:34742744

NCBI chr X:71,390,328...71,395,023
Ensembl chr X:71,390,331...71,393,649

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

ISO

CITED2 protein inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; CITED2 protein inhibits the reaction [Dexamethasone results in increased expression of TRIM63 mRNA]

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CITED4 mRNA

NCBI chr 5:139,532,165...139,533,056
Ensembl chr 5:139,531,584...139,533,361

G

CDKN1A interacting zinc finger protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CIZ1 mRNA

NCBI chr 3:36,055,753...36,071,510
Ensembl chr 3:36,056,370...36,075,192

G

cytoskeleton-associated protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CKAP4 mRNA

NCBI chr 7:21,118,527...21,126,624
Ensembl chr 7:21,118,085...21,126,624

G

cytoskeleton associated protein 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CKAP5 mRNA

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:97,947,031...98,049,049

G

creatine kinase B

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CKB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CKB mRNA

PMID:14618091 PMID:28628672

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

chemokine-like factor

multiple interactions

ISO

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CKLF mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CKLF mRNA

PMID:23503329 PMID:28628672

NCBI chr19:704,528...712,998
Ensembl chr19:697,451...712,998

G

creatine kinase, M-type

multiple interactions
increases expression
decreases expression

ISO

[Dexamethasone co-treated with IGF1 protein] results in decreased expression of CKM protein; Dexamethasone promotes the reaction [IGF1 protein results in increased expression of CKM mRNA]
Dexamethasone results in increased expression of CKM mRNA
Dexamethasone results in decreased expression of CKM protein

PMID:22936724 PMID:33567340

NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:88,189,485...88,199,719

G

creatine kinase, mitochondrial 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CKMT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CKMT2 mRNA
Dexamethasone results in decreased expression of CKMT2 protein

PMID:28628672 PMID:33567340

NCBI chr 2:24,815,008...24,845,511
Ensembl chr 2:24,815,008...24,845,511

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CKS1B mRNA

NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365

G

clathrin binding box of aftiphilin containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLBA1 mRNA

NCBI chr 6:137,703,947...137,710,743
Ensembl chr 6:137,703,619...137,710,742

G

cardiotrophin-like cytokine factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CLCF1 mRNA

NCBI chr 1:210,937,763...210,947,064
Ensembl chr 1:210,937,255...210,947,064

G

chloride voltage-gated channel 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CLCN1 mRNA

NCBI chr 4:72,138,739...72,168,113
Ensembl chr 4:72,139,162...72,168,128

G

chloride voltage-gated channel 4

decreases expression

EXP

Dexamethasone results in decreased expression of CLCN4 mRNA

NCBI chr X:27,290,769...27,356,967
Ensembl chr X:27,290,868...27,356,939

G

chloride voltage-gated channel 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLCN7 mRNA

NCBI chr10:14,656,261...14,681,632
Ensembl chr10:14,656,245...14,681,631

G

claudin 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CLDN1 protein
Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CLDN1 protein]

PMID:32619553 PMID:38729284

NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529

G

claudin 11

increases expression

ISO

Dexamethasone results in increased expression of CLDN11 mRNA

NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539

G

claudin 3

multiple interactions

ISO

Dexamethasone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of CLDN3 protein]

NCBI chr12:27,345,075...27,346,547
Ensembl chr12:27,345,076...27,348,841

G

claudin 4

multiple interactions

ISO

Dexamethasone affects the reaction [IL1B protein affects the expression of CLDN4 mRNA]

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958

G

claudin 5

multiple interactions

EXP
ISO

Dexamethasone inhibits the reaction [Hydrogen Sulfide results in decreased expression of CLDN5 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dexamethasone inhibits the reaction [sodium bisulfide results in decreased expression of CLDN5 protein]]; Dexamethasone inhibits the reaction [[sodium bisulfide results in increased abundance of Hydrogen Sulfide] which results in decreased expression of CLDN5 protein]; Dexamethasone inhibits the reaction [sodium bisulfide results in decreased expression of CLDN5 protein]

PMID:28741371 PMID:32404561

NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322

G

claudin 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLDN7 mRNA

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

claudin domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLDND2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CLDND2 mRNA

NCBI chr 1:102,985,122...102,988,010
Ensembl chr 1:102,985,122...102,987,808

G

C-type lectin domain family 3, member B

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CLEC3B mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CLEC3B mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CLEC3B mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLEC3B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CLEC3B mRNA
Dexamethasone results in increased expression of CLEC3B mRNA

PMID:16054899 PMID:25047013 PMID:28628672

NCBI chr 8:131,687,575...131,693,292

G

C-type lectin domain family 4, member A3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CLEC4A mRNA

NCBI chr 4:157,885,899...157,896,728
Ensembl chr 4:157,885,895...157,896,727

G

calmegin

decreases expression

ISO

Dexamethasone results in decreased expression of CLGN mRNA

NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325

G

chloride intracellular channel 3

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA

NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723

G

chloride intracellular channel 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CLIC4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CLIC4 mRNA

NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118

G

CAP-GLY domain containing linker protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CLIP2 mRNA

NCBI chr12:27,798,289...27,863,486
Ensembl chr12:27,799,524...27,863,484

G

CAP-GLY domain containing linker protein family, member 4

decreases expression

ISO

Dexamethasone results in decreased expression of CLIP4 mRNA

NCBI chr 6:29,359,628...29,449,365
NCBI chr 6:29,349,245...29,351,890
Ensembl chr 6:29,348,918...29,449,271

G

CDC-like kinase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CLK1 mRNA

NCBI chr 9:67,441,962...67,453,180
Ensembl chr 9:67,441,952...67,451,187

G

calmin

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CLMN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CLMN mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CLMN mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CLMN mRNA

PMID:25047013 PMID:28628672

NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027

G

CXADR-like membrane protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLMP mRNA

NCBI chr 8:49,957,639...50,065,959
Ensembl chr 8:49,957,720...50,065,959

G

CLN6, transmembrane ER protein

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CLN6 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CLN6 mRNA]

NCBI chr 8:72,198,773...72,213,777
Ensembl chr 8:72,198,712...72,213,776

G

clock circadian regulator

affects expression

ISO

Dexamethasone affects the expression of CLOCK mRNA

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

cleavage factor polyribonucleotide kinase subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CLP1 mRNA

NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538

G

calsyntenin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLSTN1 mRNA

NCBI chr 5:165,314,128...165,377,627
Ensembl chr 5:165,314,309...165,377,625

G

calsyntenin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA

NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053

G

calsyntenin 3

multiple interactions
decreases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CLSTN3 mRNA
Dexamethasone results in decreased expression of CLSTN3 mRNA

PMID:24848799 PMID:25047013

NCBI chr 4:159,017,795...159,051,069
Ensembl chr 4:159,017,795...159,051,069

G

clusterin

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CLU mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CLU mRNA]

PMID:17522070 PMID:20032058 PMID:25047013

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

chemerin chemokine-like receptor 2

increases expression

ISO

Dexamethasone results in increased expression of CMKLR2 mRNA

NCBI chr 9:72,077,164...72,111,979
Ensembl chr 9:72,078,608...72,116,257

G

cms1 ribosomal small subunit homolog

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CMSS1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CMSS1 mRNA

NCBI chr11:56,403,620...56,701,751
Ensembl chr11:56,403,499...56,701,755

G

CKLF-like MARVEL transmembrane domain containing 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CMTM3 mRNA

NCBI chr19:629,000...637,152
Ensembl chr19:628,895...636,225

G

CCHC-type zinc finger, nucleic acid binding protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CNBP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNBP mRNA

NCBI chr 4:121,860,102...121,868,976
Ensembl chr 4:121,860,105...121,869,010

G

carnosine dipeptidase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CNDP2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CNDP2 mRNA

NCBI chr18:80,314,799...80,331,900
Ensembl chr18:80,314,801...80,331,900

G

cornichon family AMPA receptor auxiliary protein 3

decreases expression

ISO

Dexamethasone results in decreased expression of CNIH3 mRNA

NCBI chr13:95,548,440...95,739,500
Ensembl chr13:95,598,998...95,772,064

G

connector enhancer of kinase suppressor of Ras 1

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of CNKSR1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CNKSR1 mRNA]

NCBI chr 5:151,731,222...151,742,049
Ensembl chr 5:151,731,224...151,742,203

G

Cnksr family member 3

increases expression

ISO

Dexamethasone results in increased expression of CNKSR3 mRNA

NCBI chr 1:45,904,581...45,996,921
Ensembl chr 1:45,904,581...45,996,921

G

calponin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CNN1 mRNA

NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482

G

calponin 2

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CNN2 mRNA

NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:10,363,102...10,370,312

G

calponin 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNN3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CNN3 mRNA

NCBI chr 2:212,203,661...212,234,772
Ensembl chr 2:212,226,640...212,234,815

G

CCR4-NOT transcription complex, subunit 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CNOT11 mRNA

NCBI chr 9:49,310,624...49,320,325
Ensembl chr 9:49,309,518...49,321,771

G

CCR4-NOT transcription complex, subunit 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNOT4 mRNA

NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083

G

CCR4-NOT transcription complex, subunit 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CNOT8 mRNA

NCBI chr10:42,782,042...42,795,207
Ensembl chr10:42,782,283...42,795,207

G

2',3'-cyclic nucleotide 3' phosphodiesterase

decreases expression

EXP

Dexamethasone results in decreased expression of CNP mRNA

NCBI chr10:86,011,504...86,018,063
Ensembl chr10:86,011,495...86,018,063

G

canopy FGF signaling regulator 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CNPY3 mRNA

NCBI chr 9:21,731,088...21,745,448
Ensembl chr 9:21,730,791...21,745,505

G

canopy FGF signaling regulator 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CNPY4 mRNA

NCBI chr12:22,178,254...22,184,432
Ensembl chr12:22,178,160...22,184,425

G

cannabinoid receptor 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CNR1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CNR1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CNR1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

contactin 1

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CNTN1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CNTN1 mRNA]

NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391

G

cytochrome C oxidase assembly factor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,720,456...86,721,440

G

cytochrome C oxidase assembly factor 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COA5 mRNA

NCBI chr 9:47,147,267...47,160,724
Ensembl chr 9:47,147,267...47,160,672

G

Coenzyme A synthase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COASY mRNA

NCBI chr10:86,514,850...86,519,130
Ensembl chr10:86,514,874...86,519,130

G

cordon-bleu WH2 repeat protein-like 1

increases expression

ISO

Dexamethasone results in increased expression of COBLL1 mRNA

NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460

G

collagen type X alpha 1 chain

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of COL10A1 mRNA; Dexamethasone results in increased expression of COL10A1 protein
PTH protein modified form inhibits the reaction [Dexamethasone results in increased expression of COL10A1 protein]

NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440

G

collagen type XI alpha 1 chain

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264

G

collagen type XII alpha 1 chain

increases expression
multiple interactions
decreases expression

ISO

Dexamethasone results in increased expression of COL12A1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL12A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of COL12A1 mRNA
Dexamethasone results in decreased expression of COL12A1 mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:89,427,834...89,545,711

G

collagen type XIII alpha 1 chain

decreases expression

ISO

Dexamethasone results in decreased expression of COL13A1 mRNA

NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800

G

collagen type XIV alpha 1 chain

decreases expression

ISO

Dexamethasone results in decreased expression of COL14A1 mRNA

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938

G

collagen type XV alpha 1 chain

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA
Dexamethasone results in decreased expression of COL15A1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL15A1 mRNA]

PMID:16997883 PMID:20032058 PMID:25047013

NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170

G

collagen type XVIII alpha 1 chain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL18A1 mRNA

NCBI chr20:11,473,645...11,582,111
Ensembl chr20:11,473,645...11,582,112

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of COL1A1 mRNA; Dexamethasone results in decreased expression of COL1A1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Particulate Matter] results in increased expression of COL1A1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of COL1A1 mRNA]; PTPN1 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; PTPN1 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]; SENP2 protein promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]]; Dexamethasone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; NLRC5 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; NLRC5 protein inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]; SIRT1 protein promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]; Theophylline promotes the reaction [Dexamethasone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]

PMID:14618091 PMID:16430859 PMID:26435214 PMID:26739621 PMID:26806094 More...

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

decreases expression

ISO

Dexamethasone results in decreased expression of COL1A2 mRNA

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

collagen type II alpha 1 chain

multiple interactions
decreases expression
affects expression

ISO
EXP

[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA; Dexamethasone inhibits the reaction [BMP2 protein results in increased expression of COL2A1 mRNA]; IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]; PTH protein modified form inhibits the reaction [Dexamethasone results in decreased expression of COL2A1 protein]; resveratrol inhibits the reaction [IL1B protein inhibits the reaction [[TGFB3 protein co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL2A1 mRNA]]
Dexamethasone results in decreased expression of COL2A1 mRNA; Dexamethasone results in decreased expression of COL2A1 protein
Dexamethasone affects the reaction [[Freund's Adjuvant co-treated with COL2A1 protein] affects the activity of GSR protein]; Dexamethasone inhibits the reaction [[Freund's Adjuvant co-treated with COL2A1 protein] results in increased expression of IL1B protein]; Dexamethasone inhibits the reaction [[Freund's Adjuvant co-treated with COL2A1 protein] results in increased expression of IL6 protein]
Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]
Dexamethasone affects the expression of COL2A1 mRNA

PMID:17299831 PMID:17502159 PMID:21277400 PMID:24709313 PMID:26526931 More...

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627

G

collagen type III alpha 1 chain

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of COL3A1 mRNA
Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Particulate Matter] results in increased expression of COL3A1 mRNA]
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL3A1 mRNA]

PMID:20032058 PMID:25047013 PMID:35335934

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 1 chain

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of COL4A1 mRNA
Dexamethasone results in increased expression of COL4A1 mRNA

PMID:16054899 PMID:22733784 PMID:25047013 PMID:35143883

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

collagen type IV alpha 2 chain

increases expression

ISO

Dexamethasone results in increased expression of COL4A2 mRNA

NCBI chr16:84,749,672...84,885,520
Ensembl chr16:84,749,672...84,885,520

G

collagen type IV alpha 6 chain

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COL4A6 mRNA

PMID:16997883 PMID:28628672

NCBI chr X:109,554,945...109,905,987
Ensembl chr X:109,552,651...109,905,944

G

collagen type V alpha 1 chain

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of COL5A1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL5A1 mRNA]

PMID:14618091 PMID:20032058 PMID:25047013

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type V alpha 2 chain

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of COL5A2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL5A2 mRNA]

PMID:20032058 PMID:25047013

NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150

G

collagen type V alpha 3 chain

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL5A3 mRNA]

NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122

G

collagen type VI alpha 1 chain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COL6A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of COL6A1 mRNA

NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107

G

collagen type VI alpha 2 chain

decreases expression

ISO

Dexamethasone results in decreased expression of COL6A2 mRNA

NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,265...12,057,042

G

collagen type VI alpha 3 chain

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of COL6A3 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of COL6A3 mRNA]
Dexamethasone results in decreased expression of COL6A3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COL6A3 mRNA]

PMID:16054899 PMID:20032058 PMID:25047013

NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990

G

collagen type VII alpha 1 chain

multiple interactions
decreases expression

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COL7A1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL7A1 mRNA
Dexamethasone results in decreased expression of COL7A1 mRNA

PMID:16997883 PMID:25047013 PMID:28628672

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439

G

collagen type VIII alpha 1 chain

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of COL8A1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of COL8A1 mRNA

PMID:22733784 PMID:28628672

NCBI chr11:56,245,998...56,378,586
Ensembl chr11:56,369,868...56,376,229

G

collagen type VIII alpha 2 chain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of COL8A2 mRNA

NCBI chr 5:143,870,754...143,897,372
Ensembl chr 5:143,870,742...143,897,884

G

collagen type IX alpha 1 chain

affects expression

ISO

Dexamethasone affects the expression of COL9A1 mRNA

NCBI chr 9:34,081,364...34,164,552
Ensembl chr 9:34,003,905...34,164,543

G

collectin sub-family member 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COLEC11 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COLEC11 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of COLEC11 mRNA

NCBI chr 6:50,952,357...50,984,845
Ensembl chr 6:50,952,357...50,999,493

G

collagen beta(1-O)galactosyltransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COLGALT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COLGALT2 mRNA

NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194

G

copper metabolism domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COMMD1 mRNA

NCBI chr14:101,081,667...101,185,738
Ensembl chr14:101,081,667...101,185,639

G

COMM domain containing 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COMMD10 mRNA

NCBI chr18:41,927,802...42,061,384
Ensembl chr18:41,921,694...42,086,729

G

COMM domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COMMD2 mRNA

NCBI chr 2:143,998,672...144,002,918
Ensembl chr 2:143,998,672...144,002,918

G

COMM domain containing 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COMMD6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of COMMD6 mRNA

NCBI chr15:84,882,069...84,889,124
Ensembl chr15:84,882,548...84,889,194

G

catechol-O-methyltransferase

multiple interactions
increases expression

EXP
ISO

Testosterone inhibits the reaction [Dexamethasone results in increased expression of COMT mRNA]

PMID:16962226 PMID:20032058 PMID:21041162

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

COPI coat complex subunit beta 2

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of COPB2 mRNA]

NCBI chr 8:108,040,687...108,062,810
Ensembl chr 8:108,040,693...108,064,550

G

COPI coat complex subunit gamma 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPG1 mRNA

NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812

G

COP9 signalosome subunit 7A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COPS7A mRNA

NCBI chr 4:159,452,878...159,478,878
Ensembl chr 4:159,452,897...159,460,315

G

COP9 signalosome subunit 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of MYEOV2 mRNA

NCBI chr 9:100,657,276...100,662,206
Ensembl chr 9:100,657,276...100,662,206

G

COPI coat complex subunit zeta 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPZ1 mRNA

NCBI chr 7:136,287,696...136,314,131
Ensembl chr 7:136,288,032...136,314,135

G

COPI coat complex subunit zeta 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COPZ2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPZ2 mRNA

NCBI chr10:82,328,888...82,341,959
Ensembl chr10:82,328,660...82,341,959

G

coenzyme Q8B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of COQ8B mRNA

NCBI chr 1:91,653,241...91,676,822
Ensembl chr 1:91,654,225...91,676,819

G

coronin 1C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CORO1C mRNA

NCBI chr12:48,373,573...48,445,718
Ensembl chr12:48,373,597...48,445,716

G

coronin 2A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CORO2A mRNA

NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602

G

coronin 2B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CORO2B mRNA

NCBI chr 8:71,802,329...71,912,739
Ensembl chr 8:71,802,329...71,912,739

G

coronin 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CORO6 mRNA

NCBI chr10:62,808,172...62,817,788
Ensembl chr10:62,809,689...62,817,787

G

coactosin-like F-actin binding protein 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of COTL1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COTL1 mRNA

PMID:22733784 PMID:28628672

NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840

G

cytochrome c oxidase copper chaperone COX11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of COX11 mRNA

NCBI chr10:75,955,825...75,962,398
Ensembl chr10:75,955,783...75,963,489

G

cytochrome c oxidase assembly factor COX16

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX16 mRNA

NCBI chr 6:106,745,424...106,912,523
Ensembl chr 6:106,899,494...106,912,484

G

cytochrome c oxidase assembly factor COX20

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of COX20 mRNA

NCBI chr13:92,592,260...92,604,129
Ensembl chr14:6,872,315...6,872,638

G

cytochrome c oxidase subunit 6B2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of COX6B2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX6B2 mRNA

NCBI chr 1:78,122,871...78,124,096
Ensembl chr 1:78,122,453...78,124,094

G

cytochrome c oxidase subunit 7A1

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of COX7A1 mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of COX7A1 mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of COX7A mRNA
Dexamethasone results in increased expression of COX7A1 mRNA

PMID:24848799 PMID:25047013 PMID:29288687 PMID:32417366

NCBI chr 1:94,549,663...94,572,330
Ensembl chr 1:94,569,216...94,570,889

G

cytochrome c oxidase subunit 7B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX7B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of COX7B mRNA

NCBI chr X:75,149,036...75,155,285
Ensembl chr X:75,148,996...75,155,284

G

cytochrome c oxidase subunit 7B2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of COX7B2 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of COX7B2 mRNA]

NCBI chr14:37,047,081...37,159,288
Ensembl chr14:37,047,081...37,159,288

G

ceruloplasmin

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CP mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CP mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CP mRNA]
Dexamethasone results in increased expression of CP mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CP mRNA]

PMID:16054899 PMID:20032058 PMID:22733784

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087

G

carboxypeptidase A1

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CPA1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CPA1 mRNA]

NCBI chr 4:60,224,801...60,230,928
Ensembl chr 4:60,224,801...60,230,928

G

centrosome assembly and centriole elongation protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CPAP mRNA

NCBI chr15:34,742,838...34,806,020
Ensembl chr15:34,742,838...34,802,421

G

carboxypeptidase E

decreases expression
increases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CPE mRNA
dexamethasone increases expression of CPE mRNA in rat hippocampal neurons
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CPE mRNA
Dexamethasone results in increased expression of CPE mRNA alternative form
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CPE mRNA]

CTD
RGD

PMID:20032058 PMID:25426952 PMID:28628672 PMID:25426952

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CPEB2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CPEB2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CPEB2 mRNA

NCBI chr14:71,999,958...72,056,012
Ensembl chr14:72,002,072...72,052,263

G

cadherin-like and PC-esterase domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CPED1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CPED1 mRNA

NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442

G

carboxypeptidase N subunit 1

increases expression

EXP

Dexamethasone results in increased expression of CPN1 protein

NCBI chr 1:252,793,786...252,822,675
Ensembl chr 1:252,793,423...252,822,664

G

copine 7

increases expression

ISO

Dexamethasone results in increased expression of CPNE7 mRNA

NCBI chr19:68,072,165...68,091,197
Ensembl chr19:68,074,545...68,091,197

G

carbamoyl-phosphate synthase 1

increases expression

ISO
EXP

Dexamethasone results in increased expression of CPS1 protein
Dexamethasone results in increased expression of CPS1 mRNA

PMID:12198645 PMID:15965953

NCBI chr 9:76,063,863...76,186,739
Ensembl chr 9:76,000,754...76,186,734

G

carnitine palmitoyltransferase 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CPT1A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

carnitine palmitoyltransferase 2

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CPT2 mRNA

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818

G

ceramide-1-phosphate transfer protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CPTP mRNA

NCBI chr 5:171,757,181...171,761,271
Ensembl chr 5:171,757,181...171,761,266

G

carboxypeptidase Z

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CPZ mRNA

NCBI chr14:79,448,242...79,471,557
Ensembl chr14:79,448,139...79,471,556

G

cellular retinoic acid binding protein 2

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA

PMID:20228061 PMID:22733784 PMID:28628672

NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385

G

CASP2 and RIPK1 domain containing adaptor with death domain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRADD mRNA

NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512

G

cereblon

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone co-treated with afuresertib] results in increased expression of CRBN protein; [pomalidomide co-treated with Dexamethasone] results in increased expression of CRBN protein

NCBI chr 4:141,255,400...141,276,722
Ensembl chr 4:141,257,243...141,276,038

G

cAMP responsive element binding protein 1

increases phosphorylation
multiple interactions
decreases expression
affects expression

ISO
EXP

Dexamethasone results in increased phosphorylation of CREB1 protein
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] promotes the reaction [CREB1 protein binds to CEBPB promoter]]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CREB1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] promotes the reaction [CREB1 protein binds to CEBPB promoter]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of CREB1 protein
Dexamethasone results in decreased expression of CREB1 mRNA
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein
Dexamethasone affects the expression of CREB1 mRNA

PMID:16239108 PMID:21041162 PMID:21804312 PMID:22676303 PMID:29111458 More...

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CREB3 regulatory factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CREBRF mRNA

NCBI chr10:16,903,607...16,967,450
Ensembl chr10:16,903,547...16,966,430

G

cellular repressor of E1A-stimulated genes 1

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of CREG mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CREG mRNA]

NCBI chr13:80,552,779...80,565,272
Ensembl chr13:80,549,933...80,565,272

G

corticotropin releasing hormone

increases expression

EXP

Dexamethasone results in increased expression of CRH mRNA

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

cysteine-rich secretory protein 1

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of CRISP1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of CRISP1 mRNA]

NCBI chr 9:28,238,326...28,265,344
Ensembl chr 9:28,238,328...28,265,344

G

cysteine-rich secretory protein LCCL domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CRISPLD2 mRNA

NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349

G

CRK proto-oncogene, adaptor protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CRK mRNA

NCBI chr10:61,028,736...61,054,971
Ensembl chr10:61,028,757...61,082,988

G

CRK like proto-oncogene, adaptor protein

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CRKL mRNA

NCBI chr11:97,033,033...97,067,457
Ensembl chr11:97,024,782...97,067,457

G

C-reactive protein

multiple interactions

ISO
EXP

Dexamethasone inhibits the reaction [[Lipopolysaccharides co-treated with IL10 protein] results in increased expression of CRP protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]
Dexamethasone promotes the reaction [Losartan inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CRP protein]]

PMID:32812458 PMID:37177863

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

CREB regulated transcription coactivator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CRTC2 mRNA

NCBI chr 2:178,007,233...178,017,397
Ensembl chr 2:178,007,240...178,017,389

G

cryptochrome circadian regulator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CRY2 mRNA

NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447

G

crystallin, alpha B

multiple interactions
decreases expression
increases expression

ISO

Ginkgo biloba extract promotes the reaction [Dexamethasone results in increased expression of CRYAB mRNA]
Dexamethasone results in decreased expression of CRYAB protein

PMID:19064852 PMID:25047013 PMID:33567340

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

crystallin beta-gamma domain containing 1

increases expression

ISO

Dexamethasone results in increased expression of CRYBG1 mRNA

NCBI chr20:49,007,673...49,204,040
Ensembl chr20:49,007,929...49,204,047

G

citrate synthase

increases expression
multiple interactions
decreases expression

ISO
EXP

Dexamethasone results in increased expression of CS mRNA
[[Dexamethasone co-treated with Spironolactone] results in increased abundance of Glucocorticoids] which results in increased activity of CS protein
Dexamethasone results in decreased expression of CS protein
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA

PMID:1328298 PMID:25047013 PMID:33091441 PMID:33567340

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine sulfinic acid decarboxylase

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CSAD mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CSAD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CSAD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CSAD mRNA

PMID:25047013 PMID:28628672

NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581

G

colony stimulating factor 1

multiple interactions
decreases expression
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CSF1 mRNA
Dexamethasone results in decreased expression of CSF1 mRNA
Dexamethasone results in increased expression of CSF1 mRNA

PMID:16054899 PMID:21041162 PMID:22733784

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

colony stimulating factor 1 receptor

increases expression

ISO

Dexamethasone results in increased expression of CSF1R protein
Dexamethasone results in increased expression of CSF1R mRNA

PMID:15679045 PMID:21041162

NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806

G

colony stimulating factor 2

multiple interactions
increases activity
decreases expression

ISO

[Theophylline co-treated with Dexamethasone] inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; [trichostatin A co-treated with Dexamethasone] inhibits the reaction [IL1B protein promotes the reaction [H4C16 protein modified form binds to CSF2 promoter]]; Dexamethasone inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; Dexamethasone inhibits the reaction [IL13 protein results in increased secretion of CSF2 protein]; Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Dexamethasone inhibits the reaction [IL4 protein results in increased secretion of CSF2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; Dexamethasone inhibits the reaction [lipoteichoic acid results in increased secretion of CSF2 protein]; Dexamethasone inhibits the reaction [TNF protein results in increased expression of CSF2 mRNA]; Dexamethasone inhibits the reaction [TNF protein results in increased secretion of CSF2 protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]]; trichostatin A inhibits the reaction [[Theophylline co-treated with Dexamethasone] inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; trichostatin A inhibits the reaction [Dexamethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]
Dexamethasone results in increased activity of CSF2 protein
Dexamethasone results in decreased expression of CSF2 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]

PMID:10596698 PMID:11730731 PMID:12070353 PMID:12077271 PMID:14998300 More...

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

colony stimulating factor 3

increases expression

ISO

Dexamethasone results in increased expression of CSF3 mRNA

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

chondroitin sulfate N-acetylgalactosaminyltransferase 2

decreases expression

ISO

Dexamethasone results in decreased expression of CSGALNACT2 mRNA

NCBI chr 4:152,944,154...152,981,237
Ensembl chr 4:152,950,028...152,981,220

G

C-terminal Src kinase

decreases expression

ISO

Dexamethasone results in decreased expression of CSK mRNA

NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274

G

casein beta

multiple interactions

ISO

[PRL protein co-treated with Dexamethasone] results in increased expression of CSN2 mRNA; beta-Naphthoflavone inhibits the reaction [[PRL protein co-treated with Dexamethasone] results in increased expression of CSN2 mRNA]

NCBI chr14:20,601,824...20,609,061
Ensembl chr14:20,601,824...20,609,060

G

cysteine and glycine-rich protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of CSRP2 mRNA

NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238

G

cysteine and glycine rich protein 3

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of CSRP3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CSRP3 mRNA]

NCBI chr 1:107,664,338...107,682,916
Ensembl chr 1:107,664,338...107,682,916

G

cystatin C

increases expression

ISO

Dexamethasone results in increased expression of CST3 mRNA

NCBI chr 3:156,790,061...156,794,116
Ensembl chr 3:156,790,079...156,793,937

G

cystatin D

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CST5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CST5 mRNA

NCBI chr 3:158,033,791...158,038,345
Ensembl chr 3:158,033,791...158,038,345

G

cystatin E/M

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA

NCBI chr 1:212,084,676...212,086,384
Ensembl chr 1:212,084,676...212,086,384

G

cystatin A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CSTA mRNA

NCBI chr11:78,125,813...78,136,818
Ensembl chr11:78,125,800...78,136,822

G

cleavage stimulation factor subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CSTF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CSTF1 mRNA

NCBI chr 3:181,562,953...181,574,727
Ensembl chr 3:181,562,955...181,574,727

G

cleavage stimulation factor subunit 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CSTF3 mRNA

NCBI chr 3:111,421,291...111,492,539
Ensembl chr 3:111,421,234...111,497,046

G

C-terminal binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA

NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:197,212,133...197,254,261

G

CTD small phosphatase like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTDSPL mRNA

NCBI chr 8:127,520,478...127,644,999
Ensembl chr 8:127,520,499...127,644,999

G

cystathionine gamma-lyase

decreases activity
multiple interactions
decreases expression

ISO

Dexamethasone results in decreased activity of CTH protein
Ibuprofen promotes the reaction [Dexamethasone results in decreased activity of CTH protein]; Ibuprofen promotes the reaction [Dexamethasone results in decreased expression of CTH mRNA]; NR3C1 protein affects the reaction [Dexamethasone results in decreased expression of CTH mRNA]; NR3C1 protein affects the reaction [Ibuprofen promotes the reaction [Dexamethasone results in decreased expression of CTH mRNA]]

NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066

G

catenin beta 1

decreases expression
increases expression
multiple interactions
affects localization

ISO
EXP

Dexamethasone results in decreased expression of CTNNB1 protein
Dexamethasone results in increased expression of CTNNB1 mRNA
[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CTNNB1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CTNNB1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CTNNB1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA]; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]; IWR-1 compound inhibits the reaction [Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CTNNB1 protein]]; Lithium Chloride affects the reaction [Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; Lithium Chloride affects the reaction [mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of CTNNB1 mRNA]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]; protosappanin B inhibits the reaction [Dexamethasone results in decreased expression of CTNNB1 protein]; Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CTNNB1 protein]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; T 0070907 affects the reaction [Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]; T 0070907 affects the reaction [mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the phosphorylation of CTNNB1 protein]]
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] inhibits the reaction [TGFB1 protein results in increased expression of CTNNB1 protein]; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of CTNNB1 mRNA]; Dexamethasone inhibits the reaction [2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine results in increased expression of CTNNB1 mRNA]; Dexamethasone results in decreased expression of and results in increased phosphorylation of CTNNB1 protein; Quercetin promotes the reaction [Dexamethasone results in decreased expression of CTNNB1 mRNA]; Quercetin promotes the reaction [Dexamethasone results in decreased expression of CTNNB1 protein]
Dexamethasone affects the localization of CTNNB1 protein
Dexamethasone results in decreased expression of CTNNB1 mRNA; Dexamethasone results in decreased expression of CTNNB1 protein

PMID:18467435 PMID:20501703 PMID:20578217 PMID:28285642 PMID:28628672 More...

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

catenin, beta like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA

NCBI chr 3:166,807,899...166,968,932
Ensembl chr 3:166,807,858...166,968,931

G

chymotrypsin-like

increases expression

ISO

Dexamethasone results in increased expression of CTRB1 mRNA

NCBI chr19:50,737,078...50,740,659
Ensembl chr19:50,737,079...50,738,979

G

cathepsin B

multiple interactions

EXP

dexamethasone decreases activity of Ctsb protein in heart and kidney; dexamethasone increases activity of Ctsb protein in serum

RGD

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cathepsin C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CTSC mRNA

NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082

G

cathepsin D

increases expression
decreases expression

ISO

Dexamethasone results in increased expression of CTSD mRNA
Dexamethasone results in decreased expression of CTSD mRNA

PMID:21041162 PMID:25047013

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

cathepsin F

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CTSF mRNA

NCBI chr 1:211,582,169...211,587,917
Ensembl chr 1:211,582,098...211,587,916

G

cathepsin H

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CTSH mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CTSH mRNA

NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:99,488,874...99,509,181

G

cathepsin K

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CTSK mRNA
[Dexamethasone co-treated with TNFSF11 protein] results in increased expression of CTSK protein

PMID:25047013 PMID:39393751

NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582

G

cathepsin L

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of CTSL mRNA
Calcitriol inhibits the reaction [Dexamethasone results in increased expression of CTSL mRNA]
Testosterone inhibits the reaction [Dexamethasone results in increased expression of CTSL mRNA]

PMID:14618091 PMID:17522070 PMID:20032058 PMID:29962435

NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113

G

cathepsin Z

decreases expression

ISO

Dexamethasone results in decreased expression of CTSZ mRNA

NCBI chr 3:183,643,077...183,653,847
Ensembl chr 3:183,643,077...183,657,012

G

CTTNBP2 N-terminal like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CTTNBP2NL mRNA

NCBI chr 2:195,196,318...195,244,792
Ensembl chr 2:195,196,318...195,243,181

G

cullin 4B

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CUL4B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CUL4B mRNA

PMID:25047013 PMID:28628672

NCBI chr X:122,154,332...122,192,299
Ensembl chr X:122,154,332...122,192,299

G

cullin 9

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CUL9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CUL9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CUL9 mRNA

PMID:25047013 PMID:28628672

NCBI chr 9:21,933,699...21,977,145
Ensembl chr 9:21,933,803...21,977,145

G

cutC copper transporter

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CUTC mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CUTC mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:252,571,489...252,586,269
Ensembl chr 1:252,571,521...252,597,272

G

CWC25 spliceosome-associated protein homolog

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CWC25 mRNA

NCBI chr10:83,232,052...83,256,722
Ensembl chr10:83,232,052...83,256,722

G

CWC27 spliceosome associated cyclophilin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CWC27 mRNA

NCBI chr 2:37,498,462...37,709,691
Ensembl chr 2:37,498,468...37,709,355

G

CWF19 like cell cycle control factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CWF19L1 mRNA

NCBI chr 1:252,946,934...252,970,194
Ensembl chr 1:252,946,934...252,970,168

G

C-X3-C motif chemokine ligand 1

multiple interactions
decreases expression
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CX3CL1 mRNA; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CX3CL1 mRNA; Tetrachlorodibenzodioxin promotes the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CX3CL1 mRNA]; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CX3CL1 mRNA]
Dexamethasone results in decreased expression of CX3CL1 mRNA
Dexamethasone results in increased expression of CX3CL1 mRNA

PMID:16054899 PMID:21041162 PMID:22733784 PMID:23503329

NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999

G

C-X-C motif chemokine ligand 1

multiple interactions

EXP

Dexamethasone inhibits the reaction [Freund's Adjuvant results in increased expression of CXCL1 mRNA]; Dexamethasone inhibits the reaction [Ozone results in increased expression of CXCL1 mRNA]; Dexamethasone promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CXCL1 mRNA]

PMID:8603703 PMID:18590720 PMID:21149847

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 10

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CXCL10 mRNA
[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL10 mRNA; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; TNF protein inhibits the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL10 mRNA]

PMID:21041162 PMID:23503329 PMID:27568862

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine ligand 11

multiple interactions

ISO

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL11 mRNA

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567

G

C-X-C motif chemokine ligand 12

multiple interactions
decreases expression
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL12 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL12 mRNA]; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL12 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL12 mRNA]; TNF protein inhibits the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL12 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CXCL12 mRNA
Dexamethasone results in decreased expression of CXCL12 mRNA
Dexamethasone results in increased expression of CXCL12 mRNA

PMID:16054899 PMID:21041162 PMID:22733784 PMID:23503329 PMID:28628672

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

C-X-C motif chemokine ligand 16

multiple interactions

ISO

[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL16 mRNA; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL16 mRNA]

NCBI chr10:55,665,355...55,669,950
Ensembl chr10:55,664,742...55,670,226

G

C-X-C motif chemokine ligand 17

multiple interactions

ISO

Dexamethasone inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CXCL17 mRNA]

NCBI chr 1:90,112,561...90,124,648
Ensembl chr 1:90,112,771...90,124,535

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression
decreases expression

EXP
ISO

Dexamethasone inhibits the reaction [Ozone results in increased expression of CXCL2 mRNA]; Dexamethasone promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CXCL2 mRNA]
Dexamethasone results in increased expression of CXCL2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CXCL2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CXCL2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CXCL2 mRNA
Dexamethasone results in decreased expression of CXCL2 mRNA
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of CXCL2 mRNA]; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL2 mRNA; Amiodarone inhibits the reaction [Dexamethasone results in increased expression of CXCL2 mRNA]; Dexamethasone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]; Dexamethasone inhibits the reaction [Ozone results in increased expression of CXCL2 protein]; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL2 mRNA]

PMID:7737418 PMID:14754758 PMID:18590720 PMID:22154906 PMID:23503329 More...

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CXCL1 mRNA
[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL1 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL1 mRNA]; [Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL1 mRNA; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CXCL1 protein]; Dexamethasone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL1 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]; Dexamethasone inhibits the reaction [Silicon Dioxide results in increased expression of CXCL1 mRNA]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]]; DUSP1 gene mutant form promotes the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL1 mRNA]; TNF protein inhibits the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CXCL1 mRNA]

PMID:16054899 PMID:16880258 PMID:21414392 PMID:22733784 PMID:23503329 More...

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine ligand 6

decreases expression

ISO

Dexamethasone results in decreased expression of CXCL6 mRNA

NCBI chr14:17,594,959...17,596,417
Ensembl chr14:17,594,959...17,596,417

G

C-X-C motif chemokine ligand 9

increases expression
decreases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CXCL9 mRNA
Dexamethasone results in decreased expression of CXCL9 protein
[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL9 mRNA; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL9 protein]; TNF protein promotes the reaction [[Zinc co-treated with Nickel co-treated with Cobalt co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CXCL9 mRNA]

PMID:21041162 PMID:21880982 PMID:23503329 PMID:27568862

NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299

G

C-X-C motif chemokine receptor 4

multiple interactions
decreases expression
increases expression

ISO

Dexamethasone inhibits the reaction [TNF protein results in increased expression of CXCR4 mRNA]
Dexamethasone results in decreased expression of CXCR4 mRNA
Dexamethasone results in increased expression of CXCR4 mRNA; Dexamethasone results in increased expression of CXCR4 protein

PMID:11872090 PMID:12732289 PMID:21041162 PMID:21420233 PMID:22733784

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

C-X-C motif chemokine receptor 6

increases expression

ISO

Dexamethasone results in increased expression of CXCR6 mRNA

NCBI chr 8:132,311,834...132,317,001
Ensembl chr 8:132,306,600...132,322,498

G

similar to human chromosome X open reading frame 38

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CXORF38 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CXORF38 mRNA

NCBI chr X:12,800,935...12,823,632
Ensembl chr X:12,802,377...12,814,198

G

CXXC finger protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CXXC1 mRNA

NCBI chr18:70,088,407...70,093,786
Ensembl chr18:70,088,460...70,093,778

G

CXXC finger protein 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of CXXC5 mRNA

NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635

G

cytochrome b-561

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CYB561 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CYB561 mRNA

PMID:22733784 PMID:28628672

NCBI chr10:91,377,866...91,388,548
Ensembl chr10:91,377,866...91,385,097

G

cytochrome b561 family, member A3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CYB561A3 mRNA

NCBI chr 1:216,641,108...216,662,495
Ensembl chr 1:216,651,128...216,662,492

G

cytochrome b5 type A

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of CYB5A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CYB5A mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094

G

cytochrome b5 domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CYB5D2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5D2 mRNA

NCBI chr10:57,892,799...57,911,831
Ensembl chr10:57,895,296...57,912,030

G

cytochrome b5 reductase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5R1 mRNA

NCBI chr13:48,401,061...48,407,466
Ensembl chr13:48,399,106...48,407,465

G

cytochrome b5 reductase 3

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CYB5R3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5R3 mRNA

PMID:17522070 PMID:28628672

NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:116,186,729...116,204,306

G

cytochrome b-245 beta chain

multiple interactions

ISO

Dexamethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CYBB mRNA]
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CYBB mRNA]

PMID:9794432 PMID:27568862

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome c, somatic

multiple interactions
decreases expression

ISO

[GCS-100 co-treated with Dexamethasone] affects the localization of CYCS protein; [IFNG protein co-treated with bisphenol AF] inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of CYCS protein]; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of CYCS protein
Dexamethasone results in decreased expression of CYCS protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CYCS mRNA

PMID:16166312 PMID:24848799 PMID:31596606 PMID:33567340

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions
decreases expression

EXP

[Dexamethasone co-treated with Dibutyl Phthalate] results in decreased expression of CYP11A1 mRNA
Dexamethasone results in decreased expression of CYP11A1 mRNA

PMID:22615892 PMID:29902490 PMID:33983380 PMID:35246761

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 11, subfamily b, polypeptide 2

decreases expression

EXP

Dexamethasone results in decreased expression of CYP11B1 mRNA

PMID:33983380 PMID:35246761

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions
decreases expression
increases expression

EXP
ISO

[Dexamethasone co-treated with Dibutyl Phthalate] results in decreased expression of CYP17A1 mRNA
Dexamethasone results in decreased expression of CYP17A1 mRNA
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA]

PMID:20462044 PMID:22615892 PMID:29902490 PMID:33983380

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
decreases expression
increases activity
increases expression

ISO

Calcitriol promotes the reaction [Dexamethasone results in increased activity of CYP19A1 protein]
Dexamethasone results in decreased expression of CYP19A1 mRNA
Dexamethasone results in increased expression of CYP19A1 mRNA

PMID:15525692 PMID:15862960 PMID:16691199 PMID:25047013 PMID:29701941

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
decreases expression
increases activity
decreases activity

ISO
EXP

[Dexamethasone co-treated with Mifepristone] promotes the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; [Dexamethasone co-treated with Mifepristone] results in increased activity of CYP1A1 protein; [NR3C1 protein co-treated with Dexamethasone] inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Dexamethasone inhibits the reaction [AHR protein results in increased expression of CYP1A1]; Dexamethasone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [cyprodinil results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Dexamethasone inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Dexamethasone inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 protein]; Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Dexamethasone results in increased expression of CYP1A1 mRNA
Dexamethasone results in decreased expression of CYP1A1 protein
Dexamethasone results in increased activity of CYP1A1 protein
Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]
[PRL protein co-treated with Dexamethasone] results in increased expression of CYP1A1 mRNA; beta-Naphthoflavone promotes the reaction [[PRL protein co-treated with Dexamethasone] results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]
Dexamethasone results in decreased activity of CYP1A1 protein

PMID:2916850 PMID:7587946 PMID:11328961 PMID:14691211 PMID:15620718 More...

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases expression
increases expression
affects expression
decreases activity

ISO
EXP

[Dexamethasone co-treated with Mifepristone] promotes the reaction [Methylcholanthrene results in increased activity of CYP1A2 protein]; [Dexamethasone co-treated with Mifepristone] results in increased activity of CYP1A2 protein; Dexamethasone inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A2 protein]; Dexamethasone promotes the reaction [Methylcholanthrene results in increased expression of CYP1A2 mRNA]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Methylcholanthrene results in increased expression of CYP1A2 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]]
Dexamethasone results in decreased expression of CYP1A2 mRNA
Dexamethasone results in increased expression of CYP1A2 mRNA
Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]]
Dexamethasone affects the expression of CYP1A2 mRNA
Dexamethasone results in decreased activity of CYP1A2 protein
Dexamethasone results in decreased expression of CYP1A2 protein

PMID:11328961 PMID:15102944 PMID:15607757 PMID:17690134 PMID:19022236 More...

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CYP1B1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CYP1B1 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of CYP1B1 mRNA
Dexamethasone results in increased expression of CYP1B1 mRNA; Dexamethasone results in increased expression of CYP1B1 protein
Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 protein]; Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]

PMID:9804617 PMID:15967407 PMID:17690134 PMID:21041162 PMID:28628672 More...

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 21, subfamily a, polypeptide 1

decreases expression

EXP

Dexamethasone results in decreased expression of CYP21A1 mRNA

NCBI chr20:4,028,323...4,031,549
Ensembl chr20:4,028,391...4,031,543

G

cytochrome P450, family 24, subfamily a, polypeptide 1

affects activity
increases expression
affects expression

ISO

Dexamethasone affects the activity of CYP24A1 protein
Dexamethasone results in increased expression of CYP24A1 mRNA
Dexamethasone affects the expression of CYP24A1 mRNA

PMID:10694374 PMID:15630458

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 26, subfamily a, polypeptide 1

decreases expression

ISO

Dexamethasone results in decreased expression of CYP26A1 mRNA

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

Dexamethasone promotes the reaction [NR3C1 protein binds to CYP27A1 promoter]
Dexamethasone results in increased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 27, subfamily b, polypeptide 1

affects expression
affects activity

ISO

Dexamethasone affects the expression of CYP27B1 mRNA
Dexamethasone affects the activity of CYP27B1 protein

NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:64,756,626...64,761,570

G

cytochrome P450, family 2, subfamily a, polypeptide 1

affects expression

EXP

Dexamethasone affects the expression of CYP2A1 mRNA

NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730

G

cytochrome P450, family 2, subfamily a, polypeptide 2

affects expression
decreases expression

EXP

Dexamethasone affects the expression of CYP2A2 mRNA
Dexamethasone results in decreased expression of CYP2A2 mRNA

PMID:11328961 PMID:15102944

NCBI chr 1:91,391,492...91,417,158
Ensembl chr 1:91,391,502...91,417,158

G

cytochrome P450, family 2, subfamily b, polypeptide 1

multiple interactions
increases expression

EXP

Dexamethasone inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Dexamethasone inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Dexamethasone inhibits the reaction [Phenobarbital results in increased expression of CYP2B1 mRNA]; Dexamethasone promotes the reaction [CYP2B1 protein results in increased oxidation of Thiotepa]
Dexamethasone results in increased expression of CYP2B1 mRNA

PMID:2105156 PMID:11328961 PMID:15607757 PMID:15965953 PMID:16125621 More...

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily b, polypeptide 15

affects expression

EXP

Dexamethasone affects the expression of CYP2B15 mRNA

NCBI chr 1:91,221,865...91,234,169
Ensembl chr 1:91,221,865...91,234,169

G

cytochrome P450, family 2, subfamily b, polypeptide 2

affects expression
increases expression

EXP

Dexamethasone affects the expression of CYP2B2 mRNA
Dexamethasone results in increased expression of CYP2B2 mRNA

PMID:11328961 PMID:15102944 PMID:16125621 PMID:20607812

NCBI chr 1:90,722,243...90,736,272

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases expression
increases activity
increases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CYP2B3 mRNA
Dexamethasone results in increased activity of CYP2B6 protein
Dexamethasone results in increased expression of CYP2B10 mRNA
Dexamethasone results in increased expression of CYP2B6 mRNA; Dexamethasone results in increased expression of CYP2B6 protein
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone results in increased expression of and results in increased activity of CYP2B6 protein; NR3C1 protein promotes the reaction [NR1I3 protein affects the reaction [[Dexamethasone co-treated with Phenobarbital] results in increased expression of CYP2B6 mRNA]]

PMID:7771797 PMID:11328961 PMID:12695351 PMID:15548381 PMID:15802389 More...

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, subfamily 2, polypeptide 11

increases expression
affects expression

EXP

Dexamethasone results in increased expression of CYP2C11; Dexamethasone results in increased expression of CYP2C11 protein
Dexamethasone affects the expression of CYP2C mRNA

PMID:15102944 PMID:15890479 PMID:19041297

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 2, subfamily c, polypeptide 13

affects expression

EXP

Dexamethasone affects the expression of CYP2C38 mRNA

NCBI chr 1:248,706,787...248,787,239
Ensembl chr 1:248,706,788...248,787,210

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
increases expression

EXP

Dexamethasone inhibits the reaction [Freund's Adjuvant results in decreased expression of CYP2C19 mRNA]
Dexamethasone results in increased expression of CYP2C6 protein

PMID:19788401 PMID:21149847

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily c, polypeptide 79

affects binding
increases expression

ISO

[Dexamethasone binds to NR3C1 protein] which binds to CYP2C8 promoter
Dexamethasone results in increased expression of CYP2C8 mRNA

PMID:15933212 PMID:19118567

G

cytochrome P450, family 2, subfamily d, polypeptide 1

increases expression

EXP

Dexamethasone results in increased expression of CYP2D9 mRNA

NCBI chr 7:115,789,026...115,793,430
Ensembl chr 7:115,789,023...115,793,479

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression

EXP
ISO

Dexamethasone results in increased expression of CYP2D4 mRNA
Dexamethasone results in increased expression of CYP2D22 mRNA

PMID:11328961 PMID:22733784

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone results in decreased expression of CYP2E1 protein
2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine inhibits the reaction [Dexamethasone results in increased expression of CYP2E1 mRNA]; Quercetin promotes the reaction [Dexamethasone results in increased expression of CYP2E1 mRNA]; Quercetin promotes the reaction [Dexamethasone results in increased expression of CYP2E1 protein]
Dexamethasone results in increased expression of CYP2E1 mRNA; Dexamethasone results in increased expression of CYP2E1 protein

PMID:11181506 PMID:14618091 PMID:15965953 PMID:20501703 PMID:20607812 More...

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily f, polypeptide 4

increases expression

ISO

Dexamethasone results in increased expression of CYP2F2 mRNA

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of CYP2S1 mRNA; Dexamethasone results in decreased expression of CYP2S1 protein
NR3C1 protein promotes the reaction [Dexamethasone results in decreased expression of CYP2S1 mRNA]; NR3C1 protein promotes the reaction [Dexamethasone results in decreased expression of CYP2S1 protein]; trichostatin A inhibits the reaction [Dexamethasone results in decreased expression of CYP2S1 mRNA]

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 18

affects expression
increases expression

EXP

Dexamethasone affects the expression of CYP3A18 mRNA
Dexamethasone results in increased expression of CYP3A18 mRNA

PMID:11328961 PMID:15102944

NCBI chr12:13,994,312...14,044,185
Ensembl chr12:13,994,311...14,045,788

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects expression
affects metabolic processing
multiple interactions
increases activity
increases expression

EXP
ISO

Dexamethasone affects the expression of CYP3A2 mRNA
CYP3A4 protein affects the metabolism of Dexamethasone
[Dexamethasone binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Dexamethasone co-treated with Diethylhexyl Phthalate] results in increased activity of CYP3A4 protein; [Dexamethasone co-treated with Diethylhexyl Phthalate] results in increased expression of CYP3A4 protein; [Dexamethasone co-treated with mono-(2-ethylhexyl)phthalate] results in increased activity of CYP3A4 protein; [Dexamethasone results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; CYP3A4 promoter mutant form inhibits the reaction [Dexamethasone results in increased expression of CYP3A4 mRNA]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Dexamethasone promotes the reaction [fenvalerate results in increased expression of CYP3A4 mRNA]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; fenvalerate promotes the reaction [Dexamethasone results in increased expression of CYP3A4 mRNA]; Mifepristone inhibits the reaction [NR3C1 protein promotes the reaction [Dexamethasone results in increased expression of CYP3A4 mRNA]]; NR3C1 protein promotes the reaction [Dexamethasone results in increased expression of CYP3A4 mRNA]
Dexamethasone results in increased activity of CYP3A4 protein
Dexamethasone results in increased expression of CYP3A4 mRNA; Dexamethasone results in increased expression of CYP3A4 protein
Plant Preparations promotes the reaction [Dexamethasone results in increased expression of CYP3A2 mRNA]
Dexamethasone results in increased expression of CYP3A11 mRNA; Dexamethasone results in increased expression of CYP3A2 mRNA; Dexamethasone results in increased expression of CYP3A2 protein; Dexamethasone results in increased expression of CYP3A4 mRNA

PMID:8114683 PMID:9512926 PMID:10219967 PMID:10640517 PMID:10923861 More...

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases activity
increases expression

EXP

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 protein]; Dexamethasone promotes the reaction [fenvalerate results in increased expression of CYP3A23-3A1 mRNA]; Dexamethasone results in increased expression of and results in increased activity of CYP3A23-3A1 protein; diphenyleneiodonium inhibits the reaction [Dexamethasone results in increased activity of CYP3A23-3A1 protein]; fenvalerate promotes the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; lactacystin inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 protein]; NR1I2 gene mutant form inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; NR1I2 protein promotes the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; Plant Preparations promotes the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; sodium arsenite inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 mRNA]; sodium arsenite inhibits the reaction [Dexamethasone results in increased expression of CYP3A23-3A1 protein]
Dexamethasone results in increased expression of CYP3A23-3A1 mRNA; Dexamethasone results in increased expression of CYP3A23-3A1 protein

PMID:10329507 PMID:10640517 PMID:11328961 PMID:11502894 PMID:11752103 More...

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression
increases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of CYP3A9 mRNA
Dexamethasone results in increased expression of CYP3A9 mRNA
Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA]; NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA]
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA
Dexamethasone results in increased expression of CYP3A13 mRNA

PMID:10696073 PMID:12538830 PMID:14570766 PMID:15102944 PMID:19118567 More...

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 4, subfamily a, polypeptide 3

increases expression

EXP

Dexamethasone results in increased expression of CYP4A3 mRNA

NCBI chr 5:134,334,396...134,352,268
Ensembl chr 5:134,334,701...134,352,236

G

cytochrome P450, family 4, subfamily a, polypeptide 8

decreases expression

EXP

Dexamethasone results in decreased expression of CYP4A8 mRNA

NCBI chr 5:133,938,882...133,970,226
Ensembl chr 5:133,938,883...133,970,226

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CYP4B1 mRNA

NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:134,375,807...134,393,116

G

cytochrome P450, family 4, subfamily f, polypeptide 6

decreases expression

EXP

Dexamethasone results in decreased expression of CYP4F6 mRNA

NCBI chr 7:12,680,799...12,708,378
Ensembl chr 7:12,680,806...12,708,402

G

cytochrome P450, family 51

decreases expression
multiple interactions
affects expression

ISO
EXP

Dexamethasone results in decreased expression of CYP51 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CYP51A1 mRNA
Dexamethasone affects the expression of CYP51 mRNA

PMID:15102944 PMID:17998272 PMID:28628672

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytochrome P450 family 7 subfamily A member 1

increases expression
decreases expression

EXP

Dexamethasone results in increased expression of CYP7A1 mRNA
Dexamethasone results in decreased expression of CYP7A1 mRNA

PMID:15965953 PMID:20888898 PMID:32599024

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CYP7B1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

EXP

Dexamethasone results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

CYFIP related Rac1 interactor B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYRIB mRNA

NCBI chr 7:97,524,941...97,649,846
Ensembl chr 7:97,523,121...97,649,853

G

cysteine-rich transmembrane module containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYSTM1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of CYSTM1 mRNA

NCBI chr18:28,219,861...28,287,574
Ensembl chr18:28,220,004...28,287,574

G

cytohesin 3

increases expression

ISO

Dexamethasone results in increased expression of CYTH3 mRNA

NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506

G

D-2-hydroxyglutarate dehydrogenase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of D2HGDH mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of D2HGDH mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of D2HGDH mRNA

NCBI chr 9:101,796,287...101,815,727
Ensembl chr 9:101,797,895...101,815,727

G

dishevelled associated activator of morphogenesis 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DAAM2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAAM2 mRNA

PMID:25047013 PMID:28628672

NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671

G

dishevelled-binding antagonist of beta-catenin 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of DACT1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of DACT1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053

G

dishevelled-binding antagonist of beta-catenin 3

decreases expression

ISO

Dexamethasone results in decreased expression of DACT3 mRNA

NCBI chr 1:86,674,989...86,686,722
Ensembl chr 1:86,674,734...86,687,421

G

defender against cell death 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAD1 mRNA

NCBI chr15:31,647,326...31,667,159
Ensembl chr15:31,647,326...31,667,287

G

diacylglycerol lipase, beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAGLB mRNA

NCBI chr12:16,173,345...16,215,777
Ensembl chr12:16,173,345...16,215,758

G

death-associated protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAP mRNA

NCBI chr 2:83,910,113...83,962,673
Ensembl chr 2:83,910,060...83,962,673

G

DBF4B-CDC7 kinase regulatory subunit

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DBF4B mRNA

NCBI chr10:88,209,913...88,219,336

G

dopamine beta-hydroxylase

multiple interactions
decreases expression
increases expression

EXP

Dexamethasone inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Dexamethasone inhibits the reaction [Simazine results in decreased expression of DBH protein]; Testosterone inhibits the reaction [Dexamethasone results in decreased expression of DBH mRNA]
Dexamethasone results in increased expression of DBH protein

PMID:14550852 PMID:20032058

NCBI chr 3:30,886,313...30,903,313
Ensembl chr 3:30,886,328...30,903,316

G

diazepam binding inhibitor

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of DBI mRNA
Dexamethasone results in increased expression of DBI mRNA

PMID:23428407 PMID:25047013

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450

G

D-box binding PAR bZIP transcription factor

decreases expression
increases expression

EXP

Dexamethasone results in decreased expression of DBP mRNA
Dexamethasone results in increased expression of DBP mRNA

NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205

G

dephospho-CoA kinase domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DCAKD mRNA

NCBI chr10:88,457,829...88,489,011
Ensembl chr10:88,457,829...88,480,118

G

discoidin, CUB and LCCL domain containing 2

increases expression

ISO

Dexamethasone results in increased expression of DCBLD2 mRNA

NCBI chr11:55,594,691...55,649,113
Ensembl chr11:55,594,691...55,649,085

G

doublecortin-like kinase 1

increases expression

ISO

Dexamethasone results in increased expression of DCLK1 mRNA

NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090

G

decorin

multiple interactions
increases expression
decreases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of DCN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DCN mRNA
Dexamethasone results in increased expression of DCN mRNA
Dexamethasone results in decreased expression of DCN mRNA

PMID:16054899 PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

decapping mRNA 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DCP1A mRNA

NCBI chr16:5,663,437...5,708,623
Ensembl chr16:5,663,203...5,708,618

G

dCMP deaminase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DCTD mRNA

NCBI chr16:50,799,699...50,831,398
Ensembl chr16:50,787,875...50,831,186

G

defective in cullin neddylation 1 domain containing 3

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DCUN1D3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DCUN1D3 mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:183,674,364...183,717,002
Ensembl chr 1:75,527,981...75,529,932
Ensembl chr 1:75,527,981...75,529,932

G

defective in cullin neddylation 1 domain containing 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DCUN1D4 mRNA

NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520

G

doublecortin

increases expression

ISO

Dexamethasone results in increased expression of DCX mRNA

NCBI chr X:112,227,455...112,370,291
Ensembl chr X:112,227,455...112,304,161

G

dicarbonyl and L-xylulose reductase

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DCXR mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DCXR mRNA

PMID:25047013 PMID:28628672

NCBI chr10:106,504,730...106,506,619

G

DET1 and DDB1 associated 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DDA1 mRNA

NCBI chr16:18,190,280...18,197,914
Ensembl chr16:18,190,306...18,197,913

G

dimethylarginine dimethylaminohydrolase 1

increases expression

ISO

Dexamethasone results in increased expression of DDAH1 mRNA

NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626

G

damage-specific DNA binding protein 1

increases expression

ISO

Dexamethasone results in increased expression of DDB1 mRNA

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

dopa decarboxylase

increases expression

ISO

Dexamethasone results in increased expression of DDC mRNA

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DNA-damage inducible transcript 3

decreases expression
multiple interactions
increases expression
increases response to substance

ISO

Dexamethasone results in decreased expression of DDIT3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DDIT3 mRNA
Dexamethasone results in increased expression of DDIT3
DDIT3 protein results in increased susceptibility to Dexamethasone

PMID:22733784 PMID:24691439 PMID:25047013 PMID:28628672

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DNA-damage-inducible transcript 4

multiple interactions
decreases expression
increases expression

EXP
ISO

[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]; bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of DDIT4 protein]
Dexamethasone results in decreased expression of DDIT4 mRNA
Dexamethasone results in increased expression of DDIT4; Dexamethasone results in increased expression of DDIT4 mRNA
Dexamethasone results in increased expression of DDIT4 mRNA; Dexamethasone results in increased expression of DDIT4 protein

PMID:17998272 PMID:20032058 PMID:22733784 PMID:22936724 PMID:25047013

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

dendrin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DDN mRNA

NCBI chr 7:131,832,270...131,836,252
Ensembl chr 7:131,832,271...131,836,294

G

discoidin domain receptor tyrosine kinase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DDR1 mRNA

NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,050,375...3,069,276

G

DEAD/H-box helicase 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DDX11 mRNA

NCBI chr 9:113,204,886...113,309,692
Ensembl chr 9:113,276,985...113,316,152

G

DEAD-box helicase 17

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DDX17 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DDX17 mRNA

NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747

G

DEAD-box helicase 19B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX19B mRNA

NCBI chr19:55,877,567...55,910,134
Ensembl chr19:55,877,567...55,906,745

G

DEAD-box helicase 23

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX23 mRNA

NCBI chr 7:131,676,636...131,693,917
Ensembl chr 7:131,676,636...131,689,074

G

DExD-box helicase 39A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

DEAD-box helicase 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DDX5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX5 mRNA

NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300

G

DEAD-box helicase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DDX6 mRNA

NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977

G

2,4-dienoyl-CoA reductase 1

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of DECR1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DECR1 mRNA

PMID:16962226 PMID:28628672

NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033

G

differentially expressed in FDCP 8 homolog

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DEF8 mRNA

NCBI chr19:68,383,293...68,404,133
Ensembl chr19:68,383,349...68,404,125

G

defensin beta 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DEFB4A mRNA

NCBI chr16:77,315,424...77,317,828
Ensembl chr16:77,315,424...77,317,828

G

delta(4)-desaturase, sphingolipid 1

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of DEGS1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of DEGS1 mRNA]

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

DENN domain containing 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DENND10 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DENND10 mRNA

NCBI chr 1:269,937,023...269,960,506
Ensembl chr 1:269,936,895...269,962,853

G

DENN domain containing 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DENND1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DENND1B mRNA

NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369

G

DENN domain containing 2A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DENND2A mRNA

NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984

G

DENN domain containing 2B

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DENND2B mRNA
Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of DENND2B mRNA]

NCBI chr 1:172,978,895...173,129,623
Ensembl chr 1:172,978,895...173,129,810

G

DENN domain containing 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DENND3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DENND3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DENND3 mRNA

NCBI chr 7:107,304,860...107,362,573
Ensembl chr 7:107,220,192...107,362,573

G

DENN domain containing 4C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DENND4C mRNA

NCBI chr 5:106,316,942...106,421,484
Ensembl chr 5:106,318,281...106,415,489

G

DEP domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DEPDC1 mRNA

NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:251,343,281...251,376,709

G

DEPP autophagy regulator 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DEPP1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DEPP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DEPP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DEPP1 mRNA

PMID:25047013 PMID:28628672

NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233

G

DEP domain containing MTOR-interacting protein

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DEPTOR mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DEPTOR mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DEPTOR mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

deoxyribose-phosphate aldolase

increases expression

ISO

Dexamethasone results in increased expression of DERA mRNA

NCBI chr 4:172,394,971...172,473,746
Ensembl chr 4:172,394,962...172,490,142

G

derlin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DERL2 mRNA

NCBI chr10:56,226,340...56,238,038
Ensembl chr10:56,226,219...56,237,993

G

desmin

increases expression

EXP

Dexamethasone results in increased expression of DES mRNA

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

DNA fragmentation factor subunit beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DFFB mRNA

NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:169,804,889...169,817,225

G

diacylglycerol O-acyltransferase 1

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of DGAT1 mRNA; [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DGAT1 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DGAT1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DGAT1 mRNA]
Dexamethasone results in increased expression of DGAT1 mRNA

PMID:16054899 PMID:23428407 PMID:25047013

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016

G

diacylglycerol O-acyltransferase 2

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of DGAT2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DGAT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DGAT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of DGAT2 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of DGAT2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of DGAT2 mRNA]

PMID:20032058 PMID:23428407 PMID:25047013 PMID:28628672 PMID:31053639

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566

G

DiGeorge syndrome critical region gene 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DGCR2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DGCR2 mRNA

NCBI chr11:96,598,247...96,648,791
Ensembl chr11:96,597,197...96,648,786

G

DGCR8 microprocessor complex subunit

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of DGCR8 mRNA
Dexamethasone promotes the reaction [NR3C1 protein binds to DGCR8 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of DGCR8 mRNA]

NCBI chr11:96,208,959...96,241,560
Ensembl chr11:96,209,038...96,241,551

G

diacylglycerol kinase, alpha

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DGKA mRNA

NCBI chr 7:1,733,247...1,761,181
Ensembl chr 7:1,733,248...1,759,569

G

24-dehydrocholesterol reductase

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DHCR24 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of DHCR24 mRNA

PMID:25047013 PMID:28628672

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

dehydrogenase/reductase 3

multiple interactions

ISO

[Dexamethasone co-treated with Genistein] results in increased expression of DHRS3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DHRS3 mRNA

PMID:25136773 PMID:28628672

NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653

G

dehydrogenase/reductase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DHRS7 mRNA

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744

G

dehydrogenase/reductase 7C

increases expression

ISO

Dexamethasone results in increased expression of DHRS7C mRNA

NCBI chr10:52,994,205...53,012,281
Ensembl chr10:52,994,205...53,012,281

G

DEAH-box helicase 37

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DHX37 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DHX37 mRNA

NCBI chr12:36,856,119...36,876,245
Ensembl chr12:36,849,701...36,876,240

G

DEAH-box helicase 38

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DHX38 mRNA

NCBI chr19:54,422,418...54,439,434
Ensembl chr19:54,422,418...54,439,423

G

DEXH-box helicase 58

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DHX58 mRNA

NCBI chr10:86,120,677...86,132,095
Ensembl chr10:86,120,677...86,131,844

G

diablo, IAP-binding mitochondrial protein

affects localization
multiple interactions

ISO

Dexamethasone affects the localization of DIABLO protein
[GCS-100 co-treated with Dexamethasone] affects the localization of DIABLO protein

PMID:12855565 PMID:16166312

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

diaphanous-related formin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DIAPH1 mRNA

NCBI chr18:29,920,889...30,020,280
Ensembl chr18:29,920,889...30,020,280

G

diaphanous-related formin 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DIAPH3 mRNA

NCBI chr15:68,951,992...69,421,623
Ensembl chr15:68,951,989...69,421,552

G

dicer 1 ribonuclease III

increases expression

ISO
EXP

Dexamethasone results in increased expression of DICER1 mRNA

NCBI chr 6:129,392,298...129,457,252
Ensembl chr 6:129,396,014...129,457,252

G

death inducer-obliterator 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DIDO1 mRNA

NCBI chr 3:188,150,100...188,203,445
Ensembl chr 3:188,150,100...188,194,823

G

iodothyronine deiodinase 1

multiple interactions

ISO

Dexamethasone inhibits the reaction [Ovalbumin results in increased expression of DIO1 mRNA]

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

iodothyronine deiodinase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DIO2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DIO2 mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of DIO2 mRNA; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of DIO2 mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of DIO2 mRNA

PMID:28628672 PMID:29288687 PMID:32417366

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

iodothyronine deiodinase 3

decreases activity

ISO

Dexamethasone results in decreased activity of DIO3 protein

NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985

G

DIRAS family GTPase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DIRAS1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of DIRAS1 mRNA

NCBI chr 7:9,338,660...9,343,524
Ensembl chr 7:9,327,335...9,347,881

G

DIRAS family GTPase 2

increases expression

ISO

Dexamethasone results in increased expression of DIRAS2 mRNA

NCBI chr17:12,882,224...12,913,366
Ensembl chr17:12,880,385...12,914,291

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions
increases expression
affects response to substance

ISO

Dexamethasone promotes the reaction [NR3C1 protein binds to DKK1 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of DKK1 mRNA]; NR3C1 protein inhibits the reaction [Dexamethasone results in increased expression of DKK1 mRNA]
DKK1 protein affects the susceptibility to Dexamethasone

PMID:22048647 PMID:25047013

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

dickkopf WNT signaling pathway inhibitor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DKK3 mRNA

NCBI chr 1:175,672,834...175,715,867
Ensembl chr 1:175,672,834...175,715,186

G

dihydrolipoamide S-acetyltransferase

increases expression

ISO

Dexamethasone results in increased expression of DLAT mRNA

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:59,868,214...59,900,818
Ensembl chr 1:59,868,214...59,900,818

G

DLC1 Rho GTPase activating protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] affects the expression of DLC1 mRNA

NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819

G

dihydrolipoamide dehydrogenase

decreases expression

ISO

Dexamethasone results in decreased expression of DLD protein

NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354

G

discs large MAGUK scaffold protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DLG1 mRNA

NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797

G

discs large MAGUK scaffold protein 4

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DLG4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DLG4 mRNA
Dexamethasone results in increased expression of DLG4 protein

PMID:28628672 PMID:34189720

NCBI chr10:55,239,397...55,267,780
Ensembl chr10:55,236,869...55,265,839

G

DLG associated protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DLGAP4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DLGAP4 mRNA

NCBI chr 3:165,584,271...165,731,868
Ensembl chr 3:165,584,360...165,730,604

G

delta like non-canonical Notch ligand 1

increases expression
decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of DLK1 mRNA
Dexamethasone results in decreased expression of DLK1 mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of DLK1 mRNA; silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of DLK1 mRNA]

PMID:23166830 PMID:25559859 PMID:25851902

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

delta like non-canonical Notch ligand 2

increases expression

ISO

Dexamethasone results in increased expression of DLK2 mRNA

NCBI chr 9:22,174,667...22,179,149
Ensembl chr 9:22,173,158...22,179,149

G

distal-less homeobox 5

decreases expression

ISO

Dexamethasone results in decreased expression of DLX5 mRNA

NCBI chr 4:35,965,579...35,969,973
Ensembl chr 4:35,965,579...35,969,845

G

DNA methyltransferase 1-associated protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DMAP1 mRNA

NCBI chr 5:136,380,211...136,388,229
Ensembl chr 5:136,380,216...136,388,219

G

dermokine

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DMKN mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of DMKN mRNA

PMID:25047013 PMID:28628672

NCBI chr 1:95,140,737...95,158,676
Ensembl chr 1:95,141,620...95,157,439

G

dentin matrix acidic phosphoprotein 1

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]

PMID:25932594 PMID:35738543

NCBI chr14:5,833,111...5,867,154
Ensembl chr14:5,833,111...5,843,993

G

cyclin D binding myb-like transcription factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DMTF1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DMTF1 mRNA

NCBI chr 4:25,864,891...25,905,916
Ensembl chr 4:25,865,447...25,905,943

G

dynein axonemal assembly factor 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAAF11 mRNA

NCBI chr 7:100,033,843...100,134,979
Ensembl chr 7:100,034,202...100,135,179

G

dynein axonemal assembly factor 19

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAAF19 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAAF19 mRNA

NCBI chr10:88,346,453...88,349,853
Ensembl chr10:88,346,453...88,349,853

G

dynein, axonemal, assembly factor 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAAF5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DNAAF5 mRNA

NCBI chr12:20,567,482...20,606,600
Ensembl chr12:20,531,267...20,607,607

G

dynein, axonemal, heavy chain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNAH1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAH1 mRNA

NCBI chr16:6,462,419...6,523,545
Ensembl chr16:6,462,419...6,524,760

G

dynein, axonemal, heavy chain 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DNAH11 mRNA

NCBI chr 6:144,982,130...145,298,523
Ensembl chr 6:144,973,797...145,298,692

G

dynein, axonemal, heavy chain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAH2 mRNA

NCBI chr10:54,641,450...54,766,502
Ensembl chr10:54,641,450...54,766,026

G

DnaJ heat shock protein family (Hsp40) member A1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DNAJA1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAJA1 mRNA

PMID:17998272 PMID:28628672

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

DnaJ heat shock protein family (Hsp40) member A4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJA4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJA4 mRNA

NCBI chr 8:63,975,177...63,998,836
Ensembl chr 8:63,981,559...63,998,836

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJB5 mRNA

NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DNAJB9 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DNAJB9 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DNAJB9 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJB9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJB9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DNAJB9 mRNA
Dexamethasone results in increased expression of DNAJB9 mRNA

PMID:16054899 PMID:17998272 PMID:28628672

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344

G

DnaJ heat shock protein family (Hsp40) member C14

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJC14 mRNA

NCBI chr 7:1,818,360...1,831,642
Ensembl chr 7:1,820,247...1,831,658

G

DnaJ heat shock protein family (Hsp40) member C19

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJC19 mRNA

NCBI chr 2:118,851,497...118,875,813
Ensembl chr 2:118,869,413...118,873,781

G

DnaJ heat shock protein family (Hsp40) member C27

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJC27 mRNA

NCBI chr 6:32,788,215...32,842,418
Ensembl chr 6:32,788,184...32,817,940

G

DnaJ heat shock protein family (Hsp40) member C4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAJC4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJC4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DNAJC4 mRNA

NCBI chr 1:213,607,397...213,611,614
Ensembl chr 1:213,607,399...213,611,729

G

dynein, axonemal, light chain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DNAL1 mRNA

NCBI chr 6:109,478,941...109,515,201
Ensembl chr 6:109,478,858...109,513,148

G

dynein, axonemal, light chain 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DNAL4 mRNA

NCBI chr 7:113,192,807...113,205,665
Ensembl chr20:21,722,009...21,723,262
Ensembl chr 7:21,722,009...21,723,262

G

dynein heavy chain domain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNHD1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DNHD1 mRNA

NCBI chr 1:169,402,615...169,486,684
Ensembl chr 1:169,394,884...169,487,646

G

dynamin 1-like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNM1L mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA; [rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA

PMID:28628672 PMID:29288687

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

DNA methyltransferase 1

multiple interactions

ISO

[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of DNMT1 mRNA

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 alpha

multiple interactions

ISO

[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of DNMT3A mRNA

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

DNA methyltransferase 3 beta

multiple interactions

ISO

[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of DNMT3B mRNA

NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313

G

DNA nucleotidylexotransferase

decreases expression

ISO

Dexamethasone results in decreased expression of DNTT mRNA

NCBI chr 1:249,805,802...249,837,685
Ensembl chr 1:249,805,802...249,837,684

G

dedicator of cytokinesis 11

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of DOCK11 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of DOCK11 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DOCK11 mRNA

PMID:25047013 PMID:28628672

NCBI chr X:119,997,523...120,180,643
Ensembl chr X:119,997,552...120,180,634

G

dedicator of cytokinesis 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOCK7 mRNA

NCBI chr 5:118,714,863...118,898,362
Ensembl chr 5:118,714,863...118,898,335

G

docking protein 1

increases expression

ISO

Dexamethasone results in increased expression of DOK1 mRNA

NCBI chr 4:117,095,171...117,098,251
Ensembl chr 4:117,095,175...117,097,825

G

docking protein 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DOK5 mRNA

NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:179,934,552...180,071,333

G

dolichol kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOLK mRNA

NCBI chr 3:33,955,642...33,957,680
Ensembl chr 3:33,954,308...33,958,365

G

dolichyldiphosphatase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOLPP1 mRNA

NCBI chr 3:34,063,825...34,072,133
Ensembl chr 3:34,063,825...34,072,132

G

DNA replication fork stabilization factor DONSON

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DONSON mRNA

NCBI chr11:44,405,794...44,419,099
Ensembl chr11:44,405,804...44,418,791

G

dolichyl-phosphate N-acetylglucosaminephosphotransferase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DPAGT1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DPAGT1 mRNA

NCBI chr 8:53,560,869...53,567,625
Ensembl chr 8:53,555,239...53,567,898

G

dipeptidase 1

increases expression

ISO

Dexamethasone results in increased expression of DPEP1 mRNA

NCBI chr19:68,118,270...68,143,781
Ensembl chr19:68,118,453...68,143,775

G

double PHD fingers 1

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPF1 mRNA

NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:93,726,970...93,743,425

G

dolichyl-phosphate mannosyltransferase subunit 2, regulatory

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DPM2 mRNA

NCBI chr 3:36,253,548...36,256,592

G

dolichyl-phosphate mannosyltransferase subunit 3, regulatory

increases expression

ISO

Dexamethasone results in increased expression of DPM3 mRNA

NCBI chr 2:176,974,290...176,974,805
Ensembl chr15:52,612,418...52,612,696

G

dipeptidyl peptidase 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DPP9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DPP9 mRNA

NCBI chr 9:1,098,505...1,133,500
Ensembl chr 9:1,095,929...1,177,715

G

developmental pluripotency-associated 2

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPPA2 mRNA

NCBI chr11:66,008,002...66,020,044
Ensembl chr11:66,011,628...66,020,994

G

dermatopontin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of DPT mRNA

NCBI chr13:79,656,341...79,684,759
Ensembl chr13:79,655,985...79,684,758

G

dihydropyrimidinase-like 3

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of DPYSL3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of DPYSL3 mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr18:35,625,357...35,731,152
Ensembl chr18:35,625,357...35,731,152

G

dihydropyrimidinase-like 4

decreases expression

ISO

Dexamethasone results in decreased expression of DPYSL4 mRNA

NCBI chr 1:203,312,646...203,328,523
Ensembl chr 1:203,311,694...203,328,523

G

DNA damage regulated autophagy modulator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DRAM2 mRNA

NCBI chr 2:196,724,052...196,752,645
Ensembl chr 2:196,723,858...196,755,103

G

Dr1 associated protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DRAP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DRAP1 mRNA

NCBI chr 1:212,161,107...212,163,833
Ensembl chr 1:212,161,125...212,163,762

G

developmentally regulated GTP binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DRG2 mRNA

NCBI chr10:45,755,072...45,769,493
Ensembl chr10:45,755,059...45,769,523

G

desmoplakin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of DSP mRNA

NCBI chr17:26,829,153...26,877,419
Ensembl chr17:26,829,153...26,877,121

G

dentin sialophosphoprotein

multiple interactions

ISO

[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA]

NCBI chr14:5,870,232...5,876,339
Ensembl chr14:5,870,232...5,876,339

G

dystonin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DST mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DST mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DST mRNA

NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533

G

dystrobrevin, alpha

increases expression

ISO

Dexamethasone results in increased expression of DTNA mRNA

NCBI chr18:14,862,801...15,218,993
Ensembl chr18:14,862,818...15,218,993

G

dystrobrevin, beta

increases expression

ISO

Dexamethasone results in increased expression of DTNB mRNA

NCBI chr 6:32,286,022...32,483,007
Ensembl chr 6:32,285,941...32,485,872

G

deltex E3 ubiquitin ligase 4

increases expression

ISO

Dexamethasone results in increased expression of DTX4 mRNA

NCBI chr 1:218,882,391...218,969,837
Ensembl chr 1:218,832,284...218,917,130

G

dual specificity phosphatase 1

multiple interactions
increases expression

ISO
EXP

Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of DUSP1 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of DUSP1 protein]; Dexamethasone inhibits the reaction [Ovalbumin results in decreased expression of DUSP1 protein]; Dexamethasone promotes the reaction [Ovalbumin results in increased expression of DUSP1 mRNA]; Dexamethasone promotes the reaction [Ovalbumin results in increased expression of DUSP1 protein modified form]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1RN mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 protein]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; DUSP1 gene mutant form promotes the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]]; DUSP1 protein promotes the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK14 protein]]; DUSP1 protein promotes the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK8 protein]]
Dexamethasone results in increased expression of DUSP1 mRNA; Dexamethasone results in increased expression of DUSP1 protein
[diisononyl phthalate co-treated with Diethylhexyl Phthalate] promotes the reaction [Dexamethasone results in increased expression of DUSP1 mRNA]; [Mifepristone co-treated with Dexamethasone] results in decreased expression of DUSP1 mRNA; [monobutyl phthalate co-treated with Dexamethasone] results in increased expression of DUSP1 mRNA; diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of DUSP1 mRNA]; Estradiol inhibits the reaction [Dexamethasone results in increased expression of DUSP1 mRNA]

PMID:16144937 PMID:16880258 PMID:22733784 PMID:23183181 PMID:24188200 More...

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 2

decreases expression
increases expression

ISO

Dexamethasone results in decreased expression of DUSP2 mRNA
Dexamethasone results in increased expression of DUSP2 mRNA

PMID:21041162 PMID:22733784

NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809

G

dual specificity phosphatase 28

increases expression

ISO

Dexamethasone results in increased expression of DUSP28 mRNA

NCBI chr 9:100,920,249...100,921,624
Ensembl chr 9:100,920,249...100,921,624

G

dual specificity phosphatase 4

decreases expression

ISO

Dexamethasone results in decreased expression of DUSP4 mRNA

NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700

G

dual specificity phosphatase 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DUSP5 mRNA

NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417

G

dual specificity phosphatase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 8

multiple interactions

ISO

Dexamethasone affects the reaction [[DUSP8 protein affects the susceptibility to Dietary Fats] which affects the abundance of Corticosterone]

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

dual specificity phosphatase 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DUSP9 mRNA

NCBI chr X:156,503,237...156,507,162
Ensembl chr X:156,503,190...156,507,161

G

dishevelled segment polarity protein 2

multiple interactions

ISO

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DVL2 mRNA

PMID:28285642 PMID:28628672

NCBI chr10:55,222,245...55,231,506
Ensembl chr10:55,222,056...55,231,506

G

dynactin associated protein

decreases expression

ISO

Dexamethasone results in decreased expression of DYNAP mRNA

NCBI chr18:66,160,548...66,227,999
Ensembl chr18:66,160,548...66,184,843

G

dynein cytoplasmic 1 heavy chain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DYNC1H1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DYNC1H1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of DYNC1H1 mRNA

NCBI chr 6:135,436,375...135,502,117
Ensembl chr 6:135,430,750...135,502,116

G

dynein cytoplasmic 1 intermediate chain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA

NCBI chr 3:76,441,621...76,492,782
Ensembl chr 3:76,424,469...76,492,782

G

dynein light chain LC8-type 1

decreases expression

ISO

Dexamethasone results in decreased expression of DYNLL1 mRNA

NCBI chr12:46,945,291...46,976,867
Ensembl chr12:46,973,050...46,976,861

G

dynein light chain Tctex-type 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYNLT3 mRNA

NCBI chr X:16,000,425...16,009,632
Ensembl chr X:16,000,395...16,009,627

G

dual specificity tyrosine phosphorylation regulated kinase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK2 mRNA

NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:56,235,276...56,265,942

G

dual specificity tyrosine phosphorylation regulated kinase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK4 mRNA

NCBI chr 4:161,401,580...161,443,816
Ensembl chr 4:161,401,580...161,443,791

G

DAZ interacting zinc finger protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DZIP3 mRNA

NCBI chr11:65,286,190...65,356,314
Ensembl chr11:65,286,190...65,356,314

G

E2F transcription factor 2

decreases expression

ISO

Dexamethasone results in decreased expression of E2F2 mRNA

NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087

G

E2F-associated phosphoprotein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EAPP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EAPP mRNA

NCBI chr 6:77,879,634...77,929,653
Ensembl chr 6:77,907,485...77,928,930

G

EBF transcription factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EBF1 mRNA

NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702

G

EBF transcription factor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EBF3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EBF3 mRNA

NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305

G

ethylmalonyl-CoA decarboxylase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ECHDC1 mRNA

NCBI chr 1:30,304,968...30,355,957
Ensembl chr 1:30,304,971...30,337,208

G

extracellular matrix protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ECM2 mRNA

NCBI chr17:15,326,359...15,358,938
Ensembl chr17:15,326,359...15,358,855

G

ectodysplasin-A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDA mRNA

NCBI chr X:69,118,577...69,520,274
Ensembl chr X:69,118,796...69,520,274

G

EDAR associated via death domain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EDARADD mRNA

NCBI chr17:92,850,791...92,894,808
Ensembl chr17:92,831,613...92,894,361

G

enhancer of mRNA decapping 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDC3 mRNA

NCBI chr 8:67,002,032...67,047,563
Ensembl chr 8:67,002,014...67,047,559

G

ER degradation enhancing alpha-mannosidase like protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EDEM1 mRNA

NCBI chr 4:143,350,989...143,385,693
Ensembl chr 4:143,353,624...143,388,060

G

ER degradation enhancing alpha-mannosidase like protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA

NCBI chr 3:164,661,741...164,687,559
Ensembl chr 3:164,661,742...164,687,559

G

ER degradation enhancing alpha-mannosidase like protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM3 mRNA

NCBI chr13:66,403,022...66,470,496
Ensembl chr13:66,408,590...66,472,270

G

endothelin 1

decreases expression
increases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of EDN1 mRNA
Dexamethasone results in increased expression of EDN1 mRNA
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of EDN1 mRNA; Dexamethasone inhibits the reaction [nitrofen results in decreased expression of EDN1 mRNA]; Dexamethasone inhibits the reaction [nitrofen results in decreased expression of EDN1 protein]

PMID:12206003 PMID:12407540 PMID:16054899 PMID:22733784

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

decreases expression

ISO

Dexamethasone results in decreased expression of EDNRA mRNA

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

multiple interactions

EXP
ISO

Dexamethasone promotes the reaction [nitrofen results in increased expression of EDNRB mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA

PMID:10693666 PMID:28628672

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF1A1 mRNA

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072

G

eukaryotic translation elongation factor 1 alpha 2

increases expression
decreases expression

ISO

Dexamethasone results in increased expression of EEF1A2 mRNA
Dexamethasone results in decreased expression of EEF1A2 protein

PMID:16144937 PMID:33567340

NCBI chr 3:188,643,455...188,652,633
Ensembl chr 3:188,643,458...188,677,712

G

EEF1A lysine methyltransferase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of N6AMT2 mRNA

NCBI chr15:35,809,842...35,826,921
Ensembl chr15:35,809,842...35,827,129

G

eukaryotic translation elongation factor 1 beta 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF1B2 mRNA

NCBI chr 9:72,074,091...72,076,591
Ensembl chr 9:72,073,802...72,076,589

G

eukaryotic translation elongation factor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EEF2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EEF2 mRNA

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544

G

endonuclease/exonuclease/phosphatase family domain containing 1

increases expression

ISO

Dexamethasone results in increased expression of EEPD1 mRNA

NCBI chr 8:32,233,834...32,340,148
Ensembl chr 8:32,233,070...32,340,147

G

EGF containing fibulin extracellular matrix protein 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of EFEMP1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EFEMP1 mRNA

PMID:25047013 PMID:28628672

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808

G

ephrin B1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EFNB1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EFNB1 mRNA

NCBI chr X:68,297,529...68,310,335
Ensembl chr X:68,297,492...68,349,546

G

embryonal Fyn-associated substrate

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EFS mRNA

NCBI chr15:32,362,401...32,374,490
Ensembl chr15:32,361,843...32,371,743

G

elongation factor Tu GTP binding domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EFTUD2 mRNA

NCBI chr10:88,304,992...88,352,229
Ensembl chr10:88,304,992...88,346,299

G

epidermal growth factor

multiple interactions

ISO
EXP

Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]; Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]; Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of CCND1 protein]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of MAPK1 protein modified form]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of MAPK3 protein modified form]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAPK8 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAPK8 protein]]
[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of AHR mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCL2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CCN5 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CP mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL12 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CXCL5 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of EMP1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of IFI47 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of IFNAR2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of KLF4 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of TIMP1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ANGPTL4 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CDO1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DGAT1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of DNAJB9 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ENPP2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of EPHX2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of GADD45G mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of HP mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP3 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MAPK4 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of NAMPT mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN2 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PTP4A1 mRNA]; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of TOB1 mRNA]; AG 1879 inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]; EGF protein inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of ARHGAP5 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CALML4 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of CLEC3B mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FAS mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FGF7 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of IIGP1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of KLF5 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of MARCKS mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of PDGFRB mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of PLTP mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of TNFRSF11B mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACSL1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of GPAM mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of HK2 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IRS2 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MGST1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ORM1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ORM2 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ORM3 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC4A4 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SREBF1 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of TEAD4 mRNA]; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of XDH mRNA]; EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]; EGF protein promotes the reaction [Vanadates inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]; methyl-beta-cyclodextrin inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]; U 0126 inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]
Dexamethasone inhibits the reaction [EGF protein results in increased expression of FOS mRNA]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of MT1A mRNA]; Dexamethasone promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]

PMID:7705776 PMID:10807665 PMID:12632255 PMID:16054899 PMID:16971554 More...

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

EGF-like, fibronectin type III and laminin G domains

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of EGFLAM mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EGFLAM mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EGFLAM mRNA

PMID:25047013 PMID:28628672

NCBI chr 2:58,029,934...58,204,010
Ensembl chr 2:58,029,935...58,203,643

G

epidermal growth factor receptor

multiple interactions

ISO
EXP

Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]; Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]; Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]; Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]]
Dexamethasone results in decreased phosphorylation of and results in decreased activity of EGFR protein

PMID:10807665 PMID:15556944

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions
decreases expression

EXP
ISO

Dexamethasone promotes the reaction [1-Naphthylisothiocyanate results in increased expression of EGR1 mRNA]; Dexamethasone promotes the reaction [EGR1 protein results in increased expression of PNMT mRNA]
Dexamethasone results in decreased expression of EGR1 mRNA

PMID:8063705 PMID:18590720 PMID:21041162

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

decreases expression

ISO

Dexamethasone results in decreased expression of EGR2 mRNA

PMID:21041162 PMID:22733784 PMID:25047013

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

early growth response 3

decreases expression

ISO

Dexamethasone results in decreased expression of EGR3 mRNA

NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712

G

EH domain binding protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EHBP1 mRNA

NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579

G

EH-domain containing 3

increases expression

ISO

Dexamethasone results in increased expression of EHD3 mRNA

NCBI chr 6:27,392,709...27,417,445
Ensembl chr 6:27,392,709...27,417,445

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

decreases expression

EXP

Dexamethasone results in decreased expression of EHHADH mRNA

NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662

G

EI24, autophagy associated transmembrane protein

increases expression

ISO

Dexamethasone results in increased expression of EI24 mRNA

NCBI chr 8:44,683,138...44,699,502
Ensembl chr 8:44,683,144...44,695,214

G

EP300 interacting inhibitor of differentiation 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EID2 mRNA

NCBI chr 1:92,665,837...92,667,162
Ensembl chr 1:92,665,481...92,675,307

G

EP300 interacting inhibitor of differentiation 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EID3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EID3 mRNA

NCBI chr 7:22,747,645...22,748,967
Ensembl chr 7:22,747,656...22,749,177

G

eukaryotic translation initiation factor 1A domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF1AD mRNA

NCBI chr 1:212,103,715...212,109,015
Ensembl chr 1:212,103,892...212,109,017

G

eukaryotic translation initiation factor 2B subunit epsilon

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF2B5 mRNA

NCBI chr11:93,898,814...93,909,431
Ensembl chr11:93,898,814...93,908,800

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

ISO

Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2S1 mRNA]; PIK3R1 protein affects the reaction [Dexamethasone results in increased phosphorylation of EIF2S1 protein]

PMID:27660012 PMID:33567340

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF3A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EIF3A mRNA

NCBI chr 1:269,888,730...269,925,785
Ensembl chr 1:269,888,615...269,919,025

G

eukaryotic translation initiation factor 3, subunit L

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF3L mRNA

NCBI chr 7:112,522,222...112,544,063
Ensembl chr 7:112,507,831...112,544,062

G

eukaryotic translation initiation factor 4E

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4E mRNA

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

eukaryotic translation initiation factor 4E binding protein 1

increases expression
multiple interactions
decreases phosphorylation

EXP
ISO

Dexamethasone results in increased expression of EIF4EBP1 mRNA; Dexamethasone results in increased expression of EIF4EBP1 protein
[pomalidomide co-treated with Dexamethasone] results in decreased phosphorylation of EIF4EBP1 protein; afuresertib promotes the reaction [[pomalidomide co-treated with Dexamethasone] results in decreased phosphorylation of EIF4EBP1 protein]
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of EIF4EBP1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of EIF4EBP1 protein; Dexamethasone inhibits the reaction [INS1 protein results in increased phosphorylation of EIF4EBP1 protein]; dorsomorphin inhibits the reaction [14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of EIF4EBP1 protein]]; PIK3R1 protein affects the reaction [Dexamethasone inhibits the reaction [INS1 protein results in increased phosphorylation of EIF4EBP1 protein]]
Dexamethasone results in decreased phosphorylation of EIF4EBP1 protein
Testosterone inhibits the reaction [Dexamethasone results in increased expression of EIF4EBP1 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of EIF4EBP1 protein]

PMID:20032058 PMID:22936724 PMID:29928335 PMID:30248417 PMID:33567340

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 4E binding protein 2

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of EIF4EBP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4EBP2 mRNA

PMID:22733784 PMID:28628672

NCBI chr20:29,922,260...29,942,922
Ensembl chr20:29,922,260...29,942,922

G

eukaryotic translation initiation factor 4E nuclear import factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4ENIF1 mRNA

NCBI chr14:82,280,566...82,328,559
Ensembl chr14:82,280,748...82,323,242

G

eukaryotic translation initiation factor 4 gamma 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EIF4G1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4G1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EIF4G1 mRNA

NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367

G

eukaryotic translation initiation factor 4, gamma 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4G2 mRNA

NCBI chr 1:174,616,102...174,628,252
Ensembl chr 1:174,616,103...174,628,252

G

eukaryotic translation initiation factor 4 gamma, 3

increases expression
multiple interactions

EXP

Dexamethasone results in increased expression of EIF4G3 mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of EIF4G3 mRNA]

NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194

G

eukaryotic translation initiation factor 4H

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4H mRNA

NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346

G

eukaryotic translation initiation factor 5A2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EIF5A2 mRNA

NCBI chr 2:113,656,748...113,674,598
Ensembl chr 2:113,657,797...113,674,594

G

eukaryotic translation initiation factor 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EIF6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF6 mRNA

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

elaC ribonuclease Z 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ELAC1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ELAC1 mRNA

NCBI chr18:69,596,475...69,617,206
Ensembl chr18:69,598,827...69,616,175

G

elastase, neutrophil expressed

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ELANE mRNA

NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:10,467,877...10,469,725

G

endosome-lysosome associated apoptosis and autophagy regulator family member 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ELAPOR2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ELAPOR2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ELAPOR2 mRNA

NCBI chr 4:25,565,298...25,760,684
Ensembl chr 4:25,568,122...25,760,684

G

ELAV like RNA binding protein 1

increases expression

EXP

Dexamethasone results in increased expression of ELAVL1 mRNA

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

E74 like ETS transcription factor 5

multiple interactions
decreases expression

ISO

[Dexamethasone co-treated with Genistein] results in decreased expression of ELF5 mRNA
Dexamethasone results in decreased expression of ELF5 mRNA

NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926

G

extracellular leucine-rich repeat and fibronectin type III domain containing 1

decreases expression

ISO

Dexamethasone results in decreased expression of ELFN1 mRNA

NCBI chr12:19,773,911...19,839,375
Ensembl chr12:19,772,908...19,841,961

G

engulfment and cell motility 1

increases expression

ISO

Dexamethasone results in increased expression of ELMO1 mRNA

NCBI chr17:48,982,188...49,518,525
Ensembl chr17:48,982,188...49,518,159

G

engulfment and cell motility 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ELMO2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ELMO2 mRNA

NCBI chr 3:174,442,965...174,716,723
Ensembl chr 3:174,442,965...174,480,459

G

ELMO domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ELMOD2 mRNA

NCBI chr19:41,690,713...41,710,194
Ensembl chr19:41,690,762...41,710,194
Ensembl chr18:41,690,762...41,710,194

G

ELMO domain containing 3

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ELMOD3 mRNA

NCBI chr 4:106,172,819...106,211,286
Ensembl chr 4:106,172,828...106,211,229

G

elastin

affects expression

ISO

Dexamethasone affects the expression of ELN mRNA

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413

G

ELOVL fatty acid elongase 3

multiple interactions

ISO

[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA; [Roscovitine co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL3 mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL3 mRNA; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL3 mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL3 mRNA; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA]

PMID:17726147 PMID:34323617

NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:254,938,731...254,942,559

G

ELOVL fatty acid elongase 5

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ELOVL5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ELOVL5 mRNA

PMID:25047013 PMID:28628672

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ELOVL fatty acid elongase 6

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of ELOVL6 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ELOVL6 mRNA
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ELOVL6 mRNA

PMID:16054899 PMID:25047013 PMID:28628672

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549

G

elongator acetyltransferase complex subunit 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ELP4 mRNA

NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963

G

embigin

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of EMB mRNA

NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:50,801,973...50,862,920

G

ER membrane protein complex subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EMC1 mRNA

NCBI chr 5:156,891,773...156,917,092
Ensembl chr 5:156,891,773...156,917,092

G

ER membrane protein complex subunit 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EMC9 mRNA

NCBI chr15:33,041,840...33,046,056
Ensembl chr15:33,041,842...33,046,102

G

EMG1 N1-specific pseudouridine methyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EMG1 mRNA

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

elastin microfibril interfacer 2

increases expression

ISO

Dexamethasone results in increased expression of EMILIN2 mRNA

NCBI chr 9:118,607,312...118,667,087
Ensembl chr 9:118,606,891...118,666,957

G

EMAP like 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EML4 mRNA

NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439

G

epithelial membrane protein 1

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of EMP1 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of EMP1 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of EMP1 mRNA]
Dexamethasone results in increased expression of EMP1 mRNA

PMID:16054899 PMID:25047013

NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365

G

epithelial membrane protein 2

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EMP2 mRNA

PMID:16997883 PMID:28628672

NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532

G

empty spiracles homeobox 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EMX2 mRNA

NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671

G

Emx2 opposite strand/antisense RNA

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EMX2OS mRNA

NCBI chr 1:268,555,719...268,612,889

G

engrailed homeobox 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EN1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EN1 mRNA
Dexamethasone results in increased expression of EN1 mRNA

PMID:28628672 PMID:34742744

NCBI chr13:34,303,684...34,309,269
Ensembl chr13:34,303,702...34,309,269

G

endonuclease domain containing 1

decreases expression

ISO

Dexamethasone results in decreased expression of ENDOD1 mRNA

NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:19,490,615...19,520,007

G

endonuclease G

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ENDOG mRNA

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573

G

endoglin

decreases expression

ISO

Dexamethasone results in decreased expression of ENG mRNA

NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933

G

enolase 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ENO1 mRNA
Dexamethasone results in decreased expression of ENO1 protein

PMID:28628672 PMID:33567340

NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003
Ensembl chr 5:77,946,261...77,986,003

G

enolase 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ENO2 mRNA
Dexamethasone results in decreased expression of ENO2 protein

PMID:28628672 PMID:33567340

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

enolase 3

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of ENO3 mRNA
Dexamethasone results in decreased expression of ENO3 protein

PMID:28628672 PMID:33567340

NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,866,101...55,874,540

G

ecto-NOX disulfide-thiol exchanger 1

decreases expression

ISO

Dexamethasone results in decreased expression of ENOX1 mRNA

NCBI chr15:58,924,519...59,488,919
Ensembl chr15:59,215,018...59,488,918

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ENPP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ENPP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ENPP1 mRNA

NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ENPP2 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ENPP2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ENPP2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ENPP2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ENPP2 mRNA
Dexamethasone results in increased expression of ENPP2 mRNA

PMID:16054899 PMID:22733784 PMID:28628672

NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957

G

ectonucleoside triphosphate diphosphohydrolase 4

multiple interactions

EXP
ISO

[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ENTPD4 mRNA

PMID:22341215 PMID:28628672

NCBI chr15:51,040,665...51,068,450
Ensembl chr15:51,040,673...51,068,441

G

ectonucleoside triphosphate diphosphohydrolase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ENTPD6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ENTPD6 mRNA

NCBI chr 3:160,036,055...160,058,580
Ensembl chr 3:160,036,121...160,059,451

G

ENY2, transcription and export complex 2 subunit

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ENY2 mRNA

NCBI chr 7:77,465,885...77,489,637
Ensembl chr 7:77,466,119...77,491,057

G

EGF domain specific O-linked N-acetylglucosamine transferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EOGT mRNA

NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926

G

eomesodermin

affects response to substance
increases expression

ISO

EOMES protein affects the susceptibility to Dexamethasone
Dexamethasone results in increased expression of EOMES mRNA

PMID:26415720 PMID:34742744

NCBI chr 8:127,059,215...127,067,070
Ensembl chr 8:127,059,215...127,067,070

G

E1A binding protein p300

multiple interactions
increases expression

EXP
ISO

Dexamethasone promotes the reaction [EP300 protein binds to SULT1A1 promoter]; Dexamethasone promotes the reaction [NR3C2 protein promotes the reaction [EP300 protein binds to TBX2 promoter]]; EP300 protein promotes the reaction [Dexamethasone results in increased expression of UCP3 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of EP300 mRNA]; SIRT1 protein inhibits the reaction [EP300 protein promotes the reaction [Dexamethasone results in increased expression of UCP3 mRNA]]
Dexamethasone results in increased expression of EP300 mRNA; Dexamethasone results in increased expression of EP300 protein
Dexamethasone promotes the reaction [EP300 protein binds to FOXO3 gene]; Dexamethasone promotes the reaction [EP300 protein binds to PIK3R1 enhancer]; EP300 protein affects the reaction [Dexamethasone results in increased expression of PIK3R1 protein]
[Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to NR3C1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to NR3C1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form]; Dexamethasone promotes the reaction [EP300 protein binds to SLC4A2 promoter]

PMID:17884810 PMID:18188457 PMID:22465009 PMID:26758684 PMID:32494933 More...

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

E1A binding protein p400

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EP400 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EP400 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EP400 mRNA

NCBI chr12:51,551,665...51,658,635
Ensembl chr12:51,551,695...51,658,634

G

erythrocyte membrane protein band 4.1-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EPB41L1 mRNA

NCBI chr 3:165,389,295...165,512,821
Ensembl chr 3:165,389,293...165,510,498

G

erythrocyte membrane protein band 4.1 like 4B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPB41L4B mRNA

NCBI chr 5:76,486,886...76,647,752
Ensembl chr 5:76,486,902...76,647,752

G

enhancer of polycomb homolog 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPC1 mRNA

NCBI chr17:59,198,513...59,289,535
Ensembl chr17:59,197,677...59,289,519

G

Eph receptor A4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EPHA4 mRNA

NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755

G

Eph receptor A7

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of EPHA7 mRNA]

NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058

G

Eph receptor B6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPHB6 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EPHB6 mRNA

NCBI chr 4:71,458,632...71,473,889
Ensembl chr 4:71,458,971...71,476,659

G

epoxide hydrolase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EPHX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EPHX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

epoxide hydrolase 2

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of EPHX2 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of EPHX2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of EPHX2 mRNA]
Dexamethasone results in increased expression of EPHX2 mRNA

PMID:14618091 PMID:16054899

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160

G

erythropoietin

multiple interactions

ISO

Dexamethasone analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein]

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

epiplakin 1

increases expression

ISO

Dexamethasone results in increased expression of EPPK1 mRNA

NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:109,697,607...109,718,468

G

EGFR pathway substrate 8, signaling adaptor

decreases expression
multiple interactions
increases expression

ISO

Dexamethasone results in decreased expression of EPS8 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EPS8 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EPS8 mRNA
Dexamethasone results in increased expression of EPS8 mRNA

PMID:22733784 PMID:25047013 PMID:28628672

NCBI chr 4:172,119,497...172,291,670
Ensembl chr 4:172,119,497...172,218,160

G

eosinophil peroxidase

multiple interactions

EXP
ISO

Dexamethasone inhibits the reaction [sephadex results in increased expression of EPX protein]
[Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of EPX protein]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of EPX protein]

PMID:10850854 PMID:34998855

NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180

G

Era-like 12S mitochondrial rRNA chaperone 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERAL1 mRNA

NCBI chr10:63,459,774...63,466,829
Ensembl chr10:63,459,774...63,468,225

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

increases expression

ISO

Dexamethasone results in increased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

erb-b2 receptor tyrosine kinase 4

increases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of ERBB4 mRNA
Dexamethasone results in increased expression of and results in increased phosphorylation of ERBB4 protein; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of ERBB4 protein]
Dexamethasone results in increased expression of ERBB4 mRNA; Dexamethasone results in increased expression of ERBB4 protein

PMID:16144937 PMID:34189720

NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772

G

ERCC excision repair 4, endonuclease catalytic subunit

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERCC4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERCC4 mRNA

NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,920,455...2,955,539

G

epiregulin

increases expression

ISO

Dexamethasone results in increased expression of EREG mRNA

NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260

G

ERH, mRNA splicing and mitosis factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERH mRNA

NCBI chr 6:106,012,255...106,022,521
Ensembl chr 6:106,012,255...106,022,623

G

ERI1 exoribonuclease family member 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERI3 mRNA

NCBI chr 5:136,252,691...136,379,832
Ensembl chr 5:136,252,683...136,379,815

G

glutamate-rich 2

decreases expression

ISO

Dexamethasone results in decreased expression of ERICH2 mRNA

NCBI chr 3:75,718,573...75,755,447
Ensembl chr 3:75,718,720...75,755,446

G

ER lipid raft associated 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERLIN2 mRNA

NCBI chr16:71,720,486...71,736,999
Ensembl chr16:71,721,364...71,736,503

G

ER membrane-associated RNA degradation

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ERMARD mRNA

NCBI chr 1:64,656,414...64,675,803
Ensembl chr 1:64,656,529...64,675,806

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ISO

Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 mRNA]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 protein]

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

endoplasmic reticulum oxidoreductase 1 alpha

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ERO1A mRNA

NCBI chr15:20,974,771...21,010,170
Ensembl chr15:20,972,679...21,018,039

G

endoplasmic reticulum protein 29

decreases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of ERP29 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERP29 mRNA

PMID:14618091 PMID:28628672

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010

G

ERBB receptor feedback inhibitor 1

increases expression

EXP
ISO

Dexamethasone results in increased expression of ERRFI1 mRNA; Dexamethasone results in increased expression of ERRFI1 protein

PMID:1472065 PMID:15556944 PMID:22733784 PMID:25047013 PMID:25851902

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

esterase D

decreases expression

ISO

Dexamethasone results in decreased expression of ESD mRNA

NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508

G

extra spindle pole bodies like 1, separase

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of ESPL1 mRNA]

NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:135,302,716...135,329,570

G

estrogen receptor 1

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of ESR1 mRNA
[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with Diethylstilbestrol] results in decreased activity of ESR1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ESR1 mRNA; [Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein; Diethylhexyl Phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein]; mono-(2-ethylhexyl)phthalate affects the reaction [[Dexamethasone co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] affects the expression of ESR1 protein]
[Estradiol co-treated with Dexamethasone] results in decreased expression of ESR1 mRNA; [Estradiol co-treated with Dexamethasone] results in decreased expression of ESR1 protein; ESR1 mutant form inhibits the reaction [Estradiol inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]; ESR1 mutant form inhibits the reaction [Genistein inhibits the reaction [Dexamethasone results in increased expression of LEFTY1 mRNA]]; ESR1 mutant form inhibits the reaction [Genistein inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]]; ESR1 mutant form promotes the reaction [Dexamethasone results in increased expression of TSC22D3 mRNA]

PMID:16691199 PMID:19022236 PMID:23183181 PMID:25136773 PMID:26944108 More...

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions
increases expression

ISO

[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of ESR2 protein; [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with Diethylstilbestrol] results in decreased activity of ESR2 protein; fulvestrant inhibits the reaction [[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of ESR2 protein]
[Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ESR2 protein
Dexamethasone results in increased expression of ESR2 mRNA

PMID:26944108 PMID:32976960 PMID:33836827

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

extended synaptotagmin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ESYT1 mRNA

NCBI chr 7:1,513,381...1,530,836
Ensembl chr 7:1,513,381...1,530,732

G

electron transfer flavoprotein subunit alpha

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ETFA mRNA
Dexamethasone results in decreased expression of ETFA protein

PMID:28628672 PMID:33567340

NCBI chr 8:64,731,192...64,787,965
Ensembl chr 8:64,731,193...64,788,080

G

electron transfer flavoprotein subunit beta

increases expression

ISO

Dexamethasone results in increased expression of ETFB protein

NCBI chr 1:102,988,499...103,002,663
Ensembl chr 1:102,988,499...103,002,659

G

electron transfer flavoprotein subunit beta lysine methyltransferase

increases expression

ISO

Dexamethasone results in increased expression of ETFBKMT mRNA

NCBI chr 4:183,871,819...183,936,843
Ensembl chr 4:183,871,827...183,881,621

G

electron transfer flavoprotein dehydrogenase

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ETFDH mRNA

NCBI chr 2:167,038,707...167,060,758
Ensembl chr 2:167,025,823...167,060,770

G

ETS proto-oncogene 1, transcription factor

decreases expression

EXP

Dexamethasone results in decreased expression of ETS1 mRNA

NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021

G

ETS proto-oncogene 2, transcription factor

increases expression
multiple interactions
decreases expression

ISO

Dexamethasone results in increased expression of ETS2 mRNA; Dexamethasone results in increased expression of ETS2 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ETS2 mRNA
Dexamethasone results in decreased expression of ETS2 mRNA

PMID:12732289 PMID:22733784 PMID:28628672

NCBI chr11:48,491,057...48,507,843
Ensembl chr11:48,491,394...48,507,842

G

ETS variant transcription factor 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ETV5 mRNA

NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767

G

eva-1 homolog A, regulator of programmed cell death

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of EVA1A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EVA1A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EVA1A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of EVA1A mRNA

PMID:25047013 PMID:28628672

NCBI chr 4:116,151,595...116,200,827
Ensembl chr 4:116,151,173...116,200,827

G

eva-1 homolog C

increases expression

ISO

Dexamethasone results in increased expression of EVA1C mRNA

NCBI chr11:43,575,613...43,649,677
Ensembl chr11:43,576,332...43,649,834

G

ecotropic viral integration site 2A

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of EVI2A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EVI2A mRNA

PMID:21041162 PMID:28628672

NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516

G

Enah/Vasp-like

multiple interactions
decreases expression

EXP

Testosterone inhibits the reaction [Dexamethasone results in decreased expression of EVL mRNA]

NCBI chr 6:133,238,547...133,358,730
Ensembl chr 6:133,238,547...133,358,729

G

exocyst complex component 2

decreases expression

EXP

Dexamethasone results in decreased expression of EXOC2 mRNA

NCBI chr17:33,714,949...33,906,901
Ensembl chr17:33,715,008...33,901,944

G

exocyst complex component 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EXOC3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EXOC3 mRNA

NCBI chr 1:30,919,871...30,950,624

G

exocyst complex component 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of EXOC7 mRNA

NCBI chr10:102,019,805...102,039,333
Ensembl chr10:102,019,806...102,039,447

G

exocyst complex component 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EXOC8 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EXOC8 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of EXOC8 mRNA

NCBI chr19:69,752,387...69,754,876
Ensembl chr19:69,727,231...69,804,820

G

exosome component 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EXOSC3 mRNA

NCBI chr 5:64,369,495...64,374,711
Ensembl chr 5:64,369,495...64,374,902

G

exostosin glycosyltransferase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EXT2 mRNA

NCBI chr 3:100,120,776...100,253,424
Ensembl chr 3:100,120,776...100,253,596

G

EYA transcriptional coactivator and phosphatase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EYA3 mRNA

NCBI chr 5:150,090,535...150,218,855
Ensembl chr 5:150,137,256...150,218,852

G

EYA transcriptional coactivator and phosphatase 4

affects expression

ISO

Dexamethasone affects the expression of EYA4 mRNA

NCBI chr 1:23,991,431...24,235,132
Ensembl chr 1:23,991,431...24,235,131

G

enhancer of zeste 1 polycomb repressive complex 2 subunit

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of EZH1 mRNA

NCBI chr10:86,626,307...86,662,257
Ensembl chr10:86,626,308...86,652,620

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 protein; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA]

NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183

G

F11 receptor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of F11R mRNA

NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816

G

coagulation factor II, thrombin

multiple interactions
affects expression

ISO
EXP

Dexamethasone promotes the reaction [F2 protein results in increased expression of F3 mRNA]
Dexamethasone affects the expression of F2 mRNA
Dexamethasone affects the expression of F2 protein

PMID:10485340 PMID:11733402 PMID:34742744

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor II (thrombin) receptor

increases expression
multiple interactions
affects expression

ISO
EXP

Dexamethasone results in increased expression of F2R protein
Mifepristone inhibits the reaction [Dexamethasone results in increased expression of F2R mRNA]
Dexamethasone results in increased expression of F2R mRNA; Dexamethasone results in increased expression of F2R protein
Dexamethasone affects the expression of F2R protein

PMID:11733402 PMID:19969022

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579

G

coagulation factor III, tissue factor

multiple interactions
increases expression

ISO
EXP

[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein; [Dexamethasone co-treated with lenalidomide] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide] results in increased expression of F3 protein; Dexamethasone promotes the reaction [F2 protein results in increased expression of F3 mRNA]
Dexamethasone results in increased expression of F3 mRNA; Dexamethasone results in increased expression of F3 protein
Dexamethasone inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of F3 mRNA]

PMID:11733402 PMID:21731756 PMID:23696885 PMID:25047013

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

coagulation factor VII

increases expression

ISO

Dexamethasone results in increased expression of F7 mRNA

NCBI chr16:83,191,896...83,202,775
Ensembl chr16:83,191,914...83,202,738

G

coagulation factor VIII-associated 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of F8A1 mRNA

NCBI chr X:155,977,859...155,979,373
Ensembl chr X:155,976,941...156,108,974

G

fatty acid binding protein 1

decreases expression

EXP

Dexamethasone results in decreased expression of FABP1 mRNA; Dexamethasone results in decreased expression of FABP1 protein

PMID:16924418 PMID:17522070

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid binding protein 3

multiple interactions
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP3 mRNA
Dexamethasone results in increased expression of FABP3 mRNA

PMID:23428407 PMID:25047013

NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881

G

fatty acid binding protein 4

multiple interactions
increases expression

ISO
EXP

2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Dexamethasone] results in increased expression of FABP4 protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Bismuth affects the susceptibility to [INS protein co-treated with Dexamethasone co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine]] which results in decreased expression of FABP4 mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] affects the expression of FABP4 protein; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone co-treated with bisphenol AF] results in increased expression of FABP4 mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of FABP4 mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of FABP4 protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of FABP4 mRNA; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 protein; avobenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Corticosterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; cyclohexylphenylketone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Cyproterone Acetate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; diethyl sulfate inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Diethylhexyl Phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Equilin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Mifepristone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of FABP4 protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Norethindrone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; Norgestrel inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; octocrylene promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; oxybenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Spironolactone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; T 0070907 inhibits the reaction [[Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of FABP4 mRNA]; T 0070907 inhibits the reaction [[triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of FABP4 mRNA]; TGFB1 protein inhibits the reaction [[Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; thiocarbohydrazide inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]
Dexamethasone results in increased expression of FABP4 mRNA; Dexamethasone results in increased expression of FABP4 protein
(+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; (+)-JQ1 compound inhibits the reaction [Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]]; 2,2',3',4,4',5-hexachlorobiphenyl promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 protein]; 2,2',4,4',5-brominated diphenyl ether promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of FABP4 mRNA]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein]; 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 protein; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] affects the expression of FABP4 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 protein; [Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 protein; [INS1 protein co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of FABP4 mRNA; [quinoxyfen co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of FABP4 mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in increased expression of FABP4 mRNA]; bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; bisphenol A promotes the reaction [Dexamethasone results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; butylparaben promotes the reaction [Dexamethasone results in increased expression of FABP4 mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Diethylhexyl Phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; GW 2331 promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; GW0072 promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; MIR155 inhibits the reaction [[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Raloxifene Hydrochloride affects the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 protein]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 protein]; sodium arsenite inhibits the reaction [[INS1 protein co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; T 0070907 inhibits the reaction [[Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; T 0070907 inhibits the reaction [[triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; TGFB1 inhibits the reaction [[Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; TNF inhibits the reaction [[Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; tributyltin promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; triphenyltin chloride promotes the reaction [Dexamethasone results in increased expression of FABP4 protein]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]
[INS co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of FABP4 mRNA

PMID:9543393 PMID:11812925 PMID:15273253 PMID:16054899 PMID:19853017 More...

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fatty acid binding protein 5

multiple interactions
decreases expression
increases expression

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP5 mRNA
Dexamethasone results in decreased expression of FABP5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FABP5 mRNA
Dexamethasone results in increased expression of FABP5 mRNA

PMID:23428407 PMID:25047013 PMID:28628672 PMID:35589016

NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127

G

fatty acid desaturase 1

decreases expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone results in decreased expression of FADS1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FADS1 mRNA
Dexamethasone results in increased expression of FADS1 mRNA

PMID:17522070 PMID:25047013 PMID:28628672

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615

G

fatty acid desaturase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

fatty acid desaturase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FADS3 mRNA

NCBI chr 1:216,110,547...216,127,431
Ensembl chr 1:216,110,201...216,141,758

G

fatty acid desaturase 6

decreases expression

ISO

Dexamethasone results in decreased expression of FADS6 mRNA

NCBI chr10:101,020,921...101,037,281
Ensembl chr10:101,021,960...101,037,160

G

fumarylacetoacetate hydrolase

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of FAH mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FAH mRNA
Testosterone inhibits the reaction [Dexamethasone results in increased expression of FAH mRNA]

PMID:20032058 PMID:28628672

NCBI chr 1:147,957,931...147,980,708
Ensembl chr 1:147,957,935...147,981,046

G

Fas apoptotic inhibitory molecule

increases expression

ISO

Dexamethasone results in increased expression of FAIM mRNA

NCBI chr 8:108,423,259...108,445,365
Ensembl chr 8:108,423,221...108,440,151

G

family with sequence similarity 107, member A

multiple interactions
increases expression

ISO

Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of FAM107A mRNA]

NCBI chr15:19,038,726...19,060,644
Ensembl chr15:19,038,616...19,065,219

G

family with sequence similarity 110, member C

increases expression

ISO

Dexamethasone results in increased expression of FAM110C mRNA

NCBI chr 6:53,366,013...53,372,270
Ensembl chr 6:53,352,870...53,401,117

G

family with sequence similarity 114, member A1

decreases expression

ISO

Dexamethasone results in decreased expression of FAM114A1 mRNA

NCBI chr14:43,629,349...43,699,800
Ensembl chr14:43,629,375...43,699,800

G

family with sequence similarity 114, member A2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM114A2 mRNA

NCBI chr10:42,162,295...42,197,307
Ensembl chr10:42,162,295...42,197,257

G

family with sequence similarity 120 member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FAM120A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM120A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FAM120A mRNA

NCBI chr17:15,890,151...15,981,337
Ensembl chr17:15,890,605...15,981,332

G

family with sequence similarity 120 member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM120B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FAM120B mRNA

NCBI chr 1:64,993,104...65,058,160
Ensembl chr 1:65,012,060...65,058,160

G

family with sequence similarity 133, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FAM133B mRNA

NCBI chr 4:31,544,458...31,571,056
Ensembl chr 4:31,544,458...31,570,780

G

family with sequence similarity 13, member C

decreases expression

ISO

Dexamethasone results in decreased expression of FAM13C mRNA

NCBI chr20:18,064,706...18,186,888
Ensembl chr20:18,064,706...18,286,674

G

family with sequence similarity 162, member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM162A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FAM162A mRNA

NCBI chr11:78,186,260...78,215,186
Ensembl chr11:78,185,852...78,216,560

G

family with sequence similarity 167, member A

decreases expression

ISO

Dexamethasone results in decreased expression of FAM167A mRNA

NCBI chr15:41,861,271...41,891,427
Ensembl chr15:41,861,227...41,891,418

G

family with sequence similarity 171, member A1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FAM171A1 mRNA

NCBI chr17:79,933,742...80,057,495
Ensembl chr17:79,934,050...80,057,495

G

family with sequence similarity 171, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM171B mRNA

NCBI chr 3:89,337,566...89,392,973
Ensembl chr 3:89,337,661...89,392,971

G

family with sequence similarity 180, member A

increases expression

ISO

Dexamethasone results in increased expression of FAM180A mRNA

NCBI chr 4:64,959,999...64,975,176
Ensembl chr 4:64,959,999...64,975,176

G

family with sequence similarity 199, X-linked

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM199X mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM199X mRNA

NCBI chr X:105,176,504...105,212,207
Ensembl chr X:105,176,504...105,212,207

G

FAM20A, golgi associated secretory pathway pseudokinase

decreases expression

ISO

Dexamethasone results in decreased expression of FAM20A mRNA

PMID:22733784 PMID:25047013

NCBI chr10:95,136,799...95,197,176
Ensembl chr10:95,142,458...95,197,053

G

FAM20C, golgi associated secretory pathway kinase

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM20C mRNA
apicidin inhibits the reaction [Dexamethasone results in decreased expression of FAM20C mRNA]; Valproic Acid inhibits the reaction [Dexamethasone results in decreased expression of FAM20C mRNA]

PMID:27645313 PMID:28628672

NCBI chr12:20,940,654...20,999,072
Ensembl chr12:20,940,654...20,998,318

G

family with sequence similarity 210, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM210B mRNA

NCBI chr 3:181,536,665...181,546,830
Ensembl chr 3:181,536,673...181,546,834

G

family with sequence similarity 216, member A

decreases expression

ISO

Dexamethasone results in decreased expression of FAM216A mRNA

NCBI chr12:39,859,307...39,868,450
Ensembl chr12:39,859,172...39,868,442

G

family with sequence similarity 219, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM219B mRNA

NCBI chr 8:66,837,230...66,842,819
Ensembl chr 8:66,837,205...66,842,819

G

family with sequence similarity 222, member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM222A mRNA

NCBI chr12:47,647,221...47,693,703
Ensembl chr12:47,647,405...47,693,703

G

family with sequence similarity 234, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM234B mRNA

NCBI chr 4:169,779,651...169,854,024
Ensembl chr 4:169,779,737...169,828,678

G

family with sequence similarity 241 member A

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FAM241A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM241A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM241A mRNA

PMID:25047013 PMID:28628672

NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770

G

family with sequence similarity 32, member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM32A mRNA

NCBI chr16:17,637,078...17,641,448
Ensembl chr16:17,637,087...17,641,399

G

family with sequence similarity 43, member A

increases expression

ISO

Dexamethasone results in increased expression of FAM43A mRNA

NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297

G

family with sequence similarity 50, member B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM50B mRNA

NCBI chr17:30,379,796...30,399,399
Ensembl chr17:30,379,171...30,399,651

G

family with sequence similarity 76, member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FAM76A mRNA

NCBI chr 5:150,391,460...150,419,526
Ensembl chr 5:150,391,463...150,419,807

G

family with sequence similarity 78, member A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM78A mRNA

NCBI chr 3:35,753,712...35,771,600
Ensembl chr 3:35,753,712...35,770,448

G

family with sequence similarity 83, member H

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM83H mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FAM83H mRNA

NCBI chr 7:109,597,129...109,605,317
Ensembl chr 7:109,597,129...109,609,188

G

family with sequence similarity 91, member A1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FAM91A1 mRNA

NCBI chr 7:91,857,261...91,897,019
Ensembl chr 7:91,859,062...91,898,195

G

family with sequence similarity 98, member C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM98C mRNA

NCBI chr 1:93,580,286...93,583,894
Ensembl chr 1:93,580,287...93,583,831

G

FANCD2 and FANCI associated nuclease 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FAN1 mRNA

NCBI chr 1:127,327,098...127,356,807
Ensembl chr 1:127,330,016...127,356,400

G

FA complementation group I

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FANCI mRNA

NCBI chr 1:142,736,636...142,792,999
Ensembl chr 1:142,736,653...142,792,999

G

FA complementation group L

multiple interactions

ISO

[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA

NCBI chr14:104,449,403...104,515,297
Ensembl chr14:104,394,590...104,515,297

G

fibroblast activation protein, alpha

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FAP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FAP mRNA

NCBI chr 3:67,547,398...67,616,271
Ensembl chr 3:67,546,921...67,617,601

G

fatty acyl CoA reductase 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FAR2 mRNA

NCBI chr 4:182,705,499...182,819,290
Ensembl chr 4:182,705,381...182,825,279

G

phenylalanyl-tRNA synthetase subunit alpha

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FARSA mRNA

NCBI chr19:40,196,255...40,205,830
Ensembl chr19:40,173,716...40,205,823

G

Fas cell surface death receptor

increases expression
decreases expression
multiple interactions

ISO
EXP

Dexamethasone results in increased expression of FAS mRNA; Dexamethasone results in increased expression of FAS protein
Dexamethasone results in decreased expression of FAS mRNA
Dexamethasone results in decreased expression of FAS mRNA; Dexamethasone results in decreased expression of FAS protein
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FAS mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FAS mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FAS mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FAS mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FAS mRNA]
FAS protein inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein]

PMID:11778176 PMID:12513834 PMID:14633444 PMID:16054899 PMID:16164824 More...

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

decreases expression
increases expression
decreases secretion

ISO
EXP

Dexamethasone results in decreased expression of FASLG protein
Dexamethasone results in increased expression of FASL mRNA
Dexamethasone results in decreased expression of FASLG mRNA; Dexamethasone results in decreased expression of FASLG protein
Dexamethasone results in decreased secretion of FASLG protein

PMID:9528991 PMID:11692113 PMID:11778176 PMID:12513834

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fatty acid synthase

increases expression
multiple interactions

EXP
ISO

Dexamethasone results in increased expression of FASN mRNA
[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] affects the expression of FASN mRNA; Dichlorodiphenyl Dichloroethylene promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FASN mRNA]; FASN protein results in decreased susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of FASN mRNA]; monobutyl phthalate inhibits the reaction [Dexamethasone results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]
14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN mRNA]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein; [ANGPTL4 gene mutant form results in increased susceptibility to Dexamethasone] which results in decreased expression of FASN mRNA; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FASN mRNA; [bisphenol A metabolite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FASN mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FASN protein; [Quercetin co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FASN protein; [thermozymocidin results in increased susceptibility to Dexamethasone] which results in decreased expression of FASN mRNA; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN mRNA]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of FASN mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FASN protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]

PMID:17522070 PMID:18586010 PMID:22956630 PMID:25047013 PMID:25559859 More...

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAST kinase domains 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FASTKD2 mRNA

NCBI chr 9:72,659,961...72,681,986
Ensembl chr 9:72,661,764...72,721,338

G

FAT atypical cadherin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FAT1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAT1 mRNA

NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609

G

fatty acid hydroxylase domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAXDC2 mRNA

NCBI chr10:42,747,323...42,772,156
Ensembl chr10:42,747,524...42,781,458

G

fibulin 1

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FBLN1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBLN1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FBLN1 mRNA

PMID:22733784 PMID:28628672

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

fibulin 5

decreases expression

ISO

Dexamethasone results in decreased expression of FBLN5 mRNA

NCBI chr 6:126,664,100...126,742,847
Ensembl chr 6:126,664,100...126,746,296

G

fibrillin 1

decreases expression

ISO

Dexamethasone results in decreased expression of FBN1 mRNA

NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283

G

fibrillin 2

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FBN2 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FBN2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FBN2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FBN2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FBN2 mRNA
Dexamethasone results in increased expression of FBN2 mRNA

PMID:16054899 PMID:25047013 PMID:28628672

NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191

G

fructose-bisphosphatase 2

decreases expression
multiple interactions

EXP

Dexamethasone results in decreased expression of FBP2 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of FBP2 mRNA]

NCBI chr17:2,241,767...2,259,371
Ensembl chr17:2,241,975...2,259,366

G

F-box and leucine-rich repeat protein 13

increases expression

ISO

Dexamethasone results in increased expression of FBXL13 mRNA

NCBI chr 4:14,307,032...14,505,491
Ensembl chr 4:14,307,096...14,499,585

G

F-box and leucine-rich repeat protein 14

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXL14 mRNA

NCBI chr 4:154,334,820...154,338,638
Ensembl chr 4:154,334,092...154,377,959

G

F-box and leucine-rich repeat protein 15

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FBXL15 mRNA

NCBI chr 1:255,131,154...255,133,395
Ensembl chr 1:255,131,154...255,133,427

G

F-box and leucine-rich repeat protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXL3 mRNA

NCBI chr15:86,321,504...86,341,387
Ensembl chr15:86,321,504...86,341,387

G

F-box and leucine-rich repeat protein 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXL7 mRNA

NCBI chr 2:78,870,236...79,239,697
Ensembl chr 2:78,871,287...79,239,697

G

F-box protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXO3 mRNA

NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:110,872,220...110,904,479

G

F-box protein 32

multiple interactions
increases expression

ISO
EXP

(+)-JQ1 compound inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; Calcitriol inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; Chir 99021 inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; CITED2 protein inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; GHRL protein modified form inhibits the reaction [Dexamethasone results in increased expression of FBXO32 protein]; PIK3R1 mutant form inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; Plant Extracts inhibits the reaction [Dexamethasone results in increased expression of FBXO32 protein]; SMYD3 mutant form inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; Tea inhibits the reaction [Dexamethasone results in increased expression of FBXO32 protein]
Dexamethasone results in increased expression of FBXO32 mRNA; Dexamethasone results in increased expression of FBXO32 protein
beta-hydroxyisovaleric acid inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]; Testosterone inhibits the reaction [Dexamethasone results in increased expression of FBXO32 mRNA]

PMID:18436443 PMID:19032942 PMID:19262011 PMID:21832246 PMID:22733784 More...

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

F-box protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXO4 mRNA

NCBI chr 2:54,902,394...54,915,388
Ensembl chr 2:54,902,394...54,915,388

G

F-box protein 41

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FBXO41 mRNA

NCBI chr 4:119,565,012...119,597,042
Ensembl chr 4:119,565,012...119,597,038

G

F-box protein 42

decreases expression

ISO

Dexamethasone results in decreased expression of FBXO42 mRNA

NCBI chr 5:158,734,165...158,792,560
Ensembl chr 5:158,734,175...158,792,565

G

F-box protein 46

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FBXO46 mRNA

NCBI chr 1:87,898,029...87,914,615
Ensembl chr 1:87,897,888...87,926,021

G

F-box protein 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXO8 mRNA

NCBI chr16:38,676,011...38,721,849
Ensembl chr16:38,676,014...38,721,906

G

F-box and WD repeat domain containing 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FBXW5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FBXW5 mRNA

NCBI chr 3:28,720,670...28,725,237
Ensembl chr 3:28,720,778...28,725,235

G

Fc epsilon receptor Ig

increases expression

ISO

Dexamethasone results in increased expression of FCER1G mRNA

NCBI chr13:86,181,908...86,186,766
Ensembl chr13:86,181,908...86,186,859

G

Fc gamma binding protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FCGBP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FCGBP mRNA

NCBI chr 1:92,502,461...92,540,658
Ensembl chr 1:92,499,498...92,540,658

G

Fc gamma receptor 2A

increases expression

ISO

Dexamethasone results in increased expression of FCGR3 mRNA

NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394

G

Fc gamma receptor 2B

increases expression

ISO

Dexamethasone results in increased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

Fc gamma receptor and transporter

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FCGRT mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FCGRT mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FCGRT mRNA

PMID:21041162 PMID:28628672

NCBI chr 1:104,710,902...104,720,685
Ensembl chr 1:104,710,909...104,720,532

G

FCH and mu domain containing endocytic adaptor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FCHO2 mRNA

NCBI chr 2:31,813,356...31,916,471
Ensembl chr 2:31,814,950...31,915,445

G

farnesyl diphosphate farnesyl transferase 1

increases expression

EXP

Dexamethasone results in increased expression of FDFT1 mRNA

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168

G

farnesyl diphosphate synthase

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FDPS mRNA

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136

G

ferredoxin 1

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FDX1 mRNA
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of FDX1 mRNA]

PMID:16054899 PMID:20032058

NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:61,164,839...61,183,583

G

fem-1 homolog A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FEM1A mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FEM1A mRNA

NCBI chr 9:1,178,857...1,181,063
Ensembl chr 9:1,177,543...1,188,006

G

fer-1-like family member 4

decreases expression
multiple interactions

ISO

Dexamethasone results in decreased expression of FER1L4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FER1L4 mRNA

PMID:25047013 PMID:28628672

NCBI chr 3:164,996,183...165,031,719
Ensembl chr 3:164,996,183...165,031,719

G

FERM domain containing kindlin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FERMT1 mRNA

NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419

G

FERM domain containing kindlin 2

increases expression

ISO

Dexamethasone results in increased expression of FERMT2 mRNA

NCBI chr15:21,162,603...21,257,995
Ensembl chr15:21,162,605...21,258,115

G

FES proto-oncogene, tyrosine kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FES mRNA

NCBI chr 1:143,746,945...143,756,181
Ensembl chr 1:143,746,945...143,756,181

G

fibrinogen beta chain

decreases expression

EXP

Dexamethasone results in decreased expression of FGB mRNA

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

FYVE, RhoGEF and PH domain containing 4

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FGD4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FGD4 mRNA

PMID:25047013 PMID:28628672

NCBI chr11:97,904,182...98,055,190
Ensembl chr11:97,904,182...98,055,190

G

fibroblast growth factor 10

increases expression

ISO

Dexamethasone results in increased expression of FGF10 mRNA

NCBI chr 2:52,533,939...52,610,980
Ensembl chr 2:52,533,939...52,610,980

G

fibroblast growth factor 19

decreases expression
multiple interactions

ISO
EXP

Dexamethasone results in decreased expression of FGF15 mRNA; Dexamethasone results in decreased expression of FGF15 protein
[Dexamethasone co-treated with Ibuprofen] results in decreased expression of FGF15 mRNA; [Dexamethasone co-treated with Ibuprofen] results in decreased expression of FGF15 protein
[Ibuprofen co-treated with Dexamethasone] results in decreased expression of FGF15 mRNA

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

fibroblast growth factor 2

multiple interactions

EXP
ISO

Dexamethasone inhibits the reaction [nitrofen results in decreased expression of FGF2 mRNA]
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]; sodium pentaborate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]

PMID:10646786 PMID:27568862 PMID:28285642

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibroblast growth factor 21

decreases expression
increases expression
multiple interactions

ISO
EXP

Dexamethasone results in decreased expression of FGF21 mRNA
dexamethasone increases Fgf21 mRNA expression in liver in rat
Dexamethasone promotes the reaction [NR1I2 protein binds to FGF21 promoter]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of FGF21 mRNA]; NR1I2 protein affects the reaction [Dexamethasone results in increased expression of FGF21 mRNA]
Dexamethasone results in increased expression of FGF21 mRNA; Dexamethasone results in increased expression of FGF21 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FGF21 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased secretion of FGF21 protein; Acetaminophen promotes the reaction [Dexamethasone results in increased expression of FGF21 mRNA]; Dexamethasone promotes the reaction [Acetaminophen results in increased expression of FGF21 mRNA]; Dexamethasone promotes the reaction [NR1I2 protein binds to FGF21 promoter]; FGF21 protein affects the reaction [Dexamethasone inhibits the reaction [Acetaminophen results in increased expression of GPT protein]]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of FGF21 mRNA]; NR1I2 protein affects the reaction [Dexamethasone results in increased expression of FGF21 mRNA]

CTD
RGD

PMID:22733784 PMID:28088388 PMID:31009676 PMID:29883717

NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:105,219,825...105,232,056

G

fibroblast growth factor 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FGF4 mRNA

NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:209,453,229...209,457,085

G

fibroblast growth factor 7

multiple interactions

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FGF7 mRNA; EGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FGF7 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FGF7 mRNA]

NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328

G

Fibroblast growth factor receptor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FGFR1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FGFR1 mRNA

PMID:28628672 PMID:31009676

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibroblast growth factor receptor 2

multiple interactions
decreases expression

ISO
EXP

[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FGFR2 mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FGFR2 mRNA]
Testosterone inhibits the reaction [Dexamethasone results in decreased expression of FGFR2 mRNA]

PMID:16054899 PMID:20032058 PMID:31009676

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

fibroblast growth factor receptor 3

decreases response to substance
multiple interactions

ISO

FGFR3 protein results in decreased susceptibility to Dexamethasone
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FGFR3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FGFR3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FGFR3 mRNA

PMID:12393593 PMID:28628672 PMID:31009676

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

fibroblast growth factor receptor 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FGFR4 mRNA

NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,466,692...9,481,389

G

fibroblast growth factor receptor-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FGFRL1 mRNA

NCBI chr14:1,154,275...1,166,334
Ensembl chr14:1,154,275...1,166,752

G

FGR proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FGR mRNA

NCBI chr 5:150,473,767...150,503,524
Ensembl chr 5:150,473,792...150,503,169

G

fumarate hydratase

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FH mRNA
Dexamethasone results in decreased expression of FH protein

PMID:28628672 PMID:33567340

NCBI chr13:90,056,565...90,082,450
Ensembl chr13:90,056,570...90,089,627

G

FHF complex subunit HOOK interacting protein 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FHIP1B mRNA

NCBI chr 1:169,137,866...169,160,305
Ensembl chr 1:169,122,654...169,160,252

G

four and a half LIM domains 1

increases expression

ISO

Dexamethasone results in increased expression of FHL1 mRNA

NCBI chr X:139,592,794...139,652,290
Ensembl chr X:139,592,604...139,652,282

G

four and a half LIM domains 2

decreases expression

ISO

Dexamethasone results in decreased expression of FHL2 mRNA

NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:52,880,998...52,923,326

G

formin homology 2 domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FHOD1 mRNA

NCBI chr19:50,116,415...50,135,868
Ensembl chr19:50,116,415...50,135,330

G

fat storage-inducing transmembrane protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FITM2 mRNA

NCBI chr 3:172,560,781...172,567,291
Ensembl chr 3:172,560,781...172,567,291

G

four-jointed box kinase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FJX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FJX1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FJX1 mRNA

NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479

G

FKBP prolyl isomerase family member 15

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FKBP15 mRNA

NCBI chr 5:80,766,356...80,830,622
Ensembl chr 5:80,766,356...80,830,565

G

FKBP prolyl isomerase 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FKBP1A mRNA

NCBI chr 3:160,500,748...160,520,492
Ensembl chr 3:160,500,726...160,524,233

G

FKBP prolyl isomerase 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FKBP1B mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FKBP1B mRNA

NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:33,558,517...33,568,129

G

FKBP prolyl isomerase 4

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FKBP4 mRNA
FKBP4 protein promotes the reaction [Dexamethasone binds to and results in increased activity of NR3C1 protein]

PMID:15697228 PMID:17998272

NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:163,389,464...163,397,918

G

FKBP prolyl isomerase 5

multiple interactions
increases expression

ISO
EXP

17 alpha-Hydroxyprogesterone Caproate inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FKBP5 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FKBP5 mRNA; [Mustard Gas results in increased alkylation of Dexamethasone] which results in increased expression of FKBP5 mRNA; aurin inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; Ciclopirox inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; Colforsin promotes the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; Mifepristone inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]
Dexamethasone results in increased expression of FKBP5 mRNA; Dexamethasone results in increased expression of FKBP5 protein
Testosterone inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]
[Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FKBP5 mRNA; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; NR3C1 gene mutant form inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]

PMID:12732289 PMID:15679045 PMID:16054899 PMID:16144937 PMID:17690134 More...

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

FKBP prolyl isomerase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FKBP7 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FKBP7 mRNA

NCBI chr 3:82,016,647...82,030,913
Ensembl chr 3:82,016,513...82,028,573

G

FKBP prolyl isomerase 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FKBP9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FKBP9 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FKBP9 mRNA

NCBI chr 4:87,436,439...87,486,909
Ensembl chr 4:87,436,478...87,508,940

G

Fli-1 proto-oncogene, ETS transcription factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FLI1 mRNA

NCBI chr 8:39,089,526...39,209,511
Ensembl chr 8:39,089,533...39,208,557

G

filamin A

decreases expression

EXP

Dexamethasone results in decreased expression of FLNA mRNA

NCBI chr X:157,159,051...157,185,559
Ensembl chr X:157,159,051...157,182,343

G

filamin B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FLNB mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FLNB mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FLNB mRNA

NCBI chr15:19,392,212...19,525,278
Ensembl chr15:19,392,216...19,525,209

G

filamin C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FLNC mRNA

NCBI chr 4:58,999,445...59,027,240
Ensembl chr 4:58,999,547...59,027,240

G

flotillin 1

multiple interactions

ISO

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA

NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,922,655...2,932,771

G

flotillin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FLOT2 mRNA

NCBI chr10:63,424,084...63,445,811
Ensembl chr10:63,423,806...63,445,810

G

fibronectin leucine rich transmembrane protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FLRT2 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

Fms related receptor tyrosine kinase 1

increases expression

ISO

Dexamethasone results in increased expression of FLT1 mRNA

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750

G

Fms related receptor tyrosine kinase 3

affects expression

ISO

Dexamethasone affects the expression of FLT3 mRNA

NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581

G

formin-like 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FMNL2 mRNA

NCBI chr 3:57,758,236...58,033,832
Ensembl chr 3:57,758,191...58,033,831

G

flavin containing dimethylaniline monoxygenase 1

affects expression
multiple interactions
increases expression

EXP
ISO

Dexamethasone affects the expression of FMO1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FMO1 mRNA
Dexamethasone results in increased expression of FMO1 mRNA
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO1 mRNA

PMID:15102944 PMID:16054899 PMID:22733784 PMID:28628672

NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874

G

flavin containing dimethylaniline monoxygenase 3

multiple interactions
increases expression

ISO

[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA
Dexamethasone results in increased expression of FMO3 mRNA

PMID:16054899 PMID:22733784 PMID:28628672

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO4 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of FMO4 mRNA

NCBI chr13:77,687,909...77,706,100
Ensembl chr13:77,687,909...77,706,100

G

fibromodulin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMOD mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FMOD mRNA

NCBI chr13:48,045,567...48,056,184
Ensembl chr13:47,990,774...48,056,183

G

fibronectin 1

multiple interactions
increases expression
decreases expression

EXP
ISO

Dexamethasone inhibits the reaction [Carbon Tetrachloride results in increased expression of FN1 protein]
Dexamethasone inhibits the reaction [Particulate Matter results in increased expression of FN1 protein]
Dexamethasone results in increased expression of FN1 mRNA
Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Particulate Matter] results in increased expression of FN1 protein]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of FN1 mRNA]; Dexamethasone inhibits the reaction [Bleomycin results in increased expression of FN1 protein]
Dexamethasone results in decreased expression of FN1 mRNA

PMID:14618091 PMID:15030980 PMID:28300665 PMID:35143883 PMID:35335934

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

formin binding protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FNBP1 mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of FNBP1 mRNA

NCBI chr 3:34,706,814...34,826,770
Ensembl chr 3:34,706,814...34,822,117

G

formin binding protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FNBP4 mRNA

NCBI chr 3:97,188,852...97,218,916
Ensembl chr 3:97,188,884...97,219,435

G

fibronectin type III domain containing 1

decreases expression

ISO

Dexamethasone results in decreased expression of FNDC1 mRNA

NCBI chr 1:49,686,856...49,769,263
Ensembl chr 1:49,686,856...49,769,263

G

fibronectin type III domain containing 3B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FNDC3B mRNA

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression
multiple interactions

EXP
ISO

Dexamethasone results in decreased expression of FOS mRNA
Dexamethasone results in increased expression of FOS mRNA
Dexamethasone inhibits the reaction [Colforsin results in increased expression of FOS protein]; Dexamethasone inhibits the reaction [EGF protein results in increased expression of FOS mRNA]; Dexamethasone promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]

PMID:7705776 PMID:9042522 PMID:11113530 PMID:12632255 PMID:25047013

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Dexamethasone results in increased expression of FOSB mRNA

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

ISO
EXP

[Dexamethasone co-treated with rosiglitazone co-treated with INS protein] results in increased expression of FOSL1 mRNA
Dexamethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of FOSL1 mRNA

PMID:11113530 PMID:11916924 PMID:28628672

NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391

G

FOS like 2, AP-1 transcription factor subunit

increases expression
multiple interactions

ISO

Dexamethasone results in increased expression of FOSL2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FOSL2 mRNA

PMID:17998272 PMID:28628672

NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:30,021,916...30,039,406

G

forkhead box A2

multiple interactions
decreases expression

ISO

Dexamethasone affects the reaction [G6PC2 promoter SNP affects the reaction [FOXA2 protein binds to G6PC2 promoter]]
Dexamethasone results in decreased expression of FOXA2 protein

PMID:27653037 PMID:34742744

NCBI chr 3:155,923,305...155,927,508
Ensembl chr 3:155,923,307...155,928,757

G

forkhead box C1

increases expression

ISO

Dexamethasone results in increased expression of FOXC1 mRNA

NCBI chr17:32,840,119...3